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Letter  of  Transmittal  
University  of  Pennsylvania,  School  of  Engineering  and  Applied  Science  
Department  of  Chemical  and  Biomolecular  Engineering  
220  South  33rd  Street  
Philadelphia,  PA  19104  
April  20,  2021  
Dear  Dr.  Miriam  Wattenbarger,  Prof.  Bruce  Vrana,  and  Dr.  Jeffrey  Cohen,   
This  report  proposes  a  process  design  that  produces  a  recombinant  spike-protein-based  
COVID-19  vaccine.  The  final  drug  substance  recovered  contains  2.60  kg  of  highly  purified  
protein,  sufficient  for  more  than  the  500  million  doses  requested  in  the  original  project  statement.  
The  process  design  involves  scale-up  of  cells  from  shake  flasks  to  bioreactors,  viral  
amplification,  and  protein  recovery  through  steps  including  filtration,  viral  inactivation,  and  
chromatography.  This  design  ensures  a  product  that  is  both  safe  and  affordable  for  consumers,  
while  easily  replicable  for  the  CMO  to  manufacture.  
An  economic  analysis  of  this  process  shows  favorable  profitability.  By  partnering  with  a  
CMO  in  North  Carolina,  the  manufacture  of  SARS-CoV-2  spike  protein-based  vaccine  brings  in  
$2  billion  in  net  earnings  at  a  net  present  value  of  $1.5  billion.  The  CMO  plant  has  a  return  on  
investment  of  18%,  an  investor’s  rate  of  return  of  at  least  16%,  and  a  net  present  value  of  
$855,000.  These  numbers  suggest  that  the  project  is  profitable,  and  a  CMO  would  respond  
favorably  to  a  manufacturing  partnership.  We  recommend  that  the  design  move  forward  
following  the  specifications  in  this  report.  The  economics  can  be  supplemented  by  considerations  
of  research  and  development  investments  and  formulation  and  packaging  costs,  which  were  
outside  the  scope  of  this  project.  
Thank  you  so  much  for  all  the  assistance  with  this  senior  design  project.  We  greatly  
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1.  Abstract  
Various  COVID-19  vaccines  are  currently  in  development,  as  the  COVID-19  pandemic  
has  created  an  unmet  need  for  protection  against  the  SARS-CoV-2  virus.  While  there  are  many  
different  types  of  vaccines,  we  focused  on  developing  one  that  would  be  safe,  affordable,  and  
quickly  available  for  emergency  use.  A  vaccine  synthesized  using  recombinant  proteins  utilizes  a  
reliable  and  well-studied  technological  platform,  avoids  the  safety  risks  inherent  to  viral  vectors,  
and  provides  a  cost-effective,  scalable  method  of  production  of  antigen  used  to  induce  an  
immune  response.  Other  vaccines  on  the  market  notably  include  Pfizer’s  and  Moderna’s  mRNA  
based  vaccines.  Although  these  are  widely  used,  there  is  still  a  large  demand  for  an  inexpensive  
yet  safe  and  effective  vaccine.  Herein,  we  propose  the  production  of  500  million  doses  of  a  
recombinant  spike  protein-based  COVID-19  vaccine  in  a  quick  time  frame  and  cost-effective  
manner,  using  the  baculovirus  expression  vector  system  (BEVS).  Our  upstream  process  involves  
a  three-stage  cellular  scale-up  from  shake  flasks  to  WAVE  bioreactors  to  perfusion  to  production  
bioreactors,  as  well  as  an  additional  two-stage  viral  amplification  from  flasks  to  WAVE  
bioreactors.  Our  downstream  process  involves  a  six-stage  protein  recovery  with  depth  filtration,  
his-tag  chromatography,  viral  inactivation,  ion-exchange  chromatography,  viral  filtration,  and  
diafiltration.  We  will  be  partnering  with  a  contract  manufacturing  organization  (CMO)  for  this  
project,  as  we  do  not  have  the  time  to  quickly  build  a  plant  to  get  these  vaccines  out  for  
emergency  use.  This  arrangement  makes  this  process  highly  profitable.  Selling  each  dose  for  $16  
yields  net  earnings  near  $2  billion  and  an  extremely  high  IRR  due  to  the  lack  of  permanent  and  
fixed  costs  other  than  our  rental  fee.  The  IRR  for  the  CMO  is  estimated  to  be  at  least  16%  with  
the  NPV  of  the  plant  at  $855,000  and  an  ROI  of  18%.  
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2.  Introduction  and  Objective-time  Chart  
2.1  Project  Background  
The  COVID-19  global  pandemic  has  been  caused  by  the  rapid  global  transmission  of  
SARS-CoV-2,  a  novel  coronavirus  that  was  first  reported  in  December  2019  following  an  initial  
outbreak  in  Wuhan,  Hubei  Province,  China  [1].  As  of  March  28,  2021,  there  have  been  over  126  
million  confirmed  cases  and  nearly  2.8  million  deaths  worldwide  [2].  In  the  United  States  alone,  
there  have  been  over  30  million  cases  and  nearly  550,000  deaths  [3].  These  numbers  stress  the  
urgent  need  for  vaccine  development,  manufacture,  and  global  distribution.  
Vaccines  are  designed  to  help  the  human  body  build  an  immune  response  to  a  particular  
pathogen.  By  inducing  an  immunogenic  response,  the  body  can  respond  to  any  future  infection  
by  minimizing  or  eliminating  symptoms  and/or  the  disease  itself.  In  developing  vaccines,  
scientists  consider  the  immune  response,  the  target  population,  and  the  best  available  technology.  
This  process  normally  takes  years:  it  took  16  years  to  develop  a  hepatitis  B  vaccine  and  5  years  
to  develop  an  Ebola  vaccine  [4].  
Due  to  the  urgency  of  the  pandemic,  there  is  immense  pressure  to  develop  a  vaccine  
against  SARS-CoV-2  within  18  months.  In  addition  to  accelerated  vaccine  development,  the  
quick  scale-up  of  a  viable  manufacturing  and  purification  process  is  crucial  to  producing  large  
quantities  of  vaccines  to  meet  global  demand.  Previous  research,  such  as  that  for  SARS-CoV  
vaccine  development  [5]  has  established  the  spike  protein  of  SARS-CoV-2  as  a  clear  target  




2.2  Project  Goals  and  Scope  
The  goal  of  this  project  will  be  to  select  a  vaccine  technology  and  design  both  an  
upstream  and  downstream  manufacturing  process  to  produce  500  million  doses  of  a  COVID-19  
vaccine.  Of  the  available  vaccine  technologies,  the  traditional  live-attenuated  and  inactivated  
virus  vaccines,  which  use  the  weakened  or  killed  virus,  respectively,  were  deemed  too  dangerous  
due  to  their  usage  of  actual  SARS-CoV-2  virus.  The  more  recent  mRNA,  viral  vector,  and  
subunit  vaccine  technologies  will  be  considered  and  discussed  in  Section  10.1  [6][7].  
The  upstream  process  will  consist  of  a  series  of  flasks  and  bioreactors  used  to  grow  a  
large  population  of  cells,  followed  by  inoculation  of  the  final  cell  population  with  viral  material  
to  produce  the  desired  active  pharmaceutical  ingredient  (API).  The  subsequent  downstream  
process  will  include  a  series  of  unit  operations  to  isolate,  purify,  and  package  the  bulk  API.  The  
genetic  modification  of  the  cell  line  and  viral  material,  and  the  formulation  and  packaging  of  the  
API  into  doses  is  outside  the  scope  of  this  project.  The  capital  investment  and  operating  costs  for  
the  upstream  and  downstream  processes  will  be  estimated  to  price  the  production  of  a  large  
volume  of  vaccine.  This  economic  analysis  will  allow  the  team  to  approach  a  CMO  with  the  
available  equipment  and  resources  to  negotiate  a  reasonable  contract.  The  urgency  of  the  
COVID-19  pandemic  necessitates  that  vaccines  be  produced  as  soon  as  possible  by  a  capable  
CMO  as  opposed  to  the  traditional  design  of  a  new  manufacturing  facility.  
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2.3  Objective-Time  Chart  
Figure  2.1  shows  the  established  timeline  the  team  followed  in  completing  this  project.  In  
January,  we  met  with  project  author  Dr.  Jeffrey  Cohen  and  faculty  advisor  Dr.  Miriam  
Wattenbarger  to  discuss  and  review  the  literature  available.  This  research  and  their  expertise  
informed  and  guided  our  preliminary  process  synthesis  of  the  manufacturing  process  in  late  
January  and  early  February.  The  month  of  February  was  dedicated  to  designing  the  overall  
upstream  (i.e.  harvest)  and  downstream  (i.e.  purification)  processes.  The  team  also  began  writing  
the  report  mid-February  to  document  information  and  decisions  made  along  the  way.  The  end  of  
February  and  the  month  of  March  focused  on  the  specific  design  of  the  equipment  used  in  each  
unit  operation.  The  first  week  of  March  was  used  to  present  our  progress  since  the  beginning  of  
the  project  and  the  next  steps  to  be  taken.  The  rest  of  March  emphasized  the  market  and  
economic  aspects  of  costing  and  profitability  analysis.  In  the  first  half  of  April,  the  process  flow  
diagrams  (PFDs),  material  balances,  energy  balances,  and  profitability  analysis  were  completed  
to  wrap  up  the  project  and  finish  the  written  report.  Afterwards,  the  written  report  and  
presentation  were  revised  and  finalized.  
  
Figure  2.1.  Objective-Time  Chart  for  the  COVID-19  Vaccine  Manufacturing  Process  Project.   
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3.  Innovation  Map  
N/A   
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4.  Market  and  Competitive  Analysis  
The  market  demand  for  SARS-CoV-2  vaccines  remains  very  high.  With  over  1  million  
total  cases,  and  the  number  of  new  cases  still  averaging  about  500,000  a  day,  the  vaccine  is  
clearly  essential.  This  global  pandemic  has  weakened  our  health  systems,  economic  systems,  and  
social  progression  as  a  whole.  In  order  for  businesses  and  schools  to  reopen,  it  is  key  that  as  
many  people  as  possible  are  vaccinated  against  this  virus.  The  global  vaccine  market  revenue  is  
currently  estimated  at  $59  billion  USD  [8].  By  the  end  of  2021,  some  have  predicted  that  the  
market  will  grow  to  be  worth  $75  billion  USD  [9].  Evidently,  there  is  a  huge  need  for  COVID-19  
vaccines  and  our  manufacturing  process  can  help  to  fill  this  gap.  
There  may  be  an  initial  drop  in  2022  because  boosters  may  not  be  needed,  and  there  may  
be  a  price  reduction  due  to  intense  competition.  However,  as  years  pass,  the  market  is  expected  
to  open  and  grow  again  due  to  an  unmet  need  for  vaccine  boosters  [8].  The  market  is  
subsequently  expected  to  grow  at  a  compound  annual  growth  rate  (CAGR)  of  over  9%,  and  reach  
$47.5  billion  USD  by  2026.  
Currently,  the  market  is  segmented  by  technology  and  geography.  Many  types  of  vaccines  
are  in  development,  as  highlighted  later  in  Section  10.1.  Additionally,  the  US,  UK,  India,  Spain,  
Italy,  and  China  were  some  of  the  most  affected  countries.  Currently,  58%  of  the  vaccine  market  
belongs  to  APAC  countries,  15%  to  Europe,  and  12%  to  North  America  [10].  However,  North  
America’s  share  of  the  market  is  expected  to  increase  to  about  46%  [9].  
There  are  some  pharmaceutical  companies  who  have  already  begun  manufacturing  and  
distributing  a  vaccine.  Notably,  Pfizer/BioNTech,  Moderna,  AstraZeneca/Oxford,  Novavax,  and  
GSK  are  among  the  largest  players.  Pfizer/BioNTech  agreed  to  provide  the  UK  with  500  million  
doses  by  the  end  of  2021  [9].  In  total,  over  1  billion  doses  of  Pfizer/BioNTech’s  vaccine  have  
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been  ordered.  Topping  this,  3  billion  doses  from  AstraZeneca/Oxford’s  vaccine,  1  billion  doses  
from  Novavax’s  vaccine,  and  800  million  doses  from  Moderna’s  vaccine  have  been  ordered.  
Others  include  Johnson  &  Johnson’s  vaccine  which  has  received  300  million  dose  orders  [11].  
With  almost  8  billion  people  in  the  world  and  most  vaccines  requiring  two  doses,  there  is  
clearly  a  large  unmet  need  for  vaccines.  Our  vaccine  only  requires  refrigeration,  as  opposed  to 
the  mRNA  vaccines  that  require  frozen  storage,  which  low  resource  countries  do  not  have  the  
infrastructure  for.  As  of  March  24th,  about  300  million  people  worldwide  have  received  at  least  
one  dose  of  a  vaccine  [12].  This  only  corresponds  to  3.56%  of  the  world's  population.  Thus,  
assuming  at  least  50%  of  the  population  will  want  a  vaccine,  billions  more  doses  are  necessary.  
Our  project  aims  to  produce  500  million  doses  of  a  vaccine  to  contribute  to  about  250  million  
complete  vaccinations.  While  competition  undoubtedly  exists,  the  most  important  thing  right  
now  is  to  ensure  that  as  many  people  as  possible  are  vaccinated  as  soon  as  possible.  Our  project  





5.  Customer  Requirements  
5.1  Customer  Analysis  
The  magnitude  and  swiftness  of  the  COVID-19  pandemic  presents  a  problem  of  unique  
proportions  in  both  a  public  health  and  economic  sense.  Customers  are  effectively  the  entire  
global  population,  particularly  the  most  vulnerable  members  of  society.  Since  the  vaccine  is  
injected  into  the  human  body,  extra  precaution  must  be  taken  to  ensure  that  the  vaccine  is  
completely  safe.  Additionally,  the  refrigeration  requirements  of  our  vaccine  provide  availability  
to  low  resource  countries  that  lack  cold  storage  for  mRNA  vaccines.  A  vaccine  presents  the  
means  of  stopping  the  spread,  protecting  the  vulnerable  population,  and  enabling  an  economic  
reopening.  This  occurs  when  herd  immunity  is  achieved  [13].  Therefore,  the  sooner  sufficient  
vaccination  is  carried  out,  the  better.  
  
  
5.2  Product  Safety  
The  vaccine  must  meet  stringent  safeguards  in  accordance  with  Good  Manufacturing  
Practices  (GMP)  to  obtain  FDA  approval  [14].  Therefore,  the  first  priority  of  this  process  is  to  
ensure  that  a  product  is  of  utmost  safety  and  purity.  Accordingly,  this  proposal  prioritizes  purity  
rather  than  yield  for  downstream  processes  and  ensures  adequate  purification  steps  to  reduce  
viral  content  and  other  contaminants  present  in  the  process.  Additionally,  the  upstream  process  
incorporates  safety  measures  such  as  replicate  batches  with  independent  supply  lines  and  media  





5.3  Rapid  Timeline  
Safe  but  rapid  delivery  of  the  vaccine  dosage  will  be  critical  in  limiting  the  spread  of  
COVID-19.  In  this  proposal,  we  focus  on  producing  the  vaccine  quickly  with  adherence  to  strict  
quality  control,  even  if  greater  capital  expenditures  are  required.  We  thus  incorporate  larger-scale  
systems  into  our  proposal  to  enable  production  in  one  batch  rather  than  in  multiple  smaller  
batches  to  ensure  that  the  desired  amount  of  doses  reaches  consumers  as  quickly  as  possible.  For  
instance,  the  downstream  process  is  anticipated  to  take  3  days  rather  than  time-intensive  
alternatives  with  drastic  capital  expenditure  reductions.  Furthermore,  we  prepare  multiple  lines  
in  the  manual  handling  stages  of  the  manufacturing  process  to  prevent  delays  due  to  line  quality.  
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6.  Critical-To-Quality  Variables  
N/A  
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7.  Product  Concepts  
N/A   
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8.  Superior  Product  Concepts  
N/A  
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9.  Competitive  Patent  Analysis  
The  three  main  types  of  vaccines  currently  in  development  are  the  subunit  vaccine,  the  
viral  vector  vaccine,  and  the  mRNA  vaccine.  The  recombinant  protein,  a  subunit  vaccine,  is  the  
most  conventional  type  where  antigens  on  the  viral  surface  are  used  to  trigger  immune  responses.  
Viral  vector  vaccines  use  genetically  engineered  capsids  of  other  viruses  to  deliver  antigenic  
genes.  The  mRNA  vaccine  is  a  relatively  recent  technology  that  uses  lipid  nanoparticles  (LNPs)  
to  encapsulate  mRNA  containing  the  genetic  information  for  the  antigen.  
In  the  manufacturing  process  of  recombinant  protein  vaccines,  insect  cells  or  mammalian  
cells  are  first  transfected  with  plasmid  containing  the  antigen.  Transfected  cells  are  next  grown  in  
a  cell  culture  seed  train  for  mass  production.  After  the  cells  have  grown  to  the  desired  amount  in  
the  harvest  bioreactor,  they  are  infected  with  viral  stock  to  induce  expression  of  protein.  Then,  
the  protein  of  interest  is  separated  and  purified  to  formulate  the  vaccine.  Published  in  2007,  an  
international  patent  [15]  is  owned  by  Merck  for  its  influenza  recombinant  subunit  vaccine.  The  
invention  of  influenza  recombinant  subunit  vaccine  involves  the  usage  of  insect  cell  expression  
system  and  saponin  adjuvant,  which  validated  our  manufacturing  model.  
For  the  manufacturing  process  of  mRNA  vaccines,  many  copies  of  the  mRNA  of  interest  
are  first  produced  in  vitro  through  transcription  of  DNA  in  a  reactor.  Then,  the  encapsulation  of  
mRNA  copies  in  LNP  components  involves  microfluidic  technology  to  undergo  self-assembly.  
To  formulate  the  vaccine,  the  LNPs  encapsulating  the  mRNA  are  isolated  and  purified.  Pfizer  
and  Moderna  are  companies  that  have  developed  the  production  of  LNPs  to  encapsulate  mRNA  
for  the  SARS-CoV-2  virus.  Published  in  2020,  a  US  patent  [16]  is  owned  by  Moderna  for  its  
betacoronavirus  mRNA  vaccine.  
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The  manufacturing  process  of  viral  vector  vaccines  is  similar  to  that  of  recombinant  
protein  vaccines  in  that  cells  are  grown  in  bioreactors,  but  different  in  that  cells  are  infected  with  
viral  vectors  for  propagation.  The  viral  vectors  are  separated  and  purified  afterward  to  formulate  
the  vaccine.  Published  in  2011,  an  international  patent  [17]  is  owned  by  Janssen  for  its  method  of  
producing  Ad26  adenoviral  vectors.  The  method  for  large-scale  production  of  Ad26  adenoviral  
vectors  involves  perfusion  systems  that  grow  cells  to  very  high  density  before  infection  and  
propagation  of  adenoviral  vectors  after  infection.  Janssen’s  patent  was  used  as  a  reference  to  
apply  the  perfusion  system  to  our  second-to-last  bioreactor.  
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10.  Preliminary  Process  Synthesis  
10.1  Types  of  Vaccines  
10.1.1  mRNA  
Messenger  RNA,  or  mRNA,  vaccines  deliver  the  genetic  information  encoding  the  spike  
protein  [18].  Gene  constructs  can  be  quickly  transcribed  in  vitro  using  just  the  genetic  sequence,  
making  production  a  purely  chemical  process  that  does  not  require  cellular  growth  [19].  The  
manufacturing  process  is  scalable,  which  allows  for  rapid  production  of  vaccines  [20].  However,  
the  Pfizer/BioNTech  and  Moderna  vaccines  currently  in  distribution  require  extreme  frozen  
storage  to  account  for  RNA  instability,  which  poses  difficulties  in  the  storage  and  transportation  
of  dosages  [21].  Challenges  in  large-scale  production  and  long-term  storage  do  not  have  past  
precedent,  thus  issues  that  arise  will  pose  significant  costs  [20][21].  While  mRNA  technology  is  
promising,  no  mRNA  vaccines  have  been  licensed  in  the  past  for  human  use  and  not  much  data  
is  widely  available.  Therefore,  we  did  not  choose  mRNA  vaccine  platform  for  our  project  [18].  
  
10.1.2  Viral  Vectors  
An  alternative  method  is  the  viral  vector  vaccine.  In  this  approach,  the  genetic  sequence  
of  a  virus  is  modified  such  that  it  is  not  pathogenic  to  the  host  while  still  stimulating  a  strong  
immunogenic  response  [22].  The  virus  is  designed  in  such  a  way  that  its  pathogenicity  is  
attenuated  but  still  capable  of  generating  antigenic  material  to  which  the  host  reacts,  producing  a 
lasting  immunogenic  response  [23].  Unlike  traditional  attenuated  vaccines,  the  actual  viral  vector  
need  not  be  the  actual  virus  itself,  but  is  often  a  chimeric  version  of  a  less  potent  virus  with  the  
particular  genetic  sequence  of  the  virus  of  interest  [22].  Additionally,  to  further  limit  
pathogenicity,  specific  replication-defective  vectors  have  been  engineered  by  precise  genetic  
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editing  of  the  chimeric  viruses  [24].  However,  these  replication-deficient  vectors  have  weakened  
immunogenicity  [25].  Additionally,  there  is  a  fair  amount  of  concern  regarding  the  ability  of  viral  
vector  vaccines  to  combine  with  wild-type  viruses  and  mutate,  thereby  regaining  full  scale  
pathogenicity  [23].  Lastly,  very  few  viral  vector  vaccines  have  been  approved  anywhere  in  the  
world,  limiting  the  ability  of  our  senior  design  group  to  properly  assess  such  a  process  [23].  Due  
to  these  concerns,  the  viral  vector  vaccine’s  advantages  in  immunogenicity  are  outweighed  by  
safety  concerns  and  the  lack  of  prior  experience.  
  
10.1.3  Subunit  
Current  subunit  vaccines  include  recombinant  protein,  receptor-binding  domain  (RBD),  
and  virus-like  particles  (VLPs).  We  chose  to  use  a  recombinant  protein-based  vaccine  using  the  
spike  protein  as  the  antigen.  The  spike  protein  was  the  most  potent  antigen  for  SARS-CoV  and 
MERS-CoV  vaccines  [26],  and  spike  protein-based  vaccines  are  known  to  develop  high-titer  
spike  protein-specific  antibodies  with  neutralizing  activity  [27].  Novavax,  the  current  leader  in  
making  recombinant  protein-based  vaccines  for  SARS-CoV-2,  uses  the  spike  protein  as  the  
antigen.  The  RBD  of  the  spike  protein  was  not  chosen  as  the  antigen  since  it  lacks  other  
neutralizing  epitopes  that  are  on  the  full  length  spike,  and  adverse  events  have  occurred  for  some  
RBD-based  vaccines  in  clinical  trials  [28].  VLPs  were  not  chosen  as  the  antigen  since  enveloped  
baculoviruses  and  VLPs  share  similar  chemical  and  physical  characteristics,  which  poses  a  major  





10.2  Protein-Based  Vaccine  
10.2.1  Spike  Protein  
The  recombinant  protein-based  vaccine  is  a  highly  conventional  vaccine  platform,  which  
has  been  studied  for  a  long  time  [30].  Spike  protein  vaccine  technology  has  proven  to  be  safe  for  
immunocompromised  people,  as  the  manufacturing  of  the  vaccine  does  not  involve  working  with  
live  pathogens  or  genetic  material  [31].  Recombinant  protein-based  vaccines  do  not  require  
frozen  storage  conditions,  which  is  another  major  advantage.  Novavax  is  currently  developing  its  
recombinant  protein-based  vaccine  with  required  storage  conditions  between  2˚C  to  8˚C  [32],  
which  is  much  more  economical  than  the  frozen  storage  requirements  of  mRNA  vaccines.  
However,  recombinant  protein-based  vaccines  require  the  usage  of  an  adjuvant,  which  is  an  
agent  mixed  with  the  vaccine  to  promote  effective  immune  response.  The  most  common  side  
effects  of  adjuvants  are  known  to  be  malaise,  fatigue,  and  headache  [21].  Despite  these  
considerations,  for  our  senior  design  project,  we  have  decided  to  use  the  recombinant  
protein-based  vaccine  as  our  vaccine  platform.  
  
10.2.2  Baculovirus  Expression  Vector  System  
The  Baculovirus  Expression  Vector  System  (BEVS)  will  be  used  to  develop  the  
recombinant  protein.  CERVARIX  manufactured  by  GlaxoSmithKline  (GSK)  was  the  first  human  
recombinant  protein  vaccine  produced  using  the  BEVS  system  [31].  In  the  BEVS  system,  insect  
cells  are  infected  using  a  recombinant  baculovirus  with  the  desired  gene.  This  gene  of  interest  
can  be  made  synthetically  by  obtaining  the  sequence  from  a  public  database,  or  it  can  be  
transcribed  from  an  inactivated  virus  obtained  from  the  CDC  and  amplified  by  Reverse  
Transcriptase  Polymerase  Chain  Reaction  (RT-PCR)  [33].  As  shown  in  Figure  10.2 ,  the  gene  is  
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then  inserted  into  the  baculovirus  plasmid  DNA  to  make  the  bacmid,  which  is  amplified  in  a  
bacterial  culture  to  increase  the  number  of  bacmid.  The  bacteria  are  lysed  to  harvest  and  purify  
the  intracellular  bacmid,  which  is  then  inserted  into  adherent  insect  cells  using  a  transfection  
reagent.  The  cells  with  the  bacmid  are  grown  in  medium  and  produce  the  baculovirus,  which  are  
secreted  into  the  supernatant.  Cellular  debris  is  removed  by  ultracentrifugation,  and  genomic  
DNA  and  RNA  is  digested  with  nuclease,  leaving  behind  only  the  baculovirus  in  the  supernatant  
to  be  harvested  and  stored  [34].  
  
Figure  10.2.  The  Baculovirus  Expression  Vector  System.  The  gene  of  interest  is  inserted  into  the  baculovirus  
genome  to  create  the  recombinant  bacmid.  The  bacmid  is  transfected  into  insect  cells,  which  produce  and  secrete  the  
recombinant  baculovirus  into  the  supernatant.  (ThermoFisher  Scientific)  
Various  advantages  are  associated  with  the  BEVS  system.  High  protein  yields,  large  
scalability,  and  fast  production  are  notable  benefits  [35].  Additionally,  there  is  inherent  safety,  as  
the  virus  only  infects  invertebrates  [35].  Using  insect  cells  is  also  ideal  because  they  are  cheaper  
than  CHO  cells  yet  still  perform  proper  post-translational  modification.  Although  bacteria  and  
yeast  cells  yield  high  protein  expression  at  a  low  cost,  they  were  not  considered  as  viable  options  
26  
  
because  of  their  inability  to  properly  perform  post-translational  modifications.  There  are  some  
disadvantages  to  the  BEVS  system,  including  quick  cell  lysis,  at  72-96  hours  post  infection  [36].  
This  can  be  combated  by  deleting  the  gene  that  produces  the  apoptotic  protein,  as  well  as  via  
various  other  methods.  The  required  media  can  also  be  expensive,  but  is  still  cheaper  than  those  
for  CHO  cells.  Overall,  the  BEVS  system  is  optimal,  so  our  group  has  decided  to  utilize  BEVS  to  
develop  a  safe  and  cost-effective  vaccine.  
  
10.2.3  Cell  Line  
The  insect  cell-baculovirus  expression  vector  system  (IC-BEVS)  can  be  manufactured  
efficiently  and  scaled  up  for  large-scale  production  of  recombinant  proteins.  The  process  consists  
of  cell  growth,  cell  infection  with  the  recombinant  baculovirus  vector,  and  purification  and  
recovery  of  the  recombinant  protein.  The  Spodoptera  frugiperda  ( Sf )  cell  line  is  an  industry  
standard  cultivated  in  suspension  using  serum-free  media  and  is  easily  detached  from  cultivation  
surfaces  with  gentle  agitation,  eliminating  the  need  for  trypsinization  [37].  Our  team  chose  Sf-9  
cells  because  they  have  higher  baculovirus  amplification  rates,  have  faster  growth  rates,  and  are  
less  fragile  —  specifically  more  tolerant  to  osmotic,  pH,  and  shear  stress  conditions  —  than  
Sf-21  cells  [37].  
  
10.2.4  Medium  
Sf-9  cells  require  specific  media  conditions  to  grow  optimally,  thus  a  variety  of  media  
lines  from  different  companies  were  assessed.  Several  considerations  were  examined:  maximum  
cell  density,  available  scale  for  purchase,  GMP  capability,  and  availability  of  growth  condition  
information.  The  Thermo  Fisher  ExpiSf™  system  has  the  largest  maximum  cell  density  at  
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20×10 6   cells/mL  using  a  specialized  line  of  Sf-9  cells  [38].  Other  versions  from  Thermo  Fisher,  
such  as  the  Sf-900 TM   II  SFM  and  Sf-900 TM   III  SFM,  have  cell  densities  that  were  also  decent  
(~10×10 6   cells/mL).  Beyond  Thermo  Fisher,  Expression  Systems  have  ESF  921 TM   media  with  
purported  maximum  cell  densities  of  15×10 6   cells/mL  [39][40][41].  However,  certain  
bioprocessing  companies,  such  as  Oxford  Expressions  Technologies,  warn  that  while  cell  
densities  greater  than  10 7   are  certainly  possible  to  achieve,  they  are  also  harder  to  sustain  for  
growth  cycles  [42].  A  study  of  Thermo  Fisher’s  ExpiSf™  line  even  found  that  optimal  cell  
density  was  actually  closer  to  5×10 6   cells/mL  [43].  This  indicates  that  maximum  cell  density  
above  10 6   is  less  significant  than  cell  density  below  that  threshold.  Regarding  the  available  scale  
for  purchase,  only  ExpiSf™  was  not  sold  at  industrial  scale,  whereas  other  media  types  had  
custom  orders  at  sizes  up  to  ten  thousands  of  liters  (see  brochure  from  Thermo  Fisher  Scientific  
on  the  Sf-900 TM   III  SFM  [40]).  Most  media  appeared  to  meet  the  GMP  standards,  one  from  
Oxford  Expressions  Technology  was  not  produced  at  GMP  levels,  disqualifying  this  media  from 
our  selection  [44].  The  choice  ultimately  came  down  to  Sf-900 TM  II,  Sf-900 TM   III  SFM,  or  ESF  
921 TM .  Due  to  the  wider  availability  of  research  papers  on  Sf-900 TM  II  SFM,  this  media  was  
chosen  to  ensure  our  process  modeling  would  be  as  accurate  as  possible.  
  
10.2.5  Adjuvant  
Since  proteins  do  not  induce  an  adequate  immune  response  on  their  own,  a  saponin-based  
adjuvant  is  necessary  to  enhance  the  response  for  a  protein-based  vaccine.  While  the  addition  of  
an  adjuvant  is  outside  the  scope  of  our  project,  adjuvants  are  necessary  for  the  final  product.  
Saponins  produce  high  antibody  titers  and  better  responses  for  T-independent  antigens  and  CD8+  
T  cells  [45].  They  also  promote  both  humoral  and  cellular  immunity,  both  of  which  are  required  
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to  control  viral  infections,  making  saponins  ideal  for  use  in  subunit  vaccines  [46].  The  Matrix  
M1™  saponin-based  adjuvant  in  the  Novavax  SARS-CoV-2  recombinant  protein  vaccine  
induced  neutralizing  antibodies  to  both  SARS  and  MERS  spike  proteins  more  effectively  than  
alum  adjuvant  [47].  ISCOM ™   and  ISCOMATRIX ™   saponin-based  adjuvants  were  more  
immunogenic  than  liposome  and  protein  micelle  systems  [46].  Saponins  were  safe  and  potent  in  
intranasal  influenza  HA  vaccines  [46].  They  also  have  a  wide  range  of  biological  properties,  such  
as  anti-inflammatory  and  antimicrobial  activity  [48].  However,  Quillaja  saponins  have  shown  
haemolytic  activity  [48],  toxicity,  and  aqueous  instability,  which  are  properties  that  have  limited  
their  usage  as  vaccine  adjuvants  [46].  In  light  of  these  issues,  other  plant-derived  saponin  
candidates  have  been  investigated  with  promising  results  [46][49].  Additionally,  while  the  use  of  
adjuvants  elicits  side  effects,  saponins  only  cause  minor  local  reactions,  namely  mild  to  moderate  
temporary  pain,  tenderness,  and  induration  at  the  site  of  injection  [46].  The  advantages  and  




10.3  Bioreactors  
When  assessing  the  choices  of  bioreactors  available,  we  evaluated  the  options  along  the  
size  variability,  sanitation  quality,  and  information  provided  about  the  bioreactor.  Out  of  the  
many  bioreactor  models,  the  regular  HyPerforma  series  was  chosen  for  our  project.  DynaDrive  is  
an  alternative  bioreactor  model  that  we  have  considered.  The  DynaDrive  model  comes  in  sizes  of  
50  L,  500  L,  3000  L,  and  5000  L.  Because  this  model  has  blades  that  are  more  robust,  it  can  
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support  cells  with  much  higher  oxygen  uptake  rate  through  more  intense  agitation.  However,  
since  DynaDrive  is  relatively  new,  many  CMO  companies  would  not  have  this  equipment.  
  
 
10.3.1  Sf-9  Cell  Seed  Train  Design  
Our  Sf-9  cell  seed  train  consists  of  6  stages:  (4x)  125  mL  flasks,  (4x)  500  mL  flasks,  (3x)  
5  L  flasks,  (3x)  200  L  WAVE  bioreactors,  (1x)  500  L  perfusion  bioreactor,  and  (1x)  2000  L  batch 
bioreactor.  Quadruplicates  are  formulated  for  the  125  mL  and  500  mL  flasks:  one  of  them  is  used  
for  baculovirus  amplification,  and  the  other  three  are  prepared  in  consideration  of  possible  
damage  or  contamination  to  a  sample  during  manual  inoculation  in  between  stages.  Triplicates  
are  not  needed  for  the  500  L  perfusion  bioreactor  and  2000  L  production  bioreactor,  since  the  
content  is  transferred  through  sterile  tube  welders  that  prevent  the  occurrence  of  contamination.  
The  working  volume  is  scaled  up  by  10-fold  to  reduce  the  number  of  stages  required,  thereby  
reducing  the  capital  cost  of  equipment.  The  scale  up  from  the  500  L  perfusion  bioreactor  to  the  
2000  L  batch  bioreactor  is  only  4-fold,  since  the  2000  L  bioreactor  is  large  enough  to  produce  
sufficient  amount  of  protein.  
Figure  10.3.1.  Overview  of  the  Sf-9  Seed  Train  Design.  Sf-9  cells  are  grown  from  a  master  cell  bank  and  scaled  up  
from  flasks  to  bioreactors.  
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Approximately  4  million  cells  are  grown  to  around  16  trillion  cells  to  produce  3.75  kg  of  
spike  protein,  which  accounts  for  the  30%  yield  loss  in  the  downstream  process.  Media  is  
pre-filled  up  to  the  maximum  working  volume  minus  the  inoculum  volume  for  all  stages  except  
the  125  mL  flasks  with  a  50  mL  working  volume  and  the  200  L  WAVE  bioreactors  with  a  50  L  
working  volume.  The  headspace  in  the  bioreactors  allows  for  the  addition  of  materials  such  as  
glucose,  base,  and  antifoam  as  well  as  the  transfer  of  oxygen  and  carbon  dioxide  at  the  liquid-gas  
interface.  The  total  amount  of  media  required  for  the  growth  stages  is  2800  L,  and  the  total  
amount  of  media  required  for  the  production  stage  is  1500  L.  The  extra  volume  of  media  
required  for  the  500  L  perfusion  bioreactor  was  calculated  by  using  the  ratio  between  the  number  
of  cells  to  the  amount  of  media  in  the  previous  stage.  
During  the  growth  and  production  stages,  the  cells  consume  oxygen  and  produce  carbon  
dioxide,  which  could  then  react  with  water  to  produce  carbonic  acid  and  drop  the  pH  level.  To  
maintain  the  optimum  pH  of  6.3,  sodium  hydroxide  is  added  as  base  if  the  pH  becomes  too  low.  
Oxygen,  glucose,  and  glutamine  are  added  to  provide  nutrients  for  the  cells,  air  is  added  to  strip  
carbon  dioxide,  and  antifoam  is  added  to  prevent  foaming.  The  time  required  for  the  growth  
stages  is  around  19  days,  and  the  time  required  for  the  production  stage  is  5  days,  totaling  an  
estimate  of  24  days  for  the  upstream  process.  
  
10.3.2  Multiplicity  of  Infection  
Multiplicity  of  Infection  (MOI)  refers  to  the  number  of  virions  added  per  cell  during  the  
infection  stage.  An  MOI  value  greater  than  1  is  considered  high  while  an  MOI  value  smaller  than  
1  is  considered  low.  For  our  project,  we  will  use  a  MOI  value  of  0.01,  which  is  on  the  lower  end.  
A  low  MOI  value  has  several  advantages  in  that  smaller  volumes  of  virus  stock  can  be  purchased  
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and  fewer  virus  amplification  steps  are  required  [50],  reducing  the  operating  costs  significantly.  
However,  using  a  low  MOI  value  leads  to  a  two-stage  infection  process  where  not  all  cells  are  
infected  immediately  after  virus  addition.  Thus,  we  assumed  that  5  days  of  infection  phase  would  
be  sufficient  for  one  virion  to  infect  100  cells,  as  suggested  by  our  project  author  Dr.  Cohen.  
  
10.3.3  Baculovirus  Preparation  
Live  baculovirus  preserved  in  liquid  will  be  purchased  from  Applied  Biological  Materials  
Incorporated  in  10  mL  quantities  with  densities  of  10 6   infectious  units/mL  [51].  Our  baculovirus  
preparation  consists  of  3  stages:  (2x)  250  mL  flasks,  (2x)  20  L  WAVE  bioreactors,  and  the  (1x)  
2000  L  batch  bioreactor  used  in  the  Sf-9  seed  train  detailed  above.  Duplicates  are  formulated  for  
the  250  mL  flasks  and  20  L  WAVE  bioreactors  to  account  for  possible  damage  or  contamination  
to  a  sample  during  manual  inoculation  in  between  stages.  The  2000  L  batch  bioreactor  does  not  
require  duplicates,  since  all  material  transfer  occurs  through  sterile  tube  welders  that  prevent  
contamination.  The  working  volume  is  scaled  up  100  fold  to  reduce  the  number  of  stages  
required,  thereby  reducing  the  capital  cost  of  equipment.  
Baculovirus  preparation  starts  with  a  duplicate  of  two  10  mL  virus  inoculums,  as  shown  
in  Figure  10.3.3 .  The  virus  will  first  be  grown  in  the  250  mL  flasks  and  subsequently  propagated  
through  viral  infection  in  the  20  L  WAVE  bioreactors  before  transfer  to  the  production  
bioreactor.  As  previously  mentioned,  we  will  use  an  MOI  value  of  0.01  at  each  stage  to  scale  up  
from  approximately  20  million  viral  infectious  units  to  200  billion  infectious  units  for  the  2000  L  
batch  bioreactor  to  produce  the  required  3.75  kg  of  protein.  A  working  volume  of  200  mL  
(including  inoculum)  will  be  used  for  the  250  mL  shake  flasks,  and  a  working  volume  of  20  L  
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will  be  used  for  the  WAVE  bioreactors.  For  information  on  the  2000  L  bioreactor,  refer  to  the  
Sf-9  cell  seed  train  (Section  10.3.1)  above.  
During  the  infection  of  cells  with  baculovirus,  cell  growth  is  not  likely  to  occur,  as  the  
virus  will  take  over  cellular  machinery  for  replication  and  prevent  cell  growth.  The  WAVE  
bioreactors  will  require  air  to  provide  oxygen  delivery  and  carbon  dioxide  stripping  for  the  cells.  
No  fresh  media  is  required  for  the  baculovirus  amplification,  since  media  will  all  come  from  the  
Sf-9  cell  seed  train.  Total  time  required  for  baculovirus  amplification,  before  the  2000  L  
bioreactor  stage,  is  about  11  days.  
  
Figure  10.3.3.  Overview  of  the  Baculovirus  Amplification  Process.  Recombinant  baculovirus  is  amplified  from  a  
master  bank  and  scaled  up  from  flasks  to  bioreactors.  
  
  
10.4  Membrane  Filtration  
Membrane  processes  are  filtration  systems  that  are  scaled  by  stacking  multiple  cartridges  
in  parallel.  They  are  adaptable  to  disposable  formats,  which  eliminate  the  risk  of  contamination  
and  the  need  for  cleaning  validation  between  runs.  Recovery  yields  are  frequently  above  90%  
[52].  The  filters  are  asymmetric,  meaning  larger  pores  are  on  the  entry  side  and  smaller  pores  are  
on  the  exit  side  for  efficient  filtration  [53].  Depth  filtration  and  tangential  flow  diafiltration  are  
employed  in  the  clarification,  purification,  and  polishing  processes.  Dead-end  disposable  depth  
filters  efficiently  retain  larger  cell  debris,  bacteria,  and  some  viral  particles,  allowing  for  the  
smaller  spike  protein  to  pass  through  the  membranes  [53].  Diafiltration  separates  the  spike  
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protein  in  the  retentate  from  smaller  solutes,  such  as  salts  and  sugars  in  the  permeate.  Fresh  
diafiltration  buffer  is  continuously  added  at  the  same  rate  of  permeate  removal,  thus  the  tank  
volume  remains  constant  throughout  the  process.  Diafiltration  is  run  in  a  tangential  flow  
configuration  to  minimize  plugging  for  more  efficient  filtration.  Equation  {1}  was  used  to  
determine  the  membrane  area  required,  assuming  no  salt  is  rejected  by  the  membrane  [54].  
n ­  l cscs0 = V
Qt {1}  
where V =  volume  of  solution  being  desalted  (L)  
c s =  concentration  of  salt  in  volume  V  (g/L)  
c s0 =  initial  concentration  of  salt  (g/L)  
Q =  filtration  rate  (L/hr)  
t  =  time  required  for  diafiltration  (hr)  
  
  
10.5  Chromatography  Columns  
Chromatography  columns  are  packed  with  specialized  resins  to  selectively  isolate  the  
protein  of  interest.  In  order  to  design  the  chromatography  columns,  the  type  of  resin-protein  
interactions,  the  specific  resin  to  be  used,  the  amount  of  resin,  the  sizing  of  the  column,  the  
buffer  volumes,  the  flow  rates,  and  the  process  times  were  selected  or  calculated.  An  affinity  
chromatography  column  plus  an  ion-exchange  chromatography  column  was  the  most  commonly  
used  combination  in  literature  [55].  Use  of  a  gel  filtration  (size-exclusion  chromatography)  
column  was  rejected  because  of  the  additional  yield  losses  it  would  cause  [55].  
For  the  affinity  chromatography  column,  immobilized  metal-affinity  chromatography  
(IMAC),  otherwise  known  as  his-tag  chromatography,  appeared  to  be  relatively  inexpensive  for  
affinity  resins  that  typically  experience  high  costs,  and  the  histidine  residue  seemed  well  adapted  
for  insertion  into  a  recombinant  protein  [56].  For  IMAC  resins,  there  are  two  broad  categories:  
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cobalt-based  resins  and  nickel-based  resins.  The  cobalt  resins  have  higher  binding  specificity,  but  
the  nickel  resins  have  higher  binding  capacity,  meaning  more  protein   binds  to  the  resin  [57].  
Because  purity  is  prioritized  in  pharmaceutical  manufacturing,  cobalt-based  resins  are  a  better  
choice  for  IMAC  resins.  The  Cobalt  Superflow  Agarose  resin,  specifically,  was  selected  because  
of  its  high  binding  capacity  and  optimal  flow  rate.  
The  two  categories  of  ion-exchange  chromatography  resins  are  cation  exchange  resins  
and  anion  exchange  resins.  From  research,  anion-exchange  resins  had  superior  binding  capacity  
and  higher  percent  recovery  than  cation-exchange  resin  for  certain  products,  so  anion-exchange  
resins  were  chosen  [58].  The  Poros  XQ  resin,  in  particular,  was  selected  because  of  its  high  
binding  capacity  and  endurance  across  pH  ranges.  
Having  determined  the  type  of  resins,  the  dynamic  binding  capacity  was  used  to  estimate  
the  total  amount  of  resin  needed.  The  approximate  amount  of  protein  that  needed  to  be  bound  at  
each  stage  was  calculated  using  percent  recovery  yields  of  downstream  units  from  literature  
sources.  The  total  amount  of  resin  required  for  the  chromatography  columns  was  then  calculated  
using  Equation  {2} .  
 PDBC = R         {2}  
where P =  total  amount  of  protein  needed  to  be  bound  (mg)  
DBC =  dynamic  binding  capacity  (mg/mL)  
R =  amount  of  resin  required  (mL) 
DBC  specifies  the  mass  of  protein  that  can  be  bound  to  a  volumetric  quantity  of  resin.  
Based  upon  the  amount  of  resin  required,  the  number  of  reuses  available  per  resin,  and  the  
economics  of  the  system,  conducting  5  runs  per  cycle  for  the  IMAC  resins  and  just  1  run  for  the  
ion-exchange  resins  was  reasonable.  To  calculate  the  total  amount  of  resin  required,  the  number  




N = R′      {3}  
where R =  amount  of  total  resin  required  (mL)  
N =  number  of  cycles  
R’ =  volumetric  amount  of  resin  required  per  cycle  (mL)  
Next,  the  chromatography  columns  were  sized.  Based  on  the  advice  of  consultant  Dr.  
Stijn  Koshari,  the  packed-bed  heights  were  kept  around  250  cm,  the  diameters  were  calculated  to  
fit  R’ ,  and  then  the  nearest  sized  columns  from  Millipore  and  Cytiva  were  identified.  By  
recycling  resin  over  multiple  cycles,  both  resin  amount  and  column  size  could  be  cut  down.  
Buffer  volumes  for  chromatography  columns  are  predominantly  dependent  on  column 
volume,  typically  from  5  to  10  column  volumes  of  buffer.  Once  column  volumes  were  obtained,  
the  required  amounts  of  buffer  for  the  two  chromatography  processes  were  calculated.  
With  column  volumes  determined,  process  flow  times  for  the  chromatography  columns  
could  also  be  calculated.  Using  the  linear  flow  rate  and  column  diameter  provided  by  the  vendor,  
the  volumetric  flow  rate  could  be  calculated.  
For  the  IMAC  resins,  the  recommended  linear  flow  of  150  cm/hr  was  used  for  stages  that  
include  recombinant  protein,  which  is  squarely  in  the  recommended  operational  range.  For  stages  
that  exclude  the  protein,  a  doubled  flow  rate  of  300  cm/hr  was  used,  which  is  at  the  maximal  
recommended  operation  range.  
For  the  ion  exchange  resins,  a  recommended  linear  flow  rate  of  300  cm/hr  was  used.  The  
pressure  drop  at  this  linear  flow  rate  is  less  than  3  bar,  which  keeps  the  operation  within  the  safe  
operational  range.  
Using  the  volumetric  flow  rates  described  above,  the  necessary  process  time  for  the  two  
chromatography  stages  was  calculated  with  Equations  {4}  and  {5} .  Again,  the  buffer  volume  
required  was  column  volume  dependent,  whereas  the  amount  of  protein  extract  flowing  through  
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was  resin  dependent.  For  the  IMAC  chromatography,  where  the  resin  was  used  over  5  cycles,  the 
protein  extract  was  brought  over  in  installments  of  ⅕  at  a  time.  







          {4}  




v protein extract        {5}  
where v x =  volume  of  buffer  or  protein  extract  (L)  
v x ’ =  volumetric  flow  rate  of  buffer  or  protein  extract  (L/hr)  
t =  time  to  flow  through  
N =  number  of  cycles  
There  is  one  key  difference  in  calculations  between  the  IMAC  and  ion-exchange  resins.  
For  the  IMAC  resins,  where  multiple  cycles  occurred,  we  accounted  for  the  per-cycle  cleaning  
time  because  the  column  had  to  be  regenerated  each  cycle.  For  the  ion-exchange  resins,  where  
only  one  run  is  required,  the  cleaning  time  could  be  ignored,  since  cleaning  could  be  done  later  
in  parallel  with  other  parts  of  the  downstream  process.  
  
  
10.6  Downstream  Process  Alternatives  
10.6.1  Cell  Lysis  
Cell  lysis  is  a  process  that  involves  breaking  open  the  insect  cells  to  obtain  intracellular  
protein  content  for  further  purification.  There  are  many  cell  lysis  techniques,  including  both  
chemical  and  physical  mechanisms.  However,  the  baculovirus  has  genes  (chitinase  and  
v-cathepsin)  that  encode  for  proteins  involved  in  early  cell  lysis  and  death  [36].  Specifically,  the  
cells  will  lyse  3  to  4  days  post-infection.  For  many  situations,  early  lysis  is  undesirable  and  its  
genome  is  altered  in  order  to  delay  lysis  [36].  However,  based  on  the  designed  seed  train,  cell  
lysis  would  have  occurred  by  the  5th  day  post-infection.  Therefore,  cell  lysis  is  not  a  necessary  
37  
  
step  of  our  downstream  process.  We  assume  that  100%  of  the  cells  will  be  lysed  by  the  time  we  
begin  our  downstream  process  and  protein  purification.  
  
10.6.2  Centrifugation  
Historically,  the  first  phase  of  downstream  processes  included  Liquid-Liquid  Extraction  
(LLE),  centrifugation  and  microfiltration,  but  membrane-filtration  technologies  are  far  more  used  
nowadays  [59].  Ultracentrifugation  has  been  commonly  used  in  the  past,  but  it  is  highly  
inefficient  in  that  combination  of  ultracentrifugation,  and  size  exclusion  chromatography  can  
only  obtain  up  to  75%  recovery  [60],  which  is  far  below  desired  percent  recovery  for  a  clinical  
grade  product  [59].  Also,  ultracentrifugation  is  time-consuming  and  labor  intensive  ,  with  poor  
reproducibility  and  limited  scalability  [59][60].  
Centrifugation  is  recommended  as  the  first  step  in  the  downstream  process  only  if  cell  
density  is  high.  High  cell  density  generally  refers  to  VCD  greater  than  10  million  cells  /  mL,  but  
the  VCD  for  our  harvest  batch  is  8  million  cells  /  mL.  Since  our  cell  density  is  low,  centrifuging  
to  get  rid  of  the  cell  debris  pellet  is  inefficient.  Therefore,  centrifugation  was  not  implemented  in  
our  downstream  process  design.  
  
  
10.7  Plant  Locations  
China,  India,  South  Korea,  and  the  United  States  were  considered  for  manufacturing  
before  deciding  on  the  United  States.  Consultation  with  Dr.  Alex  Marchut  provided  the  following  
insights.  First,  companies  have  become  more  wary  of  arranging  manufacturing  in  China,  as  its  
government  has  swiftly  changed  policies  in  the  past  that  have  caused  many  CMOs  to  shut  down.  
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India  and  South  Korea  have  more  lenient  governments,  thus  companies  are  more  open  to  
working  with  CMOs  in  these  countries.  Finally,  reshoring  in  the  United  States  has  become  more  
popular,  especially  during  the  pandemic,  and  trends  have  shown  manufacturing  shifting  to  the  
Southeastern  region.  
None  of  the  required  manufacturing  equipment,  materials,  utilities,  or  labor  requirements  
are  geographically  restricting.  Thus,  the  location  of  the  manufacturing  facility  was  completely 
dependent  on  the  location  of  the  plant(s)  operated  by  the  CMO  approached.  Dr.  Cohen  noted  that  
BioGen  is  a  favorite  choice  for  CMO,  which  heavily  motivated  our  selection  of  the  company.  
BioGen  has  two  facilities  dedicated  to  pharmaceutical  operations  and  technology:  one  in  North  
Carolina  and  the  other  in  Switzerland.  The  plant  in  North  Carolina  utilizes  single-use  technology  
that  replaces  the  traditional  stainless  steel  systems,  which  aligns  with  much  of  our  upstream  and  
downstream  processes  [61].  Single-use  technology  eliminates  contamination  risk  and  cleaning  
validation  required  by  traditional  stainless  steel  equipment,  and  it  also  allows  for  more  process  
flexibility,  which  has  made  it  such  a  popular  choice  in  the  biopharmaceutical  industry.  
Additionally,  the  plant  is  located  in  the  Southeastern  region  of  the  US,  as  recommended  by  Dr.  
Marchut.  These  factors  made  the  BioGen  facility  in  North  Carolina  a  suitable  choice  as  the  plant  
location.   
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11.  Assembly  of  Database  
11.1  Cell  Bank  
A  cell  bank  containing  1  mL  of  cell  stock  in  2  mL  vials  is  at  a  temperature  of  -80˚C  [62].  
Glycerol  or  DMSO  is  included  in  the  cell  stock  as  antifreeze  to  protect  cells  from  low  
temperatures.  An  important  precaution  is  that  the  population  of  cells  in  each  cell  bank  vial  has  
some  amount  of  uncertainty  and  variability.  Cell  bank  inoculum  with  50  million  cells  per  vial  is  
available  for  purchase  online.  
  
  
11.2  Cell  Growth  Conditions  
11.2.1  pH  
The  optimum  pH  for  Sf-9  cells  in  both  growth  and  infection  phases  is  between  6.2  and  
6.4  [63].  Therefore,  the  pH  control  and  deadband  for  all  stages  of  the  upstream  process  are  set  at  
6.3  and  0.2,  respectively.  
  
11.2.2  Temperature  
The  optimum  temperature  for  Sf-9  cells  in  terms  of  both  growth  rate  and  viable  cell  
density  (VCD)  is  around  27˚C  [64]  and  28˚C  [66].  Growth  rate  decreases  gradually  with  
temperature,  and  is  significantly  lower  at  25˚C.  VCD  decreases  at  30˚C  [65].  For  the  production  
phase,  recombinant  proteins  are  similarly  expressed  at  22˚C,  25˚C,  and  27˚C.  Although  total  
protein  yields  are  similar  in  all  three  temperatures,  lower  temperature  causes  cells  to  get  infected  
at  a  slower  rate.  Thus,  the  temperature  control  and  deadband  for  growth  stages  are  set  at  27.5˚C  
40  
  
and  1.0˚C,  respectively,  and  those  for  the  production  stage  are  set  at  26.0˚C  and  2.0˚C,  
respectively.  
  
11.2.3  Dissolved  Carbon  Dioxide  
The  optimum  dissolved  CO 2   level  for  Sf-9  cell  growth  is  between  0  to  37  mmHg  CO 2   
[67].  For  our  project,  the  dissolved  CO 2   level  is  set  at  30  mmHg  for  the  bioreactors  in  growth  and  
production  stages.  
  
11.2.4  Nutrients  
The  carbon  source  and  nitrogen  source  used  for  Sf-cells  are  glucose  and  glutamine,  
respectively.  Since  prepared  media  transfer  through  sterile  filters  to  fill  flasks  and  bioreactors,  
the  nutrients  inside  prepared  media  must  be  fully  dissolved.  Hence,  glutamine  is  used  as  the  
nitrogen  source  because  it  is  fully  soluble  in  water,  compared  to  the  commonly  used  yeast  extract  
that  is  not  fully  soluble  in  water.  
  
11.2.5  Base  
The  base  used  to  control  the  pH  level  for  our  bioreactors  is  1  M  sodium  hydroxide.  The  
amount  of  base  used  in  our  project  is  based  on  a  test  by  Thermo  Fisher  Scientific,  where  27  mL  
of  0.1  M  sodium  hydroxide  was  used  as  base  for  its  5  L  HyPerforma®  rocking  bioreactor  [68].  
  
11.2.6  Antifoam  
The  antifoam  used  to  prevent  foaming  is  in  an  emulsion  form.  Since  the  foam  covers  the  
cell  surface  and  may  affect  cell  growth  and  metabolism,  the  use  of  antifoam  minimizes  the  
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amount  of  foam  present.  However,  since  antifoam  cannot  differentiate  between  cell  surface,  wall  
surface,  and  liquid  surface,  using  too  much  antifoam  can  decrease  the  interfacial  surface  energy  
of  cells  and  thereby  slow  down  cell  metabolism.  Thus,  the  amount  of  antifoam  used  in  our  
project  is  0.3%  of  total  volume  for  each  bioreactor  [69].  
  
11.2.7  Osmolality  
One  of  the  advantages  of  insect  cells  over  mammalian  cells  is  that  insect  cells  are  less  
sensitive  to  increase  in  osmolality  than  mammalian  cells  [37].  The  osmolality  for  Sf-9  cells  is  
adjusted  between  360  and  380  mOsm/kg  using  NaCl  [65].  
  
11.2.8  Shear  Stress  
Agitation  Rate  
In  order  to  maintain  a  growth  rate  of  at  least  0.032  hr -1 ,  the  shear  stress  should  be  kept  to  
less  than  1  N/m 2  [70].  Agitation  rate  of  250  RPM  negatively  impacted  cell  growth  due  to  high  
shear  stress,  whereas  agitation  rates  of  50  RPM  and  100  RPM  did  not  [63].  
Aeration  Rate  
Aeration  rate  must  also  be  monitored  to  ensure  that  the  specific  growth  rate  does  not  
decrease.  Specifically,  data  suggests  that  if  agitation  rate  is  operating  at  200  RPM,  the  aeration  
rate  must  be  kept  below  0.04  vvm  (volume  air  per  volume  liquid  per  minute)  to  maintain  the  
maximum  specific  growth  rate  [70].  
Bubble  Diameter  
Bubble  diameter  is  also  crucial  to  monitor  because  bubbles  can  cause  cells  to  rupture.  
When  the  bubble  diameter  is  too  small,  the  specific  death  rate  increases.  Figure  11.1  below  
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depicts  the  effect  of  bubble  diameter  on  death  rate  of  Sf-9  cells  when  sparged  at  a  gas  flow  rate  
of  10  mL/min  [70].  The  optimal  bubble  diameter  should  be  greater  than  0.2  cm,  which  can  be  
controlled  by  the  sparger.  
  
  
Figure  11.1 .  Specific  Sf-9  Cell  Death  Rate  vs.  Gas  Bubble  Diameter  [70].  As  the  bubble  diameter  of  the  entering  gas  
increases,  the  specific  death  rate  of  Sf-9  insect  cells  in  the  column  decreases.  
  
  
11.3  Cell  Growth  Kinetics  
Rhiel  et  al.  [71]  cultivated  Sf-9  cells  in  Sf-900™  II  SFM  at  a  temperature  of  27°C  and  a  
pH  between  6.30  and  6.32.  Sf-9  cells  grown  in  Sf-900™  II  SFM,  represented  by  the  hollow  
circles  in  Figure  11.2 ,  had  a  growth  rate  of  0.033  hr -1   and  a  doubling  time  of  21  hr,  reaching  a  




Figure  11.2 .  Viable  Insect  Cell  Density  vs.  Time  in  Culture  [71].  As  insect  cells  are  grown  in  suspension,  the  viable  
cell  density  increases,  peaks,  then  decreases.  The  growth  kinetics  are  dependent  on  the  medium  used.  
  
  
11.4  Cell  Metabolic  Rates  
11.4.1  Oxygen  Consumption  
Cells  were  grown  in  65%  O 2   concentration  and  were  infected  at  50%  O 2   concentration.  
Studies,  overall,  seemed  to  indicate  that  cells  were  not  so  affected  by  variations  in  environmental  
oxygen  concentration,  as  long  as  the  oxygen  concentration  stayed  above  10%  and  was  less  than  
110%  for  the  growth  phase  [72].  Optimally,  cells  are  to  be  grown  between  40%  and  70%  O 2 ,  but  
deleterious  effects  were  not  seen  when  O 2   concentration  slightly  deviated  from  this  range  [73].  
Studies  also  indicated  that  while  cell  oxygen  consumption  during  the  infection  phase  does  
increase  to  as  much  as  1.3  times  the  rate  of  consumption  during  growth  phase  [74],  the  optimal  
oxygen  concentration  for  the  infection  phase  is,  paradoxically,  slightly  less  at  around  50%  [75].  
The  specific  oxygen  uptake  rate  (sOUR)  is  around  0.22  to  0.26  µM  O 2 /10 6   cell/hr  during  the  
growth  phase  [63]  and  0.2  to  0.76  µM/10 6   cell/hr  for  the  infection  phase  [37].  For  the  infection  
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phase,  the  high  end  value  of  sOUR  is  more  reasonable  due  to  the  increase  in  oxygen  
consumption  during  infection.  
  
11.4.2  Carbon  Dioxide  Production  
The  specific  carbon  dioxide  production  rate  (qCO 2 )  for  uninfected  Sf-9  cells  is  between  
2.6  and  7.4  mmol/10 9   cells/day,  and  that  for  virus-infected  Sf-9  cells  increases  to  10.3  mmol/10 9   
cells/day  [76].  
  
11.4.3  Respiratory  Quotient  
Respiratory  Quotient  (RQ)  is  the  ratio  of  carbon  dioxide  produced  by  the  cells  to  oxygen  
consumed  by  the  cells.  The  RQ  for  uninfected  Sf-9  cells  is  1.07  ±  0.06,  and  that  for  
virus-infected  Sf-9  cells  is  1.12  ±  0.03  [76].  
  
11.4.4  Metabolic  Consumption  and  Production  
Insect  cells  consume  glucose  and  glutamine  while  producing  lactate  and  ammonia  as  part  
of  their  metabolic  process.  Rhiel  et  al.  [71]  cultivated  Sf-9  cells  in  Sf-900™   II  SFM  at  a  
temperature  of  27°C  and  a  pH  between  6.30  and  6.32.  Under  these  conditions,  the  cells  
consumed  2.4×10 -17   and  1.7×10 -17   moles  of  glucose  per  cell  per  second  in  the  growth  phase  and  
infection  phase,  respectively.  The  cells  consumed  1.7×10 -17   and  0.5×10 -17   moles  of  glutamine  per  
cell  per  second  in  the  growth  phase  and  infection  phase,  respectively.  The  lactate  and  ammonia  




11.4.5  Protein  Production  
Sf-9  cells  in  TNM-FH  medium  produce  on  average  230  µg  of  protein  per  10 6   cells  over  
the  course  of  5  days  [77].  Since  data  on  protein  production  in  Sf-900™   II  SFM  could  not  be  
obtained,  we  assumed  the  cells  would  behave  similarly  in  the  media  and  would  thereby  produce  
the  same  amount  of  protein  per  million  cells.  
  
  
11.5  Protein  Stability  Concerns  
11.5.1  Temperature  
The  spike  protein  must  be  kept  in  a  certain  temperature  and  pH  range  to  ensure  that  it  
does  not  denature.  When  the  temperature  is  above  40˚C,  the  RBD  will  begin  to  adapt  to  a  closed  
conformation  [78].  Fortunately,  the  S1  and  S2  domains  proved  stable  at  temperature  conditions  
ranging  from  10˚C  to  50˚C,  so  there  are  little  temperature  stability  concerns.  
  
11.5.2  pH  
A  study  on  the  ability  of  the  spike  protein  to  bind  to  the  ACE2  receptor  at  different  pH  
levels  found  that  stability  was  maintained  at  pH  levels  above  5.5  [79].  The  spike  protein  will  thus  
be  inactive  at  low  pH  levels.  However,  the  protein  folding  is  only  temporary,  and  stability  is  
regained  when  the  pH  is  increased.  
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Figure  12.1.  Process  Flow  Diagram  for  the  Upstream  Process  (Section  1)   
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Table  12.1.  Material  Balance  for  Upstream  Process  (Section  1)  
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Upstream  (Section  1)  
  S-101a/b/c/d  S-102a/b/c/d  S-103a/b/c  S-104a/b/c  S-105    
Temperature  (˚C)  27.5 27.5 27.5 27.5 27.5   
Pressure  (bar)  1.01 1.01 1.01 1.01 1.21   
Cell  Matter  (L)  0.001 0.05 0.5 5 50   
  S-106a/b/c  S-106d  S-107a/b/c/d  S-108a/b/c/d  S-109a/b/c  S-110a/b/c  
Temperature  (˚C)  27.5 27.5 27.5 27.5 27.5 27.5 
Pressure  (bar)  1.01 1.01 1.01 1.01 1.01 1.01 
Media  (L)  49.999 0.499 0.049 0.45 4.5 45 
  S-111  S-112a/b/c  S-113  S-114  S-115a/b/c    
Temperature  (˚C)  25 25 27.5 27.5 27.5   
Pressure  (bar)  1.21 1.21 1.01 1.21 1.01   
Cell  Matter  (L)  - - 0.36 39.6 -   
Air  (kg)  33 11 - - 11   
  S-116b  S-116c  S-116d        
Temperature  (˚C)  27.5 27.5 27.5       
Pressure  (bar)  1.01 1.01 1.01       
Cell  Matter  (L)  50 10.4 0.14       
  
  
Figure  12.2.  Process  Flow  Diagram  for  the  Upstream  Process  (Baculovirus  Preparation)  
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Table  12.2.  Material  Balance  for  Upstream  Process  (Baculovirus  Preparation)  
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Upstream  (Baculovirus  Preparation)  
  S-113  S-114  S-201a/b  S-202a/b  S-203  S-204  
Temperature  (˚C)  27.5 27.5 27.5 27.5 27.5 27.5 
Pressure  (bar)  1.01 1.21 1.01 1.01 1.11 1.11 
Baculovirus  Matter  (L)  - - 0.02 0.2 20 20 
Cell  Matter  (L)  0.36 39.6 - - - - 
  S-205a/b  S-206a/b  S-207  S-208a/b  S-209a/b  S-210  
Temperature  (˚C)  27.5 27.5 25 25 27.5 27.5 
Pressure  (bar)  1.01 1.21 1.11 1.11 1.01 1.01 
Baculovirus  Matter  (L)  - - - - - 20 
Cell  Matter  (L)  0.18 19.8 - - - - 
Air  (kg)  - - 4.4 2.2 2.2 - 
  
  
Figure  12.3.  Process  Flow  Diagram  for  the  Upstream  Process  (Section  2)  
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Table  12.3.  Material  Balance  for  Upstream  Process  (Section  2)  
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Upstream  (Section  2)  
  S-105  S-204  S-301  S-302  S-303  S-304  
Temperature  (˚C)  27.5 27.5 27.5 27.5 27.5 26 
Pressure  (bar)  1.21 1.11 1.36 1.04 1.54 1.04 
Cell  Matter  (L)  50 - 50 500 500 - 
Baculovirus  Matter  (L) - 20 - - - - 
Protein  Extract  (L)  - - - - - 2000 
Protein  (kg)  - - - - - 3.75 
  S-305a/306a  S-305b/306b  S-305c  S-307a  S-307b    
Temperature  (˚C)  27.5 26 27.5 25 25   
Pressure  (bar)  1.01 1.01 1.01 2.16 2.23   
Media  (L)  450 1472.9 2190.4 - -   
Air  (kg)  - - - 229.6 1377.6   
  S-308a  S-308b  S-309a/310a  S-309b/310b  S-311a/312a  S-311b/312b  
Temperature  (˚C)  25 25 27.5 26 27.5 26 
Pressure  (bar)  1.01 1.01 1.01 1.01 1.01 1.01 
Oxygen  (kg)  82.4  (50%  O2) 61.8  (100%  O2) - - - - 
Glucose  (kg)  - - 30.5 21.6 - - 
Glutamine  (kg)  - - - - 11.3 5.15 
  S-313a/314a  S-313b/314b  S-315a/316a  S-315b/316b  S-317    
Temperature  (˚C)  27.5 26 27.5 26 27.5   
Pressure  (bar)  1.01 1.01 1.01 1.01 1.34   
Base  (L)  1.5 1.1 - - -   
Antifoam  (L) - - 8.1 6 -   
Baculovirus  Matter  (L) - - - - 20   
  S-318  S-319  S-320  S-321  S-322  S-323  
Temperature  (˚C)  27.5 27.5 4.44 27.5 4.44 26 
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Pressure  (bar)  1.04 1.04 1.01 1.01 1.01 1.01 
Media  (L)  2200 2200 - - - - 
Chilled  Water  (kg)  - - 2964.1 2964.1 3314 3314 
  S-324  S-325  S-326        
Temperature  (˚C)  27.5 26 27.5       
Pressure  (bar)  1.01 1.01 1.01       
Air  (kg)  229.6 1377.6 -       
Oxygen  (kg)  74.4  (50%  O2) 55.8  (100%  O2) -       
Carbon  Dioxide  (kg)  23.6 17.7 -       
Media  (L)  - - 2200       
  
  
Figure  12.4 .  Process  Flow  Diagram  for  the  Downstream  Process  
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Table  12.4.  Material  Balance  for  Downstream  Process  
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Downstream              
  S-304  S-401  S-402  S-403  S-404  S-405  
Temperature  (˚C)  26 26 25 25 25 25 
Pressure  (bar)  1.04 3.14 1.04 1.04 2.03 1.04 
Protein  (kg)  3.75 3.75 3.38 3.38 3.38 3.04 
Protein  Extract  (L)  2000 2000 2366 2366 2366 1257 
  S-406  S-407  S-408  S-409  S-410  S-411  
Temperature  (˚C)  25 25 25 25 25 25 
Pressure  (bar)  1.04 3.44 3.44 1.04 1.04 3.14 
Protein  (kg)  3.04 3.04 2.98 2.68 2.68 2.68 
Protein  Extract  (L)  1353 1353 1353 370.4 370.4 370.4 
  S-412  S-413  S-414  S-415  S-416  S-417  
Temperature  (˚C)  25 25 25 25 25 25 
Pressure  (bar)  1.04 1.04 1.28 1.01 1.09 1.01 
Protein  (kg)  2.63 2.63 2.63 2.60 2.60 2.60 
Protein  Extract  (L)  395.9 395.9 395.9 401.7 401.7 204.7 
  S-418  S-419  S-420  S-421  S-422  S-423  
Temperature  (˚C)  25 25 25 25 25 25 
Pressure  (bar)  3.11 2.99 1.04 3.41 3.11 1.25 
Depth  Filtration  Wetting  Buffer  
(L)  458.5 - - - - - 
Depth  Filtration  Flushing  Buffer  
(L)  458.5 - - - - - 
His-Tag  Equilibration  Buffer  (L)  - 1257 - - - - 
His-Tag  Wash  Buffer  (L)  - 2513 - - - - 
His-Tag  Elution  Buffer  (L)  - 1257 - - - - 
His-Tag  Regeneration  Buffer  (L)  - 1257 - - - - 
His-Tag  Water  Buffer  (L)  - 1257 - - - - 
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Viral  Inactivation  Acid  (L)  - - 31.4 - - - 
Viral  Inactivation  Base  (L)  - - 65.3 - - - 
IEX  Equilibration  Buffer  (L)  - - - 265 - - 
IEX  Elution  Buffer  (L)  - - - 307 - - 
IEX  Equilibration  Wash  Buffer  (L) - - - 159 - - 
IEX  NaCl  Buffer  (L)  - - - 265 -  
IEX  Ultrapure  Water  (L)  - - - 529 - - 
IEX  Acetic  Acid  Wash  (L)  - - - 265 - - 
Viral  Filtration  Wetting  Buffer  (L)  - - - - 26 - 
Viral  Filtration  Flushing  Buffer  (L) - - - - 26 - 
Diafiltration  Base  Buffer  (L)  - - - - - 68 
Diafiltration  Salt  Buffer  (L)  - - - - - 2048 
  S-424  S-425  S-426  S-427  S-428    
Temperature  (˚C)  25 25 25 25 25   
Pressure  (bar)  1.01 1.01 1.01 1.01 1.01   
Protein  (kg)  0.37 0.34 0.3 0.05 0.03   
Waste  (L)  344 8650 2835 26 2110   
  
  
Figure  12.5.  Gantt  Chart  for  a  Single  Upstream  Process  Run.  The  blue  marks  the  Sf-9  cell  seed  train  while  the  red  marks  the  baculovirus  amplification.  
  
Figure  12.5  shows  that  the  upstream  process  is  anticipated  to  take  24  days  in  total,  with  parallel  processes  of  the  baculovirus  
and  Sf-9  cell  scale-up  occurring  simultaneously  over  days  9  through  19.  Scale-up  procedure  from  one  stage  to  another  typically  takes  




Time  (Days)  
Day  1  2  3  4  5  6  7  8  9  10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 
125  mL  Flask  (Sf-9)                                                              
250  mL  Flask  (BV)                                                              
500  mL  Flask  (Sf-9)                                                              
5  L  Flask  (Sf-9)                                                              
20  L  Wave  (BV)                                                              
50  L  Wave  (Sf-9)                                                              
N-1  Bioreactor                                                              
N  Bioreactor                                                              
  
  
Figure  12.6.  Gantt  Chart  for  a  Single  Downstream  Process  Run.  
  
In  contrast,  the  downstream  process  is  significantly  shorter  than  the  upstream  process.  Figure  12.6  shows  that  the  downstream  
process  is  expected  to  take  about  three  days  to  complete  (66  hours).  The  majority  of  this  time,  hours  3  to  45,  is  taken  up  by  the  his-tag  
chromatography  process,  which  requires  5  runs  to  complete  the  process.  The  cleaning  time  added  between  each  cycle,  as  well  as  the  
low  flow  rates  required  to  operate  the  column  effectively,  combine  to  make  the  his-tag  chromatography  process  much  longer  than  the  




Time  (Hours)  
Hour  1  2  3  4  5  6  7  8  9  10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 
Depth  Filtration                                                                          
HT  Chromatography                                                                         
Viral  Inactivation                                                                          
IEX  Chromatography                                                                         
Viral  Filtration                                                                          
Dia iltration                                                                          
Hour  37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 
Depth  Filtration                                                                          
HT  Chromatography                                                                         
Viral  Inactivation                                                                          
IEX  Chromatography                                                                         
Viral  Filtration                                                                          
Dia iltration                                                                          
  
  
Figure  12.7 .  Gantt  chart  for  multiple  upstream  and  downstream  process  runs.  
  
Overall,  the  entire  upstream  and  downstream  process  takes  about  27  days  to  complete.  While  we  propose  completing  this  cycle  
once  for  our  project,  in  the  event  that  repeated  cycles  are  desired  or  necessary,  we  suggest  that  18  days  in  between  cycles  should  be  
sufficient  time  to  clean  equipment  and  account  for  manufacturing  problems  in  the  prior  process.  As  shown  in  Figure  12.7 ,  we  




Time  (Days)  
Day  3  6  9  12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60 63 66 69 72 75 78 81 84 87 90 
Upstream  1                                                              
Downstream  1                                                              
Upstream  2                                                              
Downstream  2                                                              
Upstream  3                                                              
Downstream  3                                                              
Upstream  4                                                              
Downstream  4                                                              
  
13.  Process  Description  
13.1.  Upstream  Process  
13.1.1  Sf-9  Cell  Seed  Train  
Cell  Bank  to  Flasks  
At  the  start  of  the  seed  train,  four  frozen  aliquots  all  with  the  same  specified  viable  cell  
density  are  taken  out  of  a  cell  bank.  These  frozen  aliquots  are  each  incubated  at  27.5˚C  and  
inoculated  into  the  four  125  mL  flasks  with  working  volumes  of  50  mL.  After  5.2  days  of  growth  
in  the  125  mL  flasks,  the  contents  are  then  each  inoculated  into  the  500  mL  flasks.  The  cells  are  
grown  in  each  flask  at  27.5˚C  on  a  shaker  table.  
  
Flasks  to  WAVE  Bioreactor  
After  3  days  of  growth  in  the  500  mL  flasks  at  27.5˚C,  cell  content  in  one  of  the  500  mL  
flasks  is  sent  to  the  baculovirus  preparation  line  for  virus  amplification.  Cell  content  in  the  other  
three  flasks  are  sent  to  the  5  L  flasks  for  another  3  days  of  growth,  after  which  the  contents  are  
each  inoculated  into  the  three  200  L  WAVE  bioreactors  with  working  volumes  of  50  L.  The  
rocking  motion  of  WAVE  bioreactors  allows  efficient  mixing,  carbon  dioxide  stripping,  and  
oxygen  transfer  to  the  cells  for  optimal  growth.  
  
WAVE  Bioreactor  to  Perfusion  Bioreactor  
After  3  days  of  growth  in  the  200  L  WAVE  bioreactors  at  27.5°C,  cell  content  in  one  of  
the  WAVE  bioreactors  is  sent  to  the  baculovirus  preparation  line  for  further  virus  amplification,  
and  cell  content  with  the  healthiest  growth  in  a  different  WAVE  bioreactor  is  inoculated  to  the  
500  L  perfusion  bioreactor.  The  500  L  perfusion  bioreactor  is  different  from  regular  batch  
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bioreactors  in  that  the  perfusion  system  allows  for  much  higher  viable  cell  density  than  normal  
by  constantly  feeding  fresh  medium  while  removing  used  medium.  
  
Perfusion  Bioreactor  to  Production  Bioreactor  
After  5  days  of  growth  in  the  500  L  perfusion  bioreactor  at  27.5˚C,  the  content  is  finally  
transferred  to  the  2000  L  batch  bioreactor  at  26.0˚C  and  infected  with  baculovirus  at  a  MOI  
value  of  0.01  for  protein  production.  Once  the  content  of  the  perfusion  bioreactor  is  inoculated  
into  the  2000  L  bioreactor,  the  viable  cell  density  is  already  at  its  maximum.  Thus,  cells  are  in  
the  stationary  phase,  spending  energy  only  for  protein  production  and  not  for  additional  growth.  
After  5  days  of  production  in  the  2000  L  bioreactor,  the  content  is  transferred  to  the  downstream  
process.  
  
13.1.2  Baculovirus  Amplification  
Cell  Bank  to  Flasks  
After  3  days  of  Sf-9  cell  growth  in  the  500  mL  shake  flasks  at  27.5˚C,  180  mL  of  cell  
culture  is  sent  to  both  250  mL  shake  flasks  for  infection  with  baculovirus.  The  cell  cultures  in  
each  shake  flask  will  be  infected  with  20  mL  of  purchased  baculovirus  at  an  MOI  value  of  0.01.  
Baculovirus  will  be  incubated  in  the  cell  culture  for  6  days  at  27.5˚C  on  a  shaker  table.  
  
Flasks  to  WAVE  Bioreactor  
After  6  days  of  growth  in  the  250  mL  shake  flasks  at  27.5˚C,  lysed  cells  and  virus  will  be  
transferred  to  the  20  L  WAVE  bioreactors  and  amplified  there  starting  with  an  MOI  of  0.01.  
Then,  18  L  of  grown  cell  culture  will  be  taken  from  a  50  L  WAVE  bioreactor  as  described  above  
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and  will  be  provided  for  viral  infection.  Baculovirus  will  be  incubated  by  infecting  the  cell  
culture  and  amplified  for  5  days.  
  
WAVE  Bioreactor  to  Production  Bioreactor  
After  5  days  of  growth  in  the  20  L  WAVE  bioreactor  at  27.5˚C,  the  incubated  baculovirus  
will  be  pumped  into  the  2000  L  production  bioreactor  where  it  will  infect  the  cells  and  produce  
proteins.  Protein  will  be  produced  in  the  earlier  baculovirus  scale-up  phases  as  well  but  in  
marginal  quantities.  Once  again,  the  MOI  will  be  0.01  and  the  incubation  period  will  be  5  days  
before  transfer  to  the  downstream  process.  
  
  
13.2  Downstream  Process  
13.2.1  Depth  Filtration  
Depth  filtration  is  the  first  step  in  our  downstream  process.  The  cells  have  already  lysed  
on  their  own  before  entering  the  depth  filters,  so  protein  of  interest  is  extracellular.  Depth  
filtration  is  efficient  in  that  it  is  much  more  easier  to  develop  than  an  intricate  tangential-flow  
filtration  system.  Also,  single-use  disposable  depth  filters  are  economical,  since  the  process  is  
not  run  for  multiple  times.  Fouling  is  not  an  issue  because  our  cell  density  is  low  at  8  million  
cells  /  mL.  By  using  a  series  of  filters  with  large  pore  size  followed  by  filters  with  small  pore  
size,  depth  filtration  is  able  to  filter  out  large  cell  debris,  bacteria,  and  some  viruses.  The  percent  
recovery  of  depth  filtration  step  is  approximately  90%.  The  supernatant  is  sent  to  the  his-tag  




13.2.2  His-tag  Chromatography  
After  the  supernatant  leaves  the  depth  filter,  it  will  flow  through  the  His-tag  
chromatography  column.  The  chromatography  column  works  by  binding  specifically  to  the  
genetically  engineered  his-residues  added  to  the  protein,  allowing  everything  else  to  flow  
through.  This  step  will  be  the  most  capital  and  time  intensive  step  of  the  downstream  process.  
The  packed  column  will  be  equilibrated  before  material  flows  through.  In  the  affinity  stage,  there  
will  be  five  runs  total,  so  only  one  fifth  of  the  total  amount  of  supernatant  will  flow  through  
during  each  run.  Once  the  supernatant  flows  through,  the  column  will  be  washed  and  then  eluted.  
The  eluate  will  be  sent  to  the  viral  inactivation  phase  for  the  next  process.  The  flow  rate  will  be  
189  L/hr  for  the  loading,  washing,  and  elution  stages,  and  377  L/hr  for  the  cleaning  and  
regeneration  stages.  Dr.  Stjin  Koshari  advised  using  a  slower  flow  rate  for  the  loading,  washing,  
and  elution  stages  to  avoid  protein  loss.  The  process  will  be  repeated  4  times.  We  estimate  total  
run  time  will  be  about  2  days  and  each  run  will  take  about  9  hours  including  washing.  Yield  is  
anticipated  to  be  about  90%  with  purity  of  around  95%.  
  
13.2.3  Viral  Inactivation  
Viral  inactivation  is  necessary  in  order  to  denature  the  virus  while  keeping  the  protein  
intact.  This  is  commonly  done  using  low  pH,  specifically  a  pH  of  3.5.  The  Cadence  Virus  
Inactivation  System  by  Pall  was  highly  considered,  as  it  is  a  fully  automated  system  that  lowers  
the  pH  using  a  continual  elution  stream  and  then  brings  the  pH  back  up  to  around  8.  However,  
Dr.  Koshari  recommended  doing  this  manually,  as  the  cost  for  the  system  is  not  worth  it.  Thus,  
we  will  be  inactivating  our  virus  in  the  ThermoFisher  HyPerforma  Single  Use  2000  L  Mixer.  The  
mixer  will  also  have  a  jacket  in  order  to  monitor  and  maintain  an  appropriate  temperature.  In  
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order  to  bring  the  pH  down  to  3.5,  about  2.5%  of  the  original  volume  of  1M  Acetic  acid  should  
be  added.  In  order  to  bring  the  pH  back  up,  5.2%  of  the  original  volume  of  1M  Tris  base  should  
be  added  [80].  Directly  following  this  step,  sterile  membrane  filtration  will  ensue  and  result  in  a  
98%  yield.  
  
13.2.4  Ion  Exchange  Chromatography  
Once  material  is  finished  with  the  viral  inactivation  phase,  it  will  flow  through  the  ion  
exchange  chromatography  column.  The  chromatography  column  will  be  pre-packed  and  
equilibrated  before  this  run.  Material  will  flow  through  at  289  L/hr  and  a  pH  above  7.24  to  
ensure  the  protein,  in  its  anionic  form  binds  to  the  anion-exchange  resins.  Once  the  protein  
extract  has  been  loaded  in  the  column,  the  column  pH  will  be  steadily  decreased  to  the  protein’s  
isoelectric  point  at  6.24  using  a  pH  gradient  elution  buffer  to  release  the  protein.  The  eluate  will  
be  sent  on  to  the  viral  filtration  stage  and  the  column  will  be  cleaned  during  that  stage.We  
estimate  that  total  process  time  without  cleaning  (as  that  can  be  done  in  parallel)  is  7  hours  with  
expected  yield  of  90%  and  purity  of  85%.  
  
13.2.5  Viral  Filtration  
Viral  filtration  step  is  required  to  make  sure  that  viral  clearance  of  the  final  product  is  
greater  than  log  reduction  value  (LRV)  of  6.  Filters  with  very  precise  pores  are  used,  and  a  
pre-filter  is  used  beforehand  to  prevent  fouling  and  clogging  in  the  actual  filter.  Depth  filters  are  
preferred  over  sterile  membrane  filters,  since  depth  filters  can  contain  more  particulates,  clog  
less,  and  have  charge  characteristics  that  can  bind  additional  DNA  and  host  cell  proteins.  The  
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percent  recovery  of  viral  filtration  step  is  approximately  98%.  The  protein  solution  is  sent  to  the  
diafiltration  step  for  final  purification.  
  
13.2.6.  Diafiltration  
Any  small  particles  that  are  not  filtered  out  in  the  viral  filtration  enter  as  feed  in  the  
diafiltration  process.  Membrane  cassettes  will  be  used  to  retain  and  recirculate  the  Spike  protein  
while  filtering  out  any  smaller  solutes,  such  as  any  small  salts  and  sugars.  A  tangential  flow  
filtration  configuration  will  be  used  to  minimize  clogging  of  the  membranes.  A  diafiltration  
buffer  will  be  added  to  the  feed  tank  at  the  same  rate  as  the  permeate  leaves  to  maintain  a  
constant  volume  in  the  feed  tank.  This  buffer  exchange  will  ensure  the  stability  of  the  Spike  
protein  for  shipping.  The  final  buffer  displacement  recovers  99.3%  of  the  protein  [81]  and  has  a  
99.3%  reduction  in  salt,  assuming  no  protein  goes  through  the  membrane  and  that  no  salts  are  
rejected.  We  do  not  need  to  concentrate  our  Spike  protein  because  our  final  protein  concentration  
of  6.5  g/L  is  considered  low  for  industry.  Our  final  drug  product  will  contain  Spike  protein  in  an  
appropriate  diafiltration  buffer,  which  will  be  packaged  and  shipped  in  bulk  for  formulation 
elsewhere.  
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14.  Energy  Balance  and  Utility  Requirements  
14.1  Upstream  Energy  Balance 
The  number  of  cells  in  each  cell  culture  vessel  was  calculated  by  multiplying  the  working  
volume  with  the  peak  viable  cell  density.  Then,  the  heat  generated  by  cells  was  calculated  by  
multiplying  the  number  of  cells  with  peak  specific  enthalpy  of  reaction.  Suggested  by  our  project  
author,  the  peak  specific  enthalpy  of  reaction  for  Sf-9  cells  was  assumed  to  be  40  pW/cell.  Table  
14.1  shows  the  energy  requirements  for  the  upstream  process.  
Table  14.1.  Upstream  Energy  Balance  
  
  
14.2  Process  Energy  Usage  
Since  the  cell  growth  and  metabolism  are  low  due  to  slow  oxygen  uptake  of  Sf-9  cells,  
low  gas  flow  rates  are  sufficient,  which  results  in  very  small  power  requirement  and  total  work  
per  run  for  the  air  compressors  in  general.  Power  requirement  and  total  work  per  run  is  generally  
very  small  for  peristaltic  pumps  as  well,  since  high  liquid  flow  rates  are  not  used  in  
pharmaceutical  processes  and  transport.  Table  14.2  shows  the  energy  requirements  for  each  
process.   
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Equipment  Heat  Generated  by  Cells  (W)  
Impeller  
Power  (W) 
Heat  Duty  of  Associated  
Cooling  Jacket  (W)  
125  mL  Erlenmeyer  Shake  Flask  0.01  -  -  
250  mL  Erlenmeyer  Shake  Flask  0.04  -  -  
500  mL  Erlenmeyer  Shake  Flask  0.11  -  -  
5  L  Erlenmeyer  Shake  Flask  1.16  -  -  
WAVE  Bioreactor  System  20/50EH  4.98  -  -  
WAVE  Bioreactor  System  200EH  12.44  -  -  
500  L  Perfusion  Bioreactor  652  10  662  
2000  L  Production  Bioreactor  652  40  692  
  
Table  14.2.  Process  Energy  Usage 
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Equipment  Power  Requirement Operation  Time Work  per  Run 
Upstream  
WAVE™  Bioreactor  System  20/50EH  0.69  kW  5  days  82.8  kWh  
WAVE™  Bioreactor  System  200EH  3.6  kW  3  days  259.2  kWh  
500  L  Perfusion  Bioreactor  2.4  kW  5  days  288  kWh  
2000  L  Production  Bioreactor  2.4  kW  5  days  288  kWh  
Downstream 
2000  L  Single-Use  Mixer  2.5  kW  4  hrs  10  kWh  
Diafiltration  Assembly  4.4  kW  7  hrs  30.8  kWh  
Transport  
Air  Compressor  
(for  WAVE  Brx  20/50EH)  0.12  W  5  days  14.94  Wh  
Air  Compressor  
(for  WAVE  Brx  200EH)  1.84  W  3  days  132.62  Wh  
Air  Compressor  
(for  500  L  Perfusion  Brx)  35.64  W  5  days  4277.33  Wh  
Air  Compressor  
(for  2000  L  Production  Brx)  224.46  W  5  days  26934.68  Wh  
Upstream  Peristaltic  Pump  
(BV  WAVE  to  N  Brx)  0.50  W  15  mins  0.12  Wh  
Upstream  Peristaltic  Pump  
(Sf-9  WAVE  to  N-1  Brx)  0.42  W  30  mins  0.21  Wh  
Upstream  Peristaltic  Pump  
(N-1  Brx  to  N  Brx)  6.26  W  30  mins  3.13  Wh  
Downstream  Peristaltic  Pump  
(for  Depth  Filtration)  15.66  W  2  hrs  31.32  Wh  
Downstream  Peristaltic  Pump  
(for  His-tag  Column)  0.97  W  2  days  46.53  Wh  
Downstream  Peristaltic  Pump  
(for  IEX  Column)  0.97  W  7  hrs  6.79  Wh  
Downstream  Peristaltic  Pump  
(for  Viral  Filtration)  0.54  W  3  hrs  1.61  Wh  
Downstream  Peristaltic  Pump  
(for  Diafiltration  in)  2.24  W  30  mins  1.12  Wh  
Downstream  Peristaltic  Pump  
(for  Diafiltration  out)  2.76  W  30  mins  1.38  Wh  
Storage  
200  L  Media  Vessel  1.5  kW  25  days  900  kWh  
2000  L  Media  Vessel  2.5  kW  25  days  1500  kWh  
3000  L  Media  Vessel  2.5  kW  25  days  1500  kWh  
100  L  Glucose  Vessel  0.75  kW  10  days  180  kWh  
500  L  Glutamine  Vessel  1.5  kW  10  days  360  kWh  
  
14.3  Electricity  Use  
Electricity  use  was  calculated  not  based  on  the  power  requirement,  but  based  on  the  
maximum  power  as  a  conservative  method  to  estimate  the  upper  limit  of  total  electricity.  Table  
14.3  shows  the  electricity  requirements  for  each  process.  
Table  14.3.  Electricity  Use  
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Equipment  Maximum  Power  (kW)  
Operation  
Time  
Electricity  per  Run  
(kWh)  
Upstream  
WAVE™  Bioreactor  System  20/50EH  0.69  5  days  82.8  
WAVE™  Bioreactor  System  200EH  3.6  3  days  259.2  
500  L  Perfusion  Bioreactor  2.4  5  days  288.0  
2000  L  Production  Bioreactor  2.4  5  days  288.0  
Downstream 
2000  L  Single-Use  Mixer  2.5  4  hrs  10.0  
Diafiltration  Assembly  4.4  7  hrs  30.8  
Transport  
Air  Compressor  
(for  WAVE  Brx  20/50EH)  0.516  5  days  61.9  
Air  Compressor  
(for  WAVE  Brx  200EH)  0.516  3  days  37.2  
Air  Compressor  
(for  500  L  Perfusion  Brx)  0.516  5  days  61.9  
Air  Compressor  
(for  2000  L  Production  Brx)  1.128  5  days  135.4  
Upstream  Peristaltic  Pump  
(BV  WAVE  to  N  Brx)  0.656  15  mins  0.2  
Upstream  Peristaltic  Pump  
(Sf-9  WAVE  to  N-1  Brx)  0.656  30  mins  0.3  
Upstream  Peristaltic  Pump  
(N-1  Brx  to  N  Brx)  0.656  30  mins  0.3  
Downstream  Peristaltic  Pump  
(for  Depth  Filtration)  0.656  2  hrs  1.3  
Downstream  Peristaltic  Pump  
(for  His-tag  Column)  0.656  2  days  31.5  
Downstream  Peristaltic  Pump  
(for  IEX  Column)  0.656  7  hrs  4.6  
Downstream  Peristaltic  Pump  
(for  Viral  Filtration)  0.656  3  hrs  2.0  
Downstream  Peristaltic  Pump  
(for  Diafiltration  in)  0.656  30  mins  0.3  
  
  
14.4  Other  Utilities  
Table  14.4  shows  the  chilled  and  purified  water  requirements  by  process.   
Table  14.4.  Other  Utilities  
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Downstream  Peristaltic  Pump  
(for  Diafiltration  out)  0.656  30  mins  0.3  
Storage  
200  L  Media  Vessel  1.5  25  days  900.0  
2000  L  Media  Vessel  2.5  25  days  1500.0  
3000  L  Media  Vessel  2.5  25  days  1500.0  
100  L  Glucose  Vessel  0.75  10  days  180.0  
500  L  Glutamine  Vessel  1.5  10  days  360.0  
Equipment  Utility  Usage  Amount  per  Run  
Upstream  
500  L  Perfusion  Bioreactor  Chilled  Water,  40˚F  Coolant  2964.1  kg  
2000  L  Production  Bioreactor  Chilled  Water,  40˚F  Coolant  3314.0  kg  
Downstream 
Depth  Filtration  Purified  Water,  25˚C  Buffer  917  L  
His-Tag  Chromatography  Purified  Water,  25˚C  Buffer  7555  L  
Ion-Exchange  Chromatography  Purified  Water,  25˚C  Buffer  1023  L  
Viral  Filtration  Purified  Water,  25˚C  Buffer  26  L  
Diafiltration  Purified  Water,  25˚C  Buffer  2116  L  
Diafiltration  Chilled  Water,  40˚F  Coolant  996.0  kg  
Storage  
100  L  Glucose  Vessel  Purified  Water,  25˚C  Diluent  82.4  L  
100  L  Glutamine  Vessel  Purified  Water,  25˚C  Diluent  484.3  L  
  
15.  Equipment  List  and  Unit  Descriptions  
15.1  Feed  Materials  
15.1.1  Biological/Chemical  Laboratory  Facility  
In  order  to  manually  inoculate  cells  from  one  flask  to  another,  a  biohood  is  required  to  
carry  out  sterile  pipetting.  A  shaker  table  that  is  covered  in  a  hood  at  27.5˚C  is  needed  for  cells  to  
be  well-mixed  in  the  flasks.  Cost  analysis  was  done  not  based  on  the  individual  biohood  and  
shaker  table,  but  based  on  the  entire  biological/chemical  lab  facility.  Assuming  roughly  5%  of  
the  total  capital  and  operating  costs,  the  biological/chemical  lab  cost  is  approximately  $270,623.  
  
15.1.2  Air  Compressors  
Air  compressor  AC-101  is  used  to  provide  air  from  the  surrounding  environment  for  the  
three  WAVE  Bioreactor  200EH  over  3  days.  Air  flow  is  needed  to  ensure  sufficient  oxygen  
content  for  cell  growth  as  well  as  stripping  CO 2   from  the  system.  Air  at  6  standard  liters  per  
minute  (SLPM)  will  be  compressed  to  5.01  LPM  and  divided  equally  among  the  three  
bioreactors.  Pressure  will  increase  from  1.01  bar  to  1.21  bar.  The  system  will  require  0.00247  hp  
to  operate  at  the  desired  rate.  The  purchase  cost  is  approximately  $1212.50.  
Air  compressor  AC-201  is  used  to  provide  air  from  the  surrounding  environment   for  the  
two  WAVE  Bioreactor  20/50EH  over  5  days.  Air  flow  is  needed  to  ensure  sufficient  oxygen  
content  for  cell  growth  as  well  as  stripping  CO 2   from  the  system.  Air  at  0.8  SLPM  will  be  
compressed  to  0.72  LPM  and  divided  equally  among  the  two  bioreactors.  Pressure  will  increase  
from  1.01  bar  to  1.11  bar.  The  system  will  require  0.000167  hp  to  operate  at  the  desired  rate.  The  
purchase  cost  is  approximately  $1212.50.  
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Air  compressor  AC-301  is  used  in  this  step  to  provide  air  from  the  surrounding  
environment  for  the  500  L  Perfusion  Bioreactor  over  5  days.  Air  flow  is  needed  to  help  ensure  
sufficient  oxygen  content  (along  with  the  50%  oxygen  supply)  for  cell  growth  as  well  as  
stripping  CO 2   from  the  system.  Air  at  25  SLPM  will  be  compressed  to  11.69  LPM  before  
entering  the  perfusion  bioreactor.  Pressure  will  increase  from  1.01  bar  to  2.16  bar.  The  system  
will  require  0.0478  hp  to  operate  at  the  desired  rate.  The  purchase  cost  is  approximately  
$1212.50.  
Air  compressor  AC-302  is  used  in  this  step  to  provide  air  from  the  surrounding  
environment  for  the  2000  L  production  bioreactor  over  5  days.  Air  flow  is  needed  to  help  ensure  
sufficient  oxygen  content  (along  with  the  100%  oxygen  supply)  for  cell  growth  as  well  as  
stripping  CO 2   from  the  system.  Air  at  150  SLPM  will  be  compressed  to  67.94  LPM  before  
entering  the  production  bioreactor.  Pressure  will  increase  from  1.01  bar  to  2.23  bar.  The  system  
will  require  0.301  hp  to  operate  at  the  desired  rate.  The  purchase  cost  is  approximately  $1095.92.  
  
15.1.3  Sterile  Filters  
A  sterile  filter  is  a  crucial  piece  of  equipment  used  to  purify  liquid  media  before  it  enters  
the  sterile  environment  of  a  bioreactor.  In  order  to  ensure  sterility,  liquid  filters  need  to  have  
nominal  pore  size  of  less  than  1  micron,  since  microorganisms  are  typically  greater  than  1  
micron.  All  the  sterile  filters  used  in  our  process  have  a  0.8/0.2  µm  double  pore  size,  stepped  
barb  attachments,  no  associated  energy  cost,  and  expected  purchase  price  of  $152.60  each.  The  





Sterile  filter  SF-101a,  SF-101b,  and  SF-101c  are  used  to  purify  fresh  liquid  media  for  the  
Sf-9  seed  trains  (50  mL,  500  mL,  5  L,  50  L)  coming  from  the  main  media  tank  used  in  
the  Sf-9  cell  culture  scale-up.  The  filters  process  50  L  of  media  total.  
  
Sterile  filter  SF-101d  is  used  to  purify  fresh  liquid  media  for  the  fourth  Sf-9  seed  train  (50  
mL,  500  mL)  coming  from  the  main  media  tank  used  in  the  Sf-9  cell  culture  scale-up.  
This  sterile  filter  processes  500  mL  of  media  total.  
  
Sterile  filter  SF-201  is  used  to  purify  fresh  liquid  media  emerging  from  the  20/50EH  
WAVE  bioreactor  of  the  baculovirus  scale-up  process  that  is  heading  towards  the  
production  bioreactor.  This  sterile  filter  processes  20  L  of  media  total.  
  
Sterile  filter  SF-301  is  used  to  purify  fresh  liquid  media  entering  the  500  L,  N-1  perfusion 
bioreactor.  This  sterile  filter  processes  450  L  of  media  total.  Note  that  no  additional  
sterile  filter  is  provided  for  the  media  entering  the  perfusion  system  itself  as  the  perfusion  
system  contains  its  own  liquid  filter.  
  
Sterile  filter  SF-302  is  used  to  purify  fresh  liquid  media  entering  the  2000  L  production 
bioreactor.  This  sterile  filter  processes  1473  L  of  media  total.  
  
Sterile  filter  SF-303  is  used  to  purify  fresh  glucose  entering  the  500  L,  N-1  perfusion  




Sterile  filter  SF-304  is  used  to  purify  fresh  glutamine  entering  the  500  L,  N-1  perfusion  
bioreactor.  This  sterile  filter  processes  11.3  kg  of  aqueous  glutamine  total.   
  
Sterile  filter  SF-305  is  used  to  purify  fresh  base  media  entering  the  500  L,  N-1  perfusion  
bioreactor.  This  sterile  filter  processes  1.5  L  of  media  total.   
  
Sterile  filter  SF-306  is  used  to  purify  fresh  antifoam  entering  the  500  L,  N-1  perfusion  
bioreactor.  This  sterile  filter  processes  8.1  L  of  media  total.  
   
Sterile  filter  SF-307  is  used  to  purify  fresh  glucose  entering  the  2000  L  production  
bioreactor.  This  sterile  filter  processes  21.6  kg  of  aqueous  glucose  total.  
  
Sterile  filter  SF-308  is  used  to  purify  fresh  glutamine  entering  the  2000  L  production  
bioreactor.  This  sterile  filter  processes  5.15  kg  of  aqueous  glutamine  total.  
  
Sterile  filter  SF-309  is  used  to  purify  fresh  base  entering  the  2000  L  production 
bioreactor.  This  sterile  filter  processes  1.1  L  of  base  total.  
  
Sterile  filter  SF-310  is  used  to  purify  fresh  antifoam  entering  the  2000  L  production  




15.1.4  Media  Prep  Vessels  
The  media  prep  vessels  are  crucial  features  in  providing  storage  for  the  media  until  it  can 
be  used  in  the  shake  flasks  and  bioreactors.  While  the  stainless  steel  media  and  its  storage  vessel  
must  be  clean,  they  are  not  inherently  sterile,  which  is  why  sterile  filters  are  used  for  all  material  
emerging  from  the  storage  tank.  The  storage  vessels  also  have  small  energy  requirements  
originating  from  monitors  and  mixers  present  within  the  system.  
  
The  200  L  media  storage  tank  (M-101)  is  used  to  hold  media  for  all  the  Sf-9  seed  trains  in  
the  initial  scaleup  phase  (50  mL,  500  mL,  5  L,  and  50  L).  It  has  an  energy  requirement  of  
2.01  hp.  It  will  hold  about  151  L  of  media,  and  200  L  is  the  standard  production  size.  The  
purchasing  cost  is  $4000.00.  
  
The  3000  L  storage  tank  (M-301)  is  used  to  hold  all  the  media  required  for  the  500  L,  
N-1  perfusion  bioreactor  combined  with  its  perfusion  system.  It  has  an  energy  
requirement  of  3.4  hp.  It  will  hold  about  2650  L  of  media,  and  3000  L  is  the  standard  
production  size  for  that  quantity.  The  purchasing  cost  is  about  $12,421.00.  
  
The  2000  L  storage  tank  (M-302)  is  used  to  hold  all  the  media  required  for  the  2000  L  
production  bioreactor.  It  has  an  energy  requirement  of  3.4  hp.  It  will  hold  about  1473  L  of  
media,  and  2000  L  is  the  standard  production  size  for  that  quantity.  The  purchasing  cost  




15.1.5  Oxygen  Tanks  
Oxygen  transfer  is  a  crucial  determinant  of  cell  growth  in  the  bioreactors.  As  bioreactors  
increase  in  size,  oxygen  transfer  through  diffusion  from  the  atmosphere  is  no  longer  sufficient,  
requiring  the  specific  addition  of  concentrated  oxygen  into  the  bioreactor.  Oxygen  tanks  provide  
that  extra  oxygen  supply  to  the  bioreactor.  The  oxygen  tanks  don’t  have  energy  requirements.  
Oxygen  will  be  purchased  in  large  quantities  for  the  entire  system  at  a  total  cost  of  $7186.60  
including  the  tanks  to  hold  it.  Oxygen  will  come  in  both  50%  and  100%  concentrations  to  
accommodate  the  needs  of  each  bioreactor.  No  added  filtration  will  be  required  for  the  oxygen  as  
air  filters  are  built  into  the  bioreactors.  
  
Oxygen  tank  (O-301)  provides  82.4  kg  of  50%  oxygen  supply  to  the  perfusion  bioreactor.  
The  oxygen  will  first  be  compressed  before  entering  the  bioreactor.   
  
Oxygen  tank  (O-302)  provides  61.8  kg  of  100%  oxygen  supply  to  the  perfusion  
bioreactor.  The  oxygen  will  first  be  compressed  before  entering  the  bioreactor.   
  
15.1.6  Glucose  Vessel  
Glucose  is  a  critical  nutrient  used  by  Sf-9  cells  for  cell  metabolism.  While  in  low  cell  
concentrations  and  in  small  volumes  the  Sf-900  II  SFM  media  contains  sufficient  nutrients  for  
the  cells  to  grow.  At  the  larger  scale  of  the  bioreactors,  additional  nutritional  elements  are  
required  to  provide  continued  fuel  for  cell  metabolism  and  production.  The  stainless  steel  
glucose  vessel  (GC-301)  used  to  hold  the  glucose  will  be  100  L  and  contain  75  kg  of  glucose  
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solubilized  in  purified  water.  The  glucose  vessel  has  a  mixer  and  other  electrical  implements  that  
require  about  1  hp  of  electricity.  The  vessel  has  a  purchase  cost  of  $2000.00.  
  
15.1.7  Glutamine  Vessel   
In  addition  to  glucose,  glutamine  is  another  crucial  metabolite  for  cell  growth  and  will  be  
contained  in  the  stainless  steel  500  L  vessel  (GT-301)  to  provide  glutamine  to  the  perfusion  and  
production  bioreactor.  The  vessel  will  carry  20  kg  of  glutamine  solubilized  in  purified  water.  
This  glucose  vessel  has  a  mixer  and  other  electrical  implements  that  require  about  2  hp  of  
electricity  to  operate.  The  vessel  has  a  purchase  cost  of  $3000.00.  
  
15.1.8  Base  Container   
Base  is  a  necessary  component  used  to  counteract  the  acidity  of  the  CO 2   produced  by  the  
Sf-9  cells  in  the  perfusion  and  production  bioreactor.  At  high  levels  of  CO 2   production  in  the  
perfusion  and  production  bioreactor,  the  pH  will  drop  and  cell  growth  can  be  stunted.  Base  can  
be  added  to  increase  the  pH  to  optimal  value.  As  the  volume  of  the  base  required  is  small,  no  
additional  tank  is  needed  beyond  the  4  L  container  (B-301),  in  which  the  base  is  purchased.  A  
total  of  2.6  L  will  actually  be  used  of  this  total  amount.  No  energy  requirements  are  associated  
with  this  container,  and  the  purchase  cost  of  this  amount  of  base  is  $105.45.  
  
15.1.9  Antifoam  Vessel   
As  cell  growth,  mixing,  and  sparging  of  gas  occur  in  the  bioreactors,  a  risk  of  foam  
forming  at  the  top  of  the  perfusion  or  production  bioreactor  is  a  distinct  possibility.  As  the  foam  
collapses,  it  can  create  pressure  waves  that  are  harmful  to  the  cells  in  the  bioreactor.  In  order  to  
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prevent  this,  anti-foam  is  added  and  will  be  stored  in  (AF-301).  The  vessel  itself  is  20  L,  which  is  
more  than  sufficient  to  store  the  required  14.1  L  of  antifoam  needed  for  the  system.  The  antifoam  
vessel  has  no  associated  energy  requirement  and  has  a  purchase  cost  of  $269.90.  
  
  
15.2  Upstream  Processes  
15.2.1  Erlenmeyer  Shake  Flasks  
Erlenmeyer  shake  flasks  are  generally  made  of  plastic  or  glass  material  and  have  either  
baffled  or  plain  bottom.  For  our  project,  we  chose  polycarbonate  flasks  that  have  been  sterilized  
in  advance  by  gamma  radiation.  Although  baffled  types  have  depressions  in  the  wall  that  allow  
better  oxygen  supply,  plain  types  were  chosen  for  our  purposes  because  the  growth  rate  of  Sf-9  
cells  is  slow.  The  flasks  all  have  a  microporous  vent  lid  that  keeps  the  content  sterile  and  permits  
passage  of  gas.  Room  air  is  sufficient  for  enough  oxygen  to  flow  in  and  carbon  dioxide  to  flow  
out.  All  flasks  are  maintained  at  27.5˚C  on  a  shaker  table.  
  
The  four  125  mL  flasks  (F-101)  are  used  to  grow  Sf-9  cells  from  4.05  million  cells  to  249  
million  cells  over  5.2  days  of  batch  time.  For  these  F-101  flasks,  because  the  working  
volume  is  only  50  mL,  the  shaker  table  is  shaked  slowly  to  prevent  evaporation.  The  
purchase  cost  of  F-101  is  $15.70  each.  
  
The  four  500  mL  flasks  (F-102)  are  used  to  grow  Sf-9  cells  from  249  million  cells  to  2.68  
billion  cells  over  3  days  of  batch  time.  The  working  volume  of  the  F-102  flasks  is  500  
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mL.  Out  of  the  four  F-101  flasks,  one  of  them  is  sent  to  the  baculovirus  preparation  line  
for  virus  amplification.  The  purchase  cost  of  F-102  is  $27.10  each.  
  
The  three  5  L  flasks  (F-103)  are  used  to  grow  Sf-9  cells  from  2.68  billion  cells  to  28.9  
billion  cells  over  3  days  of  batch  time.  The  working  volume  of  the  F-103  flasks  is  5  L.  
The  purchase  cost  of  F-103  is  $166.00  each.  
  
The  two  250  mL  flasks  (F-201)  are  used  to  amplify  baculovirus  from  20  million  viruses  
to  2  billion  viruses  by  infecting  2  billion  cells  over  6  days  of  batch  time.  The  working  
volume  of  the  F-201  flasks  is  200  mL.  The  purchase  cost  of  F-201  is  $17.70  each.  
  
15.2.2  WAVE  Bioreactors  
For  the  WAVE  bioreactors,  AC-101,  AC-201,  AC-301,  and  AC-302  flow  air  through  the  
headspace  in  the  WAVE  cellbags.  Because  the  viable  cell  density  is  not  high  in  the  WAVE  
bioreactors,  air  flow  needs  to  be  slow,  otherwise  carbon  dioxide  will  be  over-stripped  by  the  fast  
air  flow.  
  
The  three  WAVE  Bioreactor  200EH  (W-101)  units  are  used  to  grow  Sf-9  cells  from  28.9  
billion  cells  to  311  billion  cells  over  3  days  of  batch  time.  The  working  volume  of  W-101  
bioreactors  is  50  L,  the  rocking  speed  is  25  rocks/min,  and  the  rocking  angle  is  8˚.  The  
aeration  rate  used  for  the  W-101  units  is  2  LPM,  as  suggested  by  the  user  guide  manual  
from  GE  Healthcare®  [82].  Out  of  the  three  W-101  units,  one  of  them  is  sent  to  the  
baculovirus  preparation  line  for  further  virus  amplification,  and  only  one  of  the  other  two  
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W-101  units  is  sent  to  the  500  L  perfusion  bioreactor  for  further  cell  growth.  The  material  
of  construction  for  the  W-101  bioreactors  is  stainless  steel,  the  maximum  electrical  power  
requirement  is  0.69  kW,  and  the  purchase  cost  is  $16,000  each.  Three  200  L  cell  culture  
bags,  which  cost  $1288.64  each,  need  to  be  purchased  for  disposable  single  usage.  
  
The  two  WAVE  Bioreactor  20/50EH  (W-201)  units  are  used  to  amplify  baculovirus  from  
2  billion  viruses  to  200  billion  viruses  by  infecting  200  billion  cells  over  5  days  of  batch  
time.  The  working  volume  of  the  W-201  bioreactors  is  20  L,  the  rocking  speed  is  20  
rocks/min,  and  the  rocking  angle  is  7˚.  The  aeration  rate  used  for  the  W-201  units  is  0.4  
LPM,  as  suggested  by  the  user  guide  manual  from  GE  Healthcare®  [82].  Out  of  the  two  
W-201  bioreactors,  only  one  of  them  is  sent  through  SF-201  to  allow  baculovirus  to  pass  
but  capture  cell  debris,  and  then  pumped  to  the  2000  L  production  bioreactor  for  infection  
and  protein  expression.  The  material  of  construction  for  the  W-201  units  is  stainless  steel,  
the  maximum  electrical  power  requirement  is  3.6  kW,  and  the  purchase  cost  is  $4,000  
each.  Two  50  L  cell  culture  bags,  which  cost  $322.16  each,  need  to  be  purchased  for  
disposable  single  usage.  
  
  
15.2.3  Perfusion  Bioreactor  and  System  
The  perfusion  bioreactor  (PBrx-301)  with  the  perfusion  system  (PS-301)  is  used  to  grow  
Sf-9  cells  from  311  billion  cells  to  16.3  trillion  cells  over  5  days  of  perfusion  time.  The  working  
volume  of  PBrx-301  is  500  L.  Liquid  media,  nutrients,  base,  and  antifoam  flow  through  
SF-6/8~11  before  entering  PBrx-301.  PS-301  has  its  own  sterile  filter  for  replenishing  2200  L  of  
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fresh  media  into  PBrx-301,  allowing  the  maximum  VCD  as  well  as  number  of  cells  to  increase  
4-fold.  PBrx-301  has  its  own  built-in  sterile  filters  for  gas  materials,  i.e.  air  and  oxygen.  
PBrx-301  is  equipped  with  one  pitched  blade  impeller  with  three  blades.  The  impeller  is  
used  mainly  for  homogenizing  temperature,  pH,  and  liquid  composition.  The  impeller  can  also  
aid  in  preventing  cells  from  settling  to  the  bottom,  but  because  the  cells  typically  sink  at  a  very  
slow  rate,  the  sparger  alone  is  usually  sufficient.  The  agitation  speed  of  the  impeller  is  101  RPM,  
which  leads  to  a  mixing  time  of  27  seconds  to  reach  95%  homogeneity,  as  shown  in  Section  25.4  
calculations.  
PBrx-301  is  also  equipped  with  a  dual  sparger-configuration  with  one  porous  frit  sparger  
and  one  drilled  hole  sparger.  Oxygen  supply  at  50%  oxygen  is  sparged  through  the  frit  sparger  at  
8  SLPM;  air  is  used  for  carbon  dioxide  stripping,  which  is  sparged  through  the  drilled  hole  
sparger  at  25  SLPM.  The  air  flow  rate  out  was  assumed  to  be  the  same  as  air  flow  rate  in  at  25  
SLPM  in  order  to  find  out  the  maximum  size  of  vent  filter  needed,  as  well  as  the  permit  for  
maximum  air  vent.  
The  heat  generated  by  Sf  cells  is  652  W  and  that  by  the  impeller  is  10  W,  which  means  
that  PBrx-301’s  cooling  jacket  (CJ-301)  needs  to  use  a  total  of  662  W  to  control  the  temperature  
to  27.5˚C.  PBrx-301  has  its  own  pH  probe  that  monitors  the  change  in  pH  level  due  to  cellular 
respiration,  and  if  the  pH  becomes  too  low,  1  M  sodium  hydroxide  is  added  as  base  to  maintain  
the  pH  level  at  6.3.  
The  material  of  construction  for  PBrx-301  is  stainless  steel,  the  maximum  electrical  
power  requirement  is  2.4  kW  The  purchase  cost  is  $91,473.39  for  PBrx-301  and  $18,560.00  for  
PS-301.  One  500  L  BioProcess  Container  (BPC),  which  costs  $4,453.99,  needs  to  be  purchased  




15.2.4  Production  Bioreactor  
The  production  bioreactor  (Brx-301)  is  used  to  express  3.75  kg  of  spike  protein  over  5  
days  of  batch  time  by  infecting  16.3  trillion  Sf-9  cells  with  200  billion  baculovirus  from  one  of  
the  two  W-201  units.  Taking  into  consideration  the  30%  yield  loss  in  the  downstream  process,  
the  amount  of  expressed  spike  protein  is  50%  more  than  what  is  needed  for  500  million  doses.  
The  working  volume  of  Brx-301  is  2000  L.  Liquid  media,  nutrients,  base,  and  antifoam  flow  
through  SF-7/12~15  before  entering  the  Brx-301.  
Brx-301  is  equipped  with  one  pitched  blade  impeller  with  three  blades  as  well,  but  with  a  
larger  size.  The  impeller  is,  again,  used  mainly  for  homogenizing  temperature,  pH,  and  liquid  
composition.  The  agitation  speed  of  the  impeller  is  75  RPM,  which  leads  to  a  mixing  time  of  36  
seconds  to  reach  95%  homogeneity,  as  shown  in  Section  25.4  calculations.  
Brx-301  is  also  equipped  with  a  dual  sparger-configuration  with  one  porous  frit  sparger  
and  one  drilled  hole  sparger.  Oxygen  supply  at  100%  oxygen  is  sparged  through  the  frit  sparger  
at  6  SLPM;  air  is  used  for  carbon  dioxide  stripping,  which  is  sparged  through  the  drilled  hole  
sparger  at  150  SLPM.  The  air  flow  rate  out  was  assumed  to  be  the  same  as  air  flow  rate  in  at  150  
SLPM  in  order  to  find  out  the  maximum  size  of  vent  filter  needed,  as  well  as  the  permit  for  
maximum  air  vent.  
The  heat  generated  by  Sf  cells  is  652  W  and  that  by  the  impeller  is  40  W,  which  means  
that  Brx-301’s  cooling  jacket  (CJ-302)  needs  to  use  a  total  of  692  W  to  control  the  temperature  to  
26˚C.  Brx-301  also  has  its  own  pH  probe  that  monitors  the  change  in  pH  level  due  to  cellular  
respiration,  and  again  if  the  pH  becomes  too  low,  1  M  sodium  hydroxide  is  added  as  base  to  
maintain  the  pH  level  at  6.3.  
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The  material  of  construction  for  Brx-301  is  stainless  steel,  the  maximum  electrical  power  
requirement  is  2.4  kW,  and  the  purchase  cost  is  $214,065.99.  One  2000  L  BPC,  which  costs  
$10,233.13,  needs  to  be  purchased  for  disposable  single  usage.  The  2000  L  BPC  has  been  
sterilized  in  advance  by  gamma  radiation.  
  
  
15.3  Downstream  Processes  
15.3.1  Depth  Filtration  
The  depth  filtration  unit  (DeF-401)  filters  out  large  cell  debris,  bacteria,  and  some  viruses  
in  feed  stream  S-401  that  comes  from  Brx-301  by  using  a  two-stage  depth  filter  train.  
Traditionally,  non-synthetic  HC  filters  have  been  used,  but  these  filters  have  leachables  that  
impact  the  product  quality.  Thus,  industries  are  leaning  towards  using  synthetic  SP  filters,  which  
have  similar  functionality  but  no  leachables.  The  26  D0SP  filters  and  13  X0SP  filters  from  
Millipore  are  used  in  our  two-stage  depth  filter  train.  The  D0SP  filters  have  a  pore  size  of  10  µm  
that  filter  out  large  sized  cell  debris,  and  the  X0SP  filters  have  a  pore  size  of  0.1  µm  that  filter  
out  bacteria  and  some  viruses.  The  size  of  our  protein  of  interest  is  around  180  to  200  kDa  
[1][83],  which  is  much  smaller  than  the  pore  size  of  X0SP  filters  and  allows  the  protein  to  pass  
through.  A  process-scale  pod  (PSP)  device  format  of  two  2-rack  holders,  which  can  process  up  to  
20  filters  each,  is  used.  One  of  the  2-rack  holders  holds  20  D0SP  filters,  and  the  other  one  holds  
6  D0SP  filters  and  13  X0SP  filters.  
After  setting  up  the  PSP  device,  459  L  of  buffer  (purified  water)  is  added  for  wetting.  
Then,  the  2000  L  harvest  batch  with  3.75  kg  of  protein  enters  the  depth  filters  at  a  flow  rate  of  
2002  L/hr.  The  titer  from  the  harvest  batch  is  1.875  g  of  protein/L  medium,  which  is  suitable  for  
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entry  into  depth  filtration.  Next,  75%  of  the  buffer  (344  L  of  buffer)  is  discarded,  and  the  
remaining  25%  of  the  buffer  (115  L  of  buffer)  is  obtained  with  the  2000  L  feed  by  flushing  the  
depth  filters  again  using  459  L  of  buffer.  Additional  251  L  of  volume  is  recovered  after  air  
blowdown,  totaling  a  final  volume  of  2366  L  for  processing  in  the  next  downstream  operation  
unit.  The  time  required  for  depth  filtration  is  roughly  1  hour  of  feed  process  time  and  1  hour  of  
wetting/flushing  time,  which  adds  up  to  2  hours.  The  percent  yield  of  depth  filtration  is  around  
90%,  which  means  3.38  kg  of  protein  is  recovered  in  exit  stream  S-402  for  further  downstream  
processing.  
The  material  of  construction  for  the  PSP  2-rack  holders  is  316L  stainless  steel.  D0SP  
filters  are  made  of  non-woven,  silica  filter  aid  /  polyacrylic  fiber  pulp,  and  X0SP  filters  are  made  
of  silica  filter  aid  /  polyacrylic  fiber  pulp.  The  purchase  cost  is  $52,090  for  the  2-rack  process  
pod  holder,  $834  for  each  of  the  D0SP  filters,  and  $1,050  for  each  of  the  X0SP  filters.  
  
15.3.2  His-tag  Chromatography  
Before  the  protein  solution  from  DeF-401  is  added  to  the  Cytiva  Chromaflow  
Chromatography  Column  (HC-401),  which  has  a  diameter  of  400  mm  and  a  height  of  400  mm,  
the  column  will  be  packed  using  33.75  L  of  the  HisPur™  Cobalt  Superflow  Agarose  resin.  The  
column  will  then  be  equilibrated  by  using  10  column  volumes,  or  503  L,  of  an  equilibration  
buffer  flowed  through  at  300  cm/hr  (377  L/hr),  and  only  then  473  L  of  the  protein  extract  from  
S-404  will  flow  through  the  column.  As  five  runs  will  be  conducted,  only  one  fifth  of  the  loading  
material  i.e.  will  need  to  flow  through  the  column  per  run,  hence  473  L.  The  protein  extract  will  
be  run  through  at  a  rate  of  150  cm/hr  or  188.5  L/hr  when  sizing  appropriately  for  the  column.  
Once  all  the  material  has  run  through,  10  column  volumes,  503  L,  of  the  washing  buffer  will  be  
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applied  to  the  column  at  188.5  L/hr.  10  column  volumes  of  the  elution  buffer  will  next  be  applied  
to  the  column  at  188.5  L/hr  and  the  eluate  will  be  transferred  to  the  2000  L  single-use  mixer  
(VI-401)  in  viral  inactivation  stage.  The  column  will  then  be  washed  with  10  column  volumes  of  
a  washing  buffer,  followed  by  10  column  volumes  of  a  regeneration  buffer.  Both  of  these  
cleaning  buffers  can  be  run  faster  at  377  L/hr,  as  there  is  no  concern  for  protein  loss.  
The  process  will  repeat  from  the  equilibration  buffer  phase  onwards  until  all  protein  
extract  has  been  processed.  Total  run  time  will  be  approximately  2  days  and  each  run  will  take  
about  9  hours  including  washing.  Yield  is  anticipated  to  be  about  90%  with  purity  of  around  95%  
[84],  which  means  that  about  3.04  kg  of  protein  exits  the  stream  S-405.  The  purchase  cost  of  
his-tag  chromatography  column  is  approximately  $76,000.  
  
15.3.3  Viral  Inactivation  and  Filtration  
The  viral  inactivation  step  will  denature  the  virus  particles  remaining  in  stream  [S-405].  
The  ThermoFisher  HyPerforma  Single  Use  2000  L  Jacketed  Mixer  (VI-401)  will  be  used.  The  
tank  is  135  cm  in  diameter  and  185  cm  tall.  The  feed  volume  will  be  1257  L.  First,  31.4  L  of  1  M  
acetic  acid  will  be  added  to  VI-401  in  stream  S-420  to  bring  the  pH  down  to  3.5.  The  average  
acid-addition  flow  rate  will  be  30  L/hr,  with  a  faster  slow  rate  at  the  start  and  slower  flow  rate  at  
the  end.  This  will  take  approximately  1  hour.  Then,  a  holding  time  of  1  hour  will  ensue.  Next,  
65.3  L  of  1  M  tris  base  will  be  added  through  stream  S-420  at  an  average  flow  rate  of  60  L/hr,  
done  so  in  the  same  fashion  as  the  acid-addition  with  a  fast  start  and  slow  finish.  The  base  can  be  
added  at  double  the  flow  rate  as  the  acid  because  it  is  not  as  strong  as  the  acid,  according  to  Dr.  
Koshari.  The  base-addition  will  therefore  take  about  1  hour.  The  purchase  cost  for  VI-401  is  
estimated  to  be  about  $160,550.  The  electrical  requirement  for  the  single-use  mixer  is  2.5  kWh.  
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The  next  step  will  be  a  sterile  membrane  filtration.  We  will  use  the  Millipore  Express  
SHF  Hydrophilic  Filter  with  Opticap  XL  10  Capsule  (MF-401),  which  has  a  surface  area  of  0.54  
m 2  and  a  flux  of  20  ml/min-cm 2 .  This  correlates  to  200L/min-m 2 ,  which  in  turn  yields  a  flow  rate  
of  108  L/min.  This  is  quite  high,  as  we  believe  that  the  data  available  on  small  scale  flux  would  
not  directly  correlate.  Therefore,  we  assume  the  flow  rate  to  be  about  30L/hr  and  will  take  at  
most  1  hour  to  complete.  The  yield  is  98%  with  2.98  kg  of  protein  leaving  stream  S-406.  The  
cost  for  the  sterile  membrane  filter  is  $970.  The  total  time  for  viral  inactivation  and  sterile  
membrane  filtration  will  be  4  hours.  
  
15.3.4  Ion  Exchange  Chromatography  
The  Millipore  QuickScale  Biochromatography  Column  (IEX-401)  has  a  diameter  of  350  
mm  and  a  height  of  550  mm.  It  will  be  packed  with  21.3  L  of  resin  and  equilibrated  with  5  
column  volumes  of  equilibration  buffer  at  289  L/hr.  Then,  material  in  S-408  will  be  run  through  
IEX-401  all  at  once  at  300  cm/hr  or  289  L/hr.  Once  the  protein  extract  has  run  through  the  
column,  the  elution  buffer  will  be  applied  to  change  the  pH  in  the  column,  and  gradually  release  
the  protein.  The  370  L  eluate  will  be  collected  and  sent  on  to  VF-401.  The  column  will  then  be  
washed  and  regenerated  for  another  cycle.  
Total  process  time  without  cleaning  (which  could  be  done  in  parallel)  is  anticipated  to  be  
7  hours  with  expected  yield  of  90%  [85]  and  purity  of  85%  [86],  which  means  that  about  2.68  kg  




15.3.5  Viral  Filtration  
The  viral  filtration  unit  (VF-401)  removes  viruses  in  feed  stream  S-411  coming  from  
IEX-401,  and  the  Viresolve®  adsorptive  depth  prefilter  is  used  with  Magnus  2.1  filter  for  the  
VF-401.  These  filters  together  have  been  shown  to  provide  log  reduction  value  greater  than  4  for  
28  nm  sized  bacteriophage  challenged  at  10 7   pfu/cm 2   [87].  The  nucleocapsids  of  baculovirus  in  
our  solution  average  30  to  70  nm  in  diameter  and  200  to  400  nm  in  length  [88],  which  suggests  
that  final  log  reduction  value  of  6  for  viral  clearance  is  very  likely  to  be  achieved,  since  some  
viruses  have  already  been  filtered  out  in  the  depth  filtration  and  chromatography  steps.  
After  setting  up  the  prefilter  and  Magnus  2.1  device,  26  L  of  purified  water  is  added  for  
wetting.  Then,  the  370  L  with  2.68  kg  of  protein  from  the  ion  exchange  chromatography  column  
enters  the  viral  filters  at  a  flow  rate  of  155.3  L/hr.  The  titer  load  entering  the  viral  filtration  step  
is  7.23  g  of  protein/L  medium,  which  corresponds  to  a  mass  throughput  of  8.4  kg/m 2   as  shown  in  
the  Viresolve®  Pro  Solution  Performance  Guide  [89].  Then,  26  L  of  50  mM  acetate  buffer  is  
added  last  for  flushing,  totaling  a  final  volume  of  396  L  for  processing  in  the  next  downstream  
operation  unit.  The  time  required  for  viral  filtration  is  around  3  hours  with  98%  yield,  which  
means  2.63  kg  of  protein  is  leaving  stream  S-412  for  further  downstream  processing.  
The  adsorptive  depth  prefilter  is  composed  of  diatomaceous  earth  (DE),  cellulose  fibers,  
and  a  binder  containing  cationic  imine  groups.  Materials  of  construction  for  the  Magnus  2.1  filter  
are  polyethersulfone  (PES)  for  the  membrane,  polyvinylidene  fluoride  (PVDF)  for  the  housing,  
and  silicone  for  the  gaskets.  The  purchase  cost  is  $10,270  for  the  Magnus  2.1  filter,  and  $1,340  




15.3.6  Diafiltration  
The  diafiltration  unit  (DiF-401)  retains  the  Spike  protein  and  filters  out  any  small  
particles  from  the  feed  stream  S-414  pumped  from  the  viral  filtration  outlet  stream  S-413.  Since  
the  Spike  protein  is  180  kDa  in  size  [1][83],  a  nominal  molecular  weight  limit  of  30  kDa  was  
chosen  for  the  membrane  cassettes  using  Millipore  supplier  guidelines  to  retain  the  protein  and  
filter  out  any  smaller  solutes.  The  Millipore®  Ultracel®  membrane  made  of  regenerated  
cellulose  was  chosen  due  to  its  extremely  low  protein  binding,  since  our  protein  product  is  highly  
valuable.  This  membrane  line  provides  the  highest  product  recovery  from  Millipore®  and  is  
ideal  for  solutions  with  protein  concentrations  below  20  g/L.  Three  1.14m 2   Millipore®  Pellicon®  
cassette  filters  are  stacked  and  run  in  parallel  for  a  total  membrane  area  of  3.42m 2 ,  accounting  for  
a  20%  safety  factor  for  the  membrane  area  [90].  
The  400  L  feed  stream  S-414  contains  6.6  g  Spike  protein  /  L  buffer.  The  process  will  be  
run  twice,  each  at  200  L  of  feed  and  5  diavolumes  to  remove  99.3%  of  smaller  solutes  [90][91].  
This  means  1000  L  of  diafiltration  buffer  will  be  used  each  run,  totaling  to  2000  L  of  buffer  
required  for  two  runs  entering  in  S-423  and  exiting  in  S-428.  The  diafiltration  buffer  will  consist  
of  150mM  NaCl  and  2.5mM  NaPO 4   in  WFI  (water  for  injection),  at  a  pH  between  6.8  and  7.2,  
based  on  a  diafiltration  buffer  used  in  the  development  of  a  SARS  recombinant  spike  protein  
vaccine  [92].  Each  run  takes  3.5  hours  at  a  feed  flow  of  4  L/min  and  a  permeate  flow  of  4.7  
L/min,  totaling  to  7  hours  of  combined  processing  time.  The  final  buffer  displacement  will  
recover  99.3%  of  the  protein  [81]  using  3  L  of  buffer  for  each  run,  totaling  to  a  6  L  dilution  using  
additional  buffer.  The  final  product  contains  6.5  g  Spike  protein  /  L  buffer,  which  totals  to  a  final  
mass  of  2.6  kg  Spike  protein.  This  is  more  than  the  2.5  kg  of  protein  required  to  produce  500  
million  doses,  which  leaves  room  for  unforeseen  losses  in  between  processes.  
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Based  on  energy  balance  calculations,  the  heat  generated  by  the  mixing  and  pumping  of  
liquid  will  lead  to  an  8°C  increase  in  temperature,  which  will  be  brought  back  down  to  the  
operating  temperature  of  25°C  using  a  heating  jacket  that  comes  with  the  system.  The  system  
requires  4.4  kW  of  electrical  utility  to  run  and  3.4  kW  to  cool.  After  consultation  with  Dr.  
Koshari,  the  diafiltration  system  was  estimated  to  be  between  $200,000  and  $400,000  as  a  
single-use  operation  based  on  the  $1.2  million  cost  of  a  stainless  steel  version.  To  be  
conservative,  this  system  was  estimated  to  cost  about  $300,000.  
  
  
15.4  Storage  and  Transfer  
15.4.1  Peristaltic  Pumps  
Pumps  are  used  to  transport  liquid  between  vessels.  Although  centrifugal  pumps  can  
handle  very  high  flow  rate  and  high  discharge  pressure,  peristaltic  pumps  are  favored  over  
centrifugal  pumps  in  that  peristaltic  pumps  preserve  sterility,  since  fluid  never  touches  the  
equipment  itself  and  only  flows  through  peristaltic  tubes.  These  peristaltic  pumps  are  positive  
displacement  pumps  that  are  capable  of  emptying  all  liquid  with  air,  which  means  that  there  is  no  
dead  volume  waste.  They  are  also  specifically  designed  to  be  compatible  with  the  B/T  87  and  
B/T  91  series  of  tubing.   
  
Pump  (PP-301)  is  used  to  transport  the  feed  stream  (S-105)  from  the  WAVE  bioreactor  
200EH  (W-101a)  to  the  perfusion  bioreactor  (PBrx-301).  PP-301  transports  50  L  at  1.67  
LPM  while  increasing  the  pressure  from  1.21  bar  to  1.36  bar.  It  requires  0.00056  hp  to  




Pump  (PP-302)  is  used  to  transport  the  feed  stream  (S-302)  from  the  500  L  N-1  perfusion  
bioreactor  (PBrx-301)  to  the  2000  L  production  bioreactor  (Brx-301).  PP-302  transports  
500  L  at  16.67  LPM  while  increasing  the  pressure  from  1.04  bar  to  1.54  bar.  It  requires  
0.0084  hp  to  operate  and  has  a  purchasing  cost  of  $7390.00.  
  
Pump  (PP-303)  is  used  to  transport  the  feed  stream  (S-203)  from  the  WAVE  bioreactor  
20/50EH  (W-201a)  to  the  2000  L  production  bioreactor  (Brx-301).  This  pump  transports  
20  L  at  1.33  LPM  while  increasing  the  pressure  from  1.11  bar  to  1.54  bar.  The  pump  
requires  0.00067  hp  to  operate  and  has  a  purchasing  cost  of  $7390.00.  
  
Pump  (PP-401)  is  used  to  transport  the  protein  extract  (S-304)  from  the  2000  L  
production  bioreactor  (Brx-301)  through  the  depth  filtration  (DeF-401)  to  the  3000  L  
storage  tank  (ST-401).  PP-401  transports  2000  L  at  33.37  LPM  while  increasing  the  
pressure  from  1.04  bar  to  3.14  bar.  It  requires  0.021  hp  to  operate  and  has  a  purchasing  
cost  of  $7390.00.  
  
Pump  (PP-402)  is  used  to  transport  the  protein  extract  (S-403)  from  the  3000  L  storage  
tank  (ST-401)  through  the  his-tag  chromatography  column  (HC-401)  to  the  2000  L  single  
use  mixer  (VI-401)  at  the  viral  inactivation  tank.  PP-402  transports  2366  L  at  3.13  LPM  
while  increasing  the  pressure  from  1.04  bar  to  2.03  bar.  It  requires  0.0013  hp  to  operate  




Pump  (PP-403)  is  used  to  transport  the  protein  extract  (S-406)  from  the  2000  L  single  use  
mixer  (VI-401)  at  the  viral  inactivation  tank  through  the  ion-exchange  chromatography  
column  (IEX-401)  to  the  500  L  storage  tank  (ST-402).  PP-403  transports  1353  L  at  4.82  
LPM  while  increasing  the  pressure  from  1.04  bar  to  3.44  bar.  It  requires  0.0013  hp  to  
operate  and  has  a  purchasing  cost  of  $7390.00.  
  
Pump  (PP-404)  is  used  to  transport  the  protein  extract  (S-410)  from  the  first  500  L  
storage  tank  (ST-402)  through  the  viral  filtration  unit  (VF-401)  to  the  second  500  L  
storage  tank  (ST-403).  PP-404  transports  370.4  L  at  2.59  LPM  while  increasing  the  
pressure  from  1.04  bar  to  3.14  bar.  It  requires  0.00072  hp  to  operate  and  has  a  purchasing  
cost  of  $7390.00.  
  
Pump  (PP-405)  is  used  to  transport  the  protein  extract  (S-413)  from  the  second  500  L  
storage  tank  (ST-403)  to  the  diafiltration  unit  (DiF-401).  PP-405  transports  396  L  at  13.33  
LPM  while  increasing  the  pressure  from  1.04  bar  to  1.28  bar.  It  requires  0.0030  hp  to  
operate  and  has  a  purchasing  cost  of  $7390.00.  
  
Pump  (PP-406)  is  used  to  transport  the  protein  extract  (S-415)  from  the  diafiltration  unit  
(DiF-401)  to  the  third  500  L  storage  tank  (ST-404).  PP-406  transports  402  L  at  13.33  
LPM  while  increasing  the  pressure  from  1.01  bar  to  1.09  bar.  It  requires  0.0037  hp  to  




15.4.2  Peristaltic  Tubes  
The  peristaltic  tubes  used  in  the  process  are  a  crucial  part  of  ensuring  product  sterility  
during  transfer  between  production  phases.  The  peristaltic  tubing  used  is  made  of  platinum-cured  
silicone  to  ensure  compatibility  with  pharmaceutical  grade  products  as  well  as  a  sterile  
environment.  The  tubing  is  also  sufficiently  flexible  to  withstand  the  compressions  occurring  
during  the  pumping.  Straight  hose  barb  unions  will  be  used  to  connect  the  tubing  to  ensure  sterile  
connections.  Each  unit  of  tubing  is  10  ft  long.  However,  in  order  to  ensure  sufficient  spacing  
between  pieces  of  equipment,  20  ft  (i.e.  2  pieces  of  tubing)  will  be  used  between  equipment  
items.  The  tubing  itself  has  no  associated  energy  costs  although  energy  will  be  required  to  pump  
material  through.  The  tubing  itself  is  designed  to  be  smooth  to  minimize  flow  obstruction.  Due  to  
differences  in  the  required  flow  rate  throughout  the  process,  two  tubing  sizes  will  be  used:  the  
B/T  87  and  the  B/T  91.   
  
The  B/T  87  has  an  internal  diameter  of  ½  inch  and  is  used  for  smaller  flow  rates  as  it  has  
a  flow  rate  capacity  of  up  to  18.9  LPM.  It  can  withstand  up  to  2.4  bar  of  pressure.  It  is  
used  for  all  tubing  requirements  except  for  the  tubing  between  the  production  phase  
bioreactor  and  the  first  storage  tank.  The  tubing  has  a  purchase  cost  of  $484.00/10  ft.  
  
The  B/T  91  has  an  internal  diameter  of  ¾  inch  and  is  used  for  larger  flow  rates  as  it  has  a  
flow  rate  capacity  of  up  to  42  LPM.  It  can  withstand  up  to  2.06  bar  of  pressure.  It  is  used  
for  the  tubing  between  the  production  phase  bioreactor  and  the  first  storage  tank.  





15.4.3  Storage  Vessels  
Storage  vessels  are  large  stainless  steel  containers  that  are  meant  to  hold  material  until  it  
can  be  transferred  to  another  stage  of  the  process.  These  containers  are  built  to  be  sturdy  and  
stable  in  the  presence  of  biological  matter.  
  
The  material  coming  out  of  the  depth  filtration  step  (S-402)  requires  a  large  storage  
vessel  that  can  hold  all  protein  extract  mixed  with  the  depth  filtration  buffer.  Storage  
Tank  1  (ST-401)  is  3000  L  to  hold  all  2400  L  of  solution  and  to  be  of  a  standard  
production  size.  ST-401  is  made  out  of  stainless  steel  for  its  durability.  It  will  not  have  
any  associated  energy  requirements  and  has  a  purchase  price  of  $12,400.  
  
The  370  L  of  protein-containing  elution  buffer  flowing  from  the  ion-exchange 
chromatography  step  (S-409)  will  be  sent  to  Storage  Tank  2  (ST-402)  for  storage  before  
continuing  through  to  the  viral  filtration  stage  (VF-401)  at  a  different  flow  rate.  ST-402  is  
500  L  to  ensure  the  vessel  is  of  standard  production  size.  It  will  not  have  any  associated  
energy  requirements  and  has  a  purchase  price  of  $1,500.  
  
The  395  L  of  protein  extract  flowing  from  the  viral  filtration  system  (S-412)  will  flow  
into  Storage  Tank  3  (ST-403)  before  processing  in  the  diafiltration  stage  (DiF-401).  
ST-403  is  500  L  to  ensure  the  vessel  is  of  standard  production  size.  It  will  not  have  any  




The  402  L  of  protein  extract  flowing  from  the  diafiltration  system  (S-415)  will  flow  into  
Storage  Tank  4  (ST-404)  until  formulation  can  be  carried  out.  ST-404  is  500  L  to  ensure  
the  vessel  is  of  standard  production  size.  It  will  not  have  any  associated  energy  
requirements  and  has  a  purchase  price  of  $1,500.  
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16.  Specification  Sheets  
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SPECIFICATION  SHEET  
Corning®  125  mL  Erlenmeyer  Shake  Flasks  (with  Vent  Cap)  
Equipment  
ID  F-101a/b/c/d  
Quantity  4  
Function  Grow  cells  to  VCD  of  4.98  million  cells  /  mL  
Operation  Batch,  5.2  days  of  growth  
Materials  
  In  Out  
Feed  (with  Sf-9  Cells)  1  mL  50  mL  
Media  (Sf-900 TM   II  SFM) 49  mL  -  
Design  Data  
Flask  Material  Polycarbonate  
Cap  Material Polypropylene  
Bottom  Style  Plain  
Cap  Style  Vent  
Sterile  Yes  
Feature  Disposable  
Temperature  27.5  ±  0.5  ̊C  
pH  6.3  ±  0.1  
Pressure  1.01  bar  
Height  4.54  in  (with  cap)  4.45  in  (w/o  cap)  
Base  Diameter  2.58  in  
Working  Volume  50  mL  
Utilities  N/A 
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SPECIFICATION  SHEET  
Corning®  250  mL  Erlenmeyer  Shake  Flasks  (with  Vent  Cap)  
Equipment  
ID  F-201a/b  
Quantity  2  
Function  Grow  2  million  baculoviruses  to  100-fold  
Operation  Batch,  6  days  of  growth  
Materials  
  In  Out  
Feed  (with  Baculovirus)  20  mL  200  mL  
Media  with  Sf-9  Cells  180  mL  -  
Design  Data  
Flask  Material  Polycarbonate  
Cap  Material Polypropylene  
Bottom  Style  Plain  
Cap  Style  Vent  
Sterile  Yes  
Feature  Disposable  
Temperature  27.5  ±  0.5  ̊C  
pH  6.3  ±  0.1  
Pressure  1.01  bar  
Height  5.50  in  (with  cap)  
5.42  in  (w/o  cap)  
Base  Diameter  3.28  in  
Working  Volume  200  mL  
Utilities  N/A 
Comments :  Purchase  cost  is  $17.70  each;  flask  is  sterilized  by  gamma  radiation  and  certified  non-pyrogenic.  
  
  
   
97  
SPECIFICATION  SHEET  
Corning®  500  mL  Erlenmeyer  Shake  Flasks  (with  Vent  Cap)  
Equipment  
ID  F-102a/b/c/d  
Quantity  4  
Function  Grow  cells  to  VCD  of  5.36  million  cells  /  mL  
Operation  Batch,  3  days  of  growth  
Materials  
  In  Out  
Feed  (with  Sf-9  Cells)  50  mL  500  mL  
Media  (Sf-900 TM   II  SFM) 450  mL  -  
Design  Data  
Flask  Material  Polycarbonate  
Cap  Material Polypropylene  
Bottom  Style  Plain  
Cap  Style  Vent  
Sterile  Yes  
Feature  Disposable  
Temperature  27.5  ±  0.5  ̊C  
pH  6.3  ±  0.1  
Pressure  1.01  bar  
Height  7.05  in  (with  cap)  
6.96  in  (w/o  cap)  
Base  Diameter  3.99  in  
Working  Volume  500  mL  
Utilities  N/A 
Comments :  Purchase  cost  is  $27.10  each;  flask  is  sterilized  by  gamma  radiation  and  certified  non-pyrogenic.  
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SPECIFICATION  SHEET  
Corning®  5  L  Erlenmeyer  Shake  Flasks  (with  Vent  Cap)  
Equipment  
ID  F-103a/b/c  
Quantity  3  
Function  Grow  cells  to  VCD  of  5.78  million  cells  /  mL  
Operation  Batch,  3  days  of  growth  
Materials  
  In  Out  
Feed  (with  Sf-9  Cells)  0.5  L  5  L  
Media  (Sf-900 TM   II  SFM) 4.5  L  -  
Design  Data  
Flask  Material  Polycarbonate  
Cap  Material Polypropylene  
Bottom  Style  Plain  
Cap  Style  Vent  
Sterile  Yes  
Feature  Disposable  
Temperature  27.5  ±  0.5  ̊C  
pH  6.3  ±  0.1  
Pressure  1.01  bar  
Height  11.33  in  (with  cap)  
11.24  in  (w/o  cap)  
Base  Diameter  9.05  in  
Working  Volume  5  L  
Utilities  N/A 
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SPECIFICATION  SHEET  
Cytiva®  WAVE™  Bioreactor  System  20/50EH  
Equipment  
ID  W-201a/b  
Quantity  2  
Function  Grow  2  billion  baculoviruses  to  100-fold  
Operation  Batch,  5  days  of  growth  
Materials  
  In  Out  
Feed  (with  Baculovirus)  0.2  L  20  L  
Media  with  Sf-9  Cells  19.8  L  -  
Air  2.2  kg  (0.4  LPM)  2.2  kg  (0.4  LPM)  
Design  Data  
Material  Stainless  Steel  
Temperature  27.5  ±  0.5  ̊C  
pH  6.3  ±  0.1  
Pressure  1.11  bar  
Length  0.775  m  
Width  0.700  m  
Height  0.254  m  
Weight  15.5  kg  
Working  Volume  20  L  
Rocking  Speed  25  rocks/min  
Rocking  Angle  8  degrees  
Utilities  
Voltage  110/230  VAC 
Frequency  50/60  Hz  
Current  6/3  A  
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SPECIFICATION  SHEET  
Cytiva®  WAVE™  Bioreactor  System  200EH  
Equipment  
ID  W-101a/b/c  
Quantity  3  
Function  Grow  cells  to  VCD  of  6.22  million  cells  /  mL  
Operation  Batch,  3  days  of  growth  
Materials  
  In  Out  
Feed  (with  Sf-9  Cells)  5  L  50  L  
Media  (Sf-900 TM   II  SFM) 45  L  -  
Air  11.0  kg  (2  LPM)  11.0  kg  (2  LPM)  
Design  Data  
Material  Stainless  Steel  
Temperature  27.5  ±  0.5  ̊C  
pH  6.3  ±  0.1  
Pressure  1.21  bar  
Length  1.852  m  
Width  1.096  m  
Height  1.120  m  
Weight  350  kg  
Working  Volume  50  L  
Rocking  Speed  20  rocks/min  
Rocking  Angle  7  degrees  
Utilities  
Voltage  100-120/220-240  VAC  
Frequency  50/60  Hz  
Current  Max:  15  A  
Power  12  KVA  
Comments :  Purchase  cost  is  $16,000.00  each  
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SPECIFICATION  SHEET  
ThermoFisher®  HyPerforma®  2:1  500  L  Single-Use  Bioreactor  (Jacketed)  
Equipment  
ID  PBrx-301  (+  PS-301)  
Quantity  1  
Function  Grow  cells  to  higher  VCD  of  32.65  million  cells  /  mL  
Operation  Perfusion,  5  days  of  growth  
Materials  
  In  Out  
Feed  (with  Sf-9  Cells)  50  L  500  L  
Media  (Sf-900 TM   II  SFM) 2640.4  L  2200  L  
Air  229.6  kg  (25  LPM)  229.6  kg  (25  LPM)  
Oxygen  (50%)  82.4  kg  (8  LPM)  74.4  kg  (7.24  LPM)  
Carbon  Dioxide  -  23.6  kg  (1.67  LPM)  
Glucose  30.5  kg  (0.254  kg/hr)  -  
Glutamine  11.3  kg  (0.0943  kg/hr)  -  
Base  (1M  NaOH)  1.5  L  -  
Antifoam  8.1  L  -  
Design  Data  
Material  Stainless  Steel  
Temperature  27.5  ±  0.5  ̊C  
pH  6.3  ±  0.1  
Pressure  1.04  bar  
Sparger  Frit  +  Drilled  Hole  (Dual-Sparger  Configuration)  
Bioreactor  
Geometry  
Diameter  75.6  cm  
Height  152.4  cm  (Liquid  Height:  113.4  cm)  
Volume  660  L  (Working  Volume:  500  L)  
Impellor  
Type  Pitched  Blade  (Quantity:  1  /  #  of  Blades:  3)  
Diameter  25.1  cm  
Power  Num.  2.1  
Agitation  
Mixing  Rate  101  RPM  
Tip  Speed  137.2  cm/s  
Utilities  
Agitation  Rating  20  W/m 3  
Heating/Cooling  Load  5,000  W  
Motor  Power  Rating  372.8  W  (AC),  400  W  (DC)  
Comments :  Purchase  cost  of  bioreactor  is  $91,473.39  /  perfusion  system  is  $18,560.00  
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SPECIFICATION  SHEET  
ThermoFisher®  HyPerforma®  2:1  2000  L  Single-Use  Bioreactor  (Jacketed)  
Equipment  
ID  Brx-301  
Quantity  1  
Function  Produce  proteins  at  VCD  of  8.15  million  cells  /  mL  
Operation  Batch,  5  days  of  production  
Materials  
  In  Out  
Protein  of  Interest  -  3.75  kg  
Feed  (with  Sf-9  Cells  +  
Baculovirus)  
500  L  (Sf-9  Cells)  
20  L  (Baculovirus)  2000  L  
Media  (Sf-900 TM   II  SFM) 1472.9  L  -  
Air  1377.6  kg  (150  LPM)  1377.6  kg  (150  LPM)  
Oxygen  (100%)  61.8  kg  (6  LPM)  55.8  kg  (5.43  LPM)  
Carbon  Dioxide  -  17.7  kg  (1.25  LPM)  
Glucose  21.6  kg  (0.180  kg/hr)  -  
Glutamine  5.15  kg  (0.0429  kg/hr)  -  
Base  (1M  NaOH)  1.1  L  -  
Antifoam  6  L  -  
Design  Data  
Material  Stainless  Steel  
Temperature  26.0  ±  1.0  ̊C  
pH  6.3  ±  0.1  
Pressure  1.04  bar  
Sparger  Frit  +  Drilled  Hole  (Dual-Sparger  Configuration)  
Bioreactor  
Geometry  
Diameter  119.4  cm  
Height  229.9  cm  (Liquid  Height:  178.7  cm)  
Volume  2575  L  (Working  Volume:  2000  L)  
Impeller  
Type  Pitched  Blade  (Quantity:  1  /  #  of  Blades:  3)  
Diameter  39.8  cm  
Power  Num.  2.1  
Agitation  
Mixing  Rate  75  RPM  
Tip  Speed  154.9  cm/s  
Utilities  
Agitation  Rating  20  W/m 3  
Heating/Cooling  Load  18,000  W  
Motor  Power  Rating  372.8  W  (AC),  400  W  (DC)  
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SPECIFICATION  SHEET  
Grainger  -  Stationary  Air  Compressor,  2.0  (for  WAVE  Bioreactor  20/50EH)  
Equipment  
ID  AC-201  
Quantity  1  
Function  Supply  air  for  two  20  L,  working-volume,  wave  bioreactors  
Operation  5  days  
Materials  
Air  Inlet  Outlet  
Flow  Rate  0.4  LPM  (Total:  0.8  LPM)  0.36  LPM  (Total:  0.72  LPM)  
Pressure  1.01  bar  1.11  bar  
Temperature  25.0˚C  25.0˚C  
Design  Data  
Tank  Size  7.6  L  
Dimensions  (LxWxH)  0.46  x  0.20  x  0.43  m  
Power  Requirement  0.000167  hp  
Utilities  
Maximum  Power  0.17  hp  
Voltage  120  VAC  
Current  4.3  A  
Comments :  Purchase  cost  is  $1212.50 
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SPECIFICATION  SHEET  
Grainger  -  Stationary  Air  Compressor,  2.0  (for  WAVE  Bioreactor  200EH)  
Equipment  
ID  AC-101  
Quantity  1  
Function  Supply  air  for  three  50  L,  working-volume,  wave  bioreactors  
Operation  3  days  
Materials  
Air  Inlet  Outlet  
Flow  Rate  2  LPM  (Total:  6  LPM)  1.67  LPM  (Total:  5.01  LPM)  
Pressure  1.01  bar  1.21  bar  
Temperature  25.0˚C  25.0˚C  
Design  Data  
Tank  Size  7.6  L  
Dimensions  (LxWxH)  0.46  x  0.20  x  0.43  m  
Power  Requirement  0.00247  hp  
Utilities  
Maximum  Power  0.17  hp  
Voltage  120  VAC  
Current  4.3  A  
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SPECIFICATION  SHEET  
Grainger  -  Stationary  Air  Compressor,  2.0  (for  500  L  Perfusion  Bioreactor)  
Equipment  
ID  AC-301  
Quantity  1  
Function  Supply  air  for  500  L  perfusion  bioreactor  
Operation  5  days  
Materials  
Air  Inlet   Outlet  
Flow  Rate  25  LPM  11.69  LPM  
Pressure  1.01  bar  2.16  bar  
Temperature  25.0˚C  25.0˚C  
Design  Data  
Tank  Size  7.6  L  
Dimensions  (LxWxH)  0.46  x  0.20  x  0.43  m  
Power  Requirement  0.0478  hp  
Utilities  
Maximum  Power  0.17  hp  
Voltage  120  VAC  
Current  4.3  A  
Comments :  Purchase  cost  is  $1212.50 
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SPECIFICATION  SHEET  
Grainger-Fire  Sprinkler  Air  Compressor  (for  2000  L  Production  Bioreactor)  
Equipment  
ID  AC-302  
Quantity  1  
Function  Supply  air  for  2000  L  production  bioreactor 
Operation  5  days  
Materials  
Air  Inlet   Outlet  
Flow  Rate  150  LPM  67.94  LPM  
Pressure  1.01  bar  2.23  bar  
Temperature  25.0˚C  25.0˚C  
Design  Data  
Tank  Size  114  L  
Dimensions  (LxWxH)  0.46  x  0.20  x  0.43  m  
Power  Requirement  0.301  hp  
Utilities  
Maximum  Power  0.5  hp  
Voltage  120  VAC  
Current  9.4  A  
Comments :  Purchase  cost  is  $1095.92 
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SPECIFICATION  SHEET  
Millipore®  Process-Scale  Pod  (2-Rack  Holders)  
Equipment  
ID  DeF-401  
Quantity  2  
Function  Filter  out  large  cell  debris,  bacteria,  and  some  viruses  by  using two-stage  depth  filter  train  
Operation  2  hours  
Materials  
  In  Out  
Protein  of  Interest  3.75  kg  3.38  kg  
Feed  2000  L  2366  L  
Buffer  (Purified  Water)  917  L  (Wetting  +  Flushing)  344  L  (+  Hold-up:  207  L)  
Design  Data  
Material  316L  Stainless  Steel  
Temperature  25.0  ±  1.0  ̊C  
Pressure  Drop  2.1  bar  
Process  Flux  100  LMH  
Flow  Rate  2002  L/hr  
Filters  D0SP  X0SP  
Filter  Material  Nonwoven,  Silica  Filter  Aid  /  
Polyacrylic  Fiber  Pulp 
Silica  Filter  Aid  /  Polyacrylic  
Fiber  Pulp  
Filter  Quantity  26  13  
Capacity  100  L/m 2  150  L/m 2  
Pore  Size  10  µm  0.1  µm  
Effective  Surface  Area  0.77  m 2   each  1.1  m 2   each  
Hold-up  Volume  
12.9  L  each  
6.30  L  each  (after  gravity  drain)  
5.04  L  each  (after  blow  down)  
9.47  L  each  
6.72  L  each  (after  gravity  drain)  
5.85  L  each  (after  blow  down)  
Utilities  N/A 
Comments :  Purchase  cost  is  $52,090.00 
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SPECIFICATION  SHEET  
Cytiva®  Chromaflow®  Chromatography  Column  
Equipment  
ID  HC-401  
Quantity  1  
Function  Separates  out  recombinant  protein  from  solution  by  using  his-tag  
based  resins  
Operation  43  hours  
Materials  
  In  Out  
Protein  of  Interest  3.38  kg  3.04  kg  
Feed  2366  L  (473  L/run)  1257  L  
Waste  -  2366  L  
Equilibration  Buffer  1257  L  (251  L/run)  1257  L  (251  L/run)  
Wash  Buffer  2513  L  (503  L/run)  2513  L  (503  L/run)  
Elution  Buffer  1257  L  (251  L/run)  -  
Regeneration  Buffer  1257  L  (251  L/run)  1257  L  (251  L/run)  
Regeneration  Water  Wash  1257  L  (251  L/run)  1257  L  (251  L/run)  
Design  Data  
Material  Polypropylene,  316L,  S32205  Stainless  Steel  
Temperature  25.0  ±  1.0  ̊C  
Pressure  Drop  Min:  0.99  bar  Max:  1.98  bar  
Diameter  40  cm  
Column  Height  40  cm  
Packed  Bed  Height  27.5  cm  
Overall  Height  158.6  cm  
Volume  50.3  L  
Packed  Bed  Volume  33.8  L  
Total  Resin  Volume  168.8  L  
Binding  Capacity  20  mg/mL  
Flow  Rate  150  cm/hr  
#  of  Runs  5  
Utilities  N/A 
Comments :  Purchase  cost  is  $76,000.00  
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SPECIFICATION  SHEET  
ThermoFisher®  HyPerforma®  5:1  2000L  Single-Use  Mixer  (Non-Jacketed)  
Equipment  
ID  VI-401  
Quantity  1  
Function  Perform  viral  inactivation,  followed  by  sterile  membrane  filtration  
Operation  4  hours  
Materials  
  In  Out  
Protein  of  Interest  3.04  kg  2.98  kg  
Feed  1257  L  1354  L  (Feed  +  Acid  +  Base)  
1M  Acetic  Acid  31.4  L  (30  L/hr)  -  
1M  Tris  Base  65.3  L  (60  L/hr)  -  
Design  Data  
Material  AISI  304  (Stainless  Steel)  
Temperature  25.0  ±  1.0  ̊C  
Pressure  1.04  bar  
Diameter  135  cm  
Height  185  cm  
Volume  1353  L  
Impeller  Diameter  25.02  cm  
Agitation  Speed  100  -  200  RPM  
Tip  Speed  39.4  -  459.7  cm/s  
Utilities  
Motor  Power  Rating  745.7  W  
Motor  Torque  Rating  18  N-m  
Electrical  Power  Rating  100-120  VAC,  50/60  Hz,  Single,  15  A  
220-240  VAC,  50/60  Hz,  Single,  10.4  A  
Comments :  Purchase  cost  is  $160,549.49  (sterile  membrane  filter  is  $970.00)  
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SPECIFICATION  SHEET  
Millipore®  QuikScale®  Biochromatography  Column   
Equipment  
ID  IEX-401  
Quantity  1  
Function  Separates  out  recombinant  protein  from  solution  by  using  charge  
differences  in  different  pH’s  
Operation  7  hours  
Materials  
  In  Out  
Protein  of  Interest  2.98  kg  2.68  kg  
Feed  1353  L  370  L  
Waste  -  1353  L  
Equilibration  Buffer  265  L  265  L  
Elution  Buffer  370  L  -  
Equilibration  Wash  Buffer  159  L  159  L  
1  M  NaCl  Wash  Buffer  265  L  265  L  
Ultrapure  Water   529  L  529  L  
1  M  Acetic  Acid  Wash  
Buffer  
265  L  265  L  
Design  Data  
Material  Stainless  Steel  1.4539  
Temperature  25.0  ±  1.0  ̊C  
Pressure  Drop  2.4  bar  
Diameter  35  cm  
Height  55  cm  
Packed  Bed  Height  25  cm  
Volume  53  L  
Packed  Bed  Volume  21.3  L  
Total  Resin  Volume  21.3  L  
Binding  Capacity  140  mg/mL  
Flow  Rate  300  cm/hr  
#  of  Runs  1  
Utilities  N/A 
Comments :  Purchase  cost  is  $43,320.00 
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SPECIFICATION  SHEET  
Millipore®  Viresolve®  Pre-filter  +  Pro  Device  
Equipment  
ID  VF-401  
Quantity  1  
Function  Filter  out  viruses  to  satisfy  final  log  reduction  value  (LRV)  of  6  for  viral  clearance  
Operation  3  hours  
Materials  
  In  Out  
Protein  of  Interest  2.68  kg  2.63  kg  
Feed  370  L  396  L  
Buffer  
(Wetting:  Purified  Water  /  
Flushing:  50  mM  Acetate)  
52  L  26  L  
Design  Data  
Temperature  25.0  ±  1.0  ̊C  
Pressure  Drop  2.1  bar  
Dimensions  (L  ×  W  ×  H)  34.29  ×  20.96  ×  4.42  cm  
Process  Flux  304.5  LMH  
Flow  Rate  155.3  L/hr  
Filter  Adsorptive  depth  prefilter  Magnus  2.1  
Filter  Quantity  1  1  
Filter  Material  
Diatomaceous  Earth  (DE)  
+  Cellulose  Fibers  
+  Cationic  Imine  Groups  
Membrane:  PES  
Housing:  PVDF  
Gaskets:  Silicone  
Mass  Throughput  8.4  kg/m 2  
Effective  Surface  Area  1.1  m 2   (Prefilter)  +  0.51  m 2   (Magnus  2.1)  
Wetting  /  Flushing  
Capacity  50  L/m 
2  
Utilities  N/A 
Comments :  Purchase  cost  of  Viresolve®  Prefilter  is  $1,340.00  /  Viresolve®  Magnus  2.1  is  $10,270.00  
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SPECIFICATION  SHEET  
Millipore®  Mobius®  Smart  Flexware®  Assemblies  for  TFF,  Model  TF3S,  Jacketed  
Equipment  
ID  DiF-401  
Quantity  1  
Function  Diafiltration  to  remove  small  solutes  in  solution  and  retain  spike  protein  at  a  final  drug  concentration  of  6.5  g/L  
Operation  Batch,  3.5  hours  for  2  runs,  totaling  7  hours  processing  time 
Materials  
  In  Out  
Protein  of  Interest  2.63  kg  2.60  kg  
Feed  396  L  402  L  
0.1N  NaOH  68  L  68  L  
150mM  NaCl  /  2.5mM  NaPO 4  2048  L  2042  L  
Bulk  Medium  4  L/min  Feed  (200  L  Feed)  
4  L/min  Retentate  
4.7  L/min  Permeate  
Design  Data  
Temperature  25.0  ±  1.0°C  
Pressure  
Feed  bag:  atmospheric  
Feed  and  Retentate  pump:  4  bar  
Transmembrane  and  Permeate:  2  bar  
Dimensions  (L  ×  W  ×  H)  2022  ×  2160  ×  1014  mm  
Feed  Container  LLDPE  (linear  low-density  polyethylene)  with  jacket  
Feed  Volume  200  L  
Recirculation  Volume  2.2  L  
Membrane  Hold-up  Volume  0.7  L  
Unrecoverable  Volume  Virtually  zero  using  a  displacement  by  buffer  
Membrane  Area  3.42  m 2   total  using  three  (3)  cassettes,  each  1.14  m 2   
Utilities  
SmartCart  1  kW  
Tank  Cart  0.4  kW  
Pump  Cart  3  kW  
Comments :  Purchase  cost  is  $300,000.00  
The  system  will  be  cleaned  with  0.1N  NaOH,  then  equilibrated  with  diafiltration  buffer  before  running  the  
process.  There  will  be  2  runs,  each  with  200  L  of  feed.  
The  diafiltration  buffer  will  be  150  mM  NaCl,  2.5  mM  NaPO4,  pH  6.8–7.2  in  WFI  (water  for  injection).  
Three  filters  of  Pellicon®  3  Cassettes  with  Ultracel®  30kDa  Membrane,  D  screen,  1.14  m 2   will  be  used.  
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SPECIFICATION  SHEET  
Masterflex  B/T®  Digital  Drive,  Modular,  Washdown  Pump  
Equipment  
ID  PP-301  
Quantity  1  
Function  Transport  liquid  from  WAVE  bioreactor  200EH  to  perfusion  bioreactor  
Operation  30  mins  
Operations  
  In  Out  
Feed  50  L  (1.67  LPM)  50  L  (1.67  LPM)  
Pressure  1.21  bar  1.36  bar  
Temperature  27.5˚C  27.5˚C  
Design  Data  
Control  Type  Digital  Variable  Speed  
Washdown  Capable  Yes  
Flow  Rate  Min:  1.3  LPM  Max:  42  LPM  
Controller  Dimensions  (LxWxH) 0.28  x  0.11  x  0.23  m  
Drive  Dimensions  (LxWxH)  0.40  x  0.38  x  0.69  m  
Power  Requirement  0.00056  hp  
Utilities  
Maximum  Power  0.75  hp  
Voltage  115  VAC  (90  to  130)  
Current  5.7  A  
Frequency  50/60  Hz  
Comments :  Purchase  cost  is  $7390.00 
  
  
   
114  
SPECIFICATION  SHEET  
Masterflex  B/T®  Digital  Drive,  Modular,  Washdown  Pump  
Equipment  
ID  PP-302  
Quantity  1  
Function  Transport  liquid  from  perfusion  bioreactor  to  production  bioreactor  
Operation  30  mins  
Operations  
  In  Out  
Feed  500  L  (16.67  LPM)  500  L  (16.67  LPM)  
Pressure  1.04  bar  1.54  bar  
Temperature  27.5˚C  27.5˚C  
Design  Data  
Control  Type  Digital  Variable  Speed  
Washdown  Capable  Yes  
Flow  Rate  Min:  1.3  LPM  Max:  42  LPM  
Controller  Dimensions  (LxWxH) 0.28  x  0.11  x  0.23  m  
Drive  Dimensions  (LxWxH)  0.40  x  0.38  x  0.69  m  
Power  Requirement  0.0084  hp  
Utilities  
Maximum  Power  0.75  hp  
Voltage  115  VAC  (90  to  130)  
Current  5.7  A  
Frequency  50/60  Hz  
Comments :  Purchase  cost  is  $7390.00 
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SPECIFICATION  SHEET  
Masterflex  B/T®  Digital  Drive,  Modular,  Washdown  Pump  
Equipment  
ID  PP-303  
Quantity  1  
Function  Transport  liquid  from  WAVE  bioreactor  20/50EH  to  production  bioreactor  
Operation  15  mins  
Operations  
  In  Out  
Feed  20  L  (1.33  LPM)  20  L  (1.33  LPM)  
Pressure  1.11  bar  1.34  bar  
Temperature  27.5˚C  27.5˚C  
Design  Data  
Control  Type  Digital  Variable  Speed  
Washdown  Capable  Yes  
Flow  Rate  Min:  1.3  LPM  Max:  42  LPM  
Controller  Dimensions  (LxWxH) 0.28  x  0.11  x  0.23  m  
Drive  Dimensions  (LxWxH)  0.40  x  0.38  x  0.69  m  
Power  Requirement  0.00067  hp  
Utilities  
Maximum  Power  0.75  hp  
Voltage  115  VAC  (90  to  130)  
Current  5.7  A  
Frequency  50/60  Hz  
Comments :  Purchase  cost  is  $7390.00 
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SPECIFICATION  SHEET  
Masterflex  B/T®  Digital  Drive,  Modular,  Washdown  Pump  
Equipment  
ID  PP-401  
Quantity  1  
Function  Transport  liquid  from  production  bioreactor  through  depth  filtration  to  3000  L  storage  tank  
Operation  2  hours  
Operations  
  In  Out  
Feed  2000  L  (33.37  LPM)  2000  L  (33.37  LPM)  
Pressure  1.04  bar  3.14  bar  
Temperature  26.0˚C  26.0˚C  
Design  Data  
Control  Type  Digital  Variable  Speed  
Washdown  Capable  Yes  
Flow  Rate  Min:  1.3  LPM  Max:  42  LPM  
Controller  Dimensions  (LxWxH) 0.28  x  0.11  x  0.23  m  
Drive  Dimensions  (LxWxH)  0.40  x  0.38  x  0.69  m  
Power  Requirement  0.021  hp  
Utilities  
Maximum  Power  0.75  hp  
Voltage  115  VAC  (90  to  130)  
Current  5.7  A  
Frequency  50/60  Hz  
Comments :  Purchase  cost  is  $7390.00 
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SPECIFICATION  SHEET  
Masterflex  B/T®  Digital  Drive,  Modular,  Washdown  Pump  
Equipment  
ID  PP-402  
Quantity  1  
Function  Transport  liquid  from  3000  L  storage  tank  through  his-tag  chromatography  column  to  2000  L  single-use  mixer  
Operation  2  days  
Operations  
  In  Out  
Feed  2366  L  (3.13  LPM)  2366  L  (3.13  LPM)  
Pressure  1.04  bar  2.03  bar  
Temperature  25.0˚C  25.0˚C  
Design  Data  
Control  Type  Digital  Variable  Speed  
Washdown  Capable  Yes  
Flow  Rate  Min:  1.3  LPM  Max:  42  LPM  
Controller  Dimensions  (LxWxH) 0.28  x  0.11  x  0.23  m  
Drive  Dimensions  (LxWxH)  0.40  x  0.38  x  0.69  m  
Power  Requirement  0.0013  hp  
Utilities  
Maximum  Power  0.75  hp  
Voltage  115  VAC  (90  to  130)  
Current  5.7  A  
Frequency  50/60  Hz  
Comments :  Purchase  cost  is  $7390.00 
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SPECIFICATION  SHEET  
Masterflex  B/T®  Digital  Drive,  Modular,  Washdown  Pump  
Equipment  
ID  PP-403  
Quantity  1  
Function  Transport  liquid  from  2000  L  single-use  mixer  through  IEX  chromatography  column  to  500  L  storage  tank  1  
Operation  7  hours  
Operations  
  In  Out  
Feed  1353  L  (4.82  LPM)  1353  L  (4.82  LPM)  
Pressure  1.04  bar  3.44  bar  
Temperature  25.0˚C  25.0˚C  
Design  Data  
Control  Type  Digital  Variable  Speed  
Washdown  Capable  Yes  
Flow  Rate  Min:  1.3  LPM  Max:  42  LPM  
Controller  Dimensions  (LxWxH) 0.28  x  0.11  x  0.23  m  
Drive  Dimensions  (LxWxH)  0.40  x  0.38  x  0.69  m  
Power  Requirement  0.0013  hp  
Utilities  
Maximum  Power  0.75  hp  
Voltage  115  VAC  (90  to  130)  
Current  5.7  A  
Frequency  50/60  Hz  
Comments :  Purchase  cost  is  $7390.00 
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SPECIFICATION  SHEET  
Masterflex  B/T®  Digital  Drive,  Modular,  Washdown  Pump  
Equipment  
ID  PP-404  
Quantity  1  
Function  Transport  liquid  from  500  L  storage  tank  1  through  viral  filtration  to  500  L  storage  tank  2  
Operation  3  hours  
Operations  
  In  Out  
Feed  370.4  L  (2.59  LPM)  370.4  L  (2.59  LPM)  
Pressure  1.04  bar  3.14  bar  
Temperature  25.0˚C  25.0˚C  
Design  Data  
Control  Type  Digital  Variable  Speed  
Washdown  Capable  Yes  
Flow  Rate  Min:  1.3  LPM  Max:  42  LPM  
Controller  Dimensions  (LxWxH) 0.28  x  0.11  x  0.23  m  
Drive  Dimensions  (LxWxH)  0.40  x  0.38  x  0.69  m  
Power  Requirement  0.00072  hp  
Utilities  
Maximum  Power  0.75  hp  
Voltage  115  VAC  (90  to  130)  
Current  5.7  A  
Frequency  50/60  Hz  
Comments :  Purchase  cost  is  $7390.00 
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SPECIFICATION  SHEET  
Masterflex  B/T®  Digital  Drive,  Modular,  Washdown  Pump  
Equipment  
ID  PP-405  
Quantity  1  
Function  Transport  liquid  from  500  L  Storage  Tank  2  to  diafiltration  feed  tank  
Operation  30  mins  
Operations  
  In  Out  
Feed  395.9  L  (13.33  LPM)  395.9  L  (13.33  LPM)  
Pressure  1.04  bar  1.28  bar  
Temperature  25.0˚C  25.0˚C  
Design  Data  
Control  Type  Digital  Variable  Speed  
Washdown  Capable  Yes  
Flow  Rate  Min:  1.3  LPM  Max:  42  LPM  
Controller  Dimensions  (LxWxH) 0.28  x  0.11  x  0.23  m  
Drive  Dimensions  (LxWxH)  0.40  x  0.38  x  0.69  m  
Power  Requirement  0.0030  hp  
Utilities  
Maximum  Power  0.75  hp  
Voltage  115  VAC  (90  to  130)  
Current  5.7  A  
Frequency  50/60  Hz  
Comments :  Purchase  cost  is  $7390.00 
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SPECIFICATION  SHEET  
Masterflex  B/T®  Digital  Drive,  Modular,  Washdown  Pump  
Equipment  
ID  PP-406  
Quantity  1  
Function  Transport  liquid  from  diafiltration  feed  tank  to  500  L  Storage  Tank  3  
Operation  30  mins  
Operations  
  In  Out  
Feed  401.7  L  (13.33  LPM)  401.7  L  (13.33  LPM)  
Pressure  1.01  bar  1.09  bar  
Temperature  25.0˚C  25.0˚C  
Design  Data  
Control  Type  Digital  Variable  Speed  
Washdown  Capable  Yes  
Flow  Rate  Min:  1.3  LPM  Max:  42  LPM  
Controller  Dimensions  (LxWxH) 0.28  x  0.11  x  0.23  m  
Drive  Dimensions  (LxWxH)  0.40  x  0.38  x  0.69  m  
Power  Requirement  0.0037  hp  
Utilities  
Maximum  Power  0.75  hp  
Voltage  115  VAC  (90  to  130)  
Current  5.7  A  
Frequency  50/60  Hz  
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SPECIFICATION  SHEET  
Masterflex  B/T®  PerfectPosition™  Pump  Tubing  
Equipment  
ID  N/A 
Quantity  90  (B/T  87)  +  10  (B/T  91)  
Function  Transport  of  fluid  between  process  units  
Operation  Continuous  
B/T  87  
Length  10  ft  (3  m)  
Inner  Diameter  0.5  in  (12.7  mm)  
Material  Platinum-Cured  Silicone  
Sterilization  Autoclave  
  Min  Max  
Flow  Rate  0.67  LPM  18.9  LPM  
Temperature  (Dynamic)  -40°C  100°C  
Temperature  -50°C  230°C  
Pressure  N/A 2.4  bar  
B/T  91  
Length  10  ft  (3  m)  
Inner  Diameter  0.75  in  (19  mm)  
Material  Platinum-Cured  Silicone  
Sterilization  Autoclave  
  Min  Max  
Flow  Rate  1.4  LPM  42  LPM  
Temperature  (Dynamic)  -40°C  100°C  
Temperature  -50°C  230°C  
Pressure  N/A 2.06  bar  
Utilities  N/A 
Comments :  Purchase  cost  of  B/T  87  is  $484.00  per  pack  of  10  /  B/T  91  is  $691.00  per  pack  of  10  
B/T  tubing  goes  with  the  B/T  peristaltic  pumps.  The  products  are  available  as  B/T  87  and  B/T  91  tubes.  
  
17.  Equipment  Cost  Summary  
Table  17.1  lists  the  purchase  and  bare  module  costs  of  all  the  required  equipment  for  this  
process.  While  we  will  not  actually  buy  the  equipment,  we  are  assuming  these  units  or  similar  
pieces  are  available  at  the  CMO.  By  calculating  the  total  bare  module  cost,  we  can  estimate  the  
CMO  costs  and  subsequently  estimate  a  reasonable  monthly  fee  to  use  their  equipment.  The  bare  
module  costs  were  calculated  using  the  purchase  costs  obtained  from  vendors  and  the  bare  
module  factors  from  Table  16.11  in  Seider  et  al.  (2017)  [93].  For  equipment  not  included  in  
Table  16.11,  bare  module  factors  were  estimated.  Specifically,  for  storage  tanks,  bare  module  
factor  of  4.0  was  assumed  in  the  equipment  costing  spreadsheet.  A  factor  of  4.16  was  assumed  
for  mixers  and  bioreactors,  which  was  considered  to  be  similar  in  function  to  a  fermenter.  Other  
pieces  of  equipment  without  a  bare  module  factor  were  assigned  the  default  value  of  3.21  in  the  
spreadsheet.  A  CEI  index  of  600  for  2021  was  used.  The  single-use  mixer  cost  was  assumed  to  
be  ¾  the  price  of  the  bioreactor  cost.  Finally,  the  biological  and  chemical  lab  was  assumed  to  be  
5%  of  the  total  capital  and  operating  costs.  
Table  17.1.  Purchase  and  Bare  Module  Costs  of  Equipment  
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Bare  Module  
Cost  
Raw  Material  Storage  
200  L  Media  Vessel  M-101  $  4,000.00  1  4.0  $  16,000.00  
2000  L  Media  Vessel  M-302  $  10,210.53  1  4.0  $  40,842.12  
3000  L  Media  Vessel  M-301  $  12,421.05  1  4.0  $  49,684.20  
100  L  Glucose  Vessel  GC-301  $  2,000.00  1  4.0  $  8,000.00  
500  L  Glutamine  Vessel  GT-301  $  3,000.00  1  4.0  $  12,000.00  
20  L  Antifoam  Vessel  AF-301  $  269.90  1  4.0  $  1,079.60  




$  1,500.00  3  4.0  $  18,000.00  
3000  L  Storage  Tank  ST-401  $  6,000.00  1  4.0  $  24,000.00  
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Upstream  Equipment  
WAVE™  Bioreactor  
System  20/50EH  
W-201a  
W-201b  $  4,000.00  2  3.21  $  25,680.00  
WAVE™  Bioreactor  




$  16,000.00  3  3.21  $  154,080.00  
500  L  Bioreactor  
(Jacketed)  PBrx-301 $  91,473.39  1  4.16  $  380,529.30  
500  L  Perfusion  System  PS-301  $  18,560.00  1  3.21  $  59,577.60  
2000  L  Bioreactor  
(Jacketed)  Brx-301  $  214,065.99  1  4.16  $  890,514.53  
Downstream  Equipment  
2-Rack  Process  Pod  
(Filter  Frame)  DeF-401  $  52,090.00  1  2.32  $  120,848.80  
His-tag  Chromatography  
Column  HC-401  $  76,000.00  1  4.16  $  316,160.00  
2000  L  Single-Use  Mixer  
(Non-Jacketed)  VI-401  $  160,549.49  1  4.16  $  667,885.90  
Ion  Exchange  
Chromatography  Column IEX-401  $  43,320.00  1  4.16  $  180,211.20  
Diafiltration  Assembly  
(Jacketed)  DiF-401  $  300,000.00  1  3.21  $  963,000.00  
Transport  Equipment  
Air  Compressor  with  
Tank  (for  WAVE  
Bioreactor  20/50EH)  
AC-201  $  1,212.50  1  2.15  $  2,606.88  
Air  Compressor  with  
Tank  (for  WAVE  
Bioreactor  200EH)  
AC-101  $  1,212.50  1  2.15  $  2,606.88  
Air  Compressor  with  
Tank  (for  500  L  Perfusion 
Bioreactor)  
AC-301  $  1,212.50  1  2.15  $  2,606.88  
Air  Compressor  with  
Tank  (for  2000  L  
Production  Bioreactor)  
AC-302  $  1,095.92  1  2.15  $  2,356.23  









$  7,390.00  9  3.30  $  219,483.00  
  
  
The  most  significant  investments  include  the  diafiltration  unit,  2000  L  bioreactor,  and  
2000  L  single-use  mixer.  This  is  expected,  as  these  are  the  largest  or  most  complex  pieces  of  
equipment.  Unfortunately,  they  are  completely  necessary  and  cannot  be  substituted  for  cheaper  
solutions.  Additionally,  they  should  be  able  to  be  used  for  many  years,  as  we  are  using  single-use  
bags  that  should  preserve  the  equipment  quality.  The  other  bioreactors  and  chromatography  
columns  also  account  for  a  large  portion  of  the  investment  costs.  Finally,  we  are  purchasing  
storage  tanks,  drums,  and  vessels  which  accumulate  to  be  a  large  portion  of  our  capital  




Biological/Chemical  Lab -  $  270,622.93  1  -  $  270,622.93  
            
        Total  $  4,428,376.03  
  
18.  Fixed  Capital  Investment  Summary  
The  company  will  partner  with  a  CMO  to  manufacture  the  vaccine  for  emergency  use.  
Based  on  consultation  with  Professor  Bruce  Vrana,  economics  were  analyzed  using  two  
spreadsheets  made  from  the  Profitability  4.0  Excel  spreadsheet  template:  one  for  the  CMO  to  
determine  our  rental  fee,  and  one  for  our  company  to  price  the  variable  costs.  All  fixed  costs  
were  incorporated  into  the  CMO  spreadsheet.  In  this  costing  exercise,  the  CMO  was  assumed  to  
have  invested  the  necessary  capital  in  2015  for  the  plant  to  operate  for  15  years.  The  CMO  was  
assumed  to  make  1  product  a  month,  totaling  12  products  each  year.  
  
18.1  Total  Bare  Module  Cost  
All  of  the  required  equipment  bare  module  costs  were  input  into  the  CMO  spreadsheet  to  
determine  the  fixed  costs  for  our  process.  Each  piece  of  equipment  was  classified  as  either 
storage  or  process  machinery.  Process  machinery  was  equipment  bought  from  a  vendor  in  
standard  sizes.  There  was  no  fabricated  equipment,  as  none  of  the  units  required  custom  design.  
The  biochemical  lab  was  considered  to  be  a  part  of  other  equipment.  The  total  bare  module  costs  
for  our  process  are  listed  in  Figure  18.1  below.  
  




The  total  bare  module  cost  for  fixed  equipment  is  roughly  $4.4  million.  This  consists  
primarily  of  the  process  machinery  required  to  run  this  process.  Spares  were  not  accounted  for,  
but  this  cost  is  wrapped  into  a  multiplier  used  later  in  the  estimation  of  what  the  CMO  might  
charge  the  company.  The  storage  units  do  not  make  up  a  significant  amount  of  our  costs,  as  they  
are  not  nearly  as  expensive  as  the  process  equipment.  
  
18.2  Total  Permanent  Investment  
Other  fixed  costs  such  as  royalties  and  facilities  were  considered  to  calculate  the  total  
permanent  investment  of  the  CMO.  No  default  spreadsheet  values  for  these  factors  were  
changed.  Figure  18.2.1  below  breaks  down  how  the  additional  fixed  costs  were  calculated.  
Guthrie’s  factored-cost  methods  were  used,  thus  our  cost  of  site  preparation  and  service  facilities,  
for  example,  were  taken  as  percentages  of  our  bare  module  costs  [93].   
  
Figure  18.2.1 .  Total  Permanent  Investment  inputs  from  Profitability  4.0  Spreadsheet  
  
The  royalties  remained  zero,  as  we  do  not  expect  royalty  costs.  Additionally,  the  costs  for  
utility  plants  were  not  included  since  municipal  utilities  will  be  used  instead.  The  total  permanent  
investment  comes  out  to  about  $6.7  million  for  the  CMO.  Professor  Vrana  suggested  using  a  
sight  factor  of  1.05  for  North  Carolina.  Seider  et  al.  (2017)  defines  an  investment  site  factor  of  
1.00  for  states  on  the  Gulf  Coast  and  1.10  for  states  in  the  Northeast  [93].  Since  North  Carolina  
lies  between  these  regions,  1.05  was  taken  to  be  a  reasonable  estimate.  Figure  18.2.2  shows  the  




Figure  18.2.2.  Total  Permanent  Investment  Summary   
  
  
18.3  Remaining  Fixed  Costs  
Figure  18.3  below  summarizes  the  remaining  fixed  costs  used  to  determine  the  total  
capital  investment  for  the  CMO.  Notably,  it  includes  operations,  maintenance,  overhead,  
property  taxes,  and  depreciation.  No  spreadsheet  defaults  were  changed  other  than  the  




Figure  18.3.  Remaining  Fixed  Costs  of  the  CMO.  
  
18.4  Total  Fixed  Cost  Summary  
Figure  18.4  below  summarizes  the  total  fixed  cost  for  the  CMO  to  operate,  which  is  




Figure  18.4.  Fixed  Cost  Summary  for  the  CMO  
  
  
18.5  Working  Capital  
Figure  18.5.1  shows  the  CMO  working  capital  calculation  parameters  for  accounts  
receivable,  cash  reserves,  accounts  payable,  vaccine  inventory,  and  raw  materials.  The  default  
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values  were  not  changed.  Figure  18.5.2  shows  the  total  capital  investment  comes  out  to  $7.9  
million  for  the  CMO.  No  raw  materials  or  variable  costs  are  included,  as  these  costs  were  
assumed  to  be  transferred  to  the  company  partnering  with  the  CMO.  
  
Figure  18.5.1.  Calculation  Parameters  for  Working  Capital  for  the  CMO.  
  
  
Figure  18.5.2.  Total  Working  Capital  Summary  for  the  CMO.  
  
After  completing  the  analysis  for  the  CMO,  an  estimation  was  needed  for  the  fee  that  the  
CMO  chould  charge  our  company  to  use  their  space  for  3  months.  Two  months  would  be  used  
for  experiments  and  training  personnel,  while  the  last  month  would  be  used  for  actual  
production.  The  plant  was  assumed  to  be  operational  for  15  years,  and  an  IRR  of  minimally  15%  
was  required  for  the  CMO  to  be  satisfied.  To  achieve  this,  the  CMO  needs  to  earn  approximately  
$1.15  million  per  month  assuming  the  facility  operates  at  80%  design  capacity.  This  fee  was  
multiplied  by  3  to  account  for  the  3  month  rental,  then  multiplied  by  5  to  account  for  current  
competition  in  the  CMO  market  and  the  profit  the  CMO  would  want  to  incur.  This  number  was  
taken  to  be  a  rental  fee  in  our  company  spreadsheet,  where  the  variable  costs  and  other  remaining  
costs  were  input  and  explained  in  Section  19  and  summarized  in  Figure  19.5 .   
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19.  Operating  Cost  
19.1  Process  Materials  
Table  19.1  lists  the  cost  of  process  materials  for  one  operation  campaign,  with  
components  listed  by  its  usage  in  each  unit  operation:  storage  materials,  transport  materials,  
upstream  materials,  and  downstream  materials.  The  plant  spends  about  $928,000  on  raw  
products  and  process  materials  per  campaign.  Each  dose  will  take  $0.0019  of  process  materials  
to  manufacture,  which  is  significantly  below  the  selling  price  of  $16  per  dose  [94].  
Table  19.1.  Cost  of  Process  Materials  per  Run,  Grouped  by  Unit  Operation  
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Materials  Unit  Cost  Quantity  Unit  Purchase  Cost 
Storage  Materials  
50  L  WAVE  Bioreactor  
Cell  Culture  Bags  $  322.16/Cellbag  2  Cellbag  $  644.32  
200  L  WAVE  Bioreactor  
Cell  Culture  Bags  $  1,288.64/Cellbag  3  Cellbag  $  3,865.92  
500  L  BioProcess  
Containers  $  4,453.99/BPC  4  BPC  $  17,815.95  
2000  L  BioProcess  
Containers  $  10,233.13/BPC  2  BPC  $  20,466.26  
2500  L  BioProcess  
Containers  $  14,058.37/BPC  1  BPC  $  14,058.37  
Transport  Materials  
Sterile  Filter  (for  Liquid)  $  152.60/filter  15  filter  $  2,289.00  
10  ft  Peristaltic  Tube  
(B/T  87)  $  48.40/ft  (per  10  ft)  900  ft  $  43,560.00  
10  ft  Peristaltic  Tube  
(B/T  91)  $  69.10/ft  (per  10  ft)  100  ft  $  6,910.00  
10x  Fitting,  Nylon,  
Straight,  Hose  Barb  
Union  (0.5  in)  
$  2.13/fitting  (pack  of  10) 50  fitting  $  106.25  
10x  Fitting,  Nylon,  
Straight,  Hose  Barb  
Union  (0.75  in)  
$  2.65/fitting  (pack  of  10) 10  fitting  $  26.50  
Upstream  Materials  
125  mL  Erlenmeyer  
Shake  Flask  $  15.70/flask  4  flask  $  62.80  
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250  mL  Erlenmeyer  
Shake  Flask  $  17.70/flask  2  flask  $  35.40  
500  mL  Erlenmeyer  
Shake  Flask  $  27.10/flask  4  flask  $  108.40  
5  L  Erlenmeyer  Shake  
Flask  $  166.00/flask  3  flask  $  498.00  
Cell  Bank  Inoculum $  450.00/vial  (50M  cells)  4  vial  $  1,800.00  
Baculovirus  Stock  $  112.50/mL  (per  10  mL)  40  mL  $  4,500.00  
Sf-900  II  SFM  $  67.50/L  (per  20  L)  4300  L  $  290,250.00  
Oxygen  (+  Tank)  $  0.0677/L  (per  7079  L)  106,185  L  $  7,186.80  
Glucose  $  10.72/kg  (per  25  kg)  75  kg  $  804.00  
Glutamine  $  509.00/kg  20  kg  $  10,180.00  
Base  (1M  NaOH) $  26.36/L  (per  4  L)  4  L  $  105.45  
Antifoam  $  1,164.00/L  (per  50  mL)  14.1  L  $  16,412.40  
Purified  Water  /  100  L  
Glucose  Vessel  $  5.12/L  (per  200  L)  82.4  L  $  421.4884  
Purified  Water  /  100  L  
Glutamine  Vessel  $  5.12/L  (per  200  L)  484.3  L  $  2,479.6160  
Downstream  Materials  
D0SP  Filter  $  834.00/filter  26  filter  $  21,684.00  
X0SP  Filter  $  1,050.00/filter  13  filter  $  13,650.00  
Depth  Filtration  Wetting  /  
Flushing  Buffer  
(Purified  Water)  
$  5.12/L  (per  200  L)  917  L  $  4,690.59  
His-tag  Resin  $  6,660.00/L  34  L  $  226,440.00  
His-tag  Sodium  
Phosphate  $  206.44/kg  16.1  kg  $  3,323.68  
His-tag  NaCl  $  40.26/kg  95.6  kg  $  3,848.51  
His-tag  Imidazole  $  154.00/kg  15.9  kg  $  2,448.60  
His-tag  MES  $  472.00/kg  5.4  kg  $  2,548.80  
His-tag  Purified  Water  $  5.12/L  (per  200  L)  7555  L  $  38,644.96  
1M  Acetic  Acid  $  26.75/L  (per  20  L)  40  L  $  1,070.00  
1M  Tris  Base  $  91.00/kg  (per  5  kg)  10  L  $  910.00  
Sterile  Membrane  Filter  $  970.00/filter  1  filter  $  970.00  
Ion-Exchange  Resin  $  3,600.00/L  26.5  L  $  95,400.00  
Ion-Exchange  NaCl  for  
Buffers  $  52.20/kg  34  kg  $  1,774.80  
Ion-Exchange  Wash  
Buffer  (Purified  Water)  $  5.12/L  (per  200  L)  159  L  $  813.31  
Ion-Exchange  Elution  
Buffer  (Acetic  Acid)  $  14.24/L  (per  2.5  L)  7.5  L  $  106.80  




19.2  Utilities  
Data  from  the  U.S.  Energy  Information  Administration  lists  the  average  price  of  
electricity  for  the  industrial  sector  in  North  Carolina  as  $0.0575  per  kilowatt-hour  in  January  
2021  [95].  For  the  treatment  of  solid  waste,  the  cost  for  treating  biowaste  at  a  local  incinerator  
company  was  calculated  as  ten  times  the  cost  of  treating  municipal  waste,  as  per  consultation  
with  Dr.  Cohen.  The  CMO  facility  is  located  in  Durham,  North  Carolina,  where  the  cost  of  
treating  municipal  waste  is  $47.50  per  ton  [96][97],  which  we  estimated  would  cost  $475  to  treat  
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Buffer  (Sodium  Acetate)  
Ion-Exchange  Elution  
Buffer  (Purified  Water)  $  5.12/L  (per  200  L)  334  L  $  1,708.46  
Ion-Exchange  Cleaning  
Buffer  (Purified  Water)  $  5.12/L  (per  200  L)  530  L  $  2,711.03  
Ion-Exchange  Cleaning  
Buffer  (Acetic  Acid)  $  14.24/L  (per  2.5  L)  265  L  $  3,773.60  
Adsorptive  Pre-Filter  
(Viral  Pre-filter)  $  1,340.00/filter  1  filter  $  1,340.00  
Magnus  2.1  Pro  Device  
(Viral  Filter)  $  10,270.00/filter  1  filter  $  10,270.00  
Viral  Filtration  Wetting  
Buffer  (Purified  Water)  $  5.12/L  (per  200  L)  26  L  $  132.99  
Viral  Filtration  Flushing  
Buffer  (50  mM  Acetate)  $  210.08/L  (per  250  mL)  26  L  $  5,462.08  
Diafiltration  Filter  
(Pellicon  3,  30kD  
Ultracel,  D  Screen)  
$  7,160.00/cassette  3  cassette $  21,480.00  
Diafiltration  Buffer  
(NaCl)  $  16.48/kg  (per  25  kg)  412  kg  $  6,789.76  
Diafiltration  Buffer  
(NaH2PO4  ·  H2O) $  151.14/kg  (per  500  g)  0.5  kg  $  75.57  
Diafiltration  Buffer  
(Na2HPO4  ·  12H2O) $  184.80/kg  (per  500  g)  0.5  kg  $  92.40  
Diafiltration  Buffer  
(Purified  Water)  $  5.12/L  (per  200  L)  2116  L  $  10,823.66  
Diafiltration  Cleaning  
Buffer  (0.1N  NaOH)  $  133.80/kg  (per  500  g)  0.5  kg  $  66.90  
  
one  ton  of  biowaste.  Our  utilities  costs  are  summarized  below  in  Table  19.2 .  The  most  significant  
costs  include  the  electricity  for  the  media  vessels  and  wastewater  treatment.  In  total,  the  utilities  
cost  about  $6,000  per  run.  
Table  19.2.  Cost  of  Utilities  By  Unit  Operation  
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Utilities  Unit  Cost  Amount  Unit  Utilities  Cost  
Utilities  per  Process  Unit  
Chilled  Water  /  
500  L  Perfusion  Bioreactor  $  0.0178/kWh  79.44  kWh  $  1.41  
Chilled  Water  /  
2000  L  Bioreactor  $  0.0178/kWh  83.04  kWh  $  1.48  
Chilled  Water  /  
Diafiltration  Assembly  $  0.0178/kWh  23.80  kWh  $  0.42  
Electricity  /  WAVE™  
Bioreactor  System  20/50EH $  0.0575/kWh  82.80  kWh  $  4.76  
Electricity  /  WAVE™  
Bioreactor  System  200EH  $  0.0575/kWh  259.20  kWh  $  14.90  
Electricity  /  500  L  Perfusion  
Bioreactor  $  0.0575/kWh  288.00  kWh  $  16.56  
Electricity  /  2000  L  
Bioreactor  $  0.0575/kWh  288.00  kWh  $  16.56  
Electricity  /  2000  L  
Single-Use  Mixer  $  0.0575/kWh  10.00  kWh  $  0.5750  
Electricity  /  Diafiltration  
Assembly  $  0.0575/kWh  30.80  kWh  $  1.7710  
Electricity  /  Air  Compressor 
(for  WAVE  Brx  20/50EH)  $  0.0575/kWh  15.30  kWh  $  0.8798  
Electricity  /  Air  Compressor 
(for  WAVE  Brx  200EH)  $  0.0575/kWh  9.18  kWh  $  0.5279  
Electricity  /  Air  Compressor 
(for  500  L  Perfusion  Brx)  $  0.0575/kWh  15.30  kWh  $  0.8798  
Electricity  /  Air  Compressor 
(for  2000  L  Production  Brx) $  0.0575/kWh  45.00  kWh  $  2.5875  
Electricity  /  Upstream  
Peristaltic  Pump  
(BV  WAVE  to  N  Brx)  
$  0.0575/kWh  0.14  kWh  $  0.0081  
Electricity  /  Upstream  
Peristaltic  Pump  
(Sf-9  WAVE  to  N-1  Brx)  
$  0.0575/kWh  0.28  kWh  $  0.0162  
Electricity  /  Upstream  
Peristaltic  Pump  
(N-1  Brx  to  N  Brx)  
$  0.0575/kWh  0.28  kWh  $  0.0162  
Electricity  /  Downstream  $  0.0575/kWh  1.13  kWh  $  0.0647  
  
  
19.3  Labor  Costs  
Our  plant  will  require  5  operators  and  1  engineering  manager  per  shift.  There  will  be  a  
total  of  5  shifts  per  day  at  8  hours  each  for  continuous  operation  of  24/7,  including  weekends.  
Operators  will  receive  a  salary  of  $60,000,  and  the  manager  will  receive  a  salary  of  $75,000.  The  
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Peristaltic  Pump  
(for  Depth  Filtration)  
Electricity  /  Downstream  
Peristaltic  Pump  
(for  His-tag  Column)  
$  0.0575/kWh  27.00  kWh  $  1.5525  
Electricity  /  Downstream  
Peristaltic  Pump  
(for  IEX  Column)  
$  0.0575/kWh  3.94  kWh  $  0.2264  
Electricity  /  Downstream  
Peristaltic  Pump  
(for  Viral  Filtration)  
$  0.0575/kWh  1.69  kWh  $  0.0970  
Electricity  /  Downstream  
Peristaltic  Pump  
(for  Diafiltration  in)  
$  0.0575/kWh  0.28  kWh  $  0.0162  
Electricity  /  Downstream  
Peristaltic  Pump  
(for  Diafiltration  out)  
$  0.0575/kWh  0.28  kWh  $  0.0162  
Utilities  per  Storage  Unit  
Electricity  /  
200  L  Media  Vessel  $  0.0575/kWh  900  kWh  $  51.7500  
Electricity  /  
2000  L  Media  Vessel  $  0.0575/kWh  1500  kWh  $  86.2500  
Electricity  /  
3000  L  Media  Vessel  $  0.0575/kWh  1500  kWh  $  86.2500  
Electricity  /  
100  L  Glucose  Vessel  $  0.0575/kWh  180  kWh  $  10.3500  
Electricity  /  
500  L  Glutamine  Vessel  $  0.0575/kWh  360  kWh  $  20.7000  
Total  Utilities  
Chilled  Water  $  0.0178/kWh  186.28  kWh  $  3.31  
Electricity  $  0.0575/kWh  5435.80  kWh  $  317.32  
Waste  Treatment  
Solid  Waste  Treatment  $  0.24/lb  50  lb  $  11.88  
Wastewater  Treatment  $  0.33/kg  16453.54  kg  $  5429.67  
  
costs  for  the  5  operators  per  shift  were  included  in  the  CMO  analysis  in  Section  18.  The  cost  for  
our  own  engineering  manager,  who  will  oversee  plant  operations  and  quality  control  to  ensure  
adherence  to  GMP  standards,  was  included  in  our  company  spreadsheet.  
  
19.4  Variable  Costs  
Other  variable  costs  for  the  company  include  selling  and  transfer  expenses,  research,  
administrative  expenses,  and  management  incentive  compensation.  These  costs  were  included  in  
addition  the  monthly  fee  for  the  CMO  in  the  company  spreadsheet.  Both  the  company  and  the  
CMO  were  assumed  to  bear  research  and  administrative  expenses.  Figure  19.4.1  shows  the  
parameters  used.  
  
Figure  19.4.1.  Calculation  Parameters  for  Variable  Costs  
  
Figure  19.4.2  summarizes  the  variable  costs  from  our  company  spreadsheet  to  account  
for  raw  materials,  utilities  and  general  expenses.  The  total  variable  cost  is  $925  million.  
  




19.5  Remaining  Fixed  Costs  
The  fixed  costs  for  our  company  include  the  CMO  rental  fee  and  minor  costs  for  
operation  and  overhead.  Figure  19.5  summarizes  the  fixed  costs,  which  total  $18.8  million.   
  





19.6  Working  Capital  
Figure  19.6  shows  the  total  working  capital  investment  for  the  company.  The  calculation 
parameters  are  the  same  as  those  in  the  CMO  spreadsheet.  Our  total  capital  investment  for  
working  capital  comes  out  to  $553  million.  
  
Figure  19.6.  Working  Capital  Summary  for  the  Company   
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20.  Other  Important  Considerations  
20.1  Environmental  Factors  
Gaseous  Waste  
In  bioreactors,  cells  require  oxygen  to  grow  and  produce  protein,  releasing  carbon  
dioxide  in  the  process.  Carbon  dioxide,  produced  in  excessive  amounts,  presents  concerns  with  
respect  to  limiting  cell  growth,  protein  production,  and  greenhouse  gas  emissions.  To  limit  this  
concentration,  the  500L  and  2000L  bioreactors  will  be  equipped  with  spargers  that  feed  nitrogen  
in  the  form  of  air  to  strip  the  carbon  dioxide.  Since  we  anticipate  that  the  cells  will  produce  
carbon  dioxide  at  a  greater  rate  than  it  can  be  sparged,  a  base  (sodium  hydroxide,  NaOH)  will  be  
added  as  needed  to  neutralize  the  excess  carbonic  acid  that  forms  from  the  carbon  dioxide  in  
water.  Dr.  Cohen  advised  us  that  standard  industrial  practice  is  to  vent  bioreactor  gases  back  into  
the  room  after  the  stream  passes  through  a  filter  in  the  bioreactor.  This  gas  stream  contains  
oxygen,  nitrogen,  and  carbon  dioxide  present  in  negligible  amounts.  
  
Liquid  Waste  
The  upstream  and  downstream  processes  produce  liquid  waste  streams  that  contain  insect  
cells,  cell  debris,  and  inactivated  viral  particles.  The  upstream  seed  train  produces  four  parallel  
streams  of  insect  cells.  One  of  these  will  be  an  extra  stream  in  case  of  equipment  malfunction  or  
mechanical  failure  in  one  of  the  other  lines,  and  will  be  treated  with  chlorine  bleach  to  kill  the  
live  cells.  The  downstream  purification  processes  produce  large  volumes  of  buffer  and  resins.  
The  two  chromatography  columns  use  both  resins  and  buffers  that  will  contain  larger  cell  debris  
and  some  viral  particles.  The  diafiltration  unit  will  produce  buffers  that  contain  small  cellular  
components.  These  streams  will  also  be  treated  with  chlorine  bleach.  Dr.  Cohen  confirmed  that  
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liquid  streams  treated  with  chlorine  bleach  can  be  disposed  of  as  municipal  waste  poured  down  
the  drain.  
  
Solid  Waste  
The  upstream  and  downstream  processes  produce  solid  waste  in  the  form  of  membrane  
filters  that  contain  cell  debris  and  inactivated  viral  particles.  Two  of  the  insect  cell  seed  streams  
will  be  used  in  the  baculovirus  seed  train,  and  the  dead  cell  debris  will  be  filtered  out  of  the  
supernatant  using  a  sterile  filter.  The  depth  filtration,  virus  filtration,  and  diafiltration  units  use  
membrane  filters  to  separate  out  large  and  small  cell  debris  and  viral  particles.  These  filters  are  
treated  as  hazardous  waste  that  will  be  disposed  of  in  red  biohazard  bags.  Consultation  with  Dr.  
Cohen  revealed  that  solid  biowaste  is  sent  to  a  local  incinerator  that  will  burn  the  solids  to  ashes.  
Many  unit  operations  in  the  biopharmaceutical  industry  have  single-use  technologies  to  
increase  operation  flexibility,  reduce  contamination  risks,  and  eliminate  the  need  for  cleaning  
validation.  This  saves  time  and  money  by  lessening  the  need  for  certain  chemical  resources  and  
personnel.  However,  the  tradeoff  is  the  increased  generation  of  plastic  waste  in  the  form  of  
single-use  plastic  bioreactor  bags  and  plastic  piping.  To  minimize  our  plastic  waste  generation,  
we  have  designed  the  manufacturing  process  to  produce  and  purify  a  sufficient  amount  of  
vaccines  in  one  campaign.  
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20.2  Public  and  Employee  Safety  
Baculovirus  
Our  manufacturing  process  requires  the  use  of  a  baculovirus  to  infect  cells  to  produce  the  
desired  Spike  protein.  Despite  being  a  virus,  the  baculovirus  only  infects  insects  and  poses  no  
harm  to  humans.  It  only  contains  the  genetic  information  to  make  the  Spike  protein.  There  is  no  
live  handling  of  SARS-CoV-2,  thus  employees  are  in  no  danger  of  getting  COVID-19  from  this  
process.  The  process  will  also  pose  no  biological  threat  to  the  public.  
  
Chemical  Handling  
Different  processes  will  require  handling  of  acids,  bases,  and  chemical  powders.  The  viral  
inactivation  operation  requires  the  direct  addition  of  acid  and  base,  which  will  be  connected  to  
the  mixer  by  piping.  Large  volumes  of  buffers  for  chromatography  and  diafiltration  must  be  
made  by  laboratory  staff  using  various  acids,  bases,  and  powders.  Any  employee  that  handles  
these  chemicals  must  be  properly  trained  on  the  correct  preparation  and  cleaning  procedures,  as  
well  as  be  informed  on  any  necessary  emergency  procedures.  
  
  
20.3  Regulatory  Requirements  
The  safety  and  efficacy  of  any  vaccine  must  be  scientifically  tested  and  proven  before  
being  administered  to  the  public.  The  data  must  be  backed  by  the  appropriate  pre-clinical  and  
clinical  trials  and  undergo  the  necessary  vetting  and  authorization  processes  for  approval.  The  
CMO  facility  must  follow  current  good  manufacturing  practices  (cGMPs)  and  meet  the  statutory  
and  regulatory  requirements  for  quality,  development,  manufacturing,  and  control.  This  will  
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ensure  that  the  facility  and  equipment  are  sterile  and  qualified,  and  the  potency  and  stability  of  
the  vaccine  is  maintained  [14].  
  
  
20.4  Social  and  Ethical  Considerations  
Company  and  CMO  practices  should  ensure  safe  working  conditions  and  environments 
that  protect  and  support  mental  and  physical  health  of  employees,  surrounding  communities,  and  
the  public.  In  particular,  employees  must  be  properly  trained  to  handle  and  dispose  of  waste.  
Additionally,  allocation  of  vaccines  should  be  done  in  a  fair  and  equitable  manner  after  
manufacturing  and  formulation  is  complete.  All  nations  should  have  access  to  the  vaccine  at  an  
affordable  price,  regardless  of  wealth  or  global  standing.  COVAX  (COVID-19  Vaccines  Global  
Access)  is  a  global  initiative  working  toward  this  goal  in  collaboration  with  CEPI  (Coalition  for  
Epidemic  Preparedness  Innovation),  GAVI  (Gavi,  the  Vaccine  Alliance,  previously  the  Global  
Alliance  for  Vaccines  and  Immunization),  WHO  (World  Health  Organization),  and  other  
organizations  with  community  outreach  programs.  Local  distribution  should  prioritize  recipients  
of  vaccines  based  on  their  respective  priority  groups.  Public  health  departments  should  work  to  
mitigate  health  inequities  for  vulnerable  populations  to  remove  unjust,  unfair,  or  unavoidable  
barriers  to  health  and  well-being  [98].  
  
  
20.5  Formulation  and  Packaging  
The  drug  substance  in  the  final  storage  tank  after  the  last  stage  of  the  downstream  process  
comprises  2.6  kg  of  recombinant  spike  protein  with  a  buffer  volume  of  401.7  L.  According  to  the  
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clinical  study  protocol  for  Novavax’s  SARS-CoV-2  recombinant  protein  vaccine,  the  dose  level  
is  5  µg  of  protein  with  50  µg  of  Matrix-M1  saponin-based  adjuvant  (ratio  of  1:10)  in  a  0.5  mL  
solution  [99].  Since  the  Novavax  vaccine  utilizes  similar  technology  to  our  project,  their  protein  
concentration  was  sufficient  to  use  as  an  estimate.  Therefore,  2.6  kg  of  spike  protein  would  need  
to  be  formulated  with  26  kg  of  adjuvant,  and  the  total  amount  of  additional  volume  required  
would  be  about  259,522  L,  which  includes  components  such  as  buffers,  preservatives,  stabilizers,  
and  antibiotics.  Before  sending  the  drug  substance  for  formulation  of  drug  product  and  
packaging  in  vials,  the  drug  substance  is  typically  frozen  or  lyophilized  for  stability.  
  
  
20.6  Batch  Sizes  
The  number  and  size  of  production  bioreactors  are  important  design  choices.  One  large  
bioreactor  may  have  lower  capital  costs,  but  multiple  smaller  reactors  likely  have  less  financial  
losses  due  to  quality  concerns  in  the  production  bioreactor.  According  to  a  recent  article  on  
SARS-CoV-2  vaccine  manufacturing,  15  million  vaccine  doses  were  discarded  because  workers  
used  the  incorrect  ingredients  [100].  If  multiple  smaller  batches  were  used  for  the  vaccine 
manufacturing  process,  less  vaccine  doses  would  have  been  wasted.  However,  because  
SARS-CoV-2  is  an  emergency  measure  and  time  is  critical,  there  would  be  a  bigger  life  threat  if  
vaccines  are  developed  more  slowly.  Thus,  we  believe  that  if  workers  are  vigilant,  with  ready  
oversight  provided  on  the  factory  floor,  it  is  reasonable  to  choose  a  single,  large  batch  for  our  
production  of  COVID-19  vaccine  to  achieve  timely  production.  Also,  the  2000  L  production  
bioreactor  in  our  process  design  is  relatively  small  compared  to  larger  bioreactors  currently  in  
operation  at  various  CMOs.  Of  course,  if  needed,  our  process  can  be  divided  into  multiple  small  
144  
  
batches  run  over  a  longer  period  of  time  to  alleviate  any  financial  concerns  surrounding  the  
investment  of  capital  into  a  single  large  batch.  
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21.  Profitability  Analysis  
21.1  CMO  Profitability  
Two  profitability  analyses  were  concurrently  used  to  evaluate  this  project  in  consultation  
with  Professor  Bruce  Vrana.  The  first  analysis  considered  fixed  costs  for  the  CMO  while  the  
second  analysis  assessed  the  variable  costs  specific  to  this  manufacturing  process  for  our  
company.  The  CMO  facility  was  assumed  to  have  been  designed  in  2015  and  constructed  in  
2016,  with  production  and  sales  starting  in  2017.  The  plant  was  assumed  to  operate  at  40%  
capacity  in  2017,  60%  capacity  in  2018,  and  80%  capacity  from  2019  onwards.  The  COVID-19  
vaccine  production  process  is  set  to  operate  in  2021,  where  the  CMO  would  be  fully  operational  
at  80%  capacity.  
To  account  for  additional  business  that  the  CMO  is  involved  in,  the  plant  was  assumed  to  
manufacture  12  products  per  year  for  15  years,  with  each  product  priced  at  a  total  of  $1.15  
million.  The  fixed  costs  under  the  CMO  included  equipment,  labor,  maintenance,  and  technical  
assistance.  The  CMO  was  assumed  to  charge  a  multiple  of  3  times  more  than  the  total  bare  
module  cost  for  our  equipment,  in  addition  to  a  profit  and  in  consideration  of  CMO  competition  
for  another  factor  of  2.  This  multiplying  factor  was  taken  into  account  in  the  CMO  rental  fee  cost  
for  our  company  to  produce  one  campaign  of  vaccines.  The  CMO  cash  flow  summary  in  Figure  
21.1  was  generated  under  the  mentioned  assumptions  using  a  2%  general  inflation  rate  and  a  
discount  rate  of  15%  for  capital.  
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Figure  21.1.  Cash  Flow  Summary  for  the  CMO  
  
Operation  of  the  CMO  facility  is  profitable,  with  the  capital  investment  recovered  within  
the  15  year  production  timeline.  Figure  21.2  shows  that  the  plant  has  a  net  present  value  (NPV)  
of  $855,000,  a  return  on  investment  (ROI)  of  18.08%,  and  an  investor’s  rate  of  return  (IRR)  of  
16.83%.  Since  the  IRR  is  above  15%,  this  plant  is  considered  profitable  and  attractive.  These  
numbers  motivate  the  operation  of  this  plant  through  2031,  which  ensures  the  facility  can  be  
operational  in  2021  for  the  manufacture  of  our  vaccine.  
  
Figure  21.2.  Profitability  Measures  for  the  CMO  
  
Figure  21.3  shows  a  sensitivity  analysis  on  IRR  for  the  CMO  based  on  the  price  per  
project  product  and  the  variable  costs.  Clearly,  decreasing  variable  costs  and/or  increasing  
product  price  would  result  in  a  higher  IRR.  Since  the  CMO’s  variable  costs  of  a  project  are  paid  
by  the  partnering  company,  its  own  variable  costs  can  only  be  reduced  by  selling  and  transferring  
expenses,  research,  and  administrative  expenses.  The  product  price  of  $1.15  million  per  project  
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is  an  arbitrary  number,  the  CMO  can  absolutely  bring  in  more  revenue  by  increasing  the  fee  that  
partnering  companies  are  charged.  However,  dropping  the  product  price  below  $1.15  million  or  
increasing  variable  costs  by  about  $500,000  to  $2  million  would  cause  the  IRR  to  dip  below  
15%,  rendering  the  plant  unattractive  for  investment.  If  the  CMO  consistently  operates  with  
factors  that  result  in  an  IRR  of  at  least  15%,  the  CMO  would  be  more  open  to  negotiating  with  
our  company  on  manufacture  of  the  vaccine.  
Figure  21.3.  Sensitivity  Analysis  of  IRR  Using  Product  Price  and  CMO  Variable  Costs.  
  
Figure  21.4  shows  a  sensitivity  analysis  on  IRR  for  the  CMO  based  on  the  price  per  
project  product  and  the  general  inflation  rate.  Lower  inflation  rates  and/or  increasing  product  
price  would  result  in  a  higher  IRR.  However,  dropping  the  product  price  below  $1.15  million  or  
having  the  inflation  climb  above  2.60%  would  cause  the  IRR  to  dip  below  15%,  rendering  the  
plant  unattractive  for  investment  and  closed  to  partnerships  with  companies  like  ours.  
Figure  21.4.  Sensitivity  Analysis  of  IRR  Using  Product  Price  and  General  Inflation  Rate.  
  
  
21.2  Company  Profitability  
The  company  cash  flow  summary  in  Figure  21.5  was  generated  using  a  selling  price  of  
$16  per  dose  [94].  Inflation  was  considered  negligible  in  the  short  timespan  of  one  campaign,  
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and  a  discount  rate  of  15%  for  capital  was  used.  Since  the  scope  of  the  project  is  limited  to  the  
manufacture  of  500  million  vaccine  doses,  company  cash  flows  were  not  considered  outside  of  
this  campaign.  Therefore,  the  cash  flow  summary  only  has  valid  inputs  for  the  first  year.  From  
one  production  campaign,  the  project  is  estimated  to  have  a  net  present  value  of  $1.5  billion  
dollars,  with  positive  net  earnings  of  $2  billion  and  cash  flow  of  $1.5  billion  in  the  same  year  as  
production.  However,  the  short  lifespan  of  this  project  was  difficult  to  incorporate  into  the  
profitability  analysis,  which  is  typically  done  for  much  longer  projects,  such  as  in  the  case  of  the  
proposed  CMO  facility.  
  
Figure  21.5.  Cash  Flow  Summary  for  the  Company  
  
None  of  the  previous  IRR,  NPV,  or  ROI  values  could  be  calculated,  as  our  IRR  would  
appear  ridiculously  large.  Dr.  Arthur  Etchells  observed  that  this  was  due  to  the  fact  that  our  
company  had  no  investment  input  for  bare  module  costs,  direct  permanent  investment,  
depreciable  capital,  or  total  permanent  investment.  Despite  the  presence  of  variable  costs,  fixed  
costs,  and  working  capital  investments,  the  spreadsheet  was  unable  to  determine  any  of  the  
profitability  values  for  the  company.  Dr.  Koshari  reminded  the  team  that  typically  there  are  years  
of  research  and  development  (R&D),  pre-clinical,  and  clinical  trial  costs  invested  in  prior  years,  
which  were  not  accounted  for  in  this  spreadsheet.  There  is  also  a  portion  of  profit  that  
formulation  and  packaging  takes  after  completion  of  manufacture,  which  would  decrease  the  
profits  of  the  company  but  were  not  accounted  for.  Due  to  these  complications,  a  sensitivity  
analysis  on  the  vaccine  selling  price  could  not  be  performed.  However,  a  project  worth  $1.5  
billion  for  the  one  year  it  is  implemented  is  clearly  very  profitable.   
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22.  Conclusions  and  Recommendations  
The  manufacture  of  500  million  doses  of  recombinant  SARS-CoV-2  spike  protein-based  
vaccines  using  BEVS  is  economically  profitable  for  both  the  CMO  and  our  company.  We  will  
achieve  an  extremely  large  IRR,  as  our  permanent  investment  is  negligible,  as  this  cost  will  be  
taken  up  by  the  CMO.  The  IRR  for  the  CMO  plant  is  16.83%  assuming  the  CMO  charges  us  
$1.15  million  per  month  to  use  their  facilities.  Our  company  will  then  incur  the  variable  costs,  
working  capital  costs,  and  the  rental  fee  for  the  CMO.  Charging  $16  per  dosage  of  vaccine  
results  in  $8  billion  in  revenue.  Our  net  earnings  for  the  process  accumulate  to  be  about  $2  
billion.  Hence,  the  project  is  extremely  profitable  and  we  recommend  the  manufacture  of  this  
vaccine  immediately  for  emergency  use.  
Overall,  the  process  is  expected  to  produce  3.75  kg  of  spike  protein  in  the  upstream  
process  with  a  30%  yield  loss  in  the  downstream  process,  producing  a  final  drug  substance  of  2.6  
kg  of  spike  protein.  The  upstream  process  takes  24  days  to  complete,  the  downstream  process  
about  3  days.  Since  the  overall  process  is  about  27  days,  a  month  should  be  an  effective  estimate  
of  production  time.  While  multiple  production  cycles  are  not  anticipated,  a  total  of  four  cycles  
could  be  anticipated  to  reach  completion  within  the  course  of  3  months,  assuming  that  each  cycle  
starts  midway  through  the  prior  cycle.  The  process  has  low  energy  requirements  due  to  low  flow  
rates  needed  to  safely  operate  and  maintain  both  upstream  and  downstream  processes  at  room  
temperature  and  pressure.  The  main  drivers  of  energy  costs  are  the  operations  of  the  perfusion  
and  production  bioreactors.  
As  a  next  step,  we  recommend  completing  an  economic  analysis  under  the  assumption  
that  COVID-19  vaccines  will  be  needed  on  an  annual  basis  like  the  flu  vaccine.  Currently,  
scientists  are  unsure  if  yearly  vaccination  will  be  required,  if  a  booster  will  be  necessary,  or  if  
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immunity  from  a  single  vaccine  will  be  sufficient.  Optimally  a  vaccine  would  not  be  needed  
yearly,  but  we  recognize  the  likelihood  of  this  possibility.  Thus,  the  consideration  of  long-term  
operation  would  be  fruitful,  either  building  a  company  facility  to  produce  vaccines  in-house,  or  
establishing  a  years-long  contract  with  a  CMO.  Secondly,  this  project  is  designed  for  one  
campaign,  but  we  recommend  supplemental  analyses  for  smaller  manufacturing  batches  over  a  
longer  production  period.  Finally,  we  recommend  that  our  company  includes  the  R&D  
investments  and  considers  profits  lost  to  formulation  and  processing,  which  are  outside  the  scope  
of  this  project  but  would  provide  a  more  accurate  assessment  of  the  economics  of  this  project.  
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25.  Appendix  
A.  Supplemental  Calculations  
A.1  Cellular  Growth  Kinetics  
Cell  growth  in  exponential  phase  is  defined  as:  
xdt
dx = µ {6}  
 · dtx
dx = µ {7}  
   · ∫ dt∫ x
dx = µ {8}  
n  · ∆ tl xx o = µ {9}  
where µ =  specific  cell  growth  rate  
x o =  initial  cell  population  
x =  final  cell  population  
∆t =  batch  time  
As  previously  mentioned  in  Section  11.3,  the  specific  cell  growth  rate  (µ)  of  Sf-9  cells  is  
0.033  hr -1 ,  which  corresponds  to  a  doubling  time  of  21  hr  by  using  Equation  {9} .  Setting  the  
batch  times  of  each  stage  in  the  upstream  process  and  knowing  the  initial  cell  population  in  the  
inoculum  vial  from  the  cell  bank,  the  final  number  of  cells  in  each  stage  can  be  calculated,  again  
by  using  Equation  {9} .  Since  the  maximum  VCD  of  Sf-9  cells  is  8.1×10 6   cells/mL,  the  batch  
times  were  set  accordingly  so  that  the  final  cell  population  in  each  stage  does  not  exceed  the  
maximum  VCD,  except  for  the  500  L  perfusion  bioreactor  as  explained  in  Section  13.1  and  
Section  15.15.  Table  25.1  below  summarizes  the  number  of  cells  and  batch  times  in  each  stage  of  
the  upstream  process.  
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Table  25.1.  Number  of  cells  and  batch  times  in  each  stage  of  the  upstream  process.  
  
A.2  Gas-Liquid  Mass  Transfer  Coefficient  
Gas-liquid  mass  transfer  coefficient  (k L a)  is  a  measurement  of  the  efficiency  with  which  
the  bioreactor  is  capable  of  delivering  oxygen  into  or  stripping  carbon  dioxide  from  cell  culture.  
The  most  critical  variable  that  affects  k L a  is  aeration  rate  of  spargers;  agitation  rate  of  impellers  
does  not  affect  k L a  much.  In  order  to  make  sure  whether  a  bioreactor  can  support  corresponding  
aeration  rates,  k L a  values  for  oxygen  delivery  and  carbon  dioxide  stripping  must  be  calculated.  
  
The  oxygen  uptake  rate  (OUR)  is  defined  as:  
  
UR  sOUR · V CDO =   {10}  
where OUR =  oxygen  uptake  rate 
sOUR =  specific  oxygen  uptake  rate  
VCD =  viable  cell  density  
As  previously  mentioned  in  Section  11.4,  the  specific  oxygen  uptake  rate  is  0.22  to  0.26  
µM  O 2 /10 6   cell/hr  during  the  growth  phase  [63]  and  0.2  to  0.76  µM/10 6   cell/hr  for  the  infection  
phase  [37].  For  the  500  L  perfusion  bioreactor  that  has  cells  in  growth  phase,  0.26  µM  O 2 /10 6   
cell/hr  was  used  as  the  sOUR  value.  For  the  2000  L  production  bioreactor  that  has  cells  in  
165  
  Stock  Vial  
125  mL  
Flask  
500  mL  
Flask  
5  L  
Flask  
50  L  
WAVE  
500  L  
Brx  
2000  L  
Brx  
Final  VCD  
(×10 6   cells/mL)  4.05  4.98  5.36  5.78  6.22  32.65  8.15  
Working  Volume  (L)  0.001  0.05  0.5  5  50  500  2000  
Initial  #  of  Sf-9  Cells  -  4.05E6  2.49E8  2.68E9  2.89E10 3.11E11  1.63E13 
Final  #  of  Sf-9  Cells  4.05E6  2.49E8  2.68E9  2.89E10 3.11E11  1.63E13 -  
Batch  Time  (Days)  -  5.2  3  3  3  5  5  
  
infection  phase,  0.76  µM  O 2 /10 6   cell/hr  was  used  as  the  sOUR  value.  The  upper  bounds  for  the  
sOUR  values  were  used  as  a  conservative  approach.  Final  VCD  values  of  the  perfusion  and  
production  bioreactors  in  Table  25.1  were  used  for  Equation  {10}  calculations.  
  
The  oxygen  transfer  rate  (OTR)  is  defined  as:  
  
TR    a   · (p    ) · H    O = k L O2 O2,liq ­ p O2,gas O2 H2O/ {11}  
where OTR =  O 2   Transfer  Rate  
k L a O2 =  O 2   Gas-Liquid  Mass  Transfer  Coefficient  
p O2 =  O 2   Partial  Pressure  in  Liquid  or  Gas  
           H O2/H2O =  Henry’s  Law  Constant  of  O 2   in  Water  
As  previously  mentioned  in  Section  11.4,  cells  were  grown  in  65%  O 2   concentration  and  
infected  in  50%  O 2   concentration,  which  correspond  to  the  p O2,liquid   values  of  the  500  L  perfusion  
bioreactor  and  2000  L  production  bioreactor,  respectively.  For  the  p O2,gas   value  of  the  perfusion  
bioreactor,  gas  sparged  through  the  frit  sparger  for  oxygen  delivery  was  set  to  have  50%  O 2 .  For  
the  p O2,gas   value  of  the  production  bioreactor,  gas  sparged  through  the  frit  sparger  for  oxygen  
delivery  was  set  to  have  100%  O 2 .  Henry’s  law  constant  of  O 2   in  water  (H O2/H2O )  can  be  found  
from  Figure  25.1  below.  The  H O2/H2O   values  for  both  the  perfusion  bioreactor  at  27.5˚C  and  the  
production  bioreactor  at  26˚C  are  about  0.037.  
  
Figure  25.1.  Henry’s  law  constant  of  O 2   in  Water  as  a  function  of  temperature.  (Engineering  Toolbox)  
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By  setting  the  OUR  in  Equation  {10}  and  OTR  in  Equation  {11}  equal  to  each  other, 
oxygen  delivery  k L a  (k L a O2 )  can  be  calculated.  The  required  k L a O2   for  the  500  L  perfusion  
bioreactor  is  20.16  hr -1 ,  and  that  for  the  2000  L  production  bioreactor  is  5.98  hr -1 .  From  Figure  
25.2  below,  we  can  see  that  the  corresponding  aeration  rate  of  oxygen  delivery  for  the  perfusion  
bioreactor  is  8  SLPM,  and  that  for  the  production  bioreactor  is  6  SLPM.  
  
Figure  25.2.  Oxygen  delivery  k L a  with  frit  sparger  for  the  perfusion  and  production  bioreactors.  (Thermo  Scientific  
HyPerforma  Single-Use  Bioreactor  Systems  Validation  Guide)  
  
  
The  carbon  dioxide  evolution  rate  (CER)  is  defined  as:  
  
ER  sOUR · V CD · RQC =   {12}  
where CER =  carbon  dioxide  evolution  rate  
sOUR =  specific  oxygen  uptake  rate  
VCD =  viable  cell  density  
RQ =  respiratory  quotient  (mol  CO 2 /mol  O 2 )  
The  sOUR  and  VCD  values  used  for  Equation  {12}  calculations  are  the  same  as  those  
used  for  Equation  {10}  calculations.  As  described  in  Section  11.4,  the  respiratory  quotient  (RQ)  
for  uninfected  Sf-9  cells  is  1.07  ±  0.06,  and  that  for  virus-infected  cells  is  1.12  ±  0.03  [76].  
Therefore,  the  RQ  value  used  for  the  500  L  perfusion  bioreactor  was  1.07,  and  that  used  for  the  




The  carbon  dioxide  transfer  rate  (CTR)  is  defined  as:  
TR    a   · (p    ) · H    C = k L CO2 CO2,liq ­ p CO2,gas CO2 H2O/ {13}  
where CTR =  CO 2   transfer  rate  
k L a CO2 =  CO 2   gas-liquid  mass  transfer  coefficient  
p CO2 =  CO 2   partial  pressure  in  liquid  or  gas  
           H CO2/H2O =  Henry’s  law  constant  of  CO 2   in  water  
As  described  in  Section  11.2,  the  p CO2,liq   level  is  set  at  30  mmHg  for  both  the  perfusion  
and  production  bioreactors.  For  the  p CO2,gas   values  of  both  bioreactors,  the  air  sparged  through  the  
drilled  hole  sparger  for  carbon  dioxide  stripping  was  assumed  to  have  0  mmHg  CO 2 .  Henry’s  law  
constant  of  CO 2   in  water  (H CO2/H2O )  can  be  found  from  Figure  25.3  below.  The  H CO2/H2O   values  for  
the  perfusion  bioreactor  at  27.5˚C  and  the  production  bioreactor  at  26˚C  are  both  around  1.35.  
  
Figure  25.3.  Henry’s  law  constant  of  CO 2   in  Water  as  a  function  of  temperature.  (Engineering  Toolbox)  
  
By  setting  the  CER  in  Equation  {11}  and  CTR  in  Equation  {13}  equal  to  each  other,  CO 2   
stripping  k L a  (k L a CO2 )  can  be  calculated.  The  required  k L a CO2   for  the  500  L  perfusion  bioreactor  is  
7.5  hr -1 ,  and  that  for  the  2000  L  production  bioreactor  is  5.73  hr -1 .  CO 2   stripping  is  a  composite  
mass  transfer  process,  where  both  the  air  supply  from  drilled  hole  sparger  and  the  oxygen  supply  
from  frit  sparger  strip  carbon  dioxide.  From  Figure  25.4  and  Figure  25.5  below,  we  can  see  that  
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the  500  L  perfusion  bioreactor  requires  an  aeration  rate  of  25  SLPM  through  the  drilled  hole  
sparger  (k L a CO2   of  5  hr -1 )  with  the  aeration  rate  of  8  SLPM  through  the  porous  frit  sparger  (k L a CO2   
of  2.5  hr -1 )  mentioned  earlier  in  the  K L a O2   analysis.  Also,  we  can  see  that  the  2000  L  production  
bioreactor  needs  an  aeration  rate  of  about  150  SLPM  through  the  drilled  hole  sparger  (k L a CO2   of  
5.7  hr -1 )  with  the  aeration  rate  of  6  SLPM  through  the  frit  sparger  (k L a CO2   of  0.5  hr -1 ),  again  
mentioned  earlier  in  the  K L a O2   analysis.  
  
Figure  25.4.  CO 2   stripping  k L a  with  DH  sparger  for  the  perfusion  and  production  bioreactors.  (Thermo  Scientific  
HyPerforma  Single-Use  Bioreactor  Systems  Validation  Guide)  
  
  
Figure  25.5.  CO 2   stripping  k L a  with  frit  sparger  for  the  perfusion  and  production  bioreactors.  (Thermo  Scientific  





A.3  Kolmogorov  Eddy  Length  
Engineers  hypothesize  that  if  Kolmogorov  eddy  length  is  smaller  than  the  cell  diameter,  
the  cells  may  be  sheared  and  die.  In  other  words,  as  long  as  the  Kolmogorov  eddy  length  is  larger  
than  the  cell  diameter,  the  cells  would  not  be  in  danger  of  shearing.  If  the  calculated  Kolmogorov  
eddy  length  turns  out  to  be  smaller  than  the  cell  diameter,  the  agitation  rate  of  the  impeller  needs  
to  be  slowed  down  to  increase  the  eddy  size.  
  
The  Kolmogorov  eddy  length  is  defined  as:  
  )η = ( ε
v3 1 4/ {14}  
where η =  Kolmogorov  length  scale  
𝜈 =  kinematic  viscosity  
ε =  agitation  power  /  mass  
Kinematic  viscosity  (𝜈)  of  media  was  assumed  to  be  properties  of  water,  since  the  media  
solution  is  mostly  aqueous  and  very  dilute.  The  mass  in  ε  was  assumed  to  be  the  spherical  mass  
of  the  media  that  directly  contacts  the  impeller.  
  
To  calculate  the  agitation  power  (P)  in  ε:  
N  P = Pρ·n ·D3 5 {15}  
where N P =  power  number  
P =  agitation  power  
ρ =  fluid  density  
n =  agitation  rate  
D =  impeller  diameter  
According  to  the  specifications  sheets  provided  by  Thermo  Fisher  Scientific,  the  power  
number  (N P ),  impeller  diameter  (D),  and  nominal  agitation  rate  (n)  are  each  given  for  both  500  L  
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perfusion  and  2000  L  production  bioreactors.  Fluid  density  (ρ)  of  media  was  assumed  to  be  the  
same  as  water  density,  again  because  the  solution  is  mostly  aqueous  and  very  dilute.  
Table  25.3  below  summarizes  Kolmogorov  eddy  lengths  of  both  the  perfusion  and  
production  bioreactors,  calculated  by  using  Equation  {14}  and  Equation  {15}  shown  above.  
Since  the  calculated  Kolmogorov  eddy  lengths  for  both  bioreactors  are  larger  than  the  average  
diameter  of  Sf-9  cells,  which  is  18  µm  [101],  the  nominal  agitation  rates  are  safe  for  usage.  
Table  25.3.  Kolmogorov  eddy  lengths  of  the  perfusion  and  production  bioreactors  
  
  
A.4  Mixing  Time  
After  determining  whether  the  nominal  agitation  rate  is  safe  for  usage  by  calculating  the  
Kolmogorov  eddy  lengths,  mixing  time  to  reach  95%  homogeneity  (θ 95 )  must  also  be  considered,  
since  cells  need  to  be  in  bioreactors  with  good  mixing  for  even  supply  of  nutrients.  Typically,  θ 95   
of  less  than  1  minute  is  considered  good  mixing,  suggested  by  our  project  author  Dr.  Cohen.  
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  500  L  Perfusion  Bioreactor  2000  L  Production  Bioreactor  
Agitation  Rate  (n)  101  RPM  75  RPM  
Power  Number  (N P )  2.1  2.1  
Impeller  Diameter  (D)  25.1  cm  39.8  cm  
Fluid  Density  (ρ)  1  g/mL  1  g/mL  
Kinematic  Viscosity  (𝜈)  1  cp  1  cp  
Kolmogorov  Eddy  
Length  (η)  28  µm  28  µm  
  






= 5 {16}  
where N P =  power  number  
n =  agitation  rate  
θ 95 =  mixing  time  to  reach  95%  homogeneity  
D =  impeller  diameter  
T =  tank  inner  diameter  
H =  fluid  height  
Again,  the  power  number  (N P ),  impeller  diameter  (D),  as  well  as  tank  inner  diameter  (T)  
are  provided  by  the  Thermo  Fisher  Scientific  specifications  sheets  for  both  500  L  perfusion  and  
2000  L  production  bioreactors.  The  same  agitation  rate  (n)  values  used  to  check  the  Kolmogorov  
eddy  lengths  previously  were  used.  Fluid  height  (H)  was  calculated  by  using  the  working  volume  
and  tank  inner  diameter  for  each  bioreactor.  
Table  25.4  below  summarizes  the  mixing  time  to  reach  95%  homogeneity  for  both  the  
perfusion  and  production  bioreactors,  calculated  by  using  Equation  {16}  above.  Since  θ 95   for  
both  bioreactors  are  less  than  1  minute,  the  agitation  rates  are  sufficient  to  provide  good  mixing.  
Table  25.4.  Mixing  time  to  reach  95%  homogeneity  for  the  perfusion  and  production  bioreactors  
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  500  L  Perfusion  Bioreactor  (Working  Volume:  500  L)  
2000  L  Production  Bioreactor  
(Working  Volume:  2000  L)  
Agitation  Rate  (n)  101  RPM  75  RPM  
Power  Number  (N P )  2.1  2.1  
Impeller  Diameter  (D)  25.1  cm  39.8  cm  
Tank  Inner  Diameter  (T)  75.6  cm  119.4  cm  
Fluid  Height  (H)  111.4  cm  178.6  cm  
Mixing  Time  to  Reach  
95%  Homogeneity  (θ 95 )  
27  seconds  36  seconds  
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C.  Vendor  Specification  Sheets  
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Publication Number MAN0007285  Rev. 1.00 
Sf-900™ II SFM 
Description 
Sf-900™ II SFM is a complete, serum-free, protein-free, ready-to-use insect cell culture medium developed for high cell-density growth and 
high-level recombinant protein expression using the Baculovirus Expression Vector System (BEVS). Sf-900™ II SFM has optimized amino 
acid, carbohydrate, vitamin, and lipid components, as well as a biologically active raw material providing significant improvement in cell 
growth, virus production and recombinant protein expression over other serum-free or serum-supplemented media. Sf-900™ II SFM 
supports long term growth (>20 passages) of Spodoptera frugiperda (Sf9, Sf21), Trichoplusia ni (Tn-368), and Lymantia dispar (Ld) cells in both 
suspension and monolayer culture.  
Product Catalog No. Amount Storage Shelf life* 





10 × 500 mL 
1000 mL 
6 × 1000 mL 
2°C to 8°C; Protect from light 12 months 






2°C to 8°C; Protect from light 12 months 
Sf-900™ II SFM (1X), liquid w/out methionine or cysteine 21012-026 500 mL 2°C to 8°C; Protect from light 12 months 
* Shelf life duration is determined from Date of Manufacture. 
Product use 
For Research Use Only. Not for use in diagnostic procedures. 
Important information 
Sf-900™ II SFM is a complete, ready to use medium. Do not add 
L-Glutamine or surfactants such as Pluronic® F-68. 
Safety information 
Read the Safety Data Sheets (SDSs) and follow the handling 
instructions. Wear appropriate protective eyewear, clothing, and 
gloves. 
Culture Conditions 
Media: Sf-900™ II SFM 
Cell line: Sf9, Sf21, Ld, Tn-368 cells 
Culture type: Suspension or Adherent 
Culture vessels: Shake flask, spinner bottle or T-flask.  
Temperature range: 27°C to 28°C 
Incubator atmosphere: Non-humidified, air regulated non-CO2 
atmosphere. Ensure proper gas exchange and minimize exposure 
of cultures to light. 
Recovery 
1. Rapidly thaw (<1 minute) frozen cells in a 37°C water bath. 
2. Transfer entire contents of the cryovial into the 
appropriately sized vessel so that the cells are seeded at  
3–5 × 105 cells/mL of pre-warmed Sf-900™ II SFM. 
3. Incubate at 28°C in a non-humidified, air regulated non-CO2 
atmosphere, on an orbital shaker platform rotating at  
120–140 rpm. Loosen flask caps to allow for gas exchange. 
4. Subculture when cells reach >2 × 106 viable cells/mL. We 
recommend subculturing cells a minimum of 3 passages 
before using in downstream applications. 
Subculture suspension cultures 
Insect cells are sensitive to physical shearing. Ensure that 
impeller mechanisms rotate freely and do not contact vessel 
walls or base (adjust prior to autoclaving). 
1. Determine viable cell density using a Countess® Automated 
Cell Counter or alternative automated or manual method. 
2. Seed cells at 3–5 × 105 viable cells/mL in sterile culture 
vessels containing pre-warmed Sf-900™ II SFM. (30 mL per 
125-mL shake flask, 75–100 mL per 100-mL spinner bottle). 
3. Incubate at 27°C to 28°C in a non-humidified, air regulated 
non-CO2 atmosphere. Loosen caps to allow for gas exchange. 
4. Rotate shake flask cultures on an orbital shaker platform at 
120–140 rpm, set impeller stirring rate to 85–95 rpm for 
spinner bottles (optimum impeller speed must be empirically 
determined for each spinner apparatus for robust cell growth 
and viability). 
5. Subculture cells when viable cell density reaches  
>2 × 106 viable cells/mL (about twice a week) into clean, 
sterile flask(s) with fresh pre-warmed Sf-900™ II SFM. 
Note: If cell debris is observed, gently centrifuge the cell 
suspension at 100 × g for 5–10 minutes and resuspend the cell 
pellet in fresh Sf-900™ II SFM to reduce accumulation of cell 
debris and metabolic waste by-products. 
Note: We recommend thawing a fresh low-passage vial of cells 
every 3 months or 30 passages. 
Subculture monolayer cultures  
1. Observe cell monolayer to ensure 80–90% confluence. 
Aspirate medium and floating cells from a confluent 
monolayer. 
2. Add 4 mL (per 25 cm2) pre-warmed Sf-900™ II SFM to the 
flask and resuspend cells by repeatedly pipetting the 
medium across the monolayer. 
3. Observe cell monolayer to ensure cell detachment from the 
surface of the flask. Firmly rap the side of the flask on the 
palm of your hand or a hard flat surface if necessary. 
 
2.4. Transfer entire cell suspension to a sterile conical tube; any 
cell clumps quickly settle to the bottom after 1–2 minutes. 
Pipet the clumps into a 10-mL pipette and gently break up 
the clumps by pressing the pipette tip against the bottom of 
the tube and gently expell the cells back into the medium, 
repeat if necessary to break up remaining clumps. Pipetting 
too harshly will decrease cell viability due to sensitivity of 
cells to shear force. 
5. Determine viable cell density using a Countess® Automated 
Cell Counter. 
6. Inoculate 2–5 × 104 viable cells/cm2 into new culture flasks 
containing pre-warmed Sf-900™ II SFM (5 mL/25 cm2). 
7. Incubate at 27°C to 28°C in a non-humidified, air regulated 
non-CO  atmosphere. Loosen caps to allow for gas exchange. 2
8. Three days post-plating, aspirate medium from the cell 
monolayer and re-feed the culture with an equal volume of 
fresh medium gently added to the side of the flask. 
Note: Sf9 cells are not anchorage dependent and may be 
transferred between monolayer and spinner/shaker culture 
repeatedly without noticeable change in viability, morphology, 
or growth rate. 
For additional technical information such as Safety Data Sheets (SDS), Certificates of Analysis, visit www.lifetechnologies.com/support  
For further assistance, email techsupport@lifetech.com 
All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. Pluronic is a trademark of BASF Corporation. 
©2014 Thermo Fisher Scientific Inc. All rights reserved.  
DISCLAIMER - LIFE TECHNOLOGIES CORPORATION AND/OR ITS AFFILIATE(S) DISCLAIM ALL WARRANTIES WITH RESPECT TO THIS DOCUMENT, EXPRESSED OR IMPLIED, INCLUDING  
BUT NOT LIMITED TO THOSE OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT.  TO THE EXTENT ALLOWED BY LAW, IN NO EVENT SHALL 
LIFE TECHNOLOGIES AND/OR ITS AFFILIATE(S) BE LIABLE, WHETHER IN CONTRACT, TORT, WARRANTY, OR UNDER ANY STATUTE OR ON ANY OTHER BASIS FOR SPECIAL, INCIDENTAL, 
INDIRECT, PUNITIVE, MULTIPLE OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH OR ARISING FROM THIS DOCUMENT, INCLUDING BUT NOT LIMITED TO THE USE THEREOF. 
www.lifetechnologies.com  
Adapt cells to Sf-900™ II SFM 
It is critical that cell viability be ≥90% and the growth rate be in 
mid-logarithmic phase prior to initiating adaptation procedures.  
Direct adaptation 
Monolayer cultures need only have the culture media exchanged 
with prewarmed Sf-900™ II SFM as described in Subculture 
monolayer cultures. 
Transfer suspension cultures into Sf-900™ II SFM as follows: 
1. Centrifuge the cell suspension at 100 × g for 5–10 minutes. 
Aspirate and discard the supernatant. 
2. Resuspend the cell pellet in pre-warmed Sf-900™ II SFM at a 
viable cell density of >5 × 105 cells/mL and transfer to 
appropriate culture vessel. 
 3. Return to incubator and monitor cell growth. 
Note: If suboptimal performance is achieved using the direct 
adaptation method, use the sequential adaptation method. 
Sequential adaptation  
Follow the procedures for subculture of suspension or 
monolayer cultures with the following modifications. 
1. During the adaptation procedure use a seeding density of  
>5 × 105 viable cells/mL. 
2. Subculture cells into stepwise increasing ratios of Sf-900™ II 
SFM to original medium with each subsequent passage 
(25:75, 50:50, 75:25, 90:10 followed by 100% Sf-900™ II SFM). 
Multiple passages at each step may be needed. 
After several passages in 100% Sf-900™ II SFM, the viable cell count 
should exceed 2–4 × 106 cells/mL with a viability exceeding 85% 
within 4–6 days of culture. 
Cryopreservation 
1. Prepare the desired quantity of cells, harvesting in mid-log 
phase of growth with viability >90%. Reserve the 
conditioned medium to prepare cryopreservation medium. 
 Determine the viable cell density and calculate the required 
volume of cryopreservation medium to give a final cell 
density of >1 × 107 cells/mL. 
3. Prepare the required volume of cryopreservation medium of 
92.5% Sf-900™ II SFM (50:50 ratio of fresh to conditioned 
media) + 7.5% DMSO on day of intended use, store at 4°C 
until use. 
4. Centrifuge cell suspension at 100 × g for 5–10 minutes. 
Resuspend the cell pellet in the pre-determined volume of 
4°C cryopreservation medium. 
5. Dispense aliquots of this cell suspension into cryovials 
according to the manufacturer’s specifications. 
6. Cryopreserve in an automated or manual controlled rate 
freezing apparatus following standard procedures (1°C 
decrease per minute). 
7. Transfer frozen cells to liquid nitrogen, (vapor phase) 
°C to –125°C. storage at –200
Related products 
Product Catalog no. 
Sf9 Cells Adapted in Sf-900™ II SFM 12659 
Sf21 Cells Adapted in Sf-900™ II SFM 12682 
BaculoDirect™ N-Term Expression Kit 12562-054 
BaculoDirect™ N-Term Transfection Kit 12562-062 
BaculoDirect™ C-Term Expression Kit 12562-013 
BaculoDirect™ C-Term Transfection Kit 12562-039 
Bac-N-Blue™ Transfection Kit K855-01 
Bac-to-Bac® Baculovirus Expression System 10359 
Bac-to-Bac® Vector Kit 10360 
Countess® Automated Cell Counter C10227 
Explanation of symbols and warnings 
The symbols present on the product label are explained below: 
     
Temperature Limitation Manufacturer Batch code Use By: Catalog number 







Sterilized using aseptic 
processing techniques 
Limited product warranty 
Life Technologies Corporation and/or its affiliate(s) warrant 
their products as set forth in the Life Technologies’ General 
Terms and Conditions of Sale found on Life Technologies’ 
website at www.lifetechnologies.com/termsandconditions. If 
you have any questions, please contact Life Technologies at 
www.lifetechnologies.com/support. 
Important licensing information 
These products may be covered by one or more Limited Use 
Label Licenses. By use of these products, you accept the terms 
and conditions of all applicable Limited Use Label Licenses. 
 
 
APPLICATION NOTE HyPerforma Rocker Bioreactor
Cultivation of Sf9 insect cells and rSEAP 
expression in the HyPerforma Rocker Bioreactor
Summary
This application note describes the cultivation of Sf9 
suspension cells in the Thermo Scientific™ HyPerforma™ 
Rocker Bioreactor with a maximum working volume 
of 5.0 L. Using a serum-free medium without 
components of animal origin, viable cell densities of 
up to 6.2 x 106 cells/mL were achieved. Expression of 
recombinant secreted alkaline phosphatase (rSEAP) was 
induced using a baculovirus expression vector system. 
rSEAP activity up to a maximum of 58.5 U/mL was 
achieved. The results are in the typical range observed in 
previous cultivations using wave-mixed bioreactor types.
Introduction
The HyPerforma Rocker Bioreactor (Figure 1) is a lab-scale 
rocker-type bioreactor that is characterized by low shear 
stresses and is often used for seed train production in 
biopharmaceutical production processes. 
The HyPerforma Rocker Bioreactor can be controlled using 
the Thermo Scientific™ HyPerforma™ G3Lab™ Controller 
in conjunction with Thermo Scientific™ TruBio™ software 
powered by the Emerson™ DeltaV™ system (Figure 1).
The scope of the study was to demonstrate the 
applicability of the HyPerforma Rocker Bioreactor for 
cultivating a Spodoptera frugiperda (Sf9) insect cell line in 
a biphasic production process using serum-free medium 
and expressing a model protein, rSEAP. The production 
process was based on a baculovirus expression vector 
system (BEVS).
Figure 1. TruBio software with the HyPerforma G3Lab Controller and 
the HyPerforma Rocker Bioreactor.
Materials and methods
Overview of procedure setup
• Day –6/–1: Inoculum production with Sf9 suspension 
cells in shaker flasks.
• Day 0: Bioreactor preparation, inoculation with  
seeding density of 1 x 106 cells/mL in 3.0 L of  
Gibco™ Sf-900™ III SFM.
• Day 1: Sampling, starting of control loop for pH.
• Day 2: Sampling; addition of the virus suspension 
and fresh medium to achieve a final volume of 5.0 L 
and infected cell density (ICD) of 2 x 106 cells/mL at a 
multiplicity of infection (MOI) of 0.01 PFU/cell.
• Day 3: Sampling, analytics, and harvesting. Production 
was stopped 7 days postinfection. This corresponds to a 
time of harvest (TOH) of 164 hours.
Medium
Gibco™ Sf9 cells were cultivated in Sf-900 III SFM 
containing Gibco™ Pluronic™ F-68 and L-glutamine. The 
expression of rSEAP was induced by a baculovirus 
expression vector system (Sil9.1.1_GFP_SEAP_His MP 9.8 
V2, provided by ZHAW IBT Molecular Biology) with a virus 
titer of 1.5 x 109 PFU/cell.
Inoculum preparation
The inoculum for the HyPerforma Rocker Bioreactor was 
produced in single-use 250 and 500 mL shaker flasks at 
working volumes of 100 and 200 mL. The cells (passage 
#33) were inoculated at cell densities of about  
0.7–1.0 x 106 cells/mL. The flasks were placed in a shaking 
incubator (Ecotron™, Infors™ HT, CH) at 27°C with a 
shaking rate of 100 rpm and an amplitude of 25 mm. A cell 
suspension of 1,200 mL with a cell density of approximately 
3.3 x 106 cells/mL was produced for inoculation of the 
HyPerforma Rocker Bioreactor.
Bioreactor preparation
A NaOH solution was produced, put in Duran™ glass 
bottles, and autoclaved for 20 minutes at 121°C. The 
HyPerforma Rocker BioProcess Container (BPC) was 
filled with 1 L of the fresh medium using a sterile syringe 
connected to the luer lock connector, and placed on 
the rocking platform. After the aeration (0.25 slpm) and 
heating (27°C) were switched on, one-point calibration 
was performed for the pH sensor. A sample was taken 
and the pH was determined using an external pH meter 
(Mettler-Toledo). The pO2 sensor was calibrated to 
100% saturation.
Inoculation preparation
The inoculation procedure was performed under a laminar 
flow, where the Duran glass bottle with the NaOH solution 
(0.1 M) was connected to the HyPerforma Rocker BPC via 
a luer lock connector directly before inoculation. In order to 
achieve the desired cell density of 1 x 106 cells/mL, 0.95 L 
of the cell suspension was added to the bioreactor through 
a sterile funnel, followed by 1.05 L of fresh medium, to 
achieve the initial working volume of 3.0 L. Afterwards, the 
bioreactor was reconnected to the control unit and all the 
control loops for dissolved oxygen (DO) and temperature 
were started. The settings were defined as given below. 
The control loop for pH was started after 24 hours of 
process time.
Process parameters
Temperature was controlled automatically via an integrated 
heater in the rocking platform. DO concentration was 
controlled using a cascade function with rocking rate as 
the primary factor, and the addition of pure oxygen as the 
secondary factor. To automatically control the pH during 
the growth phase, a control loop with the addition of  
0.1 M NaOH solution at a maximum pump speed of 50 rpm 
(corresponding to a flow rate of 16 min/mL) was set up. The 
pH control was started 24 hours after inoculation.
Culture conditions
Temperature 27°C
DO concentration 50% saturation
pH 6.2
Rocking rate 18–32 rpm
Rocking angle 6°
Air flow rate (headspace) 0.25 min/L
Maximum O2 flow rate (headspace) 0.25 min/L
Initiation of rSEAP production
The production of rSEAP was induced by infection of 
the Sf9 cells with the baculovirus. Virus quantification 
was performed using three different methods: plaque 
assay (PA), endpoint dilution assay (EDA), and cell growth 
cessation assay (CGCA), as described [1]. The effective 
virus titer VTeff was then calculated from a combination of 
the outcomes of these assays, as follows:
where VTPA, VTEDA, and VTCGCA are the virus titers 
(in PFU/mL) from the individual virus assays. The infection 
parameters, multiplicity of infection (MOI) of 0.01 PFU/cell 
and infected cell density (ICD) of 2 x 106 cells/mL, were 
selected based on preliminary studies performed in our 
laboratory. Two days after inoculation, when the live cell 
density in the HyPerforma Rocker BPC had reached  
3.6 x 106 cells/mL, the control loops were switched off  



















































48 72 96 120 144 168–72 –48 –24 0 24
48 72 96 120 144 168–72 –48 –24 0 24













































































































































48 72 96 120 144 168–72 –48 –24 0 24
48 72 96 120 144 168–72 –48 –24 0 24



























































































DO O2 AirAgitator speed
A
B
Figure 2. Analysis of samples over the culture period.  
(A) Cell densities and viability. (B) Cell diameter and rSEAP activity. The 
arrow indicates the time of virus addition to initiate the protein expression.  
A slightly increased cell diameter of 14.9 μm and minor 
rSEAP activity of about 0.1 U/mL were detected 2 days 
postinfection (Figure 2B). Afterwards, the rSEAP activity 
increased rapidly and reached 59 ± 4 U/mL at the end of 
the process (163 hours postinfection). This is approximately 
40 hours later than in previous experiments conducted 
in our laboratory, despite comparable peak cell densities 
[2]. The reason could have been the fact that less of the 
virus was added, which caused fewer cells to be infected 
by primary infection. Hence, more infection cycles were 
required until all the cells in the HyPerforma Rocker BPC 
had been infected. The increase in rSEAP activity was 
accompanied by an increase in the average cell diameter to 
a maximum of 16.3 μm after 142 hours postinfection.
The infection procedure was performed under a laminar 
flowhood. After ensuring a live-cell density of 2 x 106 cells/
mL in a working volume of 5 L, the Rocker BPC was 
placed on scales, and 66.7 mL of the virus preparation 
at a dilution of 1:1,000 was added via a sterile syringe 
to achieve the desired MOI of 0.01 PFU/cell. The culture 
volume was topped with 2.35 L of fresh medium to achieve 
a total volume of 5 L. Afterwards, the HyPerforma Rocker 
BPC was placed on the rocking platform and all the 
controllers were switched on. The rocking rate was set to 
25 rpm for 1 hour.
Process analysis
Samples of at least 4 mL (6 mL during the production 
phase) were taken at least once a day from the HyPerforma 
Rocker BPC via the luer lock sampling port using sterile 
10 mL syringes. Cell densities and viability were determined 
using a NucleoCounter™ NC-100™ Mammalian Cell Counter 
(ChemoMetec). Dilutions were performed with PBS, after 
the cell density reached 6 x 106 cells/mL. A Cedex™ HiRes 
cell counting device (Roche Diagnostics) was used to 6 
determine cell diameter. Nutrients and metabolites were 
measured using a BioProfile™ 100 Plus multi-biosensor 
analysis system (Labor-Systeme Flükiger AG). 
The rSEAP activity was measured indirectly via enzymatic 
transformation of  p-nitrophenyl phosphate into 
p-nitrophenyl at 405 nm, using a magnesium chloride 
buffer (magnesium chloride, homoarginine hydrochloride, 
and diethanolamine adjusted to pH 9.8) and p-nitrophenyl 
phosphate (disodium salt, hexahydrate) as a substrate 
solution. The quality of the expressed product was 
not investigated.
Results
During the first 48.5 hours, the cell density in the 
HyPerforma Rocker BPC increased from 1 x 106 cells/mL 
to 3.9 x 106 cells/mL with a specific growth rate of 
0.029 per hour, corresponding to a doubling time of 23.9 
hours (Figure 2A). After infection with the baculovirus, the 
cells grew exponentially over the next 2 days and reached 
a maximum viable cell density of 6.1 x 106 cells/mL. The 
cell viability in the HyPerforma Rocker Bioreactor was 98.9 
± 0.4% up to this point in time. The process was aborted 
after 163 hours postinfection (213 hours total time), when 
the cell viability dropped to zero.
For Research Use or Further Manufacturing. Not for diagnostic use or direct administration into humans or animals.  
© 2020 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries 
unless otherwise specified. BioProfile is a trademark of Nova Biomedical. Clave is a trademark of ICU Medical, Inc. Cedex is a trademark of 
Roche. Duran is a trademark of DWK Life Sciences GmbH. Ecotron is a trademark of BHDT GmbH. Emerson and DeltaV are trademarks of 
Emerson Electric Co. Infors is a trademark of Infors AG. NucleoCounter and NC-100 are trademarks of ChemoMetec A/S.  
COL013575 1120
 Find out more at thermofisher.com/rockerbioreactor
The DO concentration decreased continuously from 
86% saturation after inoculation to 59% saturation before 
virus infection, indicating cell growth. After virus infection 
(indicated by the arrow in Figure 3), the rocking rate was set 
to a constant value of 25 rpm for 1 hour in order to ensure 
sufficient mixing to disperse the virus. After restarting 
the control loop for oxygen, the DO concentration 
immediately dropped to 33% saturation and the rocking 
rate automatically increased in order to maintain the DO 
concentration at the defined set point of 50% saturation. 
The rocking rate reached 29 rpm 57 hours postinfection, 
before the cells entered the stationary phase. The DO 
concentration in the HyPerforma Rocker BPC remained at 
50.02 ± 0.14% saturation until 172 hours postinfection. No 
addition of pure oxygen was required.
The control loop for pH was started after 24 hours of 
process time and was run for 26 hours. Overall, 27 mL 
of 0.1 M NaOH was added. During this time, the pH in 
the HyPerforma Rocker BPC was 6.20 ± 0.01, indicating 
correct pH regulation in the HyPerforma Rocker Bioreactor. 
The pH values agreed well with offline measurements, with 
deviations below 0.2 pH units.
Figure 3. Online data for DO concentration, agitation, and oxygen 
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Conclusions
The HyPerforma Rocker Bioreactor was successfully 
tested in a biphasic Sf9 cell–based growth and rSEAP 
production process. The maximum viable cell density in 
the HyPerforma Rocker BPC of 6.1 x 106 cells/mL was 
measured after 48.3 hours postinfection. The maximum 
rSEAP activity of 59 ± 4 U/mL in the HyPerforma Rocker 
BPC was measured 163 hours postinfection (213 hours of 
process time). The results for cell growth, peak cell density, 
and maximum rSEAP activity are in the typical ranges 
observed in previous cultivation using other wave-mixed 
bioreactor types.
References
1. Roldão A, Oliveira R, Carrondo MJ et al. (2009) Error assessment in recombinant 
baculovirus titration: evaluation of different methods. J Virol Methods 159(1):69–80.
2. Imseng N, Steiger N, Frasson D et al. (2014) Single‐use wave‐mixed versus stirred 
bioreactors for insect‐cell/BEVS‐based protein expression at benchtop scale. 
Engineering in Life Sciences 14(3):264–271. 
 
Authors
Stephan C. Kaiser, Staff Scientist, Research and Development, Thermo Fisher Scientific, 
Santa Clara, USA
Nadezda Perepelitsa, GMP Process Engineer, Johnson & Johnson, Basel, Switzerland
Corning Incorporated  
Life Sciences
Reg is te red
ISO 9001 Product  Descr ipt ion
Catalog Number: 431143
Product Description: Corning® 125 mL disposable Erlenmeyer flask, vent cap
Component Materials:
Flask - Virgin Polycarbonate, meets USP, Class VI requirements for plastic containers and
closures.
Cap - Virgin Polypropylene, meets USP, Class VI requirements for plastic containers and
closures. Heavy metal free (meets CONEG req.) color concentrate.
0.2 µM microporous PTFE membrane, meets USP, Class VI requirements for plastic
containers and closures.
Product Dimensions:
Height of flask with cap   -  4.54 in. Height of flask w/o cap - 4.45 in.
Diameter of flask @
widest
  -  2.58 in. Tolerances - +/- 0.05 in.
Diameter of cap   -  1.51 in.
Sterilization:
The product has been irradiated and dosimetrically released based on ANSI/AAMI/ISO 11137  Sterilization of
healthcare products-Requirements for validation and routine control-Radiation sterilization.
Sterility Assurance Level: SAL 10-6
Pyrogens:
The product has been tested and has met the criteria established in the current version of  ANSI/AAMI ST 72:
Bacterial Endotoxins - Test methodologies, routine testing, and alternative to batch testing.  Results:  less than
0.1EU/mL.
Bovine Spongiform Encephalopathy and Transmissible Spongiform Encephalopathy:
This product complies with the latest revision of EMEA/410/01 "Note for Guidance on minimizing the risk of
transmitting animal spongiform encephalopathy agents via human veterinary medicinal products" by virtue of all
bovine derived material having been processed per specific conditions of section 6.4 of EMEA/410/01.
RNase/DNase Testing:
This product has been tested and is free of any detectable RNase/DNase contamination.
Performance Testing:
Each manufacturing lot is sampled and tested in accordance with Standard Operating Procedures.
Integrity Testing: Forward pressurization of the product to 10 inches of water column.
Visual Attributes: Visual examination of the product.
Packaging: Inspection for seal and barrier integrity, accurate labeling, and correct
product configuration.
Lot Number Designation:
8 Digit Lot Number: First 3 digits - Julian date, start of manufacturing; Next 2 digits - Year of manufacture; Last 3 
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ISO 9001 Product  Descr ipt ion
Catalog Number: 431144
Product Description: Corning® 250 mL disposable Erlenmeyer flask, vent cap
Component Materials:
Flask - Virgin Polycarbonate, meets USP, Class VI requirements for plastic containers and
closures.
Cap - Virgin Polypropylene, meets USP, Class VI requirements for plastic containers and
closures. Heavy metal free (meets CONEG req.) color concentrate.
0.2 µM microporous PTFE membrane, meets USP, Class VI requirements for plastic
containers and closures.
Product Dimensions:
Height of flask with cap   -  5.50 in. Height of flask w/o cap - 5.42 in.
Diameter of flask @
widest point
  -  3.28 in. Tolerances - +/- 0.05 in.
Diameter of cap   -  1.69 in.
Sterilization:
The product has been irradiated and dosimetrically released based on ANSI/AAMI/ISO 11137  Sterilization of
healthcare products-Requirements for validation and routine control-Radiation sterilization.
Sterility Assurance Level: SAL 10-6
Pyrogens:
The product has been tested and has met the criteria established in the current version of  ANSI/AAMI ST 72:
Bacterial Endotoxins - Test methodologies, routine testing, and alternative to batch testing.  Results:  less than
0.1EU/mL.
RNase/DNase Testing:
This product has been tested and is free of any detectable RNase/DNase contamination.
Bovine Spongiform Encephalopathy and Transmissible Spongiform Encephalopathy:
This product complies with the latest revision of EMEA/410/01 "Note for Guidance on minimizing the risk of
transmitting animal spongiform encephalopathy agents via human veterinary medicinal products" by virtue of all
bovine derived material having been processed per specific conditions of section 6.4 of EMEA/410/01.
Performance Testing:
Each manufacturing lot is sampled and tested in accordance with Standard Operating Procedures.
Integrity Testing: Forward pressurization of the product to 10 inches of water column.
Visual Attributes: Visual examination of the product.
Packaging: Inspection for seal and barrier integrity, accurate labeling, and correct
product configuration.
Lot Number Designation:
8 Digit Lot Number: First 3 digits - Julian date, start of manufacturing; Next 2 digits - Year of manufacture; Last 3 
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Catalog Number: 431145
Product Description: Corning® 500 mL disposable Erlenmeyer flask, vent cap
Component Materials:
Flask - Virgin Polycarbonate, meets USP, Class VI requirements for plastic containers and
closures.
Cap - Virgin Polypropylene, meets USP, Class VI requirements for plastic containers and
closures. Heavy metal free (meets CONEG req.) color concentrate.
0.2 µM microporous PTFE membrane, meets USP, Class VI requirements for plastic
containers and closures.
Product Dimensions:
Height of flask with cap   -  7.05 in. Height of flask w/o cap - 6.96 in.
Diameter of flask @
widest point
  -  3.99 in. Tolerances - +/- 0.05 in.
Diameter of cap   -  1.91 in.
Sterilization:
The product has been irradiated and dosimetrically released based on ANSI/AAMI/ISO 11137  Sterilization of
healthcare products-Requirements for validation and routine control-Radiation sterilization.
Sterility Assurance Level: SAL 10-6
Pyrogens:
The product has been tested and has met the criteria established in the current version of  ANSI/AAMI ST 72:
Bacterial Endotoxins - Test methodologies, routine testing, and alternative to batch testing.  Results:  less than
0.1EU/mL.
RNase/DNase Testing:
This product has been tested and is free of any detectable RNase/DNase contamination.
Bovine Spongiform Encephalopathy and Transmissible Spongiform Encephalopathy:
This product complies with the latest revision of EMEA/410/01 "Note for Guidance on minimizing the risk of
transmitting animal spongiform encephalopathy agents via human veterinary medicinal products" by virtue of all
bovine derived material having been processed per specific conditions of section 6.4 of EMEA/410/01.
Performance Testing:
Each manufacturing lot is sampled and tested in accordance with Standard Operating Procedures.
Integrity Testing: Forward pressurization of the product to 10 inches of water column.
Visual Attributes: Visual examination of the product.
Packaging: Inspection for seal and barrier integrity, accurate labeling, and correct
product configuration.
Lot Number Designation:
8 Digit Lot Number: First 3 digits - Julian date, start of manufacturing; Next 2 digits - Year of manufacture; Last 3 
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ISO 9001 Product  Descr ipt ion
Catalog Number: 431685
Product Description: Corning® 5 Liter disposable Erlenmeyer Flask, easy grip vent cap with liner
Component Materials:
Flask - Virgin Polycarbonate, meets USP, Class VI requirements for plastic containers and
closures.
Vent Cap - Virgin Polypropylene, meets USP, Class VI requirements for plastic containers and
closures. Heavy metal free (meets CONEG req.) color concentrate.
0.2 µM microporous PTFE membrane, meets USP, Class VI requirements for plastic
containers and closures. Thermoplastic elastomer liner, meets USP, Class VI
requirements for plastic containers and closures.
Product Dimensions:
Height of flask with cap   -  11.33 in. Diameter of cap (OD) - 4.16 in.
Height of flask w/o cap   -  11.24 in. Diameter of neck (OD) - 3.88 in.
Diameter of flask @
widest point
  -  9.05 in. Tolerances - +/- 0.05 in.
Sterilization:
The product  has been irradiated and dosimetrically released based on ANSI/AAMI/ISO 11137 (TIR 33) 
Sterilization of healthcare products-Requirements for validation and routine control-Radiation sterilization.
Sterility Assurance Level: SAL 10-6
Pyrogens:
The product has been tested and has met the criteria established in the current version of  ANSI/AAMI ST 72:
Bacterial Endotoxins - Test methodologies, routine testing, and alternative to batch testing. Results: less than
0.1EU/mL
RNase/DNase Testing:
This product has been tested and is free of any detectable RNase/DNase contamination.
Bovine Spongiform Encephalopathy and Transmissible Spongiform Encephalopathy:
This product complies with the latest revision of EMEA/410/01 "Note for Guidance on minimizing the risk of
transmitting animal spongiform encephalopathy agents via human veterinary medicinal products" by virtue of all
bovine derived material having been processed per specific conditions of section 6.4 of EMEA/410/01.
Performance Testing:
Each manufacturing lot is sampled and tested in accordance with Standard Operating Procedures.
Integrity Testing: Inverted leak test with an alcohol based solution.
Visual Attributes: Visual examination of the product.
Packaging: Inspection for seal and barrier integrity, accurate labeling, and correct
product configuration.
Lot Number Designation:
8 Digit Lot Number: First 3 digits - Julian date, start of manufacturing; Next 2 digits - Year of manufacture; Last 3 





WAVE Bioreactor Systems  
2/10 and 20/50
The WAVE Bioreactor™ system is a cell culture platform suitable 
for applications in gene and cell therapy and regenerative 
medicine. Culture medium and cells only come into contact 
with a presterilized, disposable chamber known as the Cellbag™ 
bioreactor, which is placed on a rocking platform (Fig 1). The 
rocking motion of the platform induces waves to mix and transfer 
oxygen to the culture medium to create an optimal environment 
for cell growth (Fig 2). As a result, a single Cellbag bioreactor 
can be used to produce cell concentrations that are suitable for 
clinical trials (1, 2, 3).
Key performance characteristics are:
• Functionally closed system for single-use: no cleaning, 
cross-contamination, and minimal validation. Cells only come 
into contact with disposable sterile biocompatible plastics. 
• The system is suitable for cGMP production without the use of 
an incubator and can be easily connected to other closed cell 
processing devices by sterile welding
•	 Cellbag	bioreactors	that	include	all	fittings	and	filters	are	
supplied sterile and ready for use 
• Allows rapid production of up to 107 viable cells per mL of 
culture
•	 Multiple	instrument	configurations	for	suspension,	
microcarrier, batch, fed-batch, or perfusion culture 
• Full scalability — the featured systems are capable of handling 
culture volumes from 200 mL to 25 L 
A new way of working
There is a considerable difference between using Cellbag 
bioreactors and conventional bags. The gentle wave action limits 
shear stress on the cells in comparison to traditional stirred tank 
bioreactors. For volumes up to 25 L, only one Cellbag bioreactor 
is needed. This makes the system easy to use and considerably 
CELL PREPARATION
Fig 1. WAVE Bioreactor Systems 2/10 (left) and 20/50 (right).
less laborious than using static cultures where multiple bags 
or	flasks	are	often	needed.	The	perfusion	culture	functionality	
allows for automated feeding of cultures and maximizes the 
removal of waste products while keeping culture volumes to a 
minimum.
The system minimizes contamination risk and makes it suitable 
for cGMP production. The ability to automatically monitor 
and control multiple parameters also contributes to low 
contamination risks, shorter processing time and low costs. 
Systems	2/10	and	20/50	can	deliver	key	economic	benefits.	
Since cell cultures can reach target concentrations in one 
Cellbag bioreactor, the costs of disposables can be a fraction 
of those incurred when using other methods. The Cellbag 
bioreactor is easy to customize and allows the user to 
incorporate the WAVE Bioreactor system into their current 
workflow.	










Wave action sweeps up 




To select the correct WAVE Bioreactor system for your application, 
first	determine	the	Cellbag	bioreactor	size	you	need	by	estimating	
the culture volume you require and then select the appropriate 
instrumentation and options (see Table 1).
Table 1.	Specifications	for	WAVE	Bioreactor	Systems	2/10	and	20/50
BASE 2/10EH BASE 20/50EHT
Working volume (L) 0.2–5 0.2–25















Weight 4.2 kg (9 lbs) 15.5 kg (34 lbs)
Dimensions of base 230 × 330 × 160 mm 573 × 465 × 179 mm
Dimensions with kits KIT2EH KIT20EHT
489 × 330 × 200 mm 711 × 575 × 254 mm
KIT50EHT
775 × 700 × 254 mm
Utilities 110/230 VAC 110/230 VAC
6/3 A 50/60 Hz
WAVE Bioreactor 2/10EH is designed for quick set-up and can 
be used with working culture volumes of between 200 mL and 
5	L.	This	compact	unit	is	fitted	with	integral	features	such	as	
aeration, heating, and temperature control. The System 2/10EH 
has	an	integral	air	pump	with	mass	flow	meter	and	is	equipped	
with temperature control (heater and sensor). Other options 
include weight controllers for perfusion culture, dissolved oxygen 
amplifiers,	and	pH	controllers.	The	data	acquisition	software	
product PCDAQ/S is available for recording temperature, rocking 
speed/angle and weight.
WAVE Bioreactor System 20/50 is intended for working culture 
volumes between 200 mL and 25 L. This system is very versatile 
and is suitable for research and development as well as for 
production use. The System 20/50 is modular, consisting of a 
base unit that is electrically powered and a kit for holding the 
Cellbag bioreactor. System 20/50 has the following options: 
KIT20EHT for up to 10 L of culture or KIT50EHT for up to 25 L 
culture volume. 
Other options include weight controllers for perfusion culture, 
dissolved	oxygen	amplifiers,	and	pH	controllers.	For	added	
convenience the WAVE 20/50 system can be used with the 
WAVEPOD™	Controller	(Fig	3)	that	allows	simplified	control	of	all	




 gas mixing 
in	a	single	module.	The	System	20/50	can	also	be	configured	
to allow independent control of two individual cultures using a 
single base unit.
Bioreactor bags
Cellbag bioreactors (Fig 4) are intended for single-use and are 
suitable for cGMP production of human cells for cell therapy 
applications. The components are similar to those used for 
biological	storage	bags	and	meet	USP	Class	VI	specifications	
for plastics.
Cellbag bioreactors are manufactured from multilayer laminated 
clear	plastic	films	designed	to	provide	high	mechanical	strength	
and	bioinert	fluid	contact.	Typically,	the	fluid	contact	layer	is	a	
medical grade, low density polyethylene. The second or outer 
layer provides mechanical strength and a gas-impermeable 
barrier. This non-contact layer is typically made of low density 
polyethylene, EVA, or Nylon/EVOH copolymers. 
Cellbag bioreactors are sterilized by gamma radiation at 25–40 kGy. 
Individual	radiation	indicators	are	affixed	to	each	Cellbag	
bioreactor. Each lot is also tested for bacterial endotoxin levels. 
Lot release requires an endotoxin level below 0.125 EU/mL.
Validation data and Cellbag Drug Master File data are available 
to demonstrate biocompatibility; the user is however advised to 
validate	suitability	for	specific	applications.
Cellbag bioreactors can be used from 0°C to 50°C. Each chamber 
is tested for leakage by a pressure-hold test prior to sterilization 
(maximum operating pressure is 1.5 psig [0.1 bar]).
Fig 3. WAVEPOD Integrated controllers are available with left- or right-facing 
probe connections for ease of use.
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Ordering information
WAVE Bioreactor System 2/10
Description Quantity Code No
BASE 2/10EH 1 28-9377-86
Perfusion Controller with load cell 1 28-9884-64
CO2MIX 20 1 28-9377-95
Protective Lid, allows use of 
system with light-sensitive cells
1 28-9376-33
Cellbag 200 mL to 1 L with internal  
perfusion	filter	and	Oxywell2
1 28-9376-52




WAVE Bioreactor System 20/50
Description Quantity Code No
BASE 20/50EHT-CO2-L, 100-120V 1 28-9436-96
BASE 20/50EHT-CO2-L, 220-240V 1 28-9436-97
KIT20EHT, 100-120V 1 28-9376-34
KIT20EHT, 220-240V 1 28-9481-58
KIT50EHT, 100-120V 1 28-9384-26
KIT50EHT, 220-240V 1 28-9481-65
Protective Lid, allows use of 20 EHT Kit 
with light-sensitive cells
1 28-9376-35
Peristaltic Feed/Harvest Pump 1 28-9376-51
Cellbag 500 mL to 5 L with internal  
perfusion	filter	and	Oxywell2
1 28-9376-62




Description Quantity Code No
Cellbag 200 mL to 1 L, Basic 1 28-9378-00
Cellbag 500 mL to 5 L, Basic 1 28-9378-01
Cellbag 1 L to 10 L, Basic 1 28-9378-02
Cellbag 5 L to 25 L, Basic 1 28-9376-66
Cellbag 200 mL to 1 L with internal 
perfusion	filter	and	Oxywell2
1 28-9376-52
Cellbag 500 mL to 5 L with internal 
perfusion	filter	and	Oxywell2
1 28-9376-62
Cellbag 1 L to 10 L with internal 
perfusion	filter	and	Oxywell2
1 28-9376-64





Rapid production of clinical grade T 
lymphocytes in the WAVE Bioreactor. 
Case study
28-9331-49
Perfusion culture of T lymphocytes 
in the WAVE Bioreactor System 2/10. 
Application note
28-9650-52
Perfusion culture of human natural 
killer cells in the WAVE Bioreactor 
2/10 system. Application note
28-9936-25
Cytiva and the Drop logo are trademarks of Global Life Sciences IP 
Holdco LLC or an affiliate. WAVE Bioreactor, WAVEPOD, and Cellbag are 
trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing 
business as Cytiva.
Cellbag bioreactors with integrated optical sensors are sold under a 
sublicense from Sartorius Stedim Biotech under US patent number 
7,041,493, and/or its foreign equivalents, and please visit  
www. pall.com/patents.
© 2020 Cytiva
All goods and services are sold subject to the terms and conditions of sale 
of the supplying company operating within the Cytiva business. A copy 
of those terms and conditions is available on request. Contact your local 
Cytiva representative for the most current information.







DATA SHEET HyPerforma 2:1 500 L Single-Use Bioreactor
HyPerforma 2:1 500 L Single-Use Bioreactor 
• Integrally sealed ports in the S.U.B. BPC allow for 
addition of sensor probes and line sets
• Available in Thermo Scientifi c™ CX5-14 Film and 
Thermo Scientifi c™ Aegis™ 5-14 Film options
System options—adaptable to your needs
• Optional electrical box for remote agitation control
 – Water-jacketed S.U.B.s require a separate external 
temperature control unit 
• Exhaust gas vent fi lter heaters
• Load cells (standard on 1,000 and 2,000 L S.U.B.s)
• Cable management tree
• Process control system
• See Table 12 for auxiliary components for S.U.B. control 
management; choose an open-architecture approach or 
a turnkey, ready-to-use Thermo Scientifi c S.U.B. system
The next generation of performance
The Thermo Scientifi c™ HyPerforma™ Single-Use Bioreactor 
(S.U.B.) provides enhanced functionality, ease of use, 
and effi ciency. The complete HyPerforma S.U.B. system 
consists of a bioreactor tank and Thermo Scientifi c™
HyPerforma™ S.U.B. BioProcess Container (BPC), which 
is available in 50, 100, 250, 500, 1,000, and 2,000 L sizes 
with a 2:1 turndown ratio. The redesigned HyPerforma 
S.U.B. maintains traditional stirred-tank bioreactor design 
principles including specifi c height-to-diameter ratios and 
optimized mixer location that deliver optimum cell viability, 
performance, and scalability from process development 
through production.
This data sheet provides information on the 500 L S.U.B. 
system, which includes the tank and standard S.U.B. 
BPC. The BPC utilizes dual-sparger confi gurations with a 
porous-frit sparger and drilled-hole or open-pipe sparger 
that have been rigorously tested to provide high kLa values 
and optimal CO2 stripping for improved pH control and 
decreased foaming.
The S.U.B. system consists of the 
following components:
S.U.B. hardware unit—available in turnkey format
• Complete mixing system with water-jacketed vessel
• Drive shaft inserts into the S.U.B. BPC through the mixing 
drive motor and locks into the BPC agitator assembly
S.U.B. BPC—supplied sterile and ready to use
• Agitator assembly is a single-use (polyethylene) impeller 
with a bearing-and-seal assembly linked to an external 
mixer drive
• Dual gas spargers available with either drilled-hole or 
open-pipe sparger and standard porous-frit sparger


















Standard S.U.B. hardware units
The 500 L standard S.U.B. hardware units are available in 
the following configurations (Table 1).
• Water jacket with DC motor
• Water jacket with AC motor
Additional options are listed in Tables 3–7.
1. Exhaust vent filter holder
2. Mixing assembly with shield
3. Bearing port receiver with clamp
4. Mixer motor
5. Liquid sight windows
6. Drive shaft (stored)
7. Electrical control panel (optional)
8. Probe hanger bracket
9. Probe access windows
Design features
Front/top view
Note: Load cells are standard only on 1,000 and 2,000 L S.U.B. hardware units.
Back view
Table 1. 500 L standard S.U.B. hardware unit with casters  
(leveling feet).
Description Cat. No.
Water jacketed, DC motor SUB0500.9002
Water jacketed, 240 VAC, AC motor SUB0500.9006
Figure 1. 500 L S.U.B. hardware unit with water jacket.
10. Leveling casters
11. Cart assembly
12. 3/8 in. dimpled water jacket
13. Standard tool set: 3/8 in. x 150 in.-lb square torque 
wrench; load cell and motor cap lockout wrench
14. Stainless steel outer support container
15. Bleed valve
16. Bottom cutouts/pins for BPC attachment and alignment
17. Quick-connect water inlet/outlet ports
Front view
Table 2. 500 L S.U.B. system specifications.
Specifications for water-jacketed systems with AC and DC motors











Rated liquid working volume 500 L
Minimum liquid working volume 250 L
Total bioreactor volume (liquid and gas) 660 L
BPC chamber diameter 75.6 cm (29.8 in.) 
BPC chamber shoulder height 152.4 cm (60.0 in.)
Liquid height at rated working volume 113.4 cm (44.6 in.)
Fluid geometry at working volume (height:diameter ratio) 1.5:1







Impeller (quantity x blade count) 1 x 3
Impeller scaling (impeller diameter/tank diameter) 1/3
Impeller blade pitch (angle) 45°
Impeller diameter 25.1 cm (9.9 in.)






Maximum mixing rate 30–150 rpm
Nominal agitation rating (power/volume) 20 W/m3
Nominal agitation 50% working volume: 80 rpm 100% working volume: 101 rpm
Nominal tip speed 137.2 cm/s (270 ft/min)
Counterclockwise mixing flow direction Down-pumping
Agitation shaft resolved angle 19.6°
Agitation shaft centerline offset 5.1 cm (2.0 in.)
Overall drive shaft length 127.0 cm (50.0 in.)
Drive shaft diameter 1.9 cm (0.75 in.)
Drive shaft poly-sheath outside diameter 3.5 cm (1.4 in.)
Impeller clearance from tank bottom 25.1 cm (9.9 in.)
Top view
Figure 2. 500 L S.U.B. hardware unit dimensions.
32.0 in.  
(81 cm)
cart width
98.9 in. (251 cm) filter height
77.3 in. (196 cm) motor height
66.9 in. (170 cm) tank height
9.9 in. (25 cm) tank bottom
6.1 in. (16 cm) cart height
0 in. (0 cm)
32.1 in. (82 cm)
cart length 49.7 in. (126 cm)
overall length
50.8 in. (129 cm)
overall width
14.8 in. (38 cm)
electrical 
box width
Table 2. 500 L S.U.B. system specifications (continued).
Specifications for water-jacketed systems with AC and DC motors





Agitation motor drive (type, voltage, phase),  
AC motor only Induction, 208 VAC, 3 –
Agitation motor drive (type, voltage), DC motor only – Brushless, 48 VDC
Motor power rating (AC motor) 0.5 hp (372.8 W) –
Motor power rating (DC motor) – 0.536 hp (400 W)
Motor torque rating 9.5 N-m (82 in.-lb) –
Gear reduction 10:1
Programmable VFD, remote panel interface, power 
fault auto restart Standard –
Motor communication methods (for external 


















Jacket area: full/half volume 2.0/0.8 m2 (21.4/8.4 ft2)
Jacket volume 15.2 L
Jacket flow rate at 50 psi (3.4 bar) 136 L/min
Process connection 1 in. sanitary tri-clamp
Nominal heating/cooling load (W) 6.7 hp (5,000 W)
















Overall width 125.2 cm (49.3 in.) with E-Box 86.4 cm (34.0 in.)
Overall length 124.4 cm (47.8 in.) with E-Box 116 cm (45.7 in.)
Overall height 251 cm (99 in.)
Dry skid weight (mass) 354 kg (780 lb)





Ceiling height required for drive shaft loading 267 cm (105 in.)
Electrical power supply requirement (voltage,  
phase, current) 208–240 VAC, single, 10 A Dependent on controller
Tested system reliability (minimum) 0.9 at 90%
pH and DO probe, autoclavable type (Applisens™, 
Broadley James™, Mettler Toledo™) 12 mm diameter x 215–235 mm insertion length x 13.5 PG (pipe) thread





















Operating temperature range Ambient to 40 ± 0.1°C (104 ± 0.2°F)
Motor speed 30–150 rpm
Volume range 250–500 L
Maximum BioProcess Container pressure 0.5 psi (0.03 bar)








Table 3 lists available options for the 500 L S.U.B.
• Sparger support line (Figure 3)—keeps gas lines in an 
upright position for optimal gas transfer
• Heavy-duty tubing clamps (Figure 4)—used for each 
probe port not in use, eliminating process fluid holdup
• Sterile sampling manifolds—available in 50 and 
100 mL size for off-line sample retention
• Load cells (Figure 5)—Mettler Toledo™ FlexMount™ 
load cells allow for reading of batch liquid weight; three 
load cells are mounted with summing box on the S.U.B. 
hardware unit
• Bioreactor probe assemby (Figure 6)—required for 
each sterile electrochemical probe insertion
• Autoclave tray (Figure 7)—aids in holding the probe 
assembly during the autoclave process
• S.U.B. temperature sample port (Figure 8)—provides 
off-line temperature probe calibration prior to system 
startup
• Cable management tree (Figure 9)—allows the end 
user to organize the S.U.B. BPC tubing lines for operator 
ease of use
Table 3. 500 L S.U.B. system options.
Description Cat. No.
Cable management tree SV50992.03
Load cell with summation box, without display SV50988.03
Autoclave tray SV50177.01
Bioreactor probe assembly (nonsterile for use 
in autoclave) with KPC connector
SH30720.01
Bioreactor probe assembly (nonsterile for use 
in autoclave) with AseptiQuik™ connector
SH30720.02
Sparger line support SV50177B.14
Heavy-duty tubing clamp (each) SV20664.01
Heavy-duty tubing clamps (10 pack) SV20664.03
Sterile sampling manifold with Luer lock (each) SH30845.01
Sterile sampling manifold with Luer lock 
(10 pack)
SH30845.02
S.U.B. temperature/sample port SV20750.01
 
Figure 9. Cable management tree.
Figure 3. Sparger  
support line.
Figure 4. Heavy-duty  
tubing clamps.
Figure 5. Load cells. Figure 6. Bioreactor probe assembly.
Figure 8. S.U.B. temperature sample port.
Additional information on autoclave tray:
• Fabricated from stainless steel
• Contains plastic carry handle for easy transport right out 
of the autoclave
• Positions probes on 15% incline for greater longevity
• Prevents probe bellows from collapsing 
during sterilization
• Accommodates two probes
Figure 7. Autoclave tray for probe kits.
Vent heaters 
Vent heaters aid in reducing moisture buildup in exhaust 
filters from system off-gassing. Vent heaters are factory-
preset at 50°C to allow condensation to return to the 
vessel. Recommended gassing strategies of the S.U.B. 
system are in the S.U.B. Validation Guide. Table 4 lists 
available vent heaters.
Table 5. Harsh mount load cell display options.
Description Cat. No.
Mettler Toledo IND331 display, with analog 
interface (STD), 120 VAC U.S. line cord/plug
SV50177.306
Mettler Toledo IND331 display, with Allen-
Bradley RIO interface, 120 VAC U.S. line 
cord/plug
SV50177.307
Mettler Toledo IND331 display, with DeviceNet 
interface, 120 VAC U.S. line cord/plug
SV50177.308
Mettler Toledo IND331 display, with Ethernet/
IP and Modbus TCP interface, 120 VAC U.S. 
line cord/plug
SV50177.309
Mettler Toledo IND331 display, with Profibus 
interface, 120 VAC U.S. line cord/plug
SV50177.310
 





RTD 120 in. with Bulgin connector SV50177.363
Probe holders SV50177.23
Autoclave tray (stainless steel with plastic 
carry handle)
SV50177.01
Adjustable filter bracket SV50177.313
 
Table 7. Standard 500 L dual-sparger S.U.B. BPCs.
Film Dual-sparger configuration Cat. No.
CX5-14 film Open-pipe and porous-frit 
spargers
SH30774.04
Aegis5-14 film Open-pipe and porous-frit 
spargers
SH30972.04
CX5-14 film Drilled-hole and porous-frit 
spargers
SH30985.04
Aegis5-14 film Drilled-hole and porous-frit 
spargers
SH30999.04
Table 8. Standard 500 L S.U.B. BPC packaging.
Outer packaging Supplied “flat-packed”




Expiry date on outer packaging and 
shipping container





Documentation Certificate of Analysis provided with each 
lot for each delivery
 
Harsh mount load cell display 
Required for remote weight readout from the Mettler Toledo™ 
summing box, various signal output options are provided 
for external control monitoring (Table 5). More information 
can be found in the Load Cell Data Sheet.
Spare parts 
Table 6 lists the available spare parts of the 500 L 
S.U.B. systems.
Standard 500 L dual-sparger S.U.B. BPC systems 
Table 7 shows the available dual-sparger options for the 
500 L S.U.B. BPC system in either configuration: open-pipe 
and porous-frit spargers (Figure 10, Table 9) or drilled-hole 
and porous-frit spargers (Figure 11, Table 10). Standard 
S.U.B. BPC packaging is shown in Table 8. 
Table 4. Vent heater required for each exhaust filter on the  
S.U.B. BPC.
Description Voltage Controller Cat. No.
Meissner™ 10 in. series 
46 vent filter heater
120 VAC Preset SV50191.33
Meissner 10 in. series 
46 vent filter heater
240 VAC Preset SV50191.34
Meissner 10 in. series 
46 vent filter heater
120 VAC Integrated SV50191.47
Meissner 10 in. series 
46 vent filter heater
240 VAC Integrated SV50191.48
Pall™ Kleenpak™ KA3 
series 46 vent filter 
heater
120 VAC Preset SV50191.31
Pall Kleenpak KA3 
series 46 vent filter 
heater
240 VAC Preset SV50191.32
Pall Kleenpak KA3 
series 46 vent filter 
heater
120 VAC Integrated SV50191.45
Pall Kleenpak KA3 
series 46 vent filter 
heater
240 VAC Integrated SV50191.46
Figure 10. Standard 500 L dual-sparger S.U.B. BPC with open-pipe and porous-frit spargers.
Table 9. Specifi cations for the standard 500 L dual-sparger S.U.B. BPC with open-pipe and porous-frit spargers.
Line Description Tubing set (inner diameter x outer diameter x length) End treatment
1 Overlay gas sparger 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex™ tubing x 6 in. (15 cm) 
Hydrophobic vent fi lter with 
Emfl on™ II membrane
2 Inoculum addition
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 84 in. (213 cm) reduced 
to 1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 12 in. (30 cm)
SterilEnz™ pouch with injection site 
assembly, 3/8 in. MPC body
3–7 Probe ports (5) 1/2 in. (12.7 mm) tube ports





Thermowell adapter for 1/4 in. (6.4 mm) diameter
1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 24 in. (60 cm)
SterilEnz pouch with injection site 
assembly
9 Bottom drain harvest
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 60 in. (152 cm) reduced 
to 3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x 12 in. (30 cm) splits to
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 12 in. (30 cm) reduced 
to 1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 12 in. (30 cm) and
3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x 12 in. (30 cm)
Plugged
3/8 in. MPC insert
10 Base addition
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 6 in. (15 cm) reduced to
1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 84 in. (213 cm)
Plugged
11, 12 Feed lines
3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x 84 in. (213 cm) splits to
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 12 in. (30 cm) reduced 
to 1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 12 in. (30 cm) and
3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x 12 in. (30 cm)
SterilEnz pouch with injection site 
assembly, 3/8 in. MPC body
13 Exhaust line
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 4 in. (10 cm) splits to
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 10 in. (25 cm) and
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 10 in. (25 cm) 





1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 3 in. (8 cm) reduced to 
check valve and 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 72 in. 
(183 cm)





12 mm diameter 
(25 µm pores)
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 6 in. (15 cm) reduced to 
check valve and 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 72 in. 
(183 cm)





Impeller 3–7. Probe ports (5)
9. Bottom drain harvest
8. Thermowell/small-volume sample
1. Overlay gas sparger
13. Exhaust line
10. Base addition
15. Porous-frit micro sparger
14. Open-pipe macro sparger
11, 12. Feed line
Figure 11. Standard 500 L dual-sparger S.U.B. BPC with drilled-hole and porous-frit spargers.
Table 10. Specifications for the standard 500 L dual-sparger S.U.B. BPC with drilled-hole and porous-frit spargers.
Line Description Tubing set (inner diameter x outer diameter x length) End treatment
1 Overlay gas sparger 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 6 in. (15 cm) 
Meissner Steridyne™ 0.2 µm 
hydrophobic filter connected to  
12 in. (30 cm) C-Flex tubing
2 Inoculum addition
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 84 in. (213 cm) 
reduced to 1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 12 in. 
(30 cm)
Plugged
3–7 Probe ports (5) 1/2 in. (12.7 mm) tube ports





Thermowell adapter for 1/4 in. (6.4 mm) diameter 
1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 24 in. (60 cm)





1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 60 in. (152 cm) 
reduced to 3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x 12 in. 
(30 cm) splits to 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 
12 in. (30 cm) reduced to 1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex 
tubing x 12 in. (30 cm) and 3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex 
tubing x 12 in. (30 cm)
Plugged
3/8 in. MPC insert
10 Base addition
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 6 in. (15 cm) 
reduced to 1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 84 in. 
(213 cm)
Plugged
11, 12 Feed lines
3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x 84 in. (213 cm) 
splits to 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 12 in. 
(30 cm) reduced to 1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 
12 in. (30 cm) and 3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x 
12 in. (30 cm)
SterilEnz pouch with injection site 
assembly, 3/8 in. MPC body
13 Exhaust line
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 12 in. (30 cm) splits 
to 1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 6 in. (15 cm) and 
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 6 in. (15 cm) 
(2x) Meissner™ UltraCap™ 0.2 µm 
hydrophobic filters connected to  




6.75 in. (17.1 cm) disk 
with 1,180 holes with 
a 0.018 in. (0.445 mm) 
diameter
3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x 3 in. (8 cm) 
connected to check valve and 3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) 
C-Flex tubing x 75 in. (190 cm)
Meissner Steridyne 0.2 µm 
hydrophobic filter connected to  
6 in. (15 cm) C-Flex tubing
15
Porous-frit micro sparger
12 mm diameter  
(25 µm pores)
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 6 in. (15 cm) 
reduced to check valve and 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) 
C-Flex tubing x 78 in. (198 cm)
Meissner Steridyne 0.2 µm 
hydrophobic filter connected to  
6 in. (15 cm) C-Flex tubing
2. Inoculum addition
Impeller
3–7. Probe ports (5)
9. Bottom drain harvest
8. Thermowell/small-volume sample
1. Overlay gas sparger
13. Exhaust line
10. Base addition
15. Porous-frit micro sparger
14. Drilled-hole macro sparger
11, 12. Feed line
Front face
Back face
Table 11. Custom 500 L S.U.B. BPC options.
Category Options/capability Notes




More information is available in the Tubing 
Selection Guide
Tubing size Ranging from 1/8 to 1 in. (0.318 to 2.54 cm) ID, in 
customer-specified lengths
More information is available in the Tubing 
Selection Guide
Connectors Luers, quick-connects, SIP connectors, tri-clamp, aseptic 
connectors, sterile connectors, steam-to, steam-through, 
sample ports, plugs
More information is available in the 
Connector Selection Guide. Note: 
Reusable probe port connections use 
Kleenpak™ connector only
Probe ports Additional ports: second row of five The reusable probe port connection uses 
a Kleenpak connector only
Disposable sensors Pressure sensor: PendoTECH and Finesse Solutions 
DO and pH: Finesse Solutions and PreSens
pH: Mettler Toledo
Choice of qualified sensors available
Additional probe ports Limited engineer-to-order customization only Qualified location on second row of probe 
ports only
Port sizes Limited engineer-to-order customization only Dependent on location in BPC and fit with 
hardware (e.g., 1 in. (2.54 cm) port on 
harvest line)
Rearrangement of lines 
on existing ports
Limited customization possible (e.g., moving sample/
thermowell port to a probe tube port, or swapping overlay 
inlet line with supplement line)
Dependent on location in BPC and fit with 
hardware
Sparger Dual sparger (macro open-pipe or drilled-hole and  
micro porous-frit) standard
Sparger locations are fixed
Diptube lines Limited customization possible Length cannot interfere with impeller  
and shaft
Overlay and sparger line 
filters
Filter options available from standard component library Choice of qualified filters available
Vent filters Standard is Pall or Meissner 0.2 µm exhaust vent filter Filters must be compatible with available 
vent filter heater configurations
Vent filter tubing length Extended filter height above the S.U.B. BPC is  
made to order
Must be compatible with a vent filter 
bracket option
Filters on media and 
supplement inlets
Limited engineer-to-order customization only; choice of 
filters used to sterilize incoming media or supplements  
are available
Choice of qualified filters available
 
Custom S.U.B. BPC options 
Table 11 lists available custom 500 L S.U.B. BPC system 
options. Not all options are available for all ports. For 
additional information, please see the selection guides in 
the single-use products catalog.
Find out more at thermofisher.com/sub
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Table 12. Recommended S.U.B. parts list for first-time operators.
Description Quantity Cat. No./auxiliary part
S.U.B. hardware unit 1 Type to be configured
S.U.B. BPC 3 Type to be configured
Bioreactor probe assembly (nonsterile for use in autoclave) 12 SH30720.01
Heavy-duty tubing clamp 12 SV20664.01
Autoclave tray for autoclaving probe assemblies 1 SV50177.01
Auxiliary parts supporting the single-use bioreactor 
(supplied by end user or requested turnkey)
Necessary for gas flow control, DO, and pH set points 1 Bioreactor control system
Autoclavable probe (13 mm x 13.5 PG thread with 195–235 mm insertion length) * DO probe
Autoclavable probe (13 mm x 13.5 PG thread with 195–235 mm insertion length) * pH probe
Tubing welder, steam-in-place system, sterilizer, or laminar flow hood * Sterile/aseptic connection 
Used for fluid transfer between linesets on the containers * Stand-alone peristaltic pump
Necessary for water jacket temperature controls (not provided) * Temperature control unit (TCU)
 * Quantity based on needs.
External controller options 
The HyPerforma S.U.B. offers an open-architecture or 
turnkey system. An open-architecture system allows you 
to use any control system of your choice. The capital 
investment can be reduced by using a control system 
already utilized in your facility. A turnkey system is a ready-
to-use, out-of-the-box system with a choice of dedicated 
controls from Finesse Solutions or Applikon. These 
systems work on PC, DeltaV, Allen-Bradley, or Siemens 
formats. Contact your local sales representative for 
more information.
DATA SHEET HyPerforma 2:1 2,000 L Single-Use Bioreactor
HyPerforma 2:1 2,000 L Single-Use Bioreactor 
• Integrally sealed ports in the S.U.B. BPC allow for 
addition of sensor probes and line sets
• Available in Thermo Scientifi c™ CX5-14 Film and 
Thermo Scientifi c™ Aegis™ 5-14 Film options
System options—adaptable to your needs
• Optional electrical box for remote agitation control
• Optional condenser system
• Exhaust gas vent fi lter heaters
• Load cell displays
• Cable management tree
• Process control system
• Mobile stairs
• See Table 12 for auxiliary components for S.U.B. control 
management; choose an open-architecture approach or 
a turnkey, ready-to-use Thermo Scientifi c™ S.U.B. system
The next generation of performance
The Thermo Scientifi c™ HyPerforma™ Single-Use Bioreactor 
(S.U.B.) provides enhanced functionality, ease of use, 
and effi ciency. The complete HyPerforma S.U.B. system 
consists of a bioreactor tank and Thermo Scientifi c™
HyPerforma™ S.U.B. BioProcess Container (BPC), which 
is available in 50, 100, 250, 500, 1,000, and 2,000 L sizes 
with a 2:1 turndown ratio. The redesigned HyPerforma 
S.U.B. maintains traditional stirred-tank bioreactor design 
principles including specifi c height-to-diameter ratios and 
optimized mixer location that deliver optimum cell viability, 
performance, and scalability from process development 
through production.
This data sheet provides information on the 2,000 L S.U.B. 
system, which includes the tank and standard S.U.B. 
BPC. The BPC utilizes dual-sparger confi gurations with a 
porous-frit sparger and drilled-hole or open-pipe sparger 
that have been rigorously tested to provide high kLa values 
and optimal CO2 stripping for improved pH control and 
decreased foaming.
The S.U.B. system consists of the following 
components:
S.U.B. hardware unit—available in turnkey format
• Complete mixing system with a water-jacketed vessel
• Drive shaft inserts into the S.U.B. BPC through the mixing 
drive motor and locks into the BPC agitator assembly
• Load cells
S.U.B. BPC—supplied sterile and ready to use
• Agitator assembly is a single-use (polyethylene) impeller 
with a bearing-and-seal assembly linked to an external 
mixer drive
• Dual gas spargers available with either drilled-hole or 
open-pipe sparger and standard porous-frit sparger




















Standard S.U.B. hardware units
2,000 L standard S.U.B. hardware units are available with 
a water jacket only with either a DC or AC motor. The 
Mettler Toledo™ FlexMount™ load cells allow for batch 
liquid-weight reading. Three load cells are mounted 
with summation box on the S.U.B. hardware unit. These 
hardware units do not include other options listed in 
Tables 3–7. Base part numbers listed in Table 1 will change 
depending upon which options are chosen.
1. Mixer motor
2. Mixing assembly with shield
3. Auxiliary E-stop assembly
4. Stainless steel outer support container 
5. Bag lift assembly
6. Standard tool set 
7. Load cell display
8. Control panel 
9. Load cell summation box
10. Load cells (3)
11. Probe access window
12. Probe clips
13. Water jacket
14. Bottom cutouts for BPC alignment
15. Sparge access plate
16. Jacket quick-connect couplings
17. Pneumatic bag lift control
Design features
Front/top view
Note: Load cells are standard on 2,000 L S.U.B. hardware units.
Back view
Table 1. 2,000 L standard S.U.B. hardware.
Description Cat. No.
Water jacketed, DC motor SUB2000.9002
Water jacketed, 240 VAC, AC motor SUB2000.9008




































Table 2. 2,000 L S.U.B. system specifications.
Specifications for water-jacketed systems with AC and DC motors











Rated liquid working volume 2,000 L
Minimum liquid working volume 1,000 L
Total bioreactor volume (liquid and gas) 2,575 L
BPC chamber diameter 119.4 cm (47 in.)
BPC chamber shoulder height 229.9 cm (90.5 in.)
Liquid height at rated working volume 178.7 cm (70.4 in.)
Fluid geometry at working volume (height:diameter ratio) 1.5:1







Impeller (quantity x blade count) 1 x 3
Impeller scaling (impeller diameter/tank diameter) 1/3
Impeller blade pitch (angle) 45°
Impeller diameter 39.8 cm (15.7 in.)






Maximum mixing rate Standard: 20–75 rpmCustom: up to 95 rpm above 90% working volume only
Nominal agitation rating (power/volume) 20 W/m3
Nominal agitation 50% working volume: 60 rpm100% working volume: 75 rpm
Nominal tip speed 154.9 cm/s (305 ft/min)
Counterclockwise mixing flow direction Down-pumping
Agitation shaft resolved angle 19.6°
Agitation shaft centerline offset 6.7 cm (2.6 in.)
Overall drive shaft length (two-piece and four-piece) 210.6 cm (82.9 in.)
Drive shaft diameter 1.9 cm (0.8 in.)
Drive shaft poly-sheath outside diameter 3.5 cm (1.4 in.)




Agitation motor drive (type, voltage, phase) AC  
motor only Induction, 208 VAC, 3 –
Agitation motor drive (type, voltage) DC motor only – Brushless, 48 VDC
Motor power rating (AC motor) 0.5 hp (372.8 W) –
Motor power rating (DC motor) –  0.536 hp (400 W) 
Motor torque rating  27.7 N-m (245 in.-lb) –
Gear reduction 15:1 20:1
Programmable VFD, remote panel interface, power fault 
auto restart Standard –
Motor communication methods (for external controller) 0–10 V, 4–20 mA, ModBus –
Table 2. 2,000 L S.U.B. system specifications (continued).
Specifications for water-jacketed systems with AC and DC motors


















Jacket area: full/half-volume 67.1/53.9 ft2
Jacket volume 44 L
Jacket flow rate at 50 psi (3.4 bar) 75 L/min
Process connection 1 in. male national pipe thread (NPT) nipple provided with  Hansen™ quick-connect check valves
Nominal heating/cooling load (W) 18,000 W
Approximate liquid heat-up time (5–37°C) 4 hr
M
is
c. RTD or thermocouple, 1/8 in.  










r Overall width 179.7 cm (70.5 in.) with E-box 148.5 cm (58.5 in.)
Overall length 171.4 cm (67.5 in.)
Overall height 321 cm (126.4 in.)
Dry skid weight (mass) 962.1 kg (2,121 lb)





Ceiling height required for 2-piece driveshaft loading 381 cm (150 in.)
Ceiling height required for 4-piece driveshaft loading 353.06 cm (139 in.)
Electrical power supply requirement (voltage, phase, 
current) 208–240 VAC, single, 10 A Dependent on controller
Tested system reliability (minimum) 0.9 at 90%
pH and DO probe, autoclavable type (Applisens™, 
Broadley James™, Mettler Toledo™) 12 mm diameter x 215–235 mm insertion length x 13.5 PG thread
Noise level < 70 dB at 1.5 m



















s Operating temperature range Ambient to 40 ± 0.1°C (104 ± 0.2°F)
Motor speed Standard: 20–75 rpmCustom: up to 95 rpm above 90% working volume only
Volume range 1,000–2,000 L
Maximum BioProcess Container pressure 0.5 psi (0.03 bar)
Continuous operating time 21 days mixing time at nominal volume only
System options 
Table 3 lists available S.U.B. system options for the 
2,000 L size.
• Autoclave tray (Figure 3)—aids in holding the probe 
assembly during the autoclave process
• Sparger support line (Figure 4)—keeps gas lines in an 
upright position for optimal gas transfer
• Heavy-duty tubing clamps (Figure 5)—used for each 
probe port not in use, eliminating process fl uid holdup
• Sterile sampling manifolds—available in 50 and 
100 mL sizes for off-line sample retention
• Mobile stairs (Figure 6)—facilitates access to the 
bioreactor for top-mount drive shaft loading; the 2,000 L 
S.U.B. requires a platform for top-mount drive shaft 
loading (customer may provide their own solution)
• Bioreactor probe assemblies (Figure 7)—required for 
each sterile electrochemical probe insertion
• S.U.B. temperature sample port (Figure 8)—
provides off-line temperature probe calibration prior to 
system startup
• Condenser system (Figure 9)
Table 3. 2,000 L S.U.B. system options.
Description Cat. No.
Complete condenser system (120 V) including cart, 
chill plate and mounting post with fi lter brackets, 
TCU, and pump
SV50232.01
Complete condenser system (240 V) including cart, 




Bioreactor probe assembly (nonsterile for use in 
autoclave) with KPC connector
SH30720.01
Bioreactor probe assembly (nonsterile for use in 
autoclave) with AseptiQuik™ connector
SH30720.02
Sparger line support SV50177.65
Heavy-duty tubing clamp (each) SV20664.01
Heavy-duty tubing clamps (10 pack) SV20664.03
Sterile sampling manifold with Luer lock (each) SH30845.01
Sterile sampling manifold with Luer lock (10 each) SH30845.02
S.U.B. temperature/sample port SV20750.01
Mobile stairs SV50935.01
Additional information on autoclave tray:
• Fabricated from stainless steel
• Contains plastic carry handle for easy transport right out 
of the autoclave
• Positions probes on 15% incline for greater longevity
• Prevents probe bellows from collapsing during 
sterilization






Figure 3. Autoclave tray for probe kits.
Figure 9. Condenser system.
Figure 4. Sparger support line. Figure 5. Heavy-duty tubing clamps.
Figure 7. Bioreactor probe assembly. Figure 8. S.U.B. temperature sample port.Figure 6. Mobile stairs.
Vent heaters 
Vent heaters aid in reducing moisture buildup in exhaust 
filters from system off-gassing. Vent heaters are factory-
preset at 50°C to allow condensation to return to the 
vessel. Recommended gassing strategies of the S.U.B. 
system are in the S.U.B. Validation Guide. Table 4 lists 
available vent heaters.
Note: Vent heater is not required if condenser system 
is purchased.
Table 5. Harsh mount load cell display options.
Description Cat. No.
Mettler Toledo IND331 display, with analog interface 
(STD), 120 VAC U.S. line cord/plug
SV50177.306
Mettler Toledo IND331 display, with Allen-Bradley 
RIO interface, 120 VAC U.S. line cord/plug
SV50177.307
Mettler Toledo IND331 display, with DeviceNet 
interface, 120 VAC U.S. line cord/plug
SV50177.308
Mettler Toledo IND331 display, with Ethernet/IP and 
Modbus TCP interface, 120 VAC U.S. line cord/plug
SV50177.309
Mettler Toledo IND331 display, with Profibus 
interface, 120 VAC U.S. line cord/plug
SV50177.310
 





RTD 120 in. with Bulgin connector SV50177.363
Probe holders SV50177.23




Table 8. Standard 2,000 L S.U.B. BPC packaging.
Outer packaging Supplied "flat-packed"




Expiry date on outer packaging and 
shipping container
Sterilization Irradiation (25–40 kGy) inside outer packaging
Shipping container Durable cardboard carton
Documentation Certificate of Analysis provided with each lot 
for each delivery
 
Harsh mount load cell display 
Required for remote weight readout from the 
Mettler Toledo™ summing box, various signal output 
options are provided for external control monitoring 
(Table 5). More information can be found in the Load Cell 
Data Sheet.
Spare parts 
Table 6 lists the available spare parts of the 2,000 L 
S.U.B. systems.
Standard 2,000 L dual-sparger S.U.B. BPC systems 
Table 7 shows the available dual-sparger options for 
the 2,000 L S.U.B. BPC system in either configuration: 
open-pipe and porous-frit spargers (Figure 10, Table 9) or 
drilled-hole and porous-frit spargers (Figure 11, Table 10). 
Standard S.U.B. BPC packaging is shown in Table 8. 
Table 7. Standard 2,000 L dual-sparger S.U.B. BPCs.
Film Dual-sparger  configuration Condenser Cat. No. 
CX5-14 film Open-pipe and  
porous-frit spargers
No SH30774.07
CX5-14 film Open-pipe and  
porous-frit spargers
Yes SH30774.08
CX5-14 film Drilled-hole and 
porous-frit spargers
Yes SH30985.07
CX5-14 film Drilled-hole and 
porous-frit spargers
No SH30985.08
Aegis5-14 film Open-pipe and  
porous-frit spargers
No SH30972.07
Aegis5-14 film Open-pipe and  
porous-frit spargers
Yes SH30972.08
Aegis5-14 film Drilled-hole and 
porous-frit spargers
Yes SH30999.07




Table 4. Vent heater required for each exhaust filter on the  
S.U.B. BPC.
Description Voltage Controller Cat. No.
Meissner™ 10 in. series 
46 vent filter heater
120 VAC Preset SV50191.33
Meissner 10 in. series 46 
vent filter heater
240 VAC Preset SV50191.34
Meissner 10 in. series 46 
vent filter heater
120 VAC Integrated SV50191.47
Meissner 10 in. series 46 
vent filter heater
240 VAC Integrated SV50191.48
Pall™ Kleenpak™ KA3 
series 46 vent filter heater
120 VAC Preset SV50191.31
Pall Kleenpak KA3 series 
46 vent filter heater
240 VAC Preset SV50191.32
Pall Kleenpak KA3 series 
46 vent filter heater
120 VAC Integrated SV50191.45
Pall Kleenpak KA3 series 
46 vent filter heater
240 VAC Integrated SV50191.46
Figure 10. Standard 2,000 L dual-sparger S.U.B. BPC with open-pipe and porous-frit spargers. Available with or without the condenser assembly.
Table 9. Specifications for the standard 2,000 L dual-sparger S.U.B. BPC with open-pipe and porous-frit spargers.
Line Description Tubing set (inner diameter x outer diameter x length) End treatment
1 Overlay gas sparger
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex™ tubing x 4 in. (10 cm) reduced to
 3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x 84 in. (213 cm)





1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 3 in. (8 cm) reduced to
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 6 in. (15 cm) reduced to
1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 84 in. (213 cm)
Plugged
3–7 Probe ports (5) 1/2 in. (12.7 mm) tube ports





Thermowell adapter for 1/4 in. (6.4 mm) diameter
1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 24 in. (60 cm)
SterilEnz™ pouch with injection 
site assembly
9 Bottom drain harvest
3/4 in. (19.1 mm) x 1 in. (25.4 mm) C-Flex tubing x 48 in. (122 cm) splits to
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 24 in. (61 cm) reduced to 
1/4 in. (6.4 mm) x 3/8 in. (9.5 mm) C-Flex tubing x 12 in. (30 cm) and 1/2 in. 
(12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 24 in. (61 cm)
1/4 in. MPC insert and Pall™ Kleenpak™ 
connector (male)
10 Base addition
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 3 in. (8 cm) reduced to
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 84 in. (213 cm) reduced 
to 1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 12 in. (30 cm)
Plugged
11 Feed line
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 4 in. (10 cm) splits to
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 10 in. (25 cm) and
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 10 in. (25 cm)
SterilEnz pouch with injection site 
assembly and 3/8 in. MPC body




1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 72 in. (183 cm) reduced 
to check valve and 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 72 in. 
(183 cm)
Kleenpak Emflon II capsule
14
Porous-frit micro 
spargers (3), 12 mm 
diameter (25 µm 
pores)
(2x) 12 mm PDVF porous sparge inserts connected to
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 6 in. (15 cm) converge to 
one 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 72 in. (183 cm)




3/4 in. (19.1 mm) x 1 in. (25.4 mm) C-Flex tubing x 84 in. (213 cm) splits to
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 24 in. (61 cm) and
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 24 in. (61 cm) 








Condenser bag assembly (optional) –
18 Tri-clamp port (3 in.) NA Gasket, end cap, and clamp
3–7. Probe ports (5)
9. Bottom drain harvest





15. Media fill/auxiliary drain
Impeller
10. Base addition
1. Overlay gas sparger
2. Inoculum addition/feed line
9. Media fill
16. Condensate return line
12. Exhaust line
17. Condenser bag 
assemby (optional)
18. Tri-clamp port (3 in.)
14. Porous-frit  
micro spargers (3)









8–12. Probe ports (5)
4. Media fill/auxiliary drain




7. Overlay gas sparger
13. Feed line
13. Feed line
4. Media fill/auxiliary drain
4. Media fill




15. Drilled-hole macro sparger
17. Bottom drain harvest
16. Porous-frit  
micro sparger (2)
Table 10. Specifications for the standard 2,000 L dual-sparger S.U.B. BPC with drilled-hole and porous-frit spargers.




Condenser bag assembly (optional) –
2 Exhaust lines (2) Condenser bag assembly (optional) –
3 Condensate return line Condenser bag assembly (optional) –
4
Media fill/auxiliary drain 
lines
(3x) 3/4 in. (19.1 mm) x 1 in. (25.4 mm) C-Flex tubing x 84 in. (213 cm) splits 
to 1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 24 in. (61 cm) and
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 24 in. (61 cm) 
Pall Kleenpak aseptic connectors 
(female)
5 Base addition
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 3 in. (8 cm) reduced to
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 84 in. (213 cm) reduced 





1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 3 in. (8 cm) reduced to
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 6 in. (15 cm) reduced to
1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 84 in. (213 cm)
Plugged
7 Overlay gas sparger
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 4 in. (10 cm) reduced to 
3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x 84 in. (213 cm)
Kleenpak Emflon II capsule
and pressure transducer
8–12 Probe ports (5) 1/2 in. (12.7 mm) tube ports
Pall Kleenpak aseptic connectors 
(female)
13 Feed lines
(2x) 1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 4 in. (10 cm) splits to 
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 10 in. (25 cm) and
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 10 in. (25 cm) 
SterilEnz pouch with injection site 




Thermowell adapter for 1/4 in. (6.4 mm) diameter 
1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 24 in. (61 cm)




12 mm diameter (25 µm 
pores)
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 6 in. (15 cm) reduced to
check valve and 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x  
72 in. (183 cm)
(2x) Meissner™ Steridyne™ 0.2 µm 
hydrophobic filter
17 Bottom drain harvest
3/4 in. (19.1 mm) x 1 in. (25.4 mm) C-Flex tubing x 48 in. (122 cm) splits to
1/2 in. (12.7 mm) x 34 in. (19.1 mm) C-Flex tubing x 24 in. (61 cm) reduced to 
1/4 in. (6.4 mm) x 3/8 in. (9.5 mm) C-Flex tubing x 12 in. (30 cm) and
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 24 in. (61 cm)
1/4 in. MPC insert and 
Pall Kleenpak connector (male) 
18 Tri-clamp port (3 in.) NA Gasket, end cap, and clamp
1. Condenser bag 
assemblies
Table 11. Custom 2,000 L S.U.B. BPC options.
Category Options/capability Notes




More information is available in the Tubing 
Selection Guide
Tubing size Ranging from 1/8 to 1 in. (0.318 to 2.54 cm) ID, in 
customer-specified lengths
More information is available in the Tubing 
Selection Guide
Connectors Luers, quick-connects, SIP connectors, tri-clamp, aseptic 
connectors, sterile connectors, steam-to, steam-through, 
sample ports, plugs
More information is available in the 
Connector Selection Guide. Note: 
Reusable probe port connections use 
Kleenpak™ connector only
Probe ports Additional ports: second row of five The reusable probe port connection uses 
a Kleenpak connector only
Disposable sensors Pressure sensor: PendoTECH and Finesse Solutions 
DO and pH: Finesse Solutions and PreSens
pH: Mettler Toledo
Choice of qualified sensors available; 
PendoTECH pressure sensors come 
standard
Additional probe ports Limited engineer-to-order customization only To be designed
Port sizes Limited engineer-to-order customization only Dependent on location in BPC and fit with 
hardware (e.g., 1 in. (2.54 cm) port on 
harvest line)
Rearrangement of lines 
on existing ports
Limited customization possible (e.g., moving sample/
thermowell port to a probe tube port, or swapping overlay 
inlet line with supplement line)
Dependent on location in BPC and fit with 
hardware
Sparger Dual sparger (macro open-pipe or drilled-hole and  
micro porous-frit) standard
Sparger locations are fixed
Diptube lines Limited customization possible Length cannot interfere with impeller  
and shaft
Overlay and sparger line 
filters
Filter options available from standard component library Choice of qualified filters available
Vent filters Standard is Pall or Meissner 0.2 µm exhaust vent filter Filters must be compatible with available 
vent filter heater configurations
Vent filter tubing length Extended filter height above the S.U.B. BPC is  
made to order
Must be compatible with a vent filter 
bracket option
Filters on media and 
supplement inlets
Limited engineer-to-order customization only; choice of 
filters used to sterilize incoming media or supplements  
are available
Choice of qualified filters available
 
Custom S.U.B. BPC options 
Table 11 lists available custom 2,000 L S.U.B. BPC system 
options. Not all options are available for all ports. For 
additional information, please see the selection guides in 
the single-use products catalog.
Find out more at thermofisher.com/sub
For Research Use or Further Manufacturing. Not for diagnostic use or direct administration into humans or animals.  
© 2018 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries 
unless otherwise specified. Allen-Bradley is a trademark of Allen-Bradley Company. Applisens is a trademark of Applikon B.V. Corporation. 
AseptiQuik is a trademark of Colder Products Company. Broadley James is a trademark of Broadley-James Corporation. C-Flex and PharMed 
are trademarks of Saint-Gobain. Finesse is a trademark of Finesse Solutions, Inc. Hansen is a trademark of Hansen products. Mettler Toledo 
and FlexMount are trademarks of Mettler-Toledo AG. Meissner and Steridyne are trademarks of Meissner Filtration Products, Inc. Pall, 
Kleenpak, and Emflon are trademarks of Pall Corporation. PharmaPure is a trademark of PharmaPure Tubing. SterilEnz is a trademark of PAW 
Bioscience Products, Inc. COL21599 0218
Table 12. Recommended S.U.B. parts list for first-time operators.
Description Quantity Cat. No./auxiliary part
S.U.B. hardware unit 1 Type to be configured
S.U.B. BPC 3 Type to be configured
Bioreactor probe assembly (nonsterile for use in autoclave) 12 SH30720.01
Heavy-duty tubing clamp 12 SV20664.01
Autoclave tray for autoclaving probe assemblies 1 SV50177.01
Auxiliary parts supporting the single-use bioreactor 
(supplied by end user or requested turnkey)
Necessary for gas flow control, DO, and pH set points 1 Bioreactor control system
Autoclavable probe (13 mm x 13.5 PG thread with 195–235 mm insertion length) * DO probe
Autoclavable probe (13 mm x 13.5 PG thread with 195–235 mm insertion length) * pH probe
Tubing welder, steam-in-place system, sterilizer, or laminar flow hood * Sterile/aseptic connection 
Used for fluid transfer between linesets on the containers * Stand-alone peristaltic pump
Necessary for water jacket temperature controls (not provided) * Temperature control unit (TCU)
* Quantity based on needs.
External controller options 
The HyPerforma S.U.B. offers an open-architecture or 
turnkey system. An open-architecture system allows you 
to use any control system of your choice. The capital 
investment can be reduced by using a control system 
already utilized in your facility. A turnkey system is a ready-
to-use, out-of-the-box system with a choice of dedicated 
controls from Finesse Solutions or Applikon. These 
systems work on PC, DeltaV, Allen-Bradley, or Siemens 
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Introduction The S.U.B. BPC is designed to provide an acceptable range of kLa values 
to support rapid growth for an array of common cell platforms using the 
operating parameters shown in Table 2.7 for BPCs equipped with open 
pipe and porous frit spargers, and Table 2.8 for BPCs equipped with 
drilled hole and porous frit spargers.
Study Method Experiments were designed to estimate and model mass transfer of gasses 
in S.U.B. systems. For more information about methods and procedures, 
see the test methods detail in section 6.4 in the appendix of this manual.
2.6 Oxygen Transfer 
S.U.B. BPCs Range of Operating Parameters with Open Pipe and Frit Spargers
50L 100L 250L 500L 1,000L 2,000L
Temperature (°C) 2.0 - 40.0 ± 0.1
Operating Volume (L) 25 to 50 50 to 100 125 to 250 250 to 500 500 to 1,000 1,000 to 2,000


























































































Air (slpm) 1 0.5 5 2 1 10 5 2.5 10 10 5 15 10 8 15 12 16 15
O2 (slpm) - 0.25 - - 0.5 - - 1.25 - - 2.5 - - 4 - - 8 -
CO2 (slpm) - 0.1 - - 0.2 - - 0.5 - - 1 - - 1 - - 1 -
N2 (slpm) - 0.25 - - 0.5 - - 1.25 - - 2.5 - - 2.5 - - 2.5 -
Total (slpm) 1 0.85 5 2 1.7 10 5 4.25 10 10 8.5 15 10 13 15 12 25 15
Exhaust Load (slpm) 20 20 20 40 40 90
S.U.B. BPCs Range of Operating Parameters with Drilled Hole and Frit Spargers
50L 100L 250L 500L 1,000L 2,000L
Temperature (°C) 2.0 - 40.0 ± 0.1
Operating Volume (L) 25 to 50 50 to 100 125 to 250 250 to 500 500 to 1,000 1,000 to 2,000
Agitation Rate (rpm) 30 to 200 30 to 200 30 to 150 30 to 150 20 to 110 20 to 751
Recommended Max. 




















































































Air (slpm) 2.5 1 5 5 2 10 12 4 14 25 6 35 100 8 60 200 16 1292
O2 (slpm) - 1 - - 2 - - 4 - - 6 - - 8 - - 16 -
CO2 (slpm) - 0.25 - - 0.5 - - 1 - - 1.5 - - 2 - - 4 -
N2 (slpm) - 1 - - 2 - - 4 - - 6 - - 8 - - 16 -
Total (slpm) 2.5 1.25 5 5 2.5 10 12 5 14 25 7.5 35 100 10 60 200 20 129
Exhaust Load (slpm) 20 20 90 90 180 270
Table 2.8 Operating parameters using open pipe and porous frit spargers
Table 2.9 Operating parameters using drilled hole and porous frit spagers
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Results Overview Experiments were performed using 50, 250 and 2,000L vessels to 
measure the mass transfer of oxygen and CO2 stripping and the results 
for 100, 500 and 1,000L vessel sizes have been interpolated theoretically 
from those results.
The results in this section show the mass transfer of oxygen and CO2 
stripping, and are presented as kLa for various sparge flow rates for each 
vessel size.  Two dimensional plots are used to show individual sparger 
results for oxygen delivery and CO2 stripping, separately.  Three 
dimensional plots are used to show the combined micro/macro (porous 
frit/open pipe or porous frit/drilled hole) sparger oxygen delivery 
behavior in terms of kLa response at different combined flow rates for 
each vessel size. 
Results, unless otherwise specified, are at an agitation power input per 
volume (PIV) of 0.15 HP/1,000gal (29.6 W/m3).
Results for vessels using porous frit and open pipe spargers are presented 
first. Results for vessels using porous frit and Drilled Hole Spargers are 
presented in separate, subsequent sections.
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500L Results for Porous Frit 



























Carbon Dioxide Stripping kLa with 
Drilled Hole Sparger
Graph 2.47 Interpolated Results for 500L S.U.B. with 
porous frit sparger
Graph 2.51 Interpolated Results for 500L S.U.B. with both porous frit and drilled hole spargers
Graph 2.48 Interpolated Results for 500L S.U.B. with 
drilled hole sparger
Graph 2.49 Interpolated Results for 500L S.U.B. with 
porous frit sparger































Carbon Dioxide Stripping kLa with Frit 
Sparger
The data shown below for 500L vessels is estimated, and has been 
interpolated from experimentally-derived 250 and 2,000L data and 










































Thermo Scientific 34 Single-Use Bioreactor (S.U.B.)
Section 2
Validation

































Carbon Dioxide Stripping kLa with 
Drilled Hole Sparger
Graph 2.57 Results for 2,000L S.U.B. with porous frit 
sparger
Graph 2.61 Results for 2,000L S.U.B. with both porous frit and drilled hole spargers
Graph 2.58 Results for 2,000L S.U.B. with drilled hole 
sparger
Graph 2.59 Results for 2,000L S.U.B. with porous frit 
sparger 



































































Carbon Dioxide Stripping kLa with Frit 
Sparger
The results of experiments with 2,000L vessels using porous frit and 
drilled hole spargers are shown below.
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2.7 Mixing Studies The recommended range of mixing rates for the range of S.U.B. systems is 
as follows:
Table 2.11 Summary of mixing study results for the 50 to 1,000L S.U.B. systems
50L S.U.B. 100L S.U.B.

























50 80 50 150 50 55-60 50 80-85
100 20 100 50 100 30-35 100 40-45
150 15 150 40 150 20-25 150 35-40
200 10 200 30-35
250L S.U.B. 500L S.U.B.

























40 50 60 60 30 75 30 80
60 30 100 40 70 25 70 60
80 20 120 30 110 20 110 50
140 20 150 15 150 25
1,000L S.U.B.













30 68-89 60 37-47
45 37-40 70 30-39






The mixing efficiency was estimated for the range of agitation rates by 
measuring the conductivity of the liquid contents of the S.U.B. BPC at 
different locations within the system after the addition of sodium chloride 
solution. Conductivity was measured with three conductivity probes 
positioned at the top, middle and bottom.
 
The time to achieve uniform distribution of sodium chloride throughout 
the BPC was designated as the mixing time. Since multiple sensors were 
used the average time was determined when concentration readings 
of all the sample locations achieved a minimum of 95% of the final 
concentration. The study was conducted at maximum and minimum 
operating volumes for 50, 100, 250, 500 and 1,000L S.U.B. systems.
50L 100L 250L 500L 1,000L 2,000L
Operating Volume (L) 25-50 50-100 125-250 250-500 500-1,000 1,000-2,000
Agitation Rate (rpm) 30-200 30-200 30-150 30-150 20-110 20-75
Table 2.10 Recommended range of mixing rates
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Graph 2.69 Mixing study 500L S.U.B. – full volume
Mixing Study
























30 rpm avg 70 rpm avg 110 rpm avg 150 rpm avg
Mixing Study























30 rpm avg 70 rpm avg 110 rpm avg 150 rpm avg
Graph 2.68 Mixing study 500L S.U.B. – full volume





Mixing performance was evaluated using an electrolyte solution and 
conductivity sensors. These sensors offer a very fast response time and 
both stable and repeatable readings. Mixing time is defined as the time 
elapsed between when stock solution is added and the average sample 
location reading exceeds 95% of final concentration. These mixing tests 
represent best case time estimates as the salt is added as a pre-mix solution.
Each bag was filled with DI water to the test volume, heated to 40ºC, 
and a salt solution was prepared. For the tests a 1 liter volume of solution 
(300 grams per liter dissolved Sodium Chloride) was introduced at the 
top of the BPC. Each test consisted of verifying the correct agitation speed 
and starting values of conductivity, adding the appropriate amount of salt 
solution, and then recording the readings on the probes utilizing the Kaye 
Validator™ thermal validation system until the conductivity leveled off. 
After the data were collected and entered, the percentages compared to the 
final reading were calculated for each sample taken. The percentage values 
from the probes were then averaged to approximate the mixing time. All 
three probes were used for both full and half volume calculations.
Three conductivity sensors from the same model and manufacture were 
attached to a rod installed into the BPC from the top. These sensors were 
positioned next to the top mounted mixer drive motor. It is anticipated 
that the location on this side of the tank represents worst case mixing 
because they are located the greatest distance from the high shear region of 
the impeller. The sensor positions represent three column height locations 
of low, middle, and high. The low and high positions were each located 
approximately 30.5cm (12.0”) from the respective ends of the fluid 
column. The mid probe was located at the 1,000L mark (half volumes).  
In an effort to obtain a representative reading the sensor tips protruded 
into the tank no less than 2.54cm (1.0”) from the inside of the tank 
wall.  For half volume mix tests, the low and high probes were located 
approximately 15.2cm (6.0”) from the respective ends of the fluid column 
and the mid probe was located at the 500L mark.
Mixing Study (2,000L)
Mixing Test #* Tank Volume Impeller Location/Shaft Length
Power/Vol (Hp/1,000 
gal) RPM
M1 Nominal, 2,000L 1 diameter from bottom / 82.9” 0.05 60
M2 Nominal, 2,000L 1 diameter from bottom / 82.9” 0.1 75
M3 Nominal, 2,000L 1 diameter from bottom / 82.9” 0.2 95
M10 ½ Volume, 1,000L 1 diameter from bottom / 82.9” 0.05 47
M11 ½ Volume, 1,000L 1 diameter from bottom / 82.9” 0.1 60
M12 ½ Volume, 1,000L 1 diameter from bottom / 82.9” 0.2 75
Table 2.12 Mixing study test matrix 2,000 L S.U.B.
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Results All tests conducted were done in duplicate. The first column in results 
Table 2.13, below, was calculated by determining which probe (top, mid, 
or bottom) resulted in the slowest mix time for each respective test and 
averaging those together. The second column was calculated by averaging 
the all of the probes. 
Mixing time performance at full volume is near equivalent at 75 and 
95rpm.
Mixing at high impeller speed (>60rpm) at half volume is not 
recommended and will result in less than desirable performance and 
accelerated shaft wear (excessive power input, poor power dissipation 
result in lack of turn-over in a non-baffled tank).
2,000L S.U.B. (Full Volume Mixing Time)




2,000L S.U.B. (Half Volume Mixing Time)




Table 2.13 Mixing study results 2,000L S.U.B.
Graph 2.73 Mixing study 2,000L S.U.B. - half volumeGraph 2.72 Mixing study 2,000L S.U.B. - full volume









Effect of Agitation Speed on kLa 
2,000L S.U.B.
 Porous Frit Sparger Only Porous Frit Sparger Plus 0.01 VVM (10 LPM) Through Pipe







20 8 0 3.77 20 8 12 5.90
20 12 0 6.11 20 12 12 8.22
20 16 0 7.92 20 16 12 10.01
20 20 0 9.19 20 20 12 11.26
20 24 0 9.92 20 24 12 11.97
35 8 0 3.94 35 8 12 6.23
35 12 0 6.41 35 12 12 8.66
35 16 0 8.33 35 16 12 10.57
35 20 0 9.72 35 20 12 11.94
35 24 0 10.58 35 24 12 12.77
55 8 0 5.61 55 8 12 8.08
55 12 0 8.23 55 12 12 10.68
55 16 0 10.31 55 16 12 12.74
55 20 0 11.86 55 20 12 14.27
55 24 0 12.87 55 24 12 15.26
75 8 0 5.98 75 8 12 8.65
75 12 0 8.76 75 12 12 11.41
75 16 0 11.01 75 16 12 13.63
75 20 0 12.71 75 20 12 15.31
75 24 0 13.88 75 24 12 16.46
95* 8 0 6.77 95* 8 12 9.63
95* 12 0 9.71 95* 12 12 12.55
95* 16 0 12.11 95* 16 12 14.93
95* 20 0 13.98 95* 20 12 16.77
95* 24 0 15.31 95* 24 12 18.08
Table 6.6 Results for 2,000L S.U.B.
Graph 6.4 Results for 2,000 L S.U.B.
*NOTE: Standard operating range is 20 to 75rpm. Custom operating 
limit up to 95rpm at 90 to 110% working volume only.
Motors, Gearmotors & Compressors
Sign in to Grainger.com® to see YOUR Pricing and MORE
PNEUMATICS
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Rotary Multivane Air Gearmotors
 ▪ Max. air pressure: 90 psi































0.31 99.00 in.-lb. 198 in.-lb. 18 cfm 280 140
3⁄8" 1.00" 0.125" 1⁄4" NPT 50:1 8.87" 1.76" M004RVR050AR3 1AAF9
330.00 in.-lb. 396 in.-lb. 18 cfm 85 42 3⁄8" 1.00" 0.125" 1⁄4" NPT 167:1 8.87" 1.76" M004RVR167AR3 1AAG1
0.34 71.00 in.-lb. 142 in.-lb. 18 cfm 450 225 3⁄8" 1.00" 0.125" 1⁄4" NPT 33:1 8.11" 1.76" M004RVR033AR3 1AAF8
Face
0.61 612.00 in.-lb. 1224 in.-lb. 33 cfm 94 47
3⁄4" 2.19" 0.187" 1⁄4" NPT 188:1 13.13" 2.69" M007RVR188BR6 1AAG2
1212.00 in.-lb. 2424 in.-lb. 33 cfm 47 23 3⁄4" 2.19" 0.187" 1⁄4" NPT 374:1 13.13" 2.69" M007RVR374BR6 1AAG3
3 1800.00 in.-lb. 3600 in.-lb. 95 cfm 170 83 1" 2.25" 0.250" 1⁄2" NPT 51:1 14.50" 4.00" 4840U 1AAG5
3.2 378.00 in.-lb. 756 in.-lb. 95 cfm 975 485 1" 2.25" 0.250" 1⁄2" NPT 9:1 12.13" 4.00" 4840M 1AAG4
Provide higher torque at low speeds and continuous-duty forward or reverse operation. 
Keyed steel shafts with case-hardened gearing. Aluminum and steel construction.
No. 1AAG1
For Rotary Vane Air Motor Maintenance Kits, go to Grainger.com®
Tank-Mounted, Enclosed 
Oilless Air Compressors
 ▪ Field-adjustable 
pressure switch
 ▪ Single phase
Innovative reservoir can provide 
a blast of high pressure. Tank 
dampens pulsation from the 
reciprocating compressor.
All models except No. 5Z671 
incorporate a Gast piston 
compressor pump listed below. 
Pressure switch setting: 70 
psi-On/90 psi-Off. No. 5Z671 has 
30 psi-On/50 psi-Off. Gray finish.
1⁄8- and 1/6-HP 
Compressors—Include pres-
sure switch, manual drain, 
pressure safety valve, pressure 
gauge, and globe valve.  
1⁄3- to 1 1⁄2-HP Compressors—
Include coded tank, pressure 
switch, manual drain, pressure 
safety valve, pressure gauge, 




















1⁄8 0.2 50 psi 115 4.2 2 gal. 1⁄4" 18" 8" 15" DOA-P710T-AA 5Z671
1⁄6 0.4 100 psi 115 4.3 2 gal.
1⁄4" 18" 8" 17" 1HAB-84T-M100X 5Z672
0.9 50 psi 115 3.9 2 gal. 1⁄4" 18" 8" 17" 1LAA-251T-M100X 2CJH1
1⁄3 1.1 100 psi 115 6.6 12 gal. 1⁄4" 26" 14" 21" 3HBB-69T-M300AX 11X372
3⁄4 4.7 100 psi 115/230 15.8/7.9 2 gal.
1⁄4" 18" 13" 22" 5HCD-101T-M550NGX 5Z674
4.7 100 psi 115/230 15.8/7.9 20 gal. 1⁄4" 33" 16" 27" 5HCD-100TA-M550NGX 5Z675 *
1 1⁄2 5 100 psi 230 10.8 30 gal. 3⁄8" 38" 17" 29" 7HDD-70TA-M750X 5Z676
* No. 5Z675 is factory wired for 230V, may be converted to 115V.
Rotary Vane Air Motors
 ▪ Max. temp.: 250°F
 ▪ Variable speed
Use these compact, low-maintenance air motors in applications that would normally require similar, but 
more-expensive explosionproof electric motors. Can be operated in extreme temperatures. Cast-iron models 
include discharge muffler.













0.32 49.00 in.-lb. 21 cfm 400 1⁄2" Face 1⁄8" NPT REV 22UX55
0.34 62.00 in.-lb. 21 cfm 350 1⁄2" Face 1⁄8" NPT REV 22UX82
0.64 172.00 in.-lb. 20 cfm 110 7⁄8" Base 1⁄4" NPT CCW 22UX56
0.9 256.00 in.-lb. 27 cfm 150 5⁄8" Base 1⁄4" NPT CCW 22UX57
1.25 400.00 in.-lb. 60 cfm 200 1" Face and Foot 1⁄4" NPT REV 22UX81
1.26 274.00 in.-lb. 57.5 cfm 300 1" Face and Foot 1⁄4" NPT REV 22UX54
Cast-Iron Air Motors
0.45
2.75 in.-lb. 20.5 cfm 10,000 3⁄8" Hub 1⁄8" NPT CCW 22UX71
5.25 in.-lb. 27 cfm 6000 3⁄8" Hub 1⁄8" NPT CW 22UX41
5.25 in.-lb. 27 cfm 6000 3⁄8" Hub 1⁄8" NPT REV 22UX42
0.93
19.50 in.-lb. 30 cfm 3000 1⁄2" Hub 1⁄4" NPT CCW 22UX43
19.50 in.-lb. 30 cfm 3000 5⁄8" Flange 1⁄4" NPT REV 22UX44
19.50 in.-lb. 30 cfm 3000 1⁄2" Foot 1⁄4" NPT REV 22UX72
1.7
36.00 in.-lb. 78 cfm 3000 5⁄8" Face 3⁄8" NPT REV 22UX45
36.00 in.-lb. 78 cfm 3000 5⁄8" Flange 1⁄4" NPT REV 22UX46
36.00 in.-lb. 78 cfm 3000 1⁄2" Foot 1⁄4" NPT REV 22UX73
36.00 in.-lb. 78 cfm 3000 1⁄2" Foot 1⁄4" NPT REV 22UX74
36.00 in.-lb. 78 cfm 3000 1⁄2" Face 1⁄4" NPT REV 22UX75
4
84.00 in.-lb. 128 cfm 3000 5⁄8" Foot 1⁄2" NPT REV 22UX47
84.00 in.-lb. 128 cfm 3000 5⁄8" Flange 1⁄2" NPT REV 22UX48
84.00 in.-lb. 128 cfm 3000 5⁄8" Flange 1⁄2" NPT REV 22UX49
84.00 in.-lb. 128 cfm 3000 5⁄8" Foot 1⁄2" NPT REV 22UX76
84.00 in.-lb. 128 cfm 3000 5⁄8" Face 1⁄2" NPT REV 22UX77
5.25 132.00 in.-lb. 175 cfm 2500
3⁄4" Foot 1⁄2" NPT REV 22UX50
132.00 in.-lb. 175 cfm 2500 7⁄8" Flange 1⁄2" NPT REV 22UX51
9.5 290.00 in.-lb. 275 cfm 2000 1 
1⁄8" Face and Foot 1 1⁄4" NPT REV 22UX52
290.00 in.-lb. 275 cfm 2000 7⁄8" Foot and Flange 1 1⁄4" NPT REV 22UX53
Cast-Iron Oilless Air Motors
0.42 13.50 in.-lb. 30 cfm 2000
1⁄2" Hub and Foot 1⁄4" NPT CCW 22UX58
13.50 in.-lb. 30 cfm 2000 1⁄2" Hub and Foot 1⁄4" NPT CW 22UX59
0.82 25.50 in.-lb. 41 cfm 2000 1⁄2" Hub and Foot 1⁄4" NPT CCW 22UX60
2.5 78.75 in.-lb. 68 cfm 2000
5⁄8" Hub and Foot 1⁄2" NPT CW 22UX63
78.75 in.-lb. 68 cfm 2000 5⁄8" Hub and Foot 1⁄2" NPT CCW 22UX62
Stainless Steel Air Motors
0.45 2.75 in.-lb. 20.5 cfm 10,000 3⁄8" Face 1⁄8" NPT REV 22UX65









Details on page A1.
Fire Sprinkler Air 
Compressors and Pumps
 ▪ 115/230V
Single stage with durable powder-coated finish.
Fire Sprinkler Air Compressors—Single-stage, 
splash-lubricated compressors are rugged cast-iron 
construction with a large flywheel for extra cooling 
and to ease start-up. Feature a directional air shroud 
to reduce pump temp., large canister intake filter 
with replaceable filter elements, totally enclosed 
heavy-duty belt guard, and an open dripproof motor 
with thermal overload protection.
 ▪ Max. pressure: 40 psi
Air Compressor Pumps—Cast-iron pumps have 
stainless steel valves and use synthetic oil for longer 
life. No. 35KV12 has head unloaders.
 ▪ Max. pressure: 150 psi
No. 31LC92
HP
Free Air CFM @ 













Fire Sprinkler Air Compressors
Base Mounted
0.50 3.80 1 9.4/4.7 — 1⁄2" 25 3⁄4" 16 1⁄4" 18 1⁄4" F12S-BS-115/1-ACGF 31LC94
1.00 7.40 1 12.5/6.3 — 1⁄2" 25 3⁄4" 16 1⁄4" 18 1⁄4" K1S-BS-115/1-ACGK 31LC95
1.50 10.9 1 15.8/7.9 — 1⁄2" 25 3⁄4" 16 1⁄4" 18 1⁄4" K15S-BS-115/1-ACGK 31LC96
2.00 12.4 1 21.6/10.8 — 1⁄2" 25 3⁄4" 16 1⁄4" 18 1⁄4" K2S-BS-115/1ACGK 31LC97
Tank Mounted
0.50 3.70 1 9.4/4.7 30 gal. 1⁄2" 40" 18" 33 1⁄2" F12S-30UMS-115/1 26JY13
1.00 7.40 1 12.5/6.3 30 gal. 1⁄2" 40" 18" 34" K1S-30UMS-115/1 31LC92
1.50 10.9 1 15.8/7.9 30 gal. 1⁄2" 40" 18" 34" K15S-30UMS-115/1 31LC93
2.00 10.5 1 21.3/10.7 30 gal. 1⁄2" 40" 18" 34" K2S-30UMS-115/1 26JY14
HP





















1⁄3, 1 2.1 1200 6 21⁄64" 8 oz. 1⁄2" 10 1⁄8" A 1 F-PUMP 31LC98
1, 2 6.7 1200 6 
21⁄64" 32 oz. 1⁄2" 10 1⁄8" A 1 K-PUMP 31LC99
6.7 1200 6 21⁄64" 32 oz. 1⁄2" 10 1⁄8" A 1 KU-PUMP 35KV12 *
* Has head unloaders.
No. 31LC99
Mobile Engine-Driven 
Air Compressors and 
Compressor/Generator
Rotary screw-type with electric start. Include a lifetime manufac-
turer’s warranty on the compressor and are Tier 4 compliant.
Viper Air Compressors—Can easily power a 90-lb. jackham-
mer and include a 12V cold weather protection kit. Diesel models 
feature an automatic variable throttle control to help reduce fuel 
consumption.
Viper Air Compressor/Generator—Features multi-functioning 
capabilities and provides air and AC power in 1 portable unit. Can 
run at full load for up to 4 hr. and is easy to transport via fork lift 
or pallet truck.
PowerFlex™ Air Compressor/Generator—Diesel-powered 
model provides air and AC power in one easily transportable unit. 
Includes a 12V cold weather protection kit.
Air N Arc® Compressor/Generator/Welder/Battery Charge 
System—Multifunction systems include a 12V cold weather 
protection kit and 25-ft. weld and boost cables. Battery boost 


























Viper G60 60.0 150 psi 3⁄4" — Gasoline 5.00 gal. 45 5⁄32" 23 1⁄2" 29 3⁄4" 480 lb. 39CC67
Viper G80 59.0 100 psi 3⁄4" — Gasoline 5.00 gal. 45 5⁄32" 23 1⁄2" 29 3⁄4" 480 lb. 39CC74
Viper D60 60.0 150 psi 3⁄4" — Diesel 9.00 gal. 48" 21" 33" 800 lb. 39CC75
Viper D80 80.0 100 psi 3⁄4" — Diesel 9.00 gal. 47" 24" 38" 800 lb. 39CC71
Viper Air Compressor/Generator
— 40.0 100 psi 3⁄4" 5000/5200 Gasoline 5.00 gal. 42" 33" 34 1⁄2" 685 lb. 4TZW4
PowerFlex™ Air Compressor/Generator
Powerflex 
AE 40.0 150 psi
3⁄4" 7000 Diesel 12.0 gal. 47 39⁄64" 21" 33 13⁄32" 803 lb. 39CC70
Air N Arc® Compressor/Generator/Welder/Battery Charge System
Air N Arc® 
300 Gas 40.0 175 psi
3⁄4" 7000 Gasoline 12.0 gal. 47" 21" 31" 700 lb. 39CC68
Air N Arc® 
300 Diesel 40.0 175 psi
3⁄4" 7000 Diesel 12.0 gal. 47" 21" 33" 865 lb. 39CC73
Climate Control Air Compressors
 ▪ 3-phase duplex units require 115V for control panel power
 ▪ Max. pressure: 90 psi
 ▪ Simplex: 70 psi On/90 psi Off
 ▪ Duplex: 70 psi On/90 psi Off (lead), 60 psi On/80 psi Off (lag)
 ▪ All compressors must be hardwired
 ▪ Horizontal tank with 3⁄4" (F)NPT outlet and brass ball valves
Deliver published cfm at stated rpm and pressure and to be below 
2 ppm in oil carryover. Use for new, replacement, or upgrade HVAC 
installations and instrument air applications. Simplex packages 
include mounted and wired magnetic starter (except 1-phase); duplex 
packages include mounted and wired alternator and 2 magnetic 
starters. For duplex models, use twice the oil capacity (Compressor 






3⁄4* 980 1 1.97 2.56 15
1 1120 1 1.97 2.56 15
1 1⁄2 860 1 2.56 2.56 15
3 1050 2 2.56 2.36 24




Free Air CFM @ 
Max. Pressure
Tank 










0.75 2.1 30 gal. 120VAC, 240VAC 10.2/5.1 1 42 
1⁄2" 21 1⁄4" 38" 5Z696
2.1 30 gal. 208 to 240VAC, 480VAC 3.6-3.0/1.5 3 42 1⁄2" 21 1⁄4" 38" 5Z697
1.00 3.4 30 gal. 120VAC, 240VAC 13.4/6.7 1 42 1⁄2" 21 1⁄4" 38" 3JR83
1.50 4.5 60 gal. 208 to 240VAC, 480VAC 4.5-4.4/2.2 3 50 3⁄4" 22 1⁄4" 40" 5Z699
3.00 10.1 80 gal. 208 to 240VAC, 480VAC 8.9-8.1/4.1 3 65 1⁄2" 23 1⁄4" 34" 5Z701
Duplex
0.75 4.2 30 gal. 208 to 240VAC, 480VAC 7.4-6.2/3.1 3 41 1⁄2" 21 1⁄4" 38" 5Z698
1.00 6.8 30 gal. 208 to 240VAC, 480VAC 6.4-6.2/3.1 3 41 1⁄2" 21 1⁄4" 38" 3JR81
1.50 9 80 gal. 208 to 240VAC, 480VAC 9.3-9.0/4.5 3 64 1⁄4" 22 1⁄4" 39" 5Z700
3.00 11.0 80 gal. 208 to 240VAC, 480VAC 18.2-16.5/8.2 3 65 1⁄4" 23 1⁄4" 34" 5Z702
Base-Plate Air Compressors
 ▪ Designed to cycle On/Off while providing 
continuous air with an 80/20 duty cycle
 ▪ All compressors must be hardwired
 ▪ Max. pressure: 40 psi
No. 4B242
HP
Free Air CFM @ 















2.00 11.6 1 120VAC, 240VAC 17.5/8.75 — — 1⁄2" 22 1⁄2" 15 1⁄2" 14 3⁄4" 4B242
3.00 12.3 3 200 to 240VAC, 480VAC 9.0-7.5/3.9 11V709, 11V710 1H609/3, 1H632/3
1⁄2" 22 1⁄2" 15 1⁄2" 14 3⁄4" 4B243
2-cylinder cast-iron pumps can be used in many fire sprinkler appli-




Single- and multi-use products  
for the successful development  
and implementation of robust  
clarification processes
The life science business  
of Merck KGaA, Darmstadt, 
 Germany operates as 

















10 5 1 0.5 0.14060 µm
Millistak+® grades with diatomaceous earth 
Millistak+® HC grades with diatomaceous earth and cellulose
Millistak+® grades with cellulose only
Millistak+® grades with activated carbon
Clarisolve® grades
















































Single stage clarification of mAB pre-treated feed streams with particle size distribution 
of 60 µm (Cationic Polymers such as Clarisolve® mPAA). Utility in some bacterial, viral 
and polysaccharide vaccine applications.
60HX
Single stage clarification of mAb pre-treated feed streams with particle size distribution 
of 40 µm (Cationic Polymers such as pDADMAC). Utility in some bacterial and viral 
vaccine applications.
40MS
Single stage clarification of mAb pre-treated feed streams with particle size distribution 







































Primary clarification. In some cases, can be used as a single stage clarification step going 
directly into a sterile filter.
C0HC
C0SP (synthetic)
Primary (coarse) clarification CE
Primary clarification D0HCD0SP (synthetic)













Secondary clarification post tangential flow filtration or depth filtration A1HC
Secondary clarification post-centrifugation B1HC
Secondary clarification post–centrifugation or pre-treated feed streams F0HC
Secondary clarification post depth filtration or centrifugation. Can also be utilized in 




SP Removal of color and trace contaminants, as well as in downstream processing to reduce 






Pod Filter Systems  
(Millistak+® and Clarisolve® media)
The Pod Filter System is a scalable format 
accommodating applications from lab- to pilot- to 
process-scale. The Pod format offers flexibility because 
of its unique, modular and 100% disposable design. 
The same flow path and configuration ensures a linearly 
scalable solution from bench- to process-scale.
• Patented, disposable design eliminates need  
for housing, CIP or cleaning validation
• Self-contained Pod format protects operators  
from exposure to biohazards
• Enables use of multiple grades in one holder
• Robust construction is easy to use and set up
• Smaller footprint facilitates use in tight spaces
The Pod holder system’s modular design makes it easy 
to configure for a specific application and conveniently 
reconfigure it as process capacity requirements  
scale-up or -down. The flexible, modular format  
offers scalability up to 12,000 L or more.
Device Formats
Small-Scale Lab-Scale Pilot-Scale Process-Scale
Lenticular Discs (Millistak+® media only)
The Millistak+® 16 in. lenticular format is available 
in multiple stacked-cell configurations. The individual 
cells of filter media are combined to form a convenient 
and easy-to-install filtration unit. Each filter cell is 
independently sealed by an injection molding process 
to ensure integrity throughout each device. Edge seal 
bosses provide robustness against cell collapse during 
prolonged runs, minimizing the risk of bypass  
and process deviations.
The Millistak+® 316 L stainless steel filter housings  
are designed for high-capacity liquid clarification.  
The housings’ versatile design and a wide offering  
of accessories allow users to operate the system with 
as few as one or as many as eight stacked cartridges 
installed. These options make it easy to configure for  
a specific application and conveniently reconfigure it  








The following decision trees are focused on batch and fed-batch feeding strategies  
for mammalian cell bioreactors. The selection matrices are created for reference 
only, based on historical experience and data.
The decision trees cover direct harvest, pretreatment, and centrifugation at 
various scales. Studies have shown that direct harvest is more economical versus 
centrifuge at scales below 1000 L*. There is a “grey area” between 1000 L 
and 2000 L where either direct harvest or centrifuge may be the best choice, 
depending on cell culture characteristics and facility considerations.
Clarification Selection Guide for  
Monoclonal Antibodies, Recombinant 
Proteins, and Fc-fusion Proteins
*Process Cost and Facility Considerations in the Selection of Primary Cell Culture Clarification Technology, Felo et al., Biotechnol. Prog.,  
2013, Vol. 29, No. 5.
Molecule Types: mAb, recombinant, fusion,  
other-hydrophobic proteins
Monoclonal antibodies, recombinant proteins, and 
Fc-fusion proteins behave similarly with respect to 
capacity. Filters containing diatomaceous earth may not 
be the ideal solution for Fc-fusion proteins and highly 
hydrophobic proteins, due to recovery challenges. 
If product yield is an issue, reach out to your local 
Account Manager or Process Development Specialist.
Two filtration options are included:
1. A single-stage depth filtration train.
2. A two-stage depth filtration train run in series.
Direct Harvest Decision Tree
The single-stage train is recommended in cases of 
low-titer feeds and/or when there are concerns about 
product binding.
The information in the following tables should be 
considered as general guidance for performance 
and preliminary economic assessments. Actual 
performance should be confirmed prior to large-scale 
implementation.
Please note: The single filter will need to be optimized 
for both capacity and filtrate turbidity/sterile filter 
capacity. The second filter in the filter train is tight 
enough to protect the sterile filter in most cases. 
Secondary depth filtration is included for additional 
sterile filter and column protection in most cases.
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µPod® device format
Process-scale pod (PSP)  
device format
Lab-scale pod (LSP)  
device format
µPod® device format
Process-scale pod (PSP)  
device format
Lab-scale pod (LSP)  
device format
Note: If the filtrate turbidity is greater than 15–20 NTU or sterile sizing does not meet your target directly after the primary depth filter, consider 
additional polishing via X0HC.
Protein titer (<1 g/L, >1 g/L). Recovery should be considered during the small-scale tests. Low-titer feeds historically have slightly lower recovery 
values. This could be due to low levels of binding, hold-up volume losses during recovery (blow-down or buffer flush), and/or dilution from pre-use 
flushing and post-use recovery.
*Cell density is a critical parameter in the consideration for filter selection and capacity. High-cell-density cultures contain a high level of cells 
and with that cell debris, both soluble and insoluble. When the viability is high, most of the cells are intact and the particle size distribution shifts 
towards larger particles. When the viability is low, the particle size shifts towards the smaller particles and insoluble (unmeasured) particles.
† As a general guideline, the filter loadings for Millistak+® HC Pro Media grades (D0SP and C0SP only) are at least double (2X) the equivalent 
Millistak+® HC D0HC and C0HC grades. The X0 grades for both have similar filter loadings.
‡ Process scales are typically 1 L–20,000 L. For simplicity, the process scale increases by 10x starting with 1 L. Direct harvest is economically 
practical and feasible for manufacturing, depending on the cell density, up to approximately 2,000 L. Centrifuge is recommended at scales 
≥2,000 L for direct harvest.
Depth  
Filter Train
Single-stage Two-stage Single-stage Two-stage
Millistak+® 
Media Grade
C0HC  HC Pro C0SP† D0HC/X0HC  HC Pro  
D0SP/X0SP†
C0HC  HC Pro C0SP† D0HC/X0HC  HC Pro  
D0SP/X0SP†
Filter Loading  100 L/m2 200 L/m2 D0HC: 




















10,000 L see centrifuge
Cell Viability* High Density/Low Viability High Density/High Viability 
Cell Density 20–30E6 cells/mL (high)
Depth  
Filter Train
Single-stage Two-stage Single-stage Two-stage
Millistak+® 
Media Grade
C0HC HC Pro C0SP† D0HC/X0HC  HC Pro  
D0SP/X0SP†
C0HC  HC Pro C0SP† D0HC/X0HC  HC Pro  
D0SP/X0SP†





















10,000 L see centrifuge
Cell Viability* Low Density/Low Viability  Low Density/High Viability 
Cell Density ≤ 10E6 cells/mL (low)
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Pretreatment Decision Tree
To meet the technical challenges of high titer mammalian cell culture processes, our novel chemical flocculants can 
be used to pretreat high density cell harvests before clarification over Clarisolve® depth filters. Pretreatment, via 
flocculation or precipitation, is recommended at cell densities greater than or equal to 30×106 cells/mL. However, 
flocculation can be implemented at any cell density if the process requires such a step. The type of pretreatment 
and dosing requirements (e.g., pH adjustment, salt addition, polymer addition) depends on the cell culture and 
molecule characteristics. The Clarisolve® family of filters was developed for high-cell-density, pretreated feed 
streams. The filter selection and sizing recommendations will be based on the type of pretreatment and the 
particle size distribution of the pretreated feed stream.
Centrifuge Decision Tree
Centrate may differ depending on the cell density/viability and the centrifuge optimization/operation. Centrate 
turbidity is a good indicator as to which depth filter will have the highest capacity and best sterile filter protection.





Clarisolve® 20MS* filter 1st choice 2nd choice 2nd choice 3rd choice
Clarisolve® 40MS* filter 2nd choice 1st choice 1st choice 2nd choice
Clarisolve® 60HX* filter — — 3rd choice 1st choice
*If the filtrate turbidity is greater than 15–20 NTU or sterile sizing does not meet your target directly after the primary depth filter, consider 
additional polishing via X0HC or XOSP.
10,000 L
Millistak+® filter,  
F0HC media series (1st choice) 














Millistak+® filter, X0HC/X0SP 
media series (1st choice) 
A1HC (2nd choice)













Millistak+® filter,  
F0HC media series (1st choice) 
B1HC (2nd choice)












Millistak+® filter, X0HC/X0SP 
media series (1st choice) 
A1HC (2nd choice)





















Millistak+® filter,  











Millistak+® filter, X0HC/X0SP 
media series (1st choice) 
A1HC (2nd choice)








Cell Density < 30E6 cells/mL (low)
untreated
> 30E6 cells/mL (high)
pretreated
Cell Density > 30E6 cells/mL (volumes ≤ 5000L)
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Non-mAb Expression Systems Decision Tree
The following decision tree is focused on non-mAb expression systems at all scales. Non-mAb expression systems 
typically require more process development due to processing differences. Particle size distribution can vary 
greatly between molecules/processes. The recommendations are based on historical experience and data.
*If filtrate turbidity is greater than 15–20 NTU or sterile sizing does not meet your target directly after the primary depth filter, consider additional 
polishing via X0HC.
Expression 
System Molecule Type Application Batch Type
Pretreatment Options/





Mammalian Enzyme  
(binds to DE)
Harvest Perfusion NONE Millistak+® CE50 Polysep™ II CGW6
Polygard® CR 0.5 µm Polysep™ II CGW6
Enzyme  
(does not bind 
to DE)




Secreted Protein Harvest Batch NONE Millistak+® C0HC Millistak+® X0HC







Batch Mechanical Pellicon® 2 1000 kD 
Biomax® V-screen
—
Clarisolve® 20MS Millistak+® C0HC






Batch Mechanical Prostak™ MF 0.1 µm —
Pellicon® 2 1000kD 
Biomax® V-screen
—




Batch NONE Clarisolve® 20MS (Millistak+® X0HC - 
if needed)*
Clarisolve® 60HX (Millistak+® X0HC - 
if needed)*




Batch Mechanical Clarisolve® 60HX Millistak+® C0HC







Batch NONE Polygard® CN 5.0 µm —





Batch NONE Clarisolve® 20MS —
Polygard® CR 5.0 or 
3.0 µm
Clarigard® 1.0 or 
0.5 µm
Viral Vector Lysate 
Clarification
Batch Mechanical Clarigard® 3.0 µm Polysep™ II CGW6





Batch NONE Pellicon® 2 0.1 µm 
Durapore® V-screen
—





Batch NONE Clarisolve® 60HX —
Virus-like Particle Lysate 
Clarification




Polygard® CN 5.0 µm —
Conjugated 
Polysaccharide






Pilot-Scale Holder For Pod configurations from 1 to 2 filters





Process-Scale Holder 1-rack holder; Gemu® valves 
1-rack holder; ITT valves 
1-rack holder; no valves









2-rack holder; Gemu® valves
2-rack holder; ITT valves







3-rack holder; Gemu® valves
3-rack holder;  ITT valves







Small-Scale Lab-Scale Pilot-Scale Process-Scale
3 through adapters, 3 blind adapters MP0DADAPT
6 through adapters, required if using Disposable Diverter Plate (MP0DDIVERTR) MP0DADPTF
Disposable Adapter Kit1
1Note: Pod filters require the use of flow adaptors, which are sold separately (MP0DADAPT or MP0DADPTF). See the Millistak+® Pod 
disposable depth filter hardware Data Sheet (DS3388EN00) for information on Pod filter holders.
A retrofit kit may be required in order to accommodate the new Clarisolve® depth filters in the Pod pilot- and process-scale holders. 
Please contact your local sales representative for details.
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Millistak+® Lenticular Housings
Number of Cartridges* Inlet/Outlet Connections Cat. No.
CE Marked
Millistak+® Housings†
For 12 in. Diameter Millistak+® (DE, CE, A) Cartridges
1 x 12 in. 13- or 16-cell/6- or 9-cell 1 in. TC, ISO DN32 WM21 SET ET
2 x 12 in. 13- or 16-cell/6- or 9-cell 1 in. TC, ISO DN32 WM22 SET ET
3 x 12 in. 13- or 16-cell (4 x 12 in. 6- or 9-cell) 1 in. TC, ISO DN32 WM23 SET ET
4 x 12 in. 13- or 16-cell (5 x 12 in. 6- or 9-cell) 1 in. TC, ISO DN32 WM24 SET ET
For 16 in. Diameter Millistak+® (DE, CE, A) Cartridges
1 x 16 in. 16-cell 2 in. TC, ISO DN40 WM61 SFT FT
2 x 16 in. 16-cell (3 x HC 16 in. 8-cell) 2 in. TC, ISO DN40 WM62 SFT FT
3 x 16 in. 16-cell (4 x HC 16 in. 8-cell) 2 in. TC, ISO DN40 WM63 SFT FT
4 x 16 in. 16-cell (6 x HC 16 in. 8-cell) 2 in. TC, ISO DN40 WM64 SFT FT
Millistak+® HC Housings†
For 16 in. Diameter Millistak+® HC Cartridges
2 x 16 in. 8-cell (1 x DE, CE, A 16 in. 16-cell) 2 in. TC, ISO DN40 HC62 SFT FT
4 x 16 in. 8-cell (2 x DE, CE, A 16 in. 16-cell) 2 in. TC, ISO DN40 HC64 SFT FT
6 x 16 in. 8-cell (3 x DE, CE, A 16 in. 16-cell) 2 in. TC, ISO DN40 HC66 SFT FT
8 x 16 in. 8-cell (5 x DE, CE, A 16 in. 16-cell) 2 in. TC, ISO DN40 HC68 SFT FT
ASME® Stamped
Millistak+® Housings†
For 12 in. Diameter Millistak+® (DE, CE, A) Cartridges
1 x 12 in. 13- or 16-cell/6- or 9-cell 1 in. TC UM21 SET ET
2 x 12 in. 13- or 16-cell/6- or 9-cell 1 in. TC UM22 SET ET
3 x 12 in. 13- or 16-cell/4 x 12 in. 6- or 9-cell 1 in. TC UM23 SET ET
4 x 12 in. 13- or 16-cell/5 x 12 in. 6- or 9-cell 1 in. TC UM24 SET ET
For 16 in. Diameter Millistak+® (DE, CE, A) Cartridges
1 x 16 in. 16-cell 2 in. TC UM61 SFT FT
2 x 16 in. 16-cell (3 x HC 16 in. 8-cell) 2 in. TC UM62 SFT FT
3 x 16 in. 16-cell (4 x HC 16 in. 8-cell) 2 in. TC UM63 SFT FT
4 x 16 in. 16-cell (6 x HC 16 in. 8-cell) 2 in. TC UM64 SFT FT
Millistak+® HC Housings†
For 16 in. Diameter Millistak+® HC Cartridges
2 x 16 in. 8-cell (1 x DE, CE, A 16 in. 16-cell) 2 in. TC UC62 SFT FT
4 x 16 in. 8-cell (2 x DE, CE, A 16 in. 16-cell) 2 in. TC UC64 SFT FT
6 x 16 in. 8-cell (3 x DE, CE, A 16 in. 16-cell) 2 in. TC UC66 SFT FT
8 x 16 in. 8-cell (5 x DE, CE, A 16 in. 16-cell) 2 in. TC UC68 SFT FT
* Millistak+® Housings are also compatible with many other commercially available lenticular cartridges.
† The compression tool must be ordered separately (Compression kit assembly, Catalogue No.: 1 WM00 CAK 01).
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Prostak™ Microfiltration Modules
Pore Size (µm) 2-Stak 4-Stak 10-Stak 20-Stak
Microporous Membranes – Hydrophilic PVDF Durapore® Membrane
0.1 PSVV AG0 21 PSVV AG0 41 PSVV AG1 01 SK2P 127 E1
0.22 PSGV AG0 21 PSGV AG0 41 PSGV AG1 01 SK2P 484 E0
0.45 PSHV AG0 21 PSHV AG0 41 PSHV AG1 01 SK2P 242 E9
0.65 PSDV AGO 21 PSDV AG0 41 PSDV AG1 01 SK2P 446 E0
Microporous Membranes –Hydrophobic PVDF Durapore® Membrane
0.22 — — — SK2P 344 W2
0.45 SK2P 012 W6 — — SK2P 013 W4
PZHK Membrane – Hydrophobic PVDF
200* — — — SK2R B30 A1
Packaging: 1/pack
*Nominal Molecular Weight Limit in kDaltons. 
There is one module per package. Sanitary gaskets are supplied with each module to provide a leak-free connection 
between the module(s) and holder.
Membrane 0.1 m2/1.1 ft2 0.5 m2/5.4 ft2 2.0 m2/21.5 ft2
Biomax® Series – Modified Polyethersulfone
Biomax® 5 P2B0 05V 01 P2B0 05V 05 P2B0 05V 20
Biomax® 8 P2B0 08V 01 P2B0 08V 05 P2B0 08V 20
Biomax® 10 P2B0 10V 01 P2B0 10V 05 P2B0 10V 20
Biomax® 30 P2B0 30V 01 P2B0 30V 05 P2B0 30V 20
Biomax® 50 P2B0 50V 01 P2B0 50V 05 P2B0 50V 20
Biomax® 100 P2B 100V 01 P2B1 00V 05 P2B1 00V 20
Biomax® 300 P2B3 00V 01 P2B3 00V 05 P2B3 00V 20
Biomax® 500 P2B5 00V 01 P2B5 00V 05 P2B5 00V 20
Biomax® 1000 P2B0 1MV 01 P2B0 1MV 05 P2B0 1MV 20
Ultracel® PLC Series – Regenerated Cellulose, Composite Construction
5 kD P2C0 05V 01 P2C0 05V 05 P2C0 05V 20
10 kD P2C0 10V 01 P2C0 10V 05 P2C0 10V 20
30 kD P2C0 30V 01 P2C0 30V 05 P2C0 30V 20
100 kD P2C1 00V 01 P2C1 00V 05 P2C1 00V 20
300 kD P2C3 00V 01 P2C3 00V 05 P2C3 00V 20
1000 kD P2C0 1MV 01 P2C0 1MV 05 P2C01MV 20
Durapore® – Hydrophilic PVDF
0.1 µm P2VV PPV 01 P2VV PPV 05 P2VV PPV 20
0.22 µm P2GV PPV 01 P2GV PPV 05 P2GV PPV 20
0.45 µm P2HV MPV 01 P2HV MPV 05 P2HV MPV 20
0.65 µm P2DV PPV 01 P2DV PPV 05 P2DV PPV 20
Pellicon® 2 Filters with V Screens (loose screen)
The life science business of Merck KGaA, Darmstadt, 
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Pod Depth Filters User Guide 2
Set-Up
NOTE A tubing kit is available, contact your local representative.
 The Process Scale (surface area 0.11, 0.33, 0.55, 0.77, 1.1 and 1.4 m2) 
Pod filters must be installed in a Pod Holder as described in the Holder User 
Guide.
1. Connect the inlet port of the filter to the feed line.
2. Connect the outlet port of the filter to the collection line.
3. Connect the vent port of the filter to the vent line.
4. Install a pressure gauge on the inlet or vent line.








Pod Depth Filters User Guide 3
Flushing
Flush devices with buffer or purified water prior to use. To fully 
wet the media, flush the filter as listed in the following tables: 
Clarisolve® Depth Filters
Media Flux (LMH)
Lab Scale Pod Process Scale Pod





600 140 270 1100 3300 5500
300 70 135 550 1650 2750




Pod Process Scale Pod
0.027 0.054 0.11 0.55 0.77 1.1 1.4
Flow rate (mL/min)
CR 600 270 540 1100 5500 -- 11000 --
HC 600 270 540 1100 5500 -- 11000 --
CE, DE 600 270 540 1100 -- 7700 -- 14000
Millistak+® HC Pro Depth Filters
Media Flux (LMH)
Lab Scale 
Pod Process Scale Pod
0.0135 0.027 0.11 0.33 0.55 0.77 1.1
Flow rate (mL/min)
D0SP 300 70 135 550 1650 -- 3850 --
C0SP 300 70 135 550 1650 -- 3850 --
X0SP 300 70 135 550 -- 2750 -- 5500
Flushing Procedure
1. Install new tubing on the inlet, outlet and vent lines of the filter. 
2. Attach a pressure gauge to the vent or inlet port to monitor 
inlet pressure.
3. Attach a vent valve or clamp at the end of the vent tubing. 
4. Start flushing the filter at the flow rate listed in the tables.
5. Open the vent to purge any air from the filter. Air purge may 
be assisted by temporarily clamping the outlet line closed.
6. Close the vent and open the outlet line to allow flow through 
the filter. For 100 and 300 LMH flow rates, back pressure is 
recommended to wet the device. To create the back pressure, 
partially close the outlet valve and completely close the vent 
valve. Increase the pressure in the device up to 10 psig by 
partially closing the outlet valve slowly, then vent slowly by 
opening the outlet to purge any air.
7. Over about 30 seconds, gradually increase the flow to achieve 
the desired flux rate.
8. Start the flush.
9. Flush until the desired target volume or the desired TOC level is 
reached (see Conductivity and TOC Test Results).
10. For optimal performance with a Pod filter, run the filtration 
process with product at a flux of 100 to 300 LMH and a max 
differential pressure of 2 bar (30 psi). 
NOTE It is normal to observe an increase in the hydraulic 
pressure on the process scale pod holder during 
operation. Hydraulic pressure should never exceed 
124 bar (1800 psi). 
 Optimal flux for CR media is application dependent. Flux 
rate should be optimized through testing.
11. When filtration is complete, perform a blow down to recover 
product held up in the device by connecting air supply tubing 
to the vent port.
Pod Depth Filters User Guide 4
Media
Blow Down Pressure 
bar (psi)
Time min












increase pressure at a rate of  
0.1 bar/min (2 psi/min) until 1 bar 







increase pressure at a rate of  
0.1 bar/min (2 psi/min) until 1 bar 
(15 psi) is reached
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Conductivity and TOC
The information below was generated from a flush with purified water.
Conductivity and TOC Test Results
Millistak+® HC and Clarisolve ® filters were autoclaved for 60 
minutes at 123 °C, then flushed with purified water at a flow 
rate of 600 LMH to a throughput of 100L/m2. The filter effluent 
was then tested for conductivity and TOC. 
 
Millistak+ ® HC Pro devices were not autoclaved and were 
flushed at a flow rate of 300 LMH to a throughput of 50 L/m2.











CS20MS01L3 (CP2KA10821) 600 1.59 1.40
CS20MS01L3 (CP2KA10822) 600 0.80 1.80
CS20MS01L3 (CP2KA10823) 600 1.29 2.10










CS40MS01L3 (CP2KA10848) 600 0.91 0.90
CS40MS01L3 (CP2KA10849) 600 1.23 1.20
CS40MS01L3 (CP2KA10850) 600 1.29 1.10
60HX
CS60HX01L3 (CP2KA10842) 600 0.15 BDL
CS60HX01L3 (CP2KA10843) 600 BDL BDL
CS60HX01L3 (CP2KA10844) 600 0.14 BDL
Millistak+®
D0HC
MD0HC01FS1 (CP3NA24863) 600 1.75 0.80
MD0HC01FS1 (CP3NA24864) 600 2.22 0.90
MD0HC01FS1 (CP3NA24864) 600 2.48 1.20
C0HC
MC0HC01FS1 (CP3NA24866) 600 1.33 0.80
MC0HC01FS1 (CP3NA24867) 600 1.85 0.90
MC0HC01FS1 (CP3NA24868) 600 2.06 1.00
X0HC
MX0HC01FS1 (CP3NA24878) 600 43.87 0.90
MX0HC01FS1 (CP3NA24879) 600 31.44 0.80
MX0HC01FS1 (CP3NA24880) 600 52.26 0.90
A1HC
MA1HC01FS1 (CP3NA24860) 600 14.83 0.60
MA1HC01FS1 (CP3NA24861) 600 21.87 0.60
MA1HC01FS1 (CP3NA24861) 600 19.42 0.70
F0HC
MF0HC01FS1 (CP9JN75883) 600 40.30 1.20
MF0HC01FS1 (CP9JN75884) 600 21.40 0.46
CR40
MCR4001FS1 (CP8SN71164-13 600 4.36 1.70
MCR4001FS1 (CP8SN71165-3) 600 4.57 1.80
MCR4001FS1 (CP8SN71166-12) 600 4.56 1.60
MCR4001FS1 (CP8SN71167-11) 600 4.24 1.40
MCR4001FS1 (CP8SN71168-25) 600 4.51 1.30
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MD0SP23CL3 (W167597) 300 41.50 0.95
MD0SP23CL3 (W167612) 300 27.50 1.09
MD0SP23CL3 (W167613) 300 24.40 0.61
MD0SP01FS1 (W177017-005) 300 8.98 0.47
MD0SP01FS1 (W177016-011) 300 14.98 0.77
MD0SP01FS1 (W177016-012) 300 16.73 0.69
MD0SP01FS1 (W177016-013) 300 11.12 0.70
MD0SP01FS1 (W177015-005) 300 8.86 0.78
C0SP
MC0SP23CL3 (W167602) 300 18.90 1.15
MC0SP23CL3 (W167603) 300 23.40 2.01
MC0SP23CL3 (W167604) 300 37.20 3.18
MC0SP01FS1 (W177025-005) 300 19.20 1.24
MC0SP01FS1 (W177024-011) 300 17.53 1.0
MC0SP01FS1 (W177024-012) 300 14.15 0.88
MC0SP01FS1 (W177024-013) 300 16.37 0.74
MC0SP01FS1 (W177023-005) 300 11.34 0.71
X0SP
MX0SP23CL3 (W167607) 300 25.00 2.20
MX0SP23CL3 (W167608) 300 32.80 2.90
MX0SP23CL3 (W167609) 300 24.10 3.00
MX0SP01FS1 (W177033-005) 300 10.35* 4.9*
MX0SP01FS1 (W177032-014) 300 10.51* 2.95*
MX0SP01FS1 (W177032-015) 300 11.14* 2.95*
MX0SP01FS1 (W177032-016) 300 10.64* 3.39*
MX0SP01FS1 (W177031-005) 300 8.12* 1.6*
BDL = Below detection Limit
*TOC and conductivity testing was performed after a 30 minute 
hold with pure water, followed by a 50 L/m² pure water flush at 
300 LMH with 5 psi back pressure for these units.
Process Optimization
Measure inlet and outlet pressure, original process fluid 
turbidity, and filtrate turbidity over time to provide data to 
verify performance and calculate sizing estimates.





Housing Glass filled polypropylene
Adapters Glass filled polypropylene
Gaskets and Plugs Thermo Elastic Polymer (TPE)
Filter Media
CR Activated Carbon and cellulose fibers
CE Cellulose fibers 




Multiple layers of cellulose 
fibers and diatamaceuous 
earth
A1HC, B1HC
Multiple layers of cellulose 
fibers and diatamaceuous 
earth; 0.1 µm RW 
membrane 
Clarisolve® Depth Filters
Housing Glass filled polypropylene
Adapters Glass Filled Polypropylene




cellulose fibers combined 
with an inorganic filter aid
60HX Polypropylene
Millistak+® HC Pro Filters
Housing Glass filled Polypropylene
Adapters Glass Filled Polypropylene
Gaskets and Plugs Thermo Plastic Elastomer (TPE)
Component Material
Filter Media
D0SP Nonwoven, Silica filter aid/Polyacrylic fiber pulp
C0SP Silica filter aid/Polyacrylic fiber pulp 
X0SP Silica filter aid/Polyacrylic fiber pulp
Operating Parameters





0.027 m2, 0.054 m2




0.11, 0.77,  
1.4 m2
Inlet, Outlet and Vent 
Connections
¼ in. (6 mm) Hose 
barb Flat Seal
Operating Temperature 
Range 4 to 37 °C 4 to 37 °C
Sterilization 2 cycles of 60 minutes at 123° C
1 cycle of 60 
minutes at 123° 
C




Forward 2.1 bar (30 psid) at 4-37 °C
2.1 bar (30 psid) 
at 25° C;  
15 psid (1.0 bar) 
at 80° C
Reverse 2.1 bar (30 psid) at 37 °C
2.1 bar (30 
psid) at 25° C
Housing Operating Pressure 2.1 bar (30 psid) at 37 °C
3.5 bar (50 psig) 
at 25 °C; 15 psig 
(1.0 bar) at 80° 
C
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Parameter Lab Scale Pod Process Scale Pod
Clarisolve® Depth Filters
Effective Surface Area 0.0135, 0.027 m2 0.11, 0.33, 0.55 m2
Inlet, Outlet and Vent 
Connections
¼ in. (6 mm) Hose 
barb Flat seal
Operating Temperature 
Range 4 to 37 °C 4 to 37 °C
Sterilization
Autoclave for two 
cycles of 60 minutes 
at 123 °C
Autoclave for 
one cycle of 60 
minutes at 123 
°C




Forward 2.1 bar (30 psid) at ≤ 37 ºC
2.1 bar (30 psid) at 
< 25 ºC 
1.0 bar (15 psid) at 
< 80 ºC
Reverse 2.1 bar (30 psid) at ≤ 37 ºC
2.1 bar (30 psid) at 
< 25 ºC
Housing Operating Pressure 2.1 bar (30 psig) at ≤ 37 ºC
3.5 bar (50 psid) 
at < 25 ºC
1.0 bar (15 psid) 
at < 80 ºC









0.11, 0.55, 1.1 m2
0.027 m²
Inlet, Outlet and Vent 
Connections
1/4 in (6 mm) hose 
barb Flat seal
Operating Temperature Range 4 to 40 °C 4 to 40 °C
Sterilization
Integrity is maintained after 1 cycle of 
60 minutes at 123 °C.  Recommended 
for post-use decontamination only.
Typical Flush/Process Flux 100 to 600 LMH




Forward 2.1 bar (30 psid) at ≤ 40 °C
2.1 bar (30 psid) 
at ≤ 80 °C
Reverse 2.1 bar (30 psid) at ≤ 25 °C
2.1 bar (30 psid) 
at ≤ 25 °C
Housing Operating Pressure 2.1 bar (30 psid) at 40 °C
3.5 bar (50 psid) 
at 80 °C
Pressure must be monitored at inlet or vent connections.




Lab Scale Pod Process Scale Pod
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Millistak+® HC Pro Depth Filters
Parameter
Hold-up volume (L)
Lab Scale Pod Process scale pod
0.0135 0.027 0.11 0.33 0.55 0.77 1.1
D0SP Media
Internal void volume (L) 0.275 0.541 2.12 5.50 -- 12.9 --
Hold-up 
volume (L)
after gravity drain 0.198 0.397 1.00 2.50 -- 6.30 --
after blow down 0.094 0.139 0.643 1.99 -- 5.04 --
C0SP Media
Internal void volume (L) 0.259 0.618 2.04 5.81 -- 12.8 --
Hold-up 
volume (L)
after gravity drain 0.188 0.506 1.13 2.81 -- 6.62 --
after blow down 0.119 0.185 0.711 2.22 -- 5.44 --
X0SP Media
Internal void volume (L) 0.347 0.676 1.25 -- 4.94 -- 9.47
Hold-up 
volume (L)
after gravity drain 0.188 0.395 0.801 -- 3.32 -- 6.72




Chromaflow™ columns are a family of convenient to use,  
process-scale columns. A patented nozzle in the top and bottom 
of the column allows packing, unpacking, and cleaning when fully 
assembled, that is with the lid in place. Chromaflow columns 
simplify chromatographic procedures and offer:
• convenience





Chromaflow low-pressure columns (Fig 1) are available in a choice 
of dimensions and materials. The complete range offers inner 
diameters (i.d.) from 300 to 2000 mm (Table 1), with column tubes 
manufactured from cast acrylic (Fig 1). All dimensions are available 
with variable bed heights, providing a wide variety of bed volumes. 
All columns are pressure rated for operation at 3 bar.
Chromaflow columns incorporate a patented, pack-in-place nozzle 
(Fig 2) through which process liquids enter and exit. Manual or 
automated versions of the nozzles are available. The automated 
nozzle is controlled from the packing station or the nozzle control 
unit. The nozzle has three positions to facilitate the different 
aspects of column operation: packing, operation, unpacking and 
cleaning. In addition to this pack-in-place functionality, the nozzle 
also contains the process liquid flow path to provide a consolidated 
solution to the process stream handling.
Bed supports are available in 316L stainless steel or polyethylene. 
The multilayer, woven stainless steel bed supports have very high 
chemical resistance and longevity for use in applications where 
salt concentrations are low and pH is above 5. Polyethylene bed 
supports are recommended for applications with low pH and 
high salt concentrations. All other wetted parts in columns with 
polyethylene bed supports are manufactured from plastic or 
noncorrodible materials for use in low pH /high salt applications.
Fig 1. A Chromaflow column, 2000 mm i.d.
Fig 2. The Chromaflow nozzle that enables packing in place in a fully 
assembled column (Cytiva patent).
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Fig 3. Packing Chromaflow columns with the dedicated packing station is 
convenient and simple.
The construction materials include 316L stainless steel, acrylic, 
polypropylene, polyethylene, PEEK 450 G, EPDM rubber and 
FEP encapsulated silicone. These materials have high chemical 
resistance to the liquids typically used in process chromatography 
(Table 2). Furthermore, all polymeric materials are approved 
according to USP class VI tests for toxicity.
As an option, a dedicated packing station is available for Chromaflow 
columns. The packing station speeds up the packing procedure by 
eliminating the more time-consuming, manual maneuvers (Fig 3). 
Comprehensive documentation is delivered with each column 
and includes a User manual, a Maintenance manual, assembly 
drawings, a full spare part list, materials certificates, etc.
A Validation Support File containing information on column 
component composition, materials of construction and toxicity 
studies is also available.
Convenient and labor saving
Once the column is assembled and the lid in place, no  
lifting gear is required for packing, operation, unpacking or  
cleaning-in-place (CIP). This means that a single operator can 
perform all column operations, thereby reducing labor costs  
and increasing convenience in large-scale operations.
Reproducibility
Packing with the lid in place allows the packing parameters 
to be easily set and fixed. Manual operation is minimized and 
standard operating procedures can be followed, helping to give 
reproducible column packing and results.
Contained packing
Improved safety is another advantage of the Chromaflow column 
concept. Because all the column operations are performed in a 
“closed system” environment, there is less risk of the operator 
coming into contact with hazardous chemicals and of the target 
product being exposed to contamination. In this way, overall 
safety and hygienic operation are improved.
Principle of operation
The column has a three-position nozzle located in the center  
of the top and bottom bed support. These three positions enable 
packing, unpacking, operation and cleaning to be performed 
without any adjustments to the assembled column, that is the  
lid remains in place.
Flow profiles from the two nozzles are identical. Packing direction 
will depend on the characteristics of the media and packing 
method used. The three positions are illustrated in Figure 4.
Fig 4. The three positions of the Chromaflow nozzle showing packing from  
the top.
Packing position
The bottom nozzle is extended part of 
the way (mid position) into the column. 
The top nozzle is fully retracted. Slurry 
enters the column via the bottom nozzle 
and excess liquid exits via the top mobile 
phase outlet. After packing, the slurry 
lines are isolated from the mobile phase 
and can be cleaned independently from 
the rest of the column.
Running position
The bottom and top nozzles are 
retracted. Mobile phase enters the 
column directly into an annulus, 
immediately behind the bed support. 
The annulus is cut through at an 
angle to ensure that linear flow is kept 
constant during distribution of the 
mobile phase across the bed.
Unpacking position
In this position, both bottom and top 
nozzles are fully extended into the column 
thereby exposing a third passage through 
which medium leaves the column.
Cleaning solution can be pumped through 
the nozzles and sprayed into the column. In 
this way the column is easily and effectively 
cleaned without exposing the interior or the 




Chromaflow columns are available in a wide range of dimensions, 
all designed and constructed around the same design principle. 
Standard range columns come in dimensions from 400 to 1000 mm. 
For more information about columns and dimensions, see Ordering 
information. Scaling up a chromatographic process from small to 
larger diameters is easily performed with maintained reproducibility, 
safety and convenience.
Column dimensions
A selection of Chromaflow columns in the range 400 to 2000 mm 
i.d. are presented in Table 1. The adapter stroke length is a standard 
200 mm. Variable bed heights are available in the ranges 100 to  
300 mm, 200 to 400 mm and 300 to 500 mm.
Chromaflow 400 SFP columns
Chromaflow 400 SFP (small flow path) columns are specially 
designed for low-flow applications. The dimensions in the mobile 
phase have been optimized to reduce dead volumes to a minimum 
and the area behind the nozzle tip has also been reduced.
Column materials and their chemical 
resistance
Table 2 lists the major components of Chromaflow columns 
in contact with process fluids (wetted parts) and Table 3 lists 
the chemical resistance of materials using data compiled from 
several published sources. It is important to note that columns 
with stainless steel bed supports and other stainless steel wetted 
components must be appropriately maintained when exposed to 
NaCl. Since salt can be corrosive to stainless steel over time, it is 
recommended that residual salt is removed by rinsing columns 
with at least five column volumes (CV) of clean water.












Chromaflow column 400/100-300* 3 12.6–37.8 1568 230 700 × 700
Chromaflow column 600/100-300 3 28.3–84.9 1568 375 800 × 800
Chromaflow column 800/100-300 3 50.3–150.9 1572 610 1000 × 1000
Chromaflow column 1000/100-300 3 78.5–235.5 1573 930 1200 × 1200
Chromaflow column 1200/100-300 3 113.1–339.3
Chromaflow column 1400/100-300 3 153.9–461.7
Chromaflow column 1600/100-300 3 201.1–603.3
Chromaflow column 1800/100-300 3 254.5–763.5
Chromaflow column 2000/100-300 3 314.2–942.6
* The first figure in the column name indicates the inner diameter and the second figure indicates stroke length.
Table 2. Major components and their composition
Component Material
In contact with  
process stream
Column tube Acrylic or stainless steel 316L Yes
Column lids Stainless steel 316L No
Distributor Polypropylene Yes
Bed support Stainless steel 316L or polyethylene Yes
Chromaflow nozzle Polypropylene, stainless steel 316L, PEEK 450 G Yes
Seals EPDM or FEP encapsulated silicone Yes
Stand Stainless steel 316 No
EPDM = ethylene propylene diene, FEP = fluoroethenepropene, PEEK = polyetherether ketone
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Table 3. Chemical resistance of materials used in Chromaflow columns (60 days)
Chemical Acrylic SS 316L EPDM FEP PEEK 450 G PE PP
Acetic acid 1.7 M + + + + + + +
EtOH 20%1 + + + + + + +
EtOH 40% – + + + + (+) +
Ethylene glycol 50% + + + + + + +
Formaldehyde 1.7 M + + + + + + +
Formic acid 10% (+) + + + + + +
Glycerol 100% + + + + + + +
Hydrochloric acid 0.1 M + – + + + + +
Isopropyl alcohol 30% – + + + + (+) +
Nitric acid 0.1 M + + + + + (+) +
Phosphoric acid 25% + (+) + + + + +
Sodium chloride 0.5 M + +2 + + + + +
Sodium hydroxide 2 M3 + + + + + + +
Trifluoroacetic acid 0.1% (+) + + + + + +
Triton™ X-100 100% + + + + + + +
Urea 8 M + + + + + + +
+ Resistant    (+) Limited resistance     – Not recommended
1 Do not expose acrylic to concentrations of ethanol greater than 20%. Do not exceed the following parameters during storage: 5 yr, 23°C, 0.5 bar g. 
2 NaCl can cause corrosion on stainless steel at pH <5. Do not use NaCl in storage solutions. Rinse with at least 5 CV of clean water after use with NaCl. 
3 Maximum exposure 4 h.
SS=stainless steel, EPDM=ethylene propylene diene, FEP=fluoroethenepropene, PEEK=polyetherether ketone, PE=polyethylene, PP=polypropylene.
Sanitizing Chromaflow columns
The design of Chromaflow columns facilitates cleaning-in-place. 
Below is a recommended cleaning protocol suitable for most 
applications.
1. Circulate 1.5 CV of 20% acetic acid at a low flow velocity (60 
cm/h) for 15 min, upward flow. Then reverse the flow for 15 min.
2. Repeat this procedure with 1.0 M NaOH.
3. Following step 2, slowly circulate 1.0 M NaOH in the column  
for 60 min.
4. Re-equilibrate the column with a storing or starting buffer.
Chromaflow Packing stations
Chromaflow Packing stations make column priming and packing 
a simple operation, reducing the operator’s time to a minimum. 
The packing stations consist of a control panel with pumps and 
valves fitted underneath (Fig 5). Valves and diaphragm pumps 
are actuated pneumatically from the control panel. As they are 
brought into operation indicators on the control panel display the 
relevant flow paths. For operation, packing stations only require 
a supply of compressed air. To select an appropriate packing 
station for your column and media, refer to Tables 4 and 5. Fig 5. Chromaflow Packing station Pack 100.
5
What else do I need?
The column
The columns are supplied ready for use and are equipped with 
adjustable feet. Castors can be ordered separately for columns 
up to 1000 mm in diameter.
Isolating the column after packing 
We recommend using sanitary stainless steel valves (of the 
appropriate inner diameter) on the mobile phase to prevent 
contamination of the packed bed. For storage purposes,  
blind flanges with a clamp and gasket can be used to seal  
off the column.
Connecting the column to your system and  
packing station
Clamps and gaskets of suitable size are required to connect  
the sanitary flanged inlet/outlet to either valves or tubing of  
the same type. Preflanged tubing is also available.
Assembly or disassembly of the column
An adequate sized wrench is needed for assembly or disassembly 
of the column. A hoist is needed to remove the adapter or top lid 
from the column.
Spare parts to keep on site
It is recommended that nozzle seals, column seals, and column 
bed support kits are kept as spare parts. 
Useful accessories
Safety valve: Precalibrated valve which releases pressure if  
the calibrated value is exceeded. Recommended to install on the 
mobile phase inlet if no other pressure sensor is included in the 
chromatography system. The T-junction, clamps and gaskets 
must be ordered separately.
Pressure sensor: The sensor is installed inline, preferably on 
the mobile phase inlet. Clamps and gaskets have to be ordered 
separately.


















W × H × D  
(mm)
Pack 50 Tapflo™ T53 10–50 0.5 22.1/22.1 50.5 115 810 × 1175 × 715
Pack 100 Tapflo T103 30–100 1.0 34.8/22.1 50.5 130 810 × 1175 × 715
* Packing stations, Pack 200 and Pack 400 with pump flow capacities of 60 to 200 l/min and 100 to 400 l/min are available as custom orders.
Table 5. Approximate packing flow rates for different media at two different bed heights
Column
diameter (mm) 400 600 800 1000
Bed height (mm) 150 300 150 300 150 300 150 300
Flow cm/h L/min cm/h L/min cm/h L/min cm/h L/min cm/h L/min cm/h L/min cm/h L/min cm/h L/min
Sepharose™  
Fast Flow media
500     11    250    5.5   500   24   250   12   500     42   250   21   500      66   250   33
Sepharose  
Big Beads media





with acrylic tubes 
Bed support 
10 mm SS sinter 
Bed support 
20 mm SS sinter 
Bed support
20 mm PE sinter 
I.d. 400 mm Man. nozzle 
Stroke length 100-300 18-1150-40 18-1159-40 18-1161-40 
Stroke length 200-400 18-1157-42 18-1159-42 18-1161-42 
Stroke length 300-500 18-1157-44 18-1159-44 18-1161-44 
I.d. 400 mm Auto. nozzle 
Stroke length 100-300 18-1157-41 18-1159-41 18-1161-41 
Stroke length 200-400 18-1157-43 18-1159-43 18-1161-43 
Stroke length 300-500 18-1157-45 18-1159-45 18-1161-45 
I.d. 400 mm SFP* Man. nozzle 
Stroke length 100-300 18-1170-53 18-1176-12 11-0011-85 
Stroke length 200-400 11-0011-80 11-0011-83 11-0011-86 
Stroke length 300-500 11-0011-82 11-0011-84 11-0011-87 
I.d. 400 mm SFP Auto. nozzle 
Stroke length 100-300 11-0011-89 11-0011-91 11-0011-94 
Stroke length 200-400 11-0011-88 11-0011-92 11-0011-95 
Stroke length 300-500 11-0011-90 11-0011-93 11-0011-96 
I.d. 600 mm Man. nozzle 
Stroke length 100-300 18-1150-60 18-1159-60 18-1161-60 
Stroke length 200-400 18-1157-62 18-1159-62 18-1161-62 
Stroke length 300-500 18-1157-64 18-1159-64 18-1161-64 
I.d. 600 mm Auto. nozzle 
Stroke length 100-300 18-1157-61 18-1159-61 18-1161-61 
Stroke length 200-400 18-1157-63 18-1159-63 18-1161-63 
Stroke length 300-500 18-1157-65 18-1159-65 18-1161-65 
I.d. 800 mm Man. nozzle 
Stroke length 100-300 18-1150-80 18-1159-80 18-1161-80 
Stroke length 200-400 18-1157-82 18-1159-82 18-1161-82 
Stroke length 300-500 18-1157-84 18-1159-84 18-1161-84 
I.d. 800 mm Auto. nozzle 
Stroke length 100-300 18-1157-81 18-1159-81 18-1161-81 
Stroke length 200-400 18-1157-83 18-1159-83 18-1161-83 
Stroke length 300-500 18-1157-85 18-1159-85 18-1161-85 
I.d. 1000 mm Man. nozzle 
Stroke length 100-300 18-1150-10 18-1160-10 18-1162-10 
Stroke length 200-400 18-1158-12 18-1160-12 18-1162-12 
Stroke length 300-500 18-1158-14 18-1160-14 18-1162-14 
I.d. 1000 mm Auto. nozzle 
Stroke length 100-300 18-1158-11 18-1160-11 18-1162-11 
Stroke length 200-400 18-1158-13 18-1160-13 18-1162-13 
Stroke length 300-500 18-1158-15 18-1160-15 18-1162-15 
For column specifications other than listed in the table, please contact your local Cytiva representative.  
* SFP = Small Flow Path on mobile phase, only available on 400 mm i.d. columns. 
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Packing stations
Min (L/min) Max (L/min) Code number 
Pack 50   10   50 18-1163-74
Pack 100   30 100 18-1162-08
Pack 200   60 200 Custom order
Pack 400 100 400 Custom order
Accessories   
Designation Code number 
Valves
4 port 2 way, i.d. 10 mm, 25 mm TC 18-1012-56
4 port 4 way, i.d. 10 mm, 25 mm TC 18-1012-57
3 port 2 way, i.d. 15 mm, 25 mm TC 44-5499-90
4 port 4 way, i.d. 20 mm, 51 mm TC 44-2302-01
3 port 2 way, i.d. 22 mm, 51 mm TC 44-1583-01
3 port 2 way, i.d. 35 mm, 51 mm TC 44-5494-65
Valve sealing washer 
Fits 10 mm 2- and 4-way valves
18-1128-69
PVC tubing with sanitary fitting 25 mm TC 
i.d. 10 mm, 900 mm 18-1012-62
i.d. 10 mm, 1400 mm 18-1012-63
i.d. 10 mm, 1700 mm 18-1012-64
i.d. 10 mm, 2000 mm 18-1012-87
i.d. 14 mm, 750 mm 18-1027-28
i.d. 14 mm, 1800 mm 18-1027-29
PVC tubing with sanitary fitting 51 mm TC 
i.d. 22 mm, 900 mm 44-1616-09
i.d. 22 mm, 1400 mm 44-1616-08
i.d. 22 mm, 2000 mm 44-1616-07
i.d. 22 mm, 4000 mm 44-1616-06
Clamp gasket 
25 mm i.d., 10 mm 18-1035-79
25 mm i.d., 12 mm 18-0200-00
51 mm i.d., 22 mm 44-7133-01
51 mm i.d., 38 mm 44-0515-01
Clamp 25 mm 18-1001-31
Clamp 51 mm 44-7134-01
Blind flange 25 mm incl. gasket 18-1001-25
Blind flange 51 mm incl. gasket 44-7135-01
Safety valve, 3 bar, 51 mm TC 18-5738-01
Safety valve, 5 bar, 51 mm TC 44-5498-97
T-junction i.d., 10 mm, 2×25 mm TC, 1×51 mm TC 18-1003-63
Castors, assembly kit 400-600 18-1171-51
Castors, assembly kit 800-1000
The kit contains a complete set of wheels, fasteners  
and adapters for a column.
18-1171-52
Pressure sensor i.d. 10 mm, 25 mm TC 44-0507-02
Pressure sensor i.d. 22 mm, 51 mm TC 44-0507-03
Designation Code number 
Media stirrers
Media stirrer, 80 cm 18-1149-80
Media stirrer, 150 cm 18-1149-81
Connectors
i.d. 10, 25 mm TC-3/4"-20 UNF threaded 18-1012-68
i.d. 10, 25 mm TC-i.d. 14, 51 mm TC 18-1027-25
i.d. 14, 51 mm TC-i.d. 22, 51 mm TC 18-1027-26
Chromaflow Nozzle control unit 18-1164-61
Chromaflow Nozzle pipings 
Chromaflow Nozzle piping 400 1/2" 18-1172-01 
Chromaflow Nozzle piping 400 3/4" 18-1172-00 
Chromaflow Nozzle piping 400 1" 18-1171-99 
Chromaflow Nozzle piping 600 1/2" 18-1172-06 
Chromaflow Nozzle piping 600 3/4" 18-1172-05 
Chromaflow Nozzle piping 600 1" 18-1172-04 
Chromaflow Nozzle piping 800 1/2" 18-1171-94 
Chromaflow Nozzle piping 800 3/4" 18-1171-93 
Chromaflow Nozzle piping 800 1" 18-1171-92 
Chromaflow Nozzle piping 1000 1/2" 18-1172-09 
Chromaflow Nozzle piping 1000 3/4" 18-1172-08 
Chromaflow Nozzle piping 1000 1" 18-1172-07
Cytiva and the Drop logo are trademarks of Global Life Sciences IP Holdco 
LLC or an affiliate. Chromaflow and Sepharose are trademarks of Global Life 
Sciences Solutions USA LLC or an affiliate doing business as Cytiva.
Triton is a trademark of Union Carbide Chemicals and Plastics Co.  
Tapflo is a trademark of Tapflow AB. All other third party trademarks  
are the property of their respective owner. 
© 2020 Cytiva
All goods and services are sold subject to the terms and conditions of sale 
of the supplying company operating within the Cytiva business. A copy 
of those terms and conditions is available on request. Contact your local 
Cytiva representative for the most current information.





DATA SHEET HyPerforma 2,000 L Single-Use Mixer
HyPerforma Single-Use Mixer 
with Touchscreen Console 
The next generation of effi  ciency and performance
The Thermo Scientifi c™ HyPerforma™ Single-Use Mixer 
(S.U.M.) with Touchscreen Console off ers enhanced 
functionality, ease of use, and effi  ciency. The complete 
HyPerforma S.U.M. system consists of a mixer tank, 
available in 50, 100, 200, 500, 1,000, and 2,000 L sizes 
with the Touchscreen Console. The HyPerforma S.U.M. 
has a 5:1 turndown mixing ratio and maintains traditional 
stirred-tank mixer design principles with a directly coupled 
motor impeller drive assembly and a cylindrical tank with 
a specifi c height-to-diameter ratio. This allows quick 
turnaround times for both liquid-to-liquid mixing and 
powder-to-liquid mixing.
2,000 L HyPerforma S.U.M. standard confi gurations
• AC motor 
• 3x load cell weighing system
• Touchscreen Console
Critical upstream application steps
• Media preparation
• Final formulation steps
• Buff er preparation
• Large-volume mixing
Critical downstream application steps
• Pooling and liquid transfer
• Product suspension
• Mixing and storing multiple batches
• Buff er preparation
• Viral inactivation
Touchscreen Console capabilities
The Touchscreen Console off ers state-of-the-art in-process 
monitoring and automation capability for the HyPerforma 
S.U.M. Its modular design allows for an easy-to-use custom 
user interface. Capabilities include: control of agitation 
speed, pumps, pinch clamps, and temperature control 
unit. Users can easily view measurements from load cells, 
pH sensors, conductivity sensors, resistance temperature 
detectors (RTDs), and pressure sensors. 
Simple, routine processes can be automated by utilizing 
measurement values to control the pumps, temperature 
control unit (TCU), and agitation motor. The Touchscreen 
Console can help users semi-automate their formulation, 
pH, or saline titrations, and viral inactivation processes. 
This allows users to program their HyPerforma S.U.M. for 
a process and trust that the measurements are accurate, 
precise, and controlled. The data measured during a 
process can be exported remotely via Ethernet, Profi bus, 
or Modbus remote terminal unit (RTU), and can also be 
accessed locally with a USB fl ash drive.
Note: Models without water jackets include the same features as the water-jacketed models shown here, but without the jacket and inlet/outlet ports.  
Optional load cells and cable management system are not shown. See the accessories section for more information about these items.
HyPerforma S.U.M. design features and options
1. Powder hanger for 1 kg, 5 kg, and 25 kg 
Thermo Scientific™ Powdertainer™ BioProcess 
Containers (BPCs)
2. Mixing assembly with shield
3. Bearing port receiver with clamp
4. Mixer motor
5. Touchscreen Console
6. Drive shaft, stored
7. Cable management hooks
8. Probe access windows
9. Probe clip hangers
10. Liquid sight window
11. Shelves and basket (optional)
12. Standard tool set: 10 mm (3/8 in.) x 16.9 Nm  
(150 in.-lb.)square torque wrench, load cell and motor 
cap lockout wrench
13. 0.95 cm (3/8 in.) dimpled jacket
14. Stainless steel outer support container
15. Rear door (for BPC loading), with sight window 
16. Bottom cutouts/pins for BPC attachment  
and alignment
17. Bleed valve (jacketed models only)
18. 3.81 cm (1.5 in.) tri-clamp connection ports for water 
inlet/outlet (jacketed models only)
19. Leveling feet (3)




















HyPerforma S.U.M. design specifications 
Touchscreen Console measurement options and specifications




of full scale 0.2°C ±0.05 pH unit ±5%
±3.5% of full scale 
(30 psi)
Calibration 1 to 3 points and zero/tare function 1 to 3 points 1 to 3 points 1 to 3 points
1 point;  
zero/tare function 
Resolution 0.1 kg 0.01°C 0.01 pH unit 1 µS/cm 0.01 psi
Sensor range 0 to 3,300 kg 0 to 200°C 0 to 14 20 to 20,000 µS/cm 0 to 30 psi
Measurement units kg °C pH units µS/cm psi
Probe type 3 x Mettler Toledo 0745A load cells RTD
Electrochemical  





part of the BPC 
and/or fluid transfer 
assembly design
Top view
297 cm (116.9 in.) Powdertainer  
BPC hanger height
36 cm (14.2 in.)
Electrical panel  
width
144 cm (56.5 in.)
Cart width
171 cm (67.4 in.)
Overall length
143 cm (56.4 
in.)
Cart length 43 cm (17.0 in.)
Shelf width
190 cm (74.8 in.)
Overall width
225 cm (88.5 in.) Motor height
182 cm (71.8 in.) Tank height
137 cm (53.7 in.)  
Touchscreen height
31 cm (12.4 in.) Tank bottom
16 cm (6.3 in.) Cart height
0 cm (0 in.)
Front view
Accessories 
Sensors and pinch valves
Reusable pH and conductivity probes as well as single-use 
pressure sensors have been approved and qualified for 
use with the Touchscreen Console. pH and conductivity 
measurements can be used to control titration pumps, 
which enable automatic titration capabilities. The pressure 
sensors are used in the BPC or line sets to monitor the 
BPC or liquid pressure, respectively. The BPC can be filled 
with the proper amount of air when using the pressure 
sensor in the BPC. The liquid pressure module in the 
Touchscreen Console is used to control a transfer pump, 
based on the liquid pressure. Optional pneumatic pinch 
valves can be used on the fill and harvest line. These valves 
automatically open and shut when using the fill and/or 
harvest modules in the Touchscreen Console.
Ordering information
Standards Manufacturer Cat. No.
pH sensor






Pressure sensor  
(single use, included in 
BPC and/or fluid transfer 
assembly)
PendoTECH  
3/8 in. ID tubing
SV20826.05
PendoTECH  
1/2 in. ID tubing
SV20826.01
Pinch valve, harvest line Thermo Fisher Scientific SV51108.08
Pinch valve, fill line Thermo Fisher Scientific SV51108.05
 
Probe clips
Probe clips are used to hold the probes in place on the 
S.U.M. tank. The independently movable probe clips hang 
on a thin brace above the probe port tank cutout. 
Heavy-duty tubing clamps
Heavy-duty clamps are used to pinch off line sets that are 
not in use, to prevent process fluids from escaping. Prior to 
sterile probe insertion, tubing clamps must be in place to 
close off probe ports. 
Load cells 
Load cells are typically radially mounted in sets of three. 
The mounting location varies slightly for each size in order 




Heavy-duty tubing clamp (single) SV20664.01




4 plastic probe clips SV50177P.01
 
Cable management system
The optional cable management system connects to the 
left side of the S.U.M. and is used to properly route tubing 
and cables along the side of the S.U.M. 
Powdertainer arm
A Powdertainer arm is available as an option for 
powder-to-liquid applications. It holds the container of 
powder above the mixer and attaches it to the BPC with 
a clamp. The arm adjusts vertically and swivels to enable 















Autoclave tray and probe assembly
The autoclave tray holds the electrochemical probes and 
bellows in place during the autoclave sterilization process. 
Design elements include the following:
• Fabricated from stainless steel
• Plastic handle provides for easy transport right 
out of the autoclave
• Positions probes on 15% incline for greater probe and 
membrane longevity
• Prevents probe bellows from collapsing 
during sterilization
• Probe holder accommodates two probes
Ordering information
Description Cat. No.





Cable management system (500 L–2,000 L) SV50992.03
Ordering information
Description Cat. No.
Powdertainer arm (2,000 L) SV51002.02
Standard 2,000 L S.U.M. hardware










Rated liquid working volume 2,000 L
Minimum liquid working volume 400 L (complete impeller coverage)
Total chamber volume (liquid and gas) 2,700 L
BPC chamber diameter 135 cm (53 in.)
BPC chamber shoulder height 185 cm (73 in.)
Liquid height at rated working volume 140 cm (55 in.)
Fluid geometry at working volume (height:diameter ratio) 1:1
Hold-up volume <1 L






r Impeller (quantity x blade count) 1 x 3
Impeller scaling (impeller diameter:tank diameter) 1:5
Impeller blade pitch (angle) 45°






Mixing rate range 20–356 rpm
Tip speed 39.4–459.7 cm/sec (77.6–904.8 ft/min)
Counterclockwise mixing flow direction Down-pumping
Agitation shaft resolved angle 27°
Agitation shaft centerline offset 17.8 cm (7 in.)
Overall drive shaft length 192.5 cm (75.78 in.)
Drive shaft diameter 1.9 cm (0.75 in.)
Drive shaft poly-sheath outside diameter 2.54 cm (1 in.)




Agitation motor drive (type, voltage, phase) Induction, 208 VAC, 3 phase
Motor power rating 745.7 W (1 hp)Motor: 208 VAC, 3.2 A
Motor torque rating 18 Nm (159 in.-lb.) 
Gear reduction 5:1





Ceiling height required for drive shaft loading 292.1 cm (115 in.)
Electrical power rating 100–120 VAC, 50/60 Hz, single, 15 A220–240 VAC, 50/60 Hz, single, 10.4 A
pH & DO probe—autoclavable type  
(Applisens, Broadley James, Mettler Toledo)
12 mm diameter x 215–235 mm insertion length  
x 13.5 PG (pipe) thread
Noise level <70 dB at 1.5 m
Storage temperature –25°C to 65°C




















Operating temperature range S.U.M.: 2–40 ± 0.1°C (36–104 ± 0.2°F)AC motor: 0–40°C (32–104°F)
Motor speed 30–350 rpm
Volume range 500–2,000 L
Maximum static BPC pressure 0.03 bar (0.5 psi)
Maximum BPC pressure during operation 0.007 bar (0.1 psi)
Continuous operating time 21 days mixing at nominal volume only
Standard 2,000 L S.U.M. hardware







et Jacket area: full/half volume 5.3 m2/3.3 m2 (57.3 ft2/35.5 ft2) –
Jacket volume 26 L (6.9 gal) –
Jacket flow rate at 3.4 bar (50 psi) 93 L/min (24.5 gal/min) –












TCU model: maximum heating/cooling TF24000: 22,500/24,000 W –
Approximate liquid heat-up time (5–37°C) 2.7 hr –
Approximate liquid cool-down time (37–5°C) 3.9 hr –























Overall width 180 cm (70.7 in.) 180 cm (70.7 in.)
Overall length 171 cm (67.4 in.) 171 cm (67.4 in.)
Overall height (without Powdertainer arm) 225 cm (88.5 in.) 225 cm (88.5 in.)
Dry skid weight (mass) 755.1 kg (1,664.8 lb.) 551.1 kg (1,214.8 lb.)











Dimensions (W x H x D) 250 x 520 x 234 mm (9.9 x 20.5 x 9.3 in.)
Construction material AISI 304 (stainless steel)
Pumps Supports various pumps with 4–20 mA signal control
Load cells Mettler Toledo MTB
pH sensors supported Thermo Scientific, Mettler Toledo, and Broadley James
Conductivity sensors JUMO, Mettler Toledo
Pinch valves Bimba ACRO 935 pinch valve,  3/4 in. (19 mm) OD x 1/8 in. (3.175 mm) wall tubing
HMI 8.4 in. LCD panel with capacitive touchscreen
Alarms Factory-set and user-defined
Communication ports USB, Ethernet, Profibus, Modbus RTU
E-stop Integrated safety circuit for entire system; external E-stop also available
Data recording User-defined data record transfer via Ethernet, Profibus, or Modbus RTU. 72-hour data storage exportable via USB
File formats CSV
Data exporting Local via USB flash driveRemote via PC and network with Ethernet, Profibus, or Modbus RTU
Standard 2,000 L BPC for powder–to-liquid applications without probe ports
Line Description Tubing set (inner diameter x outer diameter x length) End treatment
1 Addition line 12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 183 cm (72 in.) Plugged 12.7 mm (1/2 in.) MPX body
2 Recirculation/sample line
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 198 cm (78 in.) splits to
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 61 cm (24 in.) and
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 30 cm (12 in.)
Capped 12.7 mm (1/2 in.) MPX insert
Plugged 12.7 mm (1/2 in.) MPX body
3 Bottom drain 12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 122 cm (48 in.) Plugged 12.7 mm (1/2 in.) MPX insert
4 Powder addition port 7.6 mm (3 in.) sanitary fitting, tri-clamp Cap with gasket
3. Bottom drain






Standard 2,000 L BPC for liquid-to-liquid applications without probe ports
 Line Description Tubing set (inner diameter x outer diameter x length) End treatment




12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 198 cm (78 in.) splits to
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 61 cm (24 in.) and  
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 30 cm (12 in.)
Capped 12.7 mm (1/2 in.) MPX insert
Plugged 12.7 mm (1/2 in.) MPX body
3 Fill line 19.1 mm (3/4 in.) x 25.4 mm (1 in.) C-Flex x 183 cm (72 in.) 38.1 mm (1 1/2 in.) tri-clamp (SterilEnz™)
4 Vent filter 6.4 mm (1/4 in.) x 12.7 mm (1/2 in.) C-Flex x 10.2 cm (4 in.)
Sterile hydrophobic vent filter  
(0.2 μm PVDF, Acro™ 50)










Open-top or closed-top Thermo Scientific™ BPC designs are available with Thermo Scientific™ CX5-14  
and Aegis™ 5-14 film options.
Standard 2,000 L BPC for powder-to-liquid applications with probe ports
 Line Description Tubing set (inner diameter x outer diameter x length) End treatment
1 Recirculation line
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 198 cm (78 in.) splits to
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 61 cm (24 in.) and
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 30 cm (12 in.)
Capped 12.7 mm (1/2 in.) MPX insert
Plugged 12.7 mm (1/2 in.) MPX body
2 Addition line 12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 122 cm (48 in.) Plugged 12.7 mm (1/2 in.) MPX insert
3–4 Probe ports (2) None Kleenpak
™ aseptic connector  
KPCHT series (female)





Thermowell adapter for 3.2 mm (1/8 in.) diameter 3.2 mm (1/8 in.) x
6.4 mm (1/4 in.) x 30 cm (12 in.) Luer and SmartSite
™ valve port
7 Bottom drain 12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 122 cm (48 in.) Capped 12.7 mm (1/2 in.) MPX body
8 Powder addition port 7.6 mm (3 in.) sanitary fitting, tri-clamp Cap with gasket
Front face
Back face




6. Thermowell/small-volume sample line





Sleeve (3/4 in. inner diameter tubing)
Impeller
Standard open-top liners 
Description Cat. No.
1,000 L standard open-top liner, 





2,000 L impeller sleeve for open-top mixing* SH30772.01





Standard 2,000 L BPC for liquid–liquid applications with probe ports
 Line Description Tubing set (inner diameter x outer diameter x length) End treatment





Thermowell adapter for 3.2 mm (1/8 in.) diameter 3.2 mm (1/8 in.) x
6.4 cm (1/4 in.) C-Flex x 30 cm (1/2 in.)
Luer and SmartSite valve port
4 Recirculation line 12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 198 cm (78 in.) splits to
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 61 cm (24 in.) and
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 30 cm (12 in.)
Capped 12.7 mm (1/2 in.) MPX insert
Plugged 12.7 mm (1/2 in.) MPX body
5 Fill line 12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 183 cm (72 in.) 38.1 mm (1 1/2 in.) tri-clamp (SterilEnz)
6 Vent filter 6.4 mm (1/4 in.) x 12.7 mm (1/2 in.) C-Flex x 10.2 cm (4 in.) Sterile hydrophobic vent filter
(0.2 μm PVDF, Acro 50)
7 Addition line 9.5 mm (3/8 in.) x 15.9 mm (5/8 in.) C-Flex x 61 cm (24 in.) Plugged 9.5 mm (3/8 in.) MPX insert
8 Bottom drain 12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 122 cm (48 in.) Plugged 12.7 mm (1/2 in.) MPX body




1-2. Probe ports (2)





Tubing type C-Flex, platinum-cured silicone, PVC, PharMed™, PharmaPure™ More information is available in the tubing selection guide
Tubing size Ranges from 3.18 mm (1/8 in.) to 25.4 mm (1 in.) inner diameter in  various lengths
More information is available in 
the tubing selection guide
Connectors
Luer, Colder Products Company™ (CPC) quick connects, SIP connectors, 
tri-clamp, Kleenpak, SmartSite, Clave™, Lynx™ steam-thru, CPC steam-
thru, Gore™ steam valve, Gore™ Mini TC, BioQuate™, SterilEnz, end plug
More information is available in 
the connection system selection 
guide. Note: the only option 
for probe port connections is 
Kleenpak connectors
Probe ports/ 
line addition ports Ports may be added if they are compatible with the hardware
The reusable probe port 
connection uses a  
Kleenpak connector
Disposable sensors
Pressure sensor: PendoTECH™ and Finesse Solutions (PendoTECH 
comes standard on 500 L and 1,000 L S.U.M.); DO and pH sensor: 
Finesse Solutions and PreSens™; pH sensor: Mettler Toledo
Choice of qualified  
vendors available
Port sizes Limited engineer-to-order customization only
Dependent on location in BPC 
and fit with hardware (e.g.,  
1 in. ID port on harvest line)
Rearrangement of 
lines on existing 
ports
Limited customization possible, such as moving sample/thermowell port 
to a probe tube port, or swapping exhaust outlet line with liquid lines
Dependent on location in BPC 
and fit with hardware
Dip tube lines Limited customization possible Length cannot interfere  with impeller and shaft
Filters on media and 
supplement inlets
Limited engineer-to-order customization only. Choice of filters used to 
sterilize incoming media or supplements are available
Note: Not all options are available for all ports. It is not possible to customize port type, port location, chamber dimensions, or mixing assembly.  
For additional information, please see the selection guides in the product catalog.
BPC packaging
Description Details
Outer packaging Supplied flat-packed with two polyethylene outer layers 
Label Description, product code, lot number, and expiry date on outer packaging and shipping container
Sterilization Irradiation (25 to 40 kGy) inside outer packaging
Shipping container Durable cardboard carton
Documentation Certificate of Analysis provided with each lot for each delivery
Find out more at thermofisher.com/sum
For Research Use or Further Manufacturing. Not for diagnostic use or direct administration into humans or animals.  
© 2019 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless 
otherwise specified. Allen Bradley is a trademark of Allen-Bradley Company. Applisens is a trademark of Applikon B.V. Corporation. BioQuate 
and PreSens are trademarks of General Electric Company. Broadley James is a trademark of Broadley-James Corporation. Clave is a trademark 
of ICU Medical, Inc. Colder Products Company is a trademark of Dover Corporation. Gore is a trademark of W. L. Gore & Associates. Kleenpak 
and Acro are trademarks of Pall Corporation. Lynx is a trademark of Merck KgAA. Mettler Toledo is a trademark of Mettler-Toledo AG. PharMed 
and PharmaPure are trademarks of Saint-Gobain Performance Plastics Corporation. PendoTECH is a trademark of PendoTECH. SmartSite is a 
trademark of Carefusion 303, Inc. SterilEnz is a trademark of PAW BioScience Products, Inc. COL8388 0119
Models without water jackets may have slightly different dimensions than the water-jacketed model shown in this data sheet. See the drawings provided with your unit for exact dimensions for non-jacketed 
models. Non-jacketed models do not have the capability to heat or cool the liquid inside the tank.
Ordering information
2,000 L S.U.M. hardware Cat. No.
Non-jacketed, AC motor, Touchscreen Console, 240 V, with load cells SUM2000.9003
Jacketed, AC motor, Touchscreen Console, 240 V, with load cells SUM2000.9004
2,000 L S.U.M. BPC Size Probe ports* Film type Cat. No.
Standard powder-to-liquid BPC
2,000 L 0 CX5-14 SH30770.01
2,000 L 0 Aegis 5-14 SH30973.05
Standard liquid-to-liquid BPC
2,000 L 0 CX5-14 SH30769.01
2,000 L 0 Aegis 5-14 SH30983.05
Standard powder-to-liquid BPC* 
2,000 L 3 CX5-14 SH30770.02
2,000 L 3 Aegis 5-14 SH30974.05
Standard liquid-to-liquid BPC*
2,000 L 3 CX5-14 SH30769.02
2,000 L 3 Aegis 5-14 SH30982.05
* All 2,000 L BPCs with probe ports are designed to allow probes to work properly at 5:1 turndown levels. These BPCs are only compatible with the HyPerforma hardware shown in this document. If you are 
using an older version of the S.U.M. hardware, do not use these items; instead refer to the legacy S.U.M. user manual or data sheets. 
Data Sheet
Millipore Express® SHF (Sterile High-Flux) filters are  
an unparalleled combination of quality and process  
performance. A sterilizing-grade, hydrophilic  
polyethersulfone (PES) membrane, these filters provide 
sterility assurance, broad chemical compatibility, and 
exceptionally high flow rates for your validated process 
steps.  Developed and designed for your validated sterile 
filtration processes, manufactured in a highly controlled 
process and supported by extensive documentation to 
fulfill your regulatory requirements. 
Benefits
•  Highly efficient sterilizing-grade membrane
•  Designed for validated filtration steps which require 
sterility assurance
 -  Drug Master File available
 -  Retention testing on each lot of membrane and  
filter device
 -  Each filter subject to the highest sensitivity integ-
rity test in the industry
 -  Validation kits available
Sterilization Capability 
•  Autoclavable 
•  Sterile 
•  Gamma Compatible 
Millipore Express® SHF  
Hydrophilic Filters
High flow sterilizing-grade PES filters for 
validated process steps
Filter Formats
•  OptiScale® small-scale disposable 
capsule filters
•  Opticap® XL and XLT disposable  
capsule filters– autoclavable,  
sterile and gamma compatible
• Cartridge filters
EMD Millipore Corp. is a subsidiary of Merck KGaA, Darmstadt, Germany
Regulatory Compliance
•  Filters are designed, developed and manufactured in  
accordance with a Quality Management System  
approved by an accredited registering body to the  
ISO® 9001 Quality Systems Standard.
•  Each filter and membrane lot is subjected to  
bacterial retention testing.
•  Every filter is subjected to the highest sensitivity  
integrity test in the industry. 
•  All filters are shipped with a Certificate of Quality. 
•  A Validation Guide, which is a summary of the product 
qualification, is available upon request.
•  For traceability and easy identification, each filter  
is identified with product name, lot number, and  
serial number.






































































*Includes 0.2 M arginine-HCl, 0.5 M sodium phosphate





Relative Water Permeability of  
10-inch Cartridges
Millipore Express® SHF Membrane Flux 
Relative to Competitors
Reduced Surface Area and Lower Costs
Millipore Express® SHF filters feature faster flow rates, 
allowing you to process equivalent volumes with reduced 
filtration area. This high-flux benefit has been shown to 
deliver greater than 50% savings in filtration costs. 
6
Specifications
Opticap® XL and XLT Disposable Capsules (Autoclavable)  
Opticap® XL 3 
Capsules
Opticap® XL 5 
Capsules
Opticap® XL 10 
Capsules
Opticap® XLT 10 
Capsules
Opticap® XLT 20 
Capsules
Opticap® XLT 30 
Capsules
Nominal Dimensions
      Maximum length: 17.3 cm (6.8 in.) 21.6 cm (8.5 in.) 33.5 cm (13.2 in.) 37.6 cm (14.8 in) 62.5 cm (24.6 in) 87.1 cm (34.3 in)
Fitting to Fitting
      Sanitary flange to sanitary flange: - 15.2 cm (6.0 in.) 15.2 cm (6.0 in.) 15.2 cm (6.0 in.)
      Sanitary flange to hose barb: - 17.5 cm (6.9 in.) 17.5 cm (6.9 in.) 17.5 cm (6.9 in.)
      Hose barb to hose barb: - 19.8 cm (7.8 in.) 19.8 cm (7.8 in.) 19.8 cm (7.8 in.)
Filtration Area 0.16 m2 (1.7 ft2) 0.29 m2 (3.1 ft2) 0.54 m2 (5.8 ft2) 0.54 m2 (5.8 ft2) 1.08 m2 (11.6 ft2) 1.62 m2 (17.4 ft2)
Materials of Construction
      Filter membrane: Hydrophilic polyethersulfone
      Film edge: Polypropylene
      Supports: Polypropylene
      Structural components*: Polypropylene
      Core: Polysulfone
      Vent O-rings: Silicone 
Vent/Drain ¼ in. hose barb with double O-ring seal
Maximum Operating pressure 6900 mbar (100 psi) intermittent 23 C° - - -
Maximum Differential Pressure  
      Forward: 5500 mbar (80 psi) at 25 °C
6900 mbar (100 psi) intermittent at 25 °C
1000 mbar (15 psi) at 80 °C
      Reverse: 2100 mbar (30 psi) intermittent at 25 °C
Bubble Point at 23 °C ≥ 4000 mbar (58 psi) air with water
Air Diffusion at 23 °C Through a water wet membrane at 2800 mbar (40 psi):  
≤ 9.1 cc/min. ≤ 16.4 cc/min. ≤ 30 cc/min. ≤ 30 cc/min. ≤ 60 cc/min. ≤ 90 cc/min.
Bacterial Retention Quantitative retention of 107 CFU/cm2 Brevundimonas diminuta ATCC®  19146 per ASTM® methodology. 
Bacterial Endotoxin Aqueous extraction contains <0.25 EU/mL as determined by the Limulus Amebocyte Lysate (LAL) Test (per 10-inch filter).
TOC/Conductivity Autoclaved capsule effluent meets the WFI criteria for USP <643>, Total Organic Carbon and USP <645>, Conductivity, after a  
WFI water flush of:
3.0 L 5.5 L 10 L 10 L 20 L 30 L
Oxidizable Substances Meets the USP Oxidizable Substances Test requirements for sterile purified water after a water flush of:
1000 mL 1000 mL 1000 mL 1000 mL 2000 mL 3000 mL
Sterilization May be autoclaved for 3 cycles of 60 minutes at 126 °C. (Cannot be steam sterilized in-line).
Non-Fiber Releasing Component materials meet criteria for a “non fiber releasing” filter as defined in 21 CFR 210.3 (b) (6).
Component Material Toxicity Component materials were tested and meet the criteria of the USP <88> Reactivity Test for Class VI plastics. Millipore Express® 
SHF filters meet the requirements of the USP <88> Safety Test, utilizing a 0.9% sodium chloride extraction.
Toxicity Non-toxic per MEM Elution ISO® 10993-05.
Good Manufacturing Practices These products are manufactured in a facility which adheres to FDA Good Manufacturing Practices.
Indirect Food Additive All component materials meet the FDA Indirect Food Additive requirements cited in 21 CFR 177–182.
* Cage, end caps and capsule housing
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      Maximum length: 17.3 cm (6.8 in.) 21.6 cm (8.5 in.) 33.5 cm (13.2 in.) 37.6 cm (14.8 in.) 62.5 cm (24.6 in.) 87.1 cm (34.3 in.)
      Body diameter: 10.7 cm (4.2 in.) 10.7 cm (4.2 in.) 10.7 cm (4.2 in.) - - -
Fitting to Fitting
      Sanitary flange to sanitary flange: - - - 15.2 cm (6.0 in.) 15.2 cm (6.0 in.) 15.2 cm (6.0 in.)
      Sanitary flange to hose barb: - - - 17.5 cm (6.9 in.) 17.5 cm (6.9 in.) 17.5 cm (6.9 in.)
      Hose barb to hose barb: - - - 19.8 cm (7.8 in.) 19.8 cm (7.8 in.) 19.8 cm (7.8 in.)
Filtration Area 0.17 m2 (1.8 ft2) 0.31 m2 (3.3 ft2) 0.57 m2 (6.1 ft2) 0.57 m2 (6.1 ft2) 1.14 m2 (12.3 ft2) 1.71 m2 (18.4 ft2)
Materials of Construction
      Filter membrane: Hydrophilic polyethersulfone
      Film edge: Polyethylene
      Supports: Polyester
      Structural components*: Gamma stable polypropylene
      Core: Polysulfone
      Vent O-rings: Silicone 
Vent/Drain ¼ in. hose barb with double O-ring seal
Maximum Differential Pressure
      Forward: 5500 mbar (80 psi) at 25 °C
6900 mbar (100 psi) intermittent at 25 °C
1000 mbar (15 psi) at 80 °C
      Reverse: 2100 mbar (30 psi) intermittent at 25 °C
Bubble Point at 23 °C ≥ 4000 mbar (58 psi) air with water
Air Diffusion at 23 °C Through a water wet membrane at 2800 mbar (40 psi):  
     ≤ 9.5 cc/min. ≤ 17.4 cc/min. ≤ 32.7 cc/min. ≤ 32.7 cc/min. ≤ 65.5 cc/min. ≤ 98.2 cc/min.
Bacterial Retention Quantitative retention of 107 CFU/cm2 Brevundimonas diminuta ATCC®  19146 per ASTM® methodology. 
Bacterial Endotoxin Aqueous extraction contains <0.25 EU/mL as determined by the Limulus Amebocyte Lysate (LAL) Test (per 10-inch filter).
TOC/Conductivity Gamma sterilized capsule effluent meets the WFI criteria for USP <643>, Total Organic Carbon, and USP <645>, Conductivity, 
after a WFI water flush of:
3.5 L 6.0 L 11 L  11 L  22 L 33 L
Oxidizable Substances Meets the USP Oxidizable Substances Test requirements for sterile purified water after 
a water flush of:
1000 mL 1000 mL 1500 mL 1500 mL 3000 mL 4500 mL
Sterilization
     Gamma compatible: Gamma compatible to 45 kGy. May be autoclaved for 3 cycles of 60 minutes at 123 °C. (Cannot be steam sterilized in-line).
     Sterile capsules: May be autoclaved for 3 cycles of 60 minutes at 123 °C. (Cannot be steam sterilized in-line.)
Sterility
      Sterile capsules: Meets current USP and AAMI guidelines for sterility utilizing a validated sterilization cycle.
Non-Fiber Releasing Component materials meet criteria for a “non fiber releasing” filter as defined in 21 CFR 210.3 (b) (6).
Component Material Toxicity Component materials were tested and meet the criteria of the USP <88> Reactivity Test for Class VI plastics. Millipore Express® 
SHF filters meet the requirements of the USP <88> Safety Test, utilizing a 0.9% sodium chloride extraction.
Toxicity Non-toxic per MEM Elution ISO® 10993-05.
Good Manufacturing Practices These products are manufactured in a facility which adheres to FDA Good Manufacturing Practices.
Indirect Food Additive All component materials meet the FDA Indirect Food Additive requirements cited in 21 CFR 177–182.
 
 
* Cage, end caps and capsule housing
Filters were tested post gamma radiation at 25-45 kGy
QuikScale® Biochromatography Columns
Innovative chromatography columns for scalable, rapid purification
Biopharmaceutical manufacturers increasingly require 
tools that maximize process yields, boost productivity, 
and shorten time-to-market. To meet these demands,  
the scalable family of QuikScale® columns delivers 
greater product purity at faster linear velocities 
than columns currently used in most pharmaceutical 
processes. As a part of our total solution, these 
innovative columns have been designed to be used 
easily with any biochromatography system, such  
as our K-Prime® systems, from small scale pilot  
processes through complex development and 
manufacturing operations. 
Ultra high throughput with all media types
Designed to achieve ultra high throughput, robust 
QuikScale® columns are easily, uniformly packed 
to deliver optimal resolution across a wide range of 
chromatographic applications, accommodating all 
media types. The innovative flow distributor assures 
full, uniform media utilization within the column, 
assuring reproducible and reliable separations. Using 
the high flow option with operating pressures up to 
7 bar, flow rates up to 1000 cm/hr are achievable 
enabling greater process design flexibility by allowing 
greater bed heights when utilizing media with high  
flow and/or backpressure requirements. 
Benefits
• High linear velocity for maximum productivity
•  Easy to pack and unpack
•  Rapid scale-up with a full range of column size 
from 70 mm to 630 mm
•  Multiple tube materials that suit a wide variety 
of applications
•  Maximum flexibility — change tube material  
and height in minutes
Data Sheet
The life science business of Merck KGaA,  
Darmstadt, Germany operates as  
MilliporeSigma in the U.S. and Canada.
Fast packing and unpacking
Column packing, processing, and unpacking are 
performed faster and with less effort. There’s no  
heavy lifting or complex disassembly involved;  
all components remain attached to the 
column. An optional removable lower  
end-cell makes unpacking simple and 
quick. The simple design eliminates 
the need for tools and hoists during 
packing and unpacking.
A yoke and central screw 
mechanism supports the flow 
distributor, ensuring this 
assembly easily moves during 
packing and unpacking. The 
flow distributor makes it easy 
to pack uniform beds. The flow 
distributor can be swiveled 
to afford easy access for 
maintenance without the  
need to lift the adjuster 
assembly from the column. 
Flow distributor seal 
technology ensures 
reliable, fail-safe operation
To make packing simple and  
efficient, the seal (patent  
pending) is spring force  
actuated and uses air to  
deactivate the seal. This  
design offers smooth vertical  
movement, and allows the  
flow distributor assembly to  
be gently positioned and  
secured, without disrupting  
the packed bed. 
The bed support, which is available for 10 μm, 20 μm  
and 30 μm sizes, consists of stainless steel mesh 
screens that enhance flow distribution efficiency. The 
screens, unlike plastic supports, allow the passage of  
air without requiring pre-wetting.
Predictable, scalable performance
Column materials and geometries were carefully chosen 
to ensure consistent chromatographic performance 
from lab scale to production. QuikScale® columns are 
available in nine diameters from 70 mm to 630 mm. 
Stainless steel mesh screens, flow cells and column 
tubes for each column diameter are made of the 
same materials and are designed to ensure reliable 
performance across the range of column diameters. 
Column materials, a unique seal design, and optimized 
flow distribution, all contribute to creating predictable, 
scalable processes.
Choice of three column tube materials, 
for any application 
QuikScale® columns meet a broad range of applications. 
Tubes are offered in three materials:
• Cast acrylic, resistant to breakage with improved 
ethanol resistance and low protein binding
• Glass, suitable for a wide range of  
process application
• Stainless steel for improved corrosion  
resistance and high cleanability  
All materials used in the manufacture of the column that 
come into contact with the process stream conform to 
relevant sections of the FDA Code of Federal Regulations 
Volume 21, parts 170 to 199, or have passed USP Class 
VI tests for toxicity. 
Dependable construction for long-lasting,  
reliable performance 
Durable frame design and construction, as well as  
robust tube materials ensure excellent physical  
stability to deliver years of trouble-free operation.  
Specially developed tube manufacturing technology  
results in excellent tube quality on a consistent basis.  
This reliability, throughout the QuikScale® column  
product line, is important for generating reproducible 
performance critical in pharmaceutical manufacturing.
Modular design 
A full line of accessories and installation kits enables 
quick set-up. Versatile configurations make it easy to 
adapt columns for use in multiple process applications.
QuikScale® Chromatography  
Columns Featuring Industry Leading 
Chromatography Resin
Eshmuno® Resin
Unique family of ion-exchange resins  
specifically designed for highly productive  
downstream purification.
Fractogel® Resin
Tentacle modified synthetic polymer resins for 
ion exchange, hydrophobic interaction, size 
exclusion and metal chelate affinity.
ProSep® Ultra Plus Resin
The highest dynamic binding capacity protein A  
affinity chromatography media, designed for 
cost effective, large-scale purification of  
today’s higher titer therapeutic antibodies.




Acetic acid (80%) R NR R
Acetone R L R
Acetonitrile R NR R
Ammonium sulphate (10 – 40%) R R R
Disodium phosphate R R R
Ethanol (40%) R R R
Ethylene glycol R R R
Formaldehyde (50%) R R R
Isopropanol R L R
Methanol R L R
Nitric acid (10%) R R R
Peracetic acid (300 ppm) L L L
Phosphoric acid (55%) R R R
Potassium chloride (30%) R R R
Potassium hydroxide (2M) R R R
Sodium bicarbonate (20%) R R R
Sodium chloride (2M) R R R
Sodium hydroxide (2M) L L L
Sodium hypochlorite (200 ppm) L L L
Triton® X-100 surfactant R R R
Urea (8M) R R R
  R = Resistant; suitable for continuous use
  L =  Limited resistance; depends on concentration  
and contact time
NR = Not resistant, not recommended
*   All substances are at 100% concentration (saturated 
solutions) unless noted otherwise. Concentrations:  
% refer to w/w. All data is referenced to room 
temperature (15 °C – 25 °C). A more extensive and 
detailed list is available in the product manual. 
Simple and convenient to clean  
and operate
QuikScale® columns are designed for clean-in-place 
(CIP), low maintenance, and sanitary operation. 
Smooth surface finish minimizes entrapment of 
contaminants and prevents corrosion. The elimination 
of O-rings in product contact areas prevents unswept 
surfaces, providing better cleanability.
A riboflavin clearance test performed on QuikScale® 
columns demonstrated that they can be effectively 
sanitized. Glass 100 mm and acrylic 450 mm 
Quikscale® columns were challenged with a 
concentrated riboflavin solution and subsequently  
cleaned with 0.5 M NaOH. The observable removal of 
riboflavin (Figure 2) indicates that there are no dead  
flow areas within the Quikscale® columns and that all 
areas are swept with sufficient and consistent velocity.
Figure 1. Quick and reliable scale-up
Separation of ovalbumin from trypsin inhibitor was scouted on a 
Millipore Vantage® L column (22 mm). The process was then linearly 
scaled up (418X by volume, 20X by diameter) to a 450 mm QuikScale® 
column with highly comparable results.
Figure 2. Before and after images of riboflavin presence (green) 
in a 100 mm QuikScale® column
Glass 100 mm and acrylic 450 mm Quikscale® columns were challenged 
with a concentrated riboflavin solution and subsequently cleaned with 
0.5 M NaOH. 
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22 mm Millipore Vantage® L Column














































QuikScale® Columns – GA and GS Range
The QuikScale® column is available in two different configurations. 
For applications that require frequent packing and unpacking, 
the column may be ordered with a removable end cell (GA) and 
optional transport dolly. For applications that require infrequent 
packing a fixed bottom end cell is available (GS). 



































































Acrylic 3 GA631321 GA631322 —
Stainless 3 GA633321 GA633322 —
Spare parts and accessories
The QuikScale® columns are complemented  
by a range of spare parts and accessories,  
including:
•  High flow kit
•  Process valves
•  Connection kits
•  Seals, clamps and adapters
•  Bubble traps
•  Column tube kits
•  Replacement parts 
Support for your application needs
We have the know-how to provide you  
with everything you need for your process  
development applications. Technical briefs  
describe the benefits you will acquire when  
using the QuikScale® columns. For more  
information, call our Technical Service  
department or ask your Application Specialists  
for in-depth technical notes. An operator’s  
manual contains full details of components,  
packing, testing, procedures for cleaning and  
sanitizing, troubleshooting and the spare  
parts list.
Lit. No. DS1224EN00 Ver 6.0
2016 - 00659
02/2017
To place an order or receive 
technical assistance
In the U.S. and Canada, call toll-free  
1-800-645-5476
For other countries across Europe  
and the world, please visit:  
emdmillipore.com/offices
For Technical Service, please visit: 
emdmillipore.com/techservice
Copyright © 2017 EMD Millipore Corporation. All Rights Reserved. MilliporeSigma, the vibrant M, K-Prime, Vantage, ProSep, Eshmuno, Fractogel and 
QuikScale are trademarks of Merck KGaA, Darmstadt, Germany. Triton is a registered trademark of Union Carbide Corporation. All other trademarks are 




Custom protection for Viresolve NFP viral 
clearance filters
Increases NFP capacity reducing overall 
filtration costs
Improves robustness by decreasing the 
impact of feed variability on the NFP filter
Maintain high product yields
Simple, predictable scale-up and scale-down
The Viresolve Prefilter improves robustness and 
filtration economics of the viral clearance step by 
protecting Viresolve NFP viral clearance filters and 
decreasing the impact of feed stream variability. 
Use of this prefilter with NFP will improve capacity 
and increase the life of the NFP filter. Available in 
scalable filter formats, this prefilter will easily fit in 
existing development and manufacturing processes. 
Improved Robustness
Use of the prefilter improves the robustness of the 
filtration step by decreasing the impact minor 
changes in feed stream quality, such as batch-to-
batch variability, effect of hold time, and freeze/
thaw, etc., could have on the Viresolve NFP filter. 
Increased Capacity and Filter Life
Utilizing this prefilter in series with  Viresolve NFP 
filters (NFP) will allow you to take advantage of 
NFP’s high flow rates and product yield. The prefilter 
effectively removes fouling components of the feed, 
leading to dramatic increases in the performance  
of the Viresolve NFP filter. This improved capacity 
significantly reduces the cost of the viral clearance 
step.
D A T A   S H E E T
®
OptiScale®-40 disposable capsule filters
  Opticap® disposable capsule filters
  Pod disposable devices 
Filter Formats
Table 1. Example of Cost Savings with Prefiltration
Economic Evaluation of Prefilter Benefits for a Low-Capacity Feed Stream 
Utilizing Viresolve NFP Filters
Process Description Without Prefilter With Prefilter
Feed volume 500 L 500 L
Viresolve NFP capacity 60 L/m2 300 L/m2
Viresolve prefilter sizing — 600 L/m2
Cost of viral clearance filter $54,000 $10,000
Cost of Viresolve Prefilter — $     400

























































Custom Prefiltration for Viresolve NFP 
Filters
Viresolve NFP filters clear parvovirus from therapeu-
tic feed streams without compromising flow rates, 
adding speed and dependability to viral clearance 
in therapeutic drug manufacturing applications. 
These reliable filters are ideal for monoclonal 
antibody polishing applications eliminating small 
virus contaminants.
Regulatory Compliance
Viresolve Prefilters are designed, developed, and 
manufactured in accordance with good manufac-
turing practices under an ISO® 9001 Quality 
Management System. Opticap capsules and Pods 
are integrity tested during manufacturing and 
supported by a Validation Guide to assist in 
compliance with regulatory requirements. For 
traceability and easy identification, each filter is 
labeled with the product name and identifying 
characteristics. Every filter is shipped with a 
Certificate of Quality.
Table 2. Viresolve Prefilter Provides High Protein Yield
Yield Analysis Summary with OptiScale-40 Devices
 Source  Recovered Mass
 Filtrate 94.5%
 Flush   2.2%
 System hold-up loss   2.5%
 Total 99.2%
Figure 1. Protection of Viresolve NFP Filter   
  Increases Capacity
Human IgG (1 g/L, pH 7.2) was processed through the Viresolve Prefilter 
at varying loading level. The filtrate from the prefilter was filtered through an 
OptiScale-25 capsule with Viresolve NFP membrane and the capacity of the NFP 
filter was measured.
Figure 2. Viresolve NFP Vmax Capacity for Prefilter  
  Scale-up
Human IgG (1 g/L, pH 7.2) was filtered through 3 lots of OptiScale-40 capsules 
with Viresolve Prefilter media, and 2 lots of 10-inch Opticap capsules with 
Viresolve Prefilter media. The filtrates were then filtered through an OptiScale-25 
with Viresolve NFP membrane and the filter capacity of the NFP was measured.
OptiScale-40 disposable 
capsule filters provide an active 
filtration area of 5 cm2. These 
small devices are useful for 
process development and 
optimization, and viral clearance 
studies. A female Luer–Lok 
fitting/male Luer slip connection 
ensures fast and secure setup. 
These capsules are used in small 
volume applications where 
feedstock requirements are 
minimal.
Opticap disposable capsule 
filters feature a patented design 
that withstands high thermal and 
hydraulic stress, assuring 
sterilization compatibility.
Scalable from pilot to process 
applications, this new innovative 
NFF device format offers process 
flexibility and linear scale-up. 
Flexible Configurations
This patented technology consists 
of three Pod sizes and an ex-
pandable holder system. 
 Pod Prefilters are offered in 
0.11 m2, 0.55 m2 and 1.1 m2 
filtration areas.
 Two basic holders are avail-
able; the pilot scale holder is 
configurable with extension rods 
that can accommodate up to five 
1.1 m2 Pods, while the process 
scale holder expands to mount 
from 5 to 30 Pod devices. The 
stainless steel holder is not wetted 
by product and the connectors 
are disposable plastic. With the 
compact, modular design of 
Millipore’s new pod system, you 
can increase productivity, shorten 
cycle-time and reduce costs.
OptiScale-40 Filters Opticap Capsule Filters Pod Filters
From process development to full-scale production, 
Millipore has the right solution for you!
OptiScale-40 Small Volume 
Disposable Capsule Filters
Opticap Disposable Capsule 
Filters Pod Disposable Devices
   A Mobius technology. 
Mobius solutions feature a range of 
disposable technologies and services 
to optimize biopharmaceutical 
processes.
Millipore, Opticap, OptiScale and Viresolve are registered trademarks of Millipore Corporation. 
Mobius is a trademark of Millipore Corporation. 
ISO is a trademark of the International Organization for Standardization. 
Luer-Lok is a registered trademark of Becton, Dickinson and Company. 
Lit. No. DS1181EN00   Rev. C    4/07   Printed in U.S.A.   07-251
© 2005, 2007 Millipore Corporation, Billerica, MA 01821 U.S.A.  All rights reserved
  OptiScale-40 10 in. Opticap 0.11 m2 Pod 0.55 m2 Pod 1.1 m2 Pod
 Effective Filtration Area 5.0 cm2 850 cm2 0.11 m2 0.55 m2 1.1 m2
 Materials of Construction
  Media: Cellulose fibers with  Cellulose fibers with  Cellulose fibers with inorganic filter aid
   inorganic filter aid inorganic filter aid  
  Membrane:  Mixed esters of cellulose Mixed esters of cellulose Mixed esters of cellulose
  O-ring:  — Silicone —
  Flat seal:  — — Thermoplastic elastomer 
  Housing: Polypropylene Polypropylene Glass-filled polypropylene
 Standard Connections Female Luer-Lok, male luer  3/4 in. Sanitary flange  Disposable 11/2 in. TC fitting    
   slip fittings
 Vent/Drain — 1/8 in. Hose barb Disposable vent
 Maximum Operating 4.1 bar (60 psi) 5.5 bar (80 psi) 3.4 bar (50 psi)     
 Line Pressure (at 23 °C)   
 Maximum Differential         
 Pressure (at 23 °C)    
  Forward:  2.1 bar (30 psi) 2.1 bar (30 psi) 2.1 bar (30 psi)  
  Reverse: 0.03 bar (0.5 psi) 0.35 bar (5 psi) 2.1 bar (30 psi)
 Autoclaving May be autoclaved for 3 cycles May be autoclaved for 3 cycles May be autoclaved for 3 cycles     
   of 60 minutes at 123 °C. of 60 minutes at 123 °C. of 60 minutes at 123 °C.   
 TOC/Conductivity — Lot release testing on effluent  Lot release testing on effluent exhibited  
    exhibited TOC <3 ppm and  TOC <4 ppm and conductivity <10 µS/cm  
    conductivity <10 µS/cm after auto- after 3 autoclave cycles and a water  
    claving and a water flush of 10 L/ft2. flush of 100 L/m2.
 Metals — Lot release testing on effluent exhibited the following values: 
    Pb    < 0.01 mg/ft2 Pb    < 0.01 mg/ft2
    Hg  < 0.01 mg/ft2 Hg  < 0.01 mg/ft2
    As   < 0.01 mg/ft2 As   < 0.012 mg/ft2
    Fe   < 0.1 mg/ft2 Fe   < 0.1 mg/ft2
    Al  < 0.5 mg/ft2 Al  < 0.5 mg/ft2
 Bacterial Endotoxin Aqueous extraction contains  <0.25 EU/mL as determined by the Limulus Amebocyte Lysate (LAL) test.
 Component Material  Component materials were tested and meet the criteria of the USP <88> Reactivity Test for Class VI Plastics.    
 Toxicity Viresolve Prefilters meet the requirements of the USP <88> Safety Test, utilizing a 0.9% sodium chloride extraction.
 Indirect Food Additive All component materials meet the FDA Indirect Food Additive requirements cited in 21 CFR 177–182.
 Quality Standard These products are manufactured in accordance with a Quality Management System that is approved by an    
   accredited registering body to the appropriate ISO 9000 Quality Systems Standard. 
Ordering Information
  Nominal  
Device  Process Volume Connections   Qty/Pk Catalogue No. 
OptiScale-40 Capsule  100 mL Female Luer-Lok, male luer slip fittings 9 SSPV A40 NB9
10 in. Opticap Capsule  20 – 40 L  3/4 in. Sanitary flange inlet and outlet  1  KSPV 01F F1
0.11 m2 Pod Filter  20 – 40 L  Disposable 11/2 in. TC inlet and outlet 1 MSPV 01 FS1 
0.55 m2 Pod Filter  100 – 200 L  Disposable 11/2 in. TC inlet and outlet 1 MSPV 05 FS1




Viresolve® Pro Solution:  
High-productivity Virus Filtration 
• Improved process economics with high mass capacity 
• High flux for faster processing
• Consistent batch-to-batch performance 
• Easy to install, use and integrity test 
• Caustic sanitizable
Viresolve® Pro Device:  
Robust Parvovirus Clearance
• ≥ 4.0 log removal of parvovirus
• Devices are 100% integrity tested with air/water 
diffusion and Binary Gas
• Robust retention maintained during process 
interruption/depressurization
Viresolve® Pro Solution 
Proven viral safety solution designed to 
provide the highest levels of retention 
assurance and productivity
Robust. Productive. Proven. 
The Viresolve® Pro Solution provides a comprehensive, 
flexible template solution for virus filtration in biologics 
manufacturing. This proven viral clearance solution 
delivers the highest levels of retention assurance and 
processing efficiency across a broad range of feed 
streams.
The Viresolve® Pro Solution is comprised of the 
innovative, high-performing Viresolve® Pro Device 
in conjunction with the Viresolve® Pro Shield or the 
Viresolve® Pro Shield H prefilters. These products are 
designed to work togther to meet your needs providing 
high parvovirus retention, capacity and flux. Our 
industry-leading products and services, coupled with 
our viral clearance expertise, will help you successfully 
develop, implement, and validate the  
Viresolve® Pro Solution.
The life science business of Merck KGaA,  
Darmstadt, Germany operates as  
MilliporeSigma in the U.S. and Canada.
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Prefilters: Viresolve® Pro Shield &  
Viresolve® Pro Shield H
Provides robust adsorptive (cation/mixed-mode) 
prefiltration to remove fouling protein aggregates 
• Enhance throughput and process robustness of 
Viresolve® Pro Devices
• Effective across a broad range of pH  
and conductivity conditions
Enhanced Process Robustness
For feed streams with high levels of fouling protein 
aggregates, the Viresolve® Pro Shield or Viresolve® Pro 
Shield H can be used to improve the capacity of the 
Viresolve® Pro Device. 
These membrane prefilters adsorb protein aggregates 
that foul or plug the pores in the Viresolve® Pro 
membrane. Viresolve® Pro Shield and Viresolve® Pro 
Shield H have different membrane surface modifications 
to maximize adsorption of protein aggregates under a 
broad range pH and conductivity conditions (Figure 1).
The Viresolve® Pro Prefilter Selector Guide 
(TB1140EN00) provides guidance and information on 
prefilter selection.
Virus Filter: Viresolve® Pro Device
Provides robust viral clearance
• ≥ 4.0 logs of Minute Virus of Mice clearance
• ≥ 5.0 logs of Murine Leukemia Virus clearance 
• Delivers high capacity
High Virus Retention
Retention performance of the Viresolve® Pro Micro 
40 Devices, containing two lots of membrane, was 
evaluated under aggressive processing conditions. 
Testing was performed with a monoclonal antibody 
feed stream at 60 psi to a filtration endpoint of 
90% flow decay, followed by a 20 L/m2 buffer flush. 
Samples were collected from final filtrate pools and a 
summary of calculated log reduction values (LRV) is 
shown in Figure 2. As can be seen from the results, 
the Viresolve® Pro Solution achieved at least 5.8 logs 
of MVM retention. These results demonstrate robust 
virus clearance, even out to 90% flow decay, at high 
pressure. 
Virus retention performance of the Viresolve® Pro 
Solution under a range of processing conditions is 
summarized in the application note Virus Retention 
Performance of Viresolve® Pro Devices under a Range 
of Processing Conditions (WP3374EN).
Figure 1.
Contour plot showing the optimal pH and conductivity conditions for 






Viresolve® Pro Shield or Shield H may be optimal
Viresolve® Pro Shield H
Figure 2.
Summary of MVM results for two membrane lots of  





















Lot 1 Lot 2
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Building Quality
The virus retention performance and integrity 
of Viresolve® Pro Devices is assured with our 
comprehensive approach to quality.
Assuring Retention
Retention performance is assured with our proprietary 
Binary Gas test which detects defects as small as 3-5 
microns, that cannot be detected using a traditional air/
water diffusion test, Figure 3. This high sensitivity test 
is especially valuable for Viresolve® Pro Devices, where 
small defects could impact virus retention performance. 
Every Viresolve® Pro Device must pass Binary Gas 
testing before release, assuring the highest levels of 


























Integrity Tested in 
Manufacturing







Principles of Binary Gas Test. This proprietary test measures the composition of a mixture of two gases on the upstream and downstream sides of 
the Viresolve® Pro membrane to detect defects as small as 3-5 microns in size.
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High Capacity and Flux
The Viresolve® Pro Solution efficiently processes feed 
streams of different pH, conductivities and protein 
concentrations. When used upstream of Viresolve® Pro 
Devices, Viresolve® Pro Shield and Shield H enhance 
the throughput and processing robustness of filtration 
operations. 
Figure 4 shows the results of throughput testing with 
Viresolve® Pro Devices alone (A) or in conjunction with 
Viresolve® Pro Shield and Shield H (B). In most cases, 
implementing the prefilter increased the capacity of 
the Viresolve® Pro Device by an average of two-fold. 
The Viresolve® Pro Solution enables rapid processing 
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Figure 4A.
Mass capacity on Viresolve® Pro Devices with mAbs of different protein concentrations. In all cases, processing time was less than four hours.
Figure 4B.
Mass capacity of the Viresolve® Pro Solution across a range of pH and 



























































The Viresolve® Pro Shield, Viresolve® Pro Shield H and Viresolve® Pro Devices are easily  
integrated into flexible, easy-to-use systems for pilot to full-scale manufacturing.
Viresolve® Pro/Pro+ Magnus Holders for 
Viresolve® Pro Solution
Viresolve® Magnus Holders are designed for large 
volume processing. The Viresolve® Pro Magnus Holder 
is designed to run the Viresolve® Pro Device alone, 
while the Viresolve® Pro+ Magnus Holder is designed to 
run the Viresolve® Pro Device coupled with either the 
Viresolve® Pro Shield or Shield H.
• Quick and easy loading and unloading 
• No product contact
• Minimized holder footprint with vertical orientation 
• Rods in multiple lengths for various sized installations
• Simple manual hydraulics
Mobius® FlexReady Solution for Virus 
Filtration
The Mobius® FlexReady Solution for large-scale 
virus filtration is an easy-to-use system featuring an 
optimized single-use flow path designed to fully support 
your virus filtration needs.
For more information on the  Mobius® FlexReady 
Solution for large scale virus filtration, refer to 
datasheet DS1259EN00.
Viresolve® Pro+ Magnus Holder Viresolve® Pro Magnus Holder Mobius® FlexReady Solution
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Partner with a leader in viral safety
Virus Filtration Process Development Service
Optimizing a virus filtration process involves evaluating 
the effects of multiple process parameters to identify 
conditions that will ensure a robust, consistent, and 
economical operation. We work side-by-side with 
development engineers and manufacturers, helping 
them develop efficient, cost-effective filtration 
operations.
We can help you:
• Maximize filtration efficiency
• Maximize process robustness
• Meet your economic targets
Viral Clearance Services
Viral clearance studies are critical to the validation of 
downstream processes, ensuring sufficient reduction 
of potential viral contaminants during downstream 
processing. 
BioReliance® viral clearance studies are designed 
and executed by experts in regulatory, downstream 
processing, and virology at our facilities in Singapore, 
the U.S., and the UK. Our global experts can support 
you with your IND and BLA studies in accordance 
to regulatory guidelines for monoclonal antibodies, 
recombinant proteins, and plasma derivatives. Our 
dedicated project management support and local teams 
of experienced technical experts accelerate your time 
to results and minimize risk as you bring your product 
to market.
Virus Filter Implementation Service
Our engineers can leverage the results of bench-scale 
studies to help implement your pilot or production 
scale virus filtration operation. This streamlines 
implementation and avoids the pitfalls that can impact 
production timelines and process economics.
The Viresolve® Pro Solution is  
supported by the Emprove® Program - 
your fast track through regulatory 
challenges. 
Complementing our product portfolio, the 
Emprove® Program provides three types 
of dossiers to support different stages of 
development and manufacturing operations 
such as qualification, risk assessment and 
process optimization. The dossiers consolidate 
comprehensive product-specific testing data, 
quality statements and regulatory information 
in a readily-available format to simplify your 
compliance needs.
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Nominal Dimensions and Weights 
Viresolve® Pro Shield, Viresolve® Pro Shield H, Viresolve® Pro Devices, and Holders
Size Nominal Dimensions
Nominal Effective 
Filtration Area Nominal Weight
Micro 40 Height: 4.03 cm (1.59 in.)  
Diameter: 4.37 cm (1.72 in.)
3.4 cm2 Empty: 14.73 grams
Modus 1.1 Length: 18.62 cm (7.33 in.) 
Width: 9.22 cm (3.63 in.) 
Height: 5.92 cm (2.33 in.)
0.017 m2 Empty: 0.37 Kg (0.8 lbs)
Modus 1.2 Length: 18.62 cm (7.33 in.) 
Width: 9.22 cm (3.63 in.) 
Height: 7.85 cm (3.09 in.)
0.07 m2 Empty: 0.63 Kg (1.4 lbs)
Modus 1.3 Length: 18.62 cm (7.33 in.) 
Width: 9.22 cm (3.63 in.) 
Height: 13.56 cm (5.34 in.)
0.22 m2 Empty: 1.39 Kg (3.1 lbs)
Magnus 2.1 Length: 34.30 cm (13.50 in.) 
Width: 20.96 cm (8.25 in.) 
Height: 4.42 cm (1.74 in.)
0.51 m2 Empty: 2.6 Kg (5.7 lbs) 
Full of water: 3.4 Kg (7.5 lbs)
Magnus 2.2 Length: 34.30 cm (13.50 in.) 
Width: 20.96 cm (8.25 in.) 
Height: 9.50 cm (3.74 in.)
1.53 m2 Empty: 5.8 Kg (12.8 lbs) 
Full of water: 8.3 Kg (18.3 lbs)
Viresolve® Pro Magnus Holder 
(VPMH103000 / VPMH105000 / 
VPMH107000)
Length: 78 cm (30.9 in.) 
Width: 76 cm (30 in.) 
Height: 127 cm (50 in.)
Not Applicable 141.5 Kg (312 lbs)
Viresolve® Pro+ Magnus Holder 
(VPMH203000 / VPMH205000 / 
VPMH207000)
Length: 104 cm (40.9 in.) 
Width: 76 cm (30 in.) 
Height: 127 cm (50 in.)
Not Applicable 186 Kg (410 lbs)
Materials of Construction 
Viresolve® Pro Shield, Viresolve® Pro Shield H, and Viresolve® Pro Devices, and Holders
Device Membrane Components O-Rings/Gaskets






Polyethersulfone (PES) Bottom Endcap/Top Endcap: Polyvinylidene fluoride (PVDF) Silicone
Shield and 
Shield H Membrane Components
O-Rings/ 
Gaskets Connections*





Inlet and Vent: Female Luer-Lok™ Fitting 




Polyethersulfone (PES) Bottom Endcap/Top Endcap: 
Polyvinylidene fluoride (PVDF)
Silicone Inlet and Outlet: 1.91 cm (.75 in.) sanitary fittings 
Integrated Vent: 0.32 cm (0.125 in.) with hose barb 
with double O-ring seal
Magnus 2.1, 
Magnus 2.2
Polyethersulfone (PES) Bottom Endcap/Top Endcap: 
Polyvinylidene fluoride (PVDF)
Silicone Inlet and Outlet: 3.81 cm (1.5 in.) sanitary fittings 
Vent: 1.90 cm (0.75 in.) sanitary fitting for the port
* Fittings sold seperately
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Materials of Construction (continued)




Viresolve® Pro Magnus Holder Not Applicable Plates & Frames: 316 L stainless steel Not Applicable Not Applicable
Clamp Rods: 300 series stainless steel
Fasteners, other components: 300 series 
stainless steel
Viresolve® Pro + Magnus 
Holder
Not Applicable Plates & Frames: 316 L stainless steel Not Applicable Not Applicable
Clamp Rods: 300 series stainless steel
Fasteners, other components: 300 series 
stainless steel
Fittings Kit Not Applicable Polyvinylidene fluoride (PVDF) Silicone Not Applicable
Specifications
Viresolve® Pro Shield, Viresolve® Pro Shield H and Viresolve® Pro Devices
ISO® 9001 Quality Standard These products are manufactured in a facility whose Quality Management System is approved 
by an accredited registering body to the appropriate ISO® 9001 Quality Systems Standard.
Particulate and Bioburden These products are manufactured in an ISO® Class 8 (Per ISO® 14644-1) controlled 
environment for particulate classification only.
Animal Origin All components used in the manufacturing of these products are either animal-free or in 
compliance with EMEA/410/01.
USP <87> Biological Reactivity Tests Component materials for these products were tested and meet the criteria for non-cytotoxicity 
for the USP <87> Cytoxicity L929 MEM Elution Tests.
USP <88> Biological Reactivity Tests Component materials for these products were tested and meet the criteria for USP <88> 
Biological Reactivity Tests for Class VI Plastics.
Bacterial Endotoxin An aqueous extract from these products contains less than 0.25 EU/mL as determined by the 
Limulus Amebocyte Lysate (LAL) test.
Membrane Bacteriophage Retention Membrane samples exhibited ≥ 4.0 LRV of φX 174 bacteriophage at a minimum challenge 
level of 107 pfu/cm2 in the presence of a model protein at V75.
Bacteriophage Retention Viresolve® Pro Device samples exhibited ≥ 4.0 LRV of φX 174 bacteriophage at a minimum 
challenge level of 107 pfu/cm2 in the presence of a model protein at V75.
Non-Fiber Releasing These products are non-fiber releasing filters as defined in 21 CFR 210.3(b)(6).
Hydraulic Stress Test Samples were integral based on an Air/ Water Diffusion Test, before and after a forward stress 
to 4.1 bar (60 psid) at 25°C.
Manufacturing Integrity Test All Viresolve® Pro Micro 40 Devices included in the Viresolve® Pro Micro 40 Device Kit must 
pass the Binary Gas Test.
All Viresolve® Pro Modus and Magnus Devices must pass the Pressure Hold, Water Flow Rate, 
Air/Water Diffusion Test and Binary Gas Test.
All Viresolve® Pro Shield and Viresolve® Pro Shield H must pass an aerosol particle challenge 
and housing pressure hold.
All Viresolve® Pro Devices exhibited an air diffusion flow rate at 3.4 bar (50 psig) in water at 
25 °C of less than or equal to:
• 0.7 cc/min per Viresolve®  Pro Modus 1.1 Device
• 2.7 cc/min per Viresolve®  Pro Modus 1.2 Device
• 8.8 cc/min per Viresolve®  Pro Modus 1.3 Device
• 20 cc/min per Viresolve®  Pro Magnus 2.1 Device
• 60 cc/min per Viresolve®  Pro Magnus 2.2 Device
Caustic Sanitization These products may be sanitized by one 60-minute flush at 1.8 bar (25 psig) in 0.5 Normal 
Sodium Hydroxide at 25 °C followed by a maximum 16-hour static soak.
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Ordering Information
Description Primary Use Qty/Pk Cat. No.
Viresolve® Pro Device
Viresolve® Pro Micro 40 Device Kit Process Development or Viral Clearance Evaluations 9 VPMKVALNB9
Viresolve® Pro Modus 1.1 Device Small-scale studies/pilot 1 VPMD101NB1
Viresolve® Pro Modus 1.2 Device Pilot/small-volume 1 VPMD102NB1
Viresolve® Pro Modus 1.3 Device Pilot/small-volume 1 VPMD103NB1
Viresolve® Pro Magnus 2.1 Device Large-volume processing 1 VPMG201NB1
Viresolve® Pro Magnus 2.2 Device Large-volume processing 1 VPMG202NB1
Viresolve® Pro Shield
Viresolve® Pro Micro Shield Kit Process Development or Viral Clearance Evaluations 9 VPMSKITNB9
Viresolve® Pro Modus 1.1 Shield Small-scale studies/pilot 1 VPPS101NB1
Viresolve® Pro Modus 1.2 Shield Pilot/small-volume 1 VPPS102NB1
Viresolve® Pro Modus 1.3 Shield Pilot/small-volume 1 VPPS103NB1
Viresolve® Pro Magnus 2.1 Shield Large-volume processing 1 VPPS201NB1
Viresolve® Pro Magnus 2.2 Shield Large-volume processing 1 VPPS202NB1
Viresolve® Pro Shield H
Viresolve® Pro Micro Shield H Kit Process Development or Virus Validation Studies 9 VPMHKITNB9
Viresolve® Pro Modus 1.1 Shield H Small-scale studies/pilot 1 VPPH101NB1
Viresolve® Pro Modus 1.2 Shield H Pilot/small-volume 1 VPPH102NB1
Viresolve® Pro Modus 1.3 Shield H Pilot/small-volume 1 VPPH103NB1
Viresolve® Pro Magnus 2.1 Shield H Large-volume processing 1 VPPH201NB1
Viresolve® Pro Magnus 2.2 Shield H Large-volume processing 1 VPPH202NB1
Holders, Accessories, Services and Spare Parts
Viresolve® Pro Magnus Holder For 1 to 3 Viresolve® Pro Devices 1 VPMH103000
For 1 to 5 Viresolve® Pro Devices 1 VPMH105000
For 1 to 7 Viresolve® Pro Devices 1 VPMH107000
Viresolve® Pro+ Magnus Holder For 1 to 3 Viresolve® Pro Devices and  
1 to 3 Viresolve® Pro Shields or Viresolve®  Pro Shield H
1 VPMH203000
For 1 to 5 Viresolve® Pro Devices and  
1 to 5 Viresolve® Pro Shields or Viresolve® Pro Shield H
1 VPMH205000
For 1 to 7 Viresolve® Pro Devices and  
1 to 7 Viresolve® Pro Shields or Viresolve® Pro Shield H
1 VPMH207000
Split clamp insert 1 VPMHINSERT
Rod handle 1 VPMHRDKN0B
Rods For 1 to 3 Viresolve® Pro Devices 2 VPMHRD0103
For 1 to 5 Viresolve® Pro Devices 2 VPMHRD0105
For 1 to 7 Viresolve® Pro Devices 2 VPMHRD0107
Fittings Kit (three 3.81 cm (1.5 in.) sanitary 
fittings, two 3.81 cm (1.5 in.) blanks, one 1.27 
cm (.5 in.) vent fitting and one 1.27 cm (.5 in.) 
blank)
Viresolve® Pro and Pro+ Magnus Holder 1 VPMHADAPSK
3.81 cm (1.5 in.) Sanitary fittings For feed/permeate port 6 VPMHADAPSF
3.81 cm (1.5 in.) Blanks For feed/permeate port 6 VPMHADAPSB
1.27 cm (.5 in.) Vent fittings For vent port 6 VPMHADAPVF
1.27 cm (.5 in.) Vent blanks For vent 6 VPMHADAPVB
Hydraulic pump 1 MP0DHYPUMP
Pressure gauge 1 MP0DHYGAGE
Hydraulic fluid (1 liter) 1 MP0DHFLUID




Description Primary Use Qty/Pk Cat. No.
Viresolve® Pro and Pro+ Magnus Holder Services
IQ/OQ Protocol Commissioning, installation and operational qualification 
(IQ/OQ) protocol
1 DOCVMHIQOQ
IQ/OQ Protocol and Service Commissioning, installation and operational qualification 
(IQ/OQ) protocol and service
1 SSVIOQMGN
On-Site Preventive Maintenance (PM) Service Equipment checks, testing for proper functionality, 
adjustments and parts replacement (sold separately).
1 CSVOPMMGN
Mobius® FlexReady Solutions for Virus Filtration
Refer to data sheets (DS2562EN00 and DS1259EN00) for specific ordering information.
 2020 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. MilliporeSigma, the vibrant M, Millipore, Flexware, 
Mobius, and Viresolve are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their 
respective owners. Detailed information on trademarks is available via publicly accessible resources.
To place an order or receive technical assistance
Please visit EMDMillipore.com/contactPS
For additional information, please visit EMDMillipore.com
MilliporeSigma 
400 Summit Drive 
Burlington, MA 01803
Specification Sheet
Mobius® FlexReady Solution with  
Smart Flexware® Assemblies for TFF
Features
• Flexible design options 
• Unique feed tank design and performance
• Smart Flexware® full single-use flow paths
• Excellent product recovery and purification
• Implement with ease and lower risks
• Full process automation with flexible recipes using 
the Common Control Platform® (CCP®) 
Benefits
• Ability to produce higher final concentrations 
• Consistently deliver safety and quality with 
less cleaning validation and lower risk of cross 
contamination 
• Ability to meet unique requirements
• Agile system able to perform at multiple scales for 
both TFF and Chromatography
• Simplified training requirements 
1. Tank cart
2. Pump and manifold cart
3. Smart cart with exchangeable 
clamshell
4. Clamshell storage rack
5. Chamshell lift
TF2S: 18L/min – 0.5 to 5.0 m2 Pellicon® cassettes or similar





The life science business of Merck KGaA,  
Darmstadt, Germany operates as  




Carts connected H x L x W in. (mm) TF2S
TF3S
2022 x 2160 x 974 +/- 20 mm
2022 x 2160 x 1014 +/- 20 mm
Net Weight
Tank cart 50 L 280 kg
Tank cart 100 L 310 kg
Tank cart 200 L 330 kg
Smart cart with clamshell 430 kg





Product temperature range 2 to 45 °C 
System operation temperature 2 to 30 °C (20 to 30 °C for TF3S)
Operating humidity 10%–90% (non-condensing)
Operating pressure 4 bar max: feed / retentate assemblies
2 bar max: transfer / filtrate assemblies
Atmospheric pressure: feed bag
Fluidic Sections
Feed Section
Feed container volume TF2S
TF3S
50 L/100 L/200 L in LLDPE or stainless steel container with jacket
200 L in LLDPE or stainless steel container with jacket
Tank jacket volume 50 L tank 3.3 L
100 L tank 6.0 L




Quattroflow 4400 SU with 3° shaft 
Flow at 4 bar max TF2S
TF3S
2 to 20 L/min
4 to 40 L/min
Minimal working volume (w/o cassettes feed volume) TF2S
TF3S
0,7 L -1,8 L from 2 to 18 L/min*
2,2 L -4,0 L from 4 to 40 L/min*
Maximum viscosity 35cP
Pressure sensor Non-intrusive 0-4 bar +/-0.2 bar; Security switch set at 4.4 bar
Tank weight 0.3% FS
Control on feed pump Fixed position (speed in %) or flow control or pressure drop control
Precision of calculated feed flow +/-10% with feed pressure at least 1 bar
Temperature sensor feed container 2-45 °C +/-2 °C
*May vary slightly depending on the configuration system and other parameters.
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Transfer Section
Pump model Quattroflow™ 1200 SU
Flow at 2 bar TF2S
TF3S
5m²: 2 to 9 L/min 
10m²: 2 to 20 L/min 
Transfer pump control Fixed position (speed in %) or level control
Pressure sensor 0-4 bar +/-0.2 bar; Security switch set at 2.3 bar
Retentate Section
Pressure sensor Non-intrusive 0-4 bar +/-0.2bar
Sampling Optional zero dead leg device – NovaSeptum® sampling solution 
compatible
Volume factor concentration VCF Precision better than 2%
Retentate PCV control Fixed position (% of closure) or TMP control or retentate pressure 
control
Filtrate Section
Pressure sensor Non-intrusive 0-4 bar +/-0.2bar




Conductivity:  0 to 100 µS/cm +2% FS 
UV: 0 to 2 AU +2% FS 
OPL: 10 mm 
Wavelength: 280 nm / 300 nm
Weight with Mobius® weight scale TF2S 0 to 600 Kg + 0.3 % FS
Weight with user supplied weight scale TF2S
TF3S
0 to 1000 Kg (accuracy linked to component connected)
0 to 1500 Kg (accuracy linked to component connected)
Flowmeter Non intrusive 
(ultrasonic by 
Emtec)
From 2LPM: +/-5% MV
Below 2LMP: +/-0,12 LPM
Sampling Optional zero dead leg device 
NovaSeptum® sampling solution compatible
Filtre PCV control Fixed position (% of opening) or TMP
Important Note: 
The single-use cell (SUC) is factory calibrated by Optek and for best performance the end-user should enter in the C8000 transmitter, the K factor 
delivered with each new sensor assembly.
As calibration is dependent on each SUC installed, the calibration loop should be verified by the end-user prior and/or after each batch (as per 
customer internal standard operating procedures.)
In consequence, during internal release test, only the proper wiring of the loops is tested using: 
•  Calibrated UV filters 
•  A conductivity tester supplied by Optek to simulate a conductivity value
Documentation
User guide on CD 
Access to template recipes upon request
1. FDA Guidance for Industry Process Validation: General Principles and Practices – January 2011
2. Annex 15 to the EU Guide to Good Manufacturing Practice Qualification and Validation – July 2001
3.  Mobius® FlexReady solution with Smart Flexware Assemblies for tangential – Flow Filtration  
Performance Guide – AN4465EN00
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Endurance 
Active process time 12 h at 50 cycles per valve
Valve pads longevity 2500 cycles / 6 months
Wetted Materials
Tubing Silicone
Smart Flexware® Assembly Pureflex™ film and PE fittings 
Feed Bag Assembly Pureflex™ film 
Pump Head EPDM, Santoprene® and Polypropylene 
Liners Polysulfone 
Connectors Polypropylene and Polysulfone 
Multi-use UV & Conductivity Sensors Quartz, EPDM and stainless steel 316 L 
Single Use UV & Conductivity Sensors Polysulfone Quartz, EPDM and stainless steel 316 L (pins only) 
Retentate Low Dead Volume TC Sampler DMDA-1250 NT 7, sampler: HDPE O-ring: silicone 
TFF Mixer Vortex Breaker & Diverter Plate HDPE 
Smart Flowpath
The smart flowpath is a unique and patented fluid management device featuring fewer connections than 
other designs. Fewer connections provide improved process effectiveness through reduced working 
volume and protein shearing, reduced leak risks, and maximum product recovery.
Feed
XV001, XV002: Normally Closed Valves 
PIT/PSH001 : High Pressure Switch Sensor
Retentate
PCV001: Normally Opened Control Valve 
XV004: Normally Opened Valve 
PT002: Retentate Pressure Sensor
Filtrate
PCV101: Normally Closed Control Valve 
PT101: Filtrate Pressure Sensor
Transfer
XV005: Normally Closed Valve 
PIT/PSH401: High Pressure Switch Sensor
Drain/recovery
XV901, XV003: Normally Closed Valves
Filtrate drain
XV102: Normally Closed Valve
A: Internal door locks and sensors






Regulatory and Quality Compliance
USP <87> Biological reactivity in vitro, USP <88> 
Biological Reactivity in vivo, Plastic Calss VI
Compliant
Irradiation dose 25–40 kG
21 CFR Part 11 Compliant ready
2004/108/CE Electromagnetic Compatibility (EMC) Compliant
2006/42/CE Machinery Directive Compliant
PSE Exempt
ASME U-1 code Tank Jacket is compliant
Data and System Control
PLC Allen-Bradley CompactLogix™
Control software system Microsoft® Windows® 7
Operator interface panel type iFix®
Operator interface 12.1” tiltable touch screen
Languages English, German, Spanish, Japanese, French, Italian, Chinese, Korean
Security Based on Microsoft® Windows® operating system 
Configurable user access group levels (4 pre-configured)
Data acquisition Stored in Read Only Database 
PC B&R
Data 21 CFR Part 11 compliance ready 




External storage media USB
Mouse USB
Air 6–10 bar oil free at 4 L/min max
Power Supply
Smart Cart 220–240 VAC, 50/60 Hz, 1 phase, 3.9 A
Or 100-120 VAC, 50/60 Hz, 1 phase, 8.4 A
Maximum power consumption 1 kW
Tank Cart 220–240 VAC, 50/60 Hz, 1 phase, 0.4 A (50 L) – 1.8 A (100/200 L)
Or 100–120 VAC, 50/60 Hz, 1 phase, 0.8 A (50 L) – 3.7 A (100/200 L)
Maximum power consumption 0.1 kW (50L) to 0.4 kW (100/200L) 
Pump cart (TF3S) 3 x 200–240 VAC, 50/60 Hz, 3 phases + neutral + ground, 10 A 
Or 3 x 400–460 VAC, 50/60 Hz, 3 phases + neutral + ground, 5 A 
Maximum power consumption 3 kW
Data Sheet
The life science business of Merck KGaA,  
Darmstadt, Germany operates as  
MilliporeSigma in the U.S. and Canada.
Pellicon® 3 cassettes with Ultracel® membrane are advanced, high-performance cassettes that 
are ideal for today’s higher titer therapeutic antibodies, as well as for the more demanding 
filtration processes that require higher operating pressures, temperatures, concentrations and 
caustic cleaning regimes.
From small-scale to full-scale production, Pellicon® 3 cassettes are designed for use in research, 
process scale-up/scale-down, applications development and full-scale manufacturing. 
The Pellicon® 3 cassette design and automated manufacturing process provides unbeatable 
performance consistency and enhanced linear scalability between cassette sizes. Pellicon® 3 
cassettes also offer greater cassette size selection for improved scale-up and scale-down process 
development. The streamlined design allows operators to quickly and easily handle, install and 
remove Pellicon® 3 cassettes. The materials of construction are compatible with a broad range 
of chemical cleaning agents that many TFF systems require to ensure proper sanitization.
Benefits
• Optimum product recovery using proven  
composite membrane technology
• Fast, reliable scale-up/-down from lab to  
production scale
• Rugged, reliable design ideally suited to filtration 
processes with higher operating pressures, 
temperatures and caustic cleaning regimes
• Automated manufacturing delivers unbeatable 
performance consistency and reliability
• Easy to install and clean
• Extreme temperature and chemical compatibility
• Choice of screens to best optimize your process
Applications
• Monoclonal antibodies
• Recombinant and non-recombinant proteins
• Vaccine
Pellicon® 3 Cassettes 
with Ultracel® Membrane 
The optimum tangential flow filtration devices for  
monoclonal antibodies and other therapeutic proteins.
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Nominal Dimensions
Filtration Area Length mm (in.) Width mm (in.) Thickness mm (in.)
C-Screen
88 cm2 206 (8.1) 56 (2.2) 8.3 (0.33)
0.11 m2 206 (8.1) 56 (2.2) 24 (0.93)
0.57 m2 206 (8.1) 178 (7.0) 26 (1.03)
1.14 m2 206 (8.1) 178 (7.0) 42 (1.66)
D-Screen 
88 cm2 206 (8.1) 56 (2.2) 8.3 (0.33)
0.11 m2 206 (8.1) 56 (2.2) 25 (0.98)
0.57 m2 206 (8.1) 178 (7.0) 29 (1.13)
1.14 m2 206 (8.1) 178 (7.0) 45 (1.78)
Specifications
Materials and Assembly
Materials of Construction • Polypropylene
• Polyethylene
• Composite regenerated cellulose
• Thermoplastic elastomer
• Stainless steel (0.57 m2 and 1.14 m2 cassettes only)
Storage Solution 3-4% benzyl alcohol, 20% glycerin and water
Membrane Ultracel® membrane – Composite regenerated cellulose (regenerated 
cellulose membrane cast on a microporous polyethylene membrane)
Assembly Design Automated assembly and testing of heat-sealed packets bound together 
by an injection-molded polypropylene jacket
Maximum Operating Conditions
Recommended Feed Flow Rate 4–8 L/m2/min
Inlet Pressure 100 psi
Forward Transmembrane Pressure 80 psi (5.5 bar) at 4–40°C, 200 hours continuous
40 psi (2.7 bar) at 4–50°C, 50 hours continuous
Reverse Transmembrane Pressure 30 psi (2.1 bar) at 25°C, 3 min intervals, 10 cycles
Maximum Caustic Exposure (One Time) 0.5N NaOH at 50°C up to 50 hours
Operating pH Range 2–13
Regulatory Information
Component Material Toxicity Component materials were tested and meet the criteria of the USP <88> 
Biological Reactivity Tests for Class VI Plastics.
Good Manufacturing Practices These products are manufactured in a facility that adheres to current 
Good Manufacturing Practices.
ISO® 9001 Quality Standard This product was manufactured in a facility whose Quality Management 
System is approved by an accredited registering body to the appropriate 
ISO® 9001 Quality Systems Standard.
100% Integrity Tested in Manufacturing Each unit must pass our integrity test based on air flow through the  
fully wetted membranes of the filter.
Validated Production Process This product was fabricated using a validated manufacturing process. 
Principles of statistical process control and determinations of process 
capability have been applied to critical variables in the device fabrication 
process. In-process controls are used to assure stability of the process.
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Pellicon® 3 Cassettes  
with Ultracel® Membrane
Description Cat. No.



























Holder Type Cassette Size Area Range Cat. No.
Pellicon® 3 Cassette Holders
Stainless Steel Mini-Holder 88 cm2 and 0.11 m2 88 cm2 to 0.55 m2 XX42PMINI
Acrylic Cassette Holder  
Low Retentate Volume
0.57 m2 and 1.14 m2 0.57 m2 to 5.7 m2 XX42PRV60
Stainless Steel Holder 0.57 m2 and 1.14 m2  0.57 m2 to 5.7 m2 XX42P0080
Stainless Steel Cassette 
Holder and Assembly
0.57 m2 and 1.14 m2  0.57 m2 to 5.7 m2 XX42P0K80
Manifold Support Plate 0.57 m2  and 1.14 m2 NA XXPEL3MAP
Process Scale Holder 0.57 m2 and 1.14 m2 1.14 m2 and up Contact Local 
Representative 
Hydraulic Process  
Scale Holder




Sodium hydroxide solution 




Sodium hydroxide solution 




Sodium hydroxide solution 






Diverter plate and silicone 
gasket kit for 88 cm2 cassette
XXSPTFF01
Diverter plate for 0.57 m2  
and 1.14 m2 cassettes
XXSPTFF02
Retentate collection plate for 




Pellicon® 3 Cassettes with Ultracel® 
membrane with C Screen
Pellicon® 3 Cassettes with Ultracel® 









88 cm2 1.5 2.4 3.6 2.0
0.11 m2 18 15 23 17
0.57 m2 85 68 118 75
1.14 m2 170 127 227 138
In ultrafiltration (UF) tangential flow filtration (TFF) 
systems, operating parameter selection will have far 
reaching impact as the process is scaled to full-scale 
manufacturing levels. While there are many factors that 
contribute to final system design, several key parameters 
should be optimized early in the process development 
phase. The goal is to develop a robust process with the 
following success criteria: superior product quality, 
consistent and high product yield, reproducible process 
flux and time, and a cleaning regime that allows extended 
membrane reuse.
The following basic experiments should be considered 
during development of processing methodology:
• Optimization
 – Impact of transmembrane pressure (TMP) and feed 
flow on process flux and retention 
 – Impact of product concentration and buffer 
conditions on process flux and retention
 – Impact of diavolumes on buffer exchange and 
contaminant removal
• Paper design and full process simulation with chosen 
processing parameters
Typically, the first three experiments are performed 
sequentially to bracket process performance and obtain 
data for analysis. This information is then combined with 
actual manufacturing considerations (batch volume, 
process time, etc.) to design a process simulation. 
The purpose of a process simulation is to duplicate the 
entire manufacturing process in a scale-down format, to 
confirm sizing, and to assess preliminary product quality 
and yield. The intent is to develop an optimized process, 
on the bench, that will efficiently scale-up to meet full-
scale manufacturing expectations.
Sequence  Purpose
1.   TMP Excursion at Initial Concentration 
(Cb initial)
↓
• Determine TMP for UF/DF
• Determine Feed Flow (QF) for UF/DF
• Demonstrate Flux Stability
• Confirm Retention of Product
2.   Concentration / Volume Reduction  
(Cb initial → Cb final)
↓
• Determine Flux as Function of Concentration
• Determine Placement of Diafiltration Step
• Determine Flux as Function of Buffer Conditions
3.   TMP Excursion at Final Concentration 
(Cb final)
↓
• Determine TMP for UF/DF
• Determine Feed Flow (QF) for UF/DF
• Confirm Retention of Product
4.   Diafiltration / Buffer Exchange
↓
• Determine Diavolume Requirement
• Confirm Retention of Product during DF
5.   Product Recovery • Crude Assessment of Step Yield
• Product Quality Evaluation
Figure 1. Basic Optimization Experiments
Use this step-by-step guide to develop a robust UF/
DF process with Pellicon® cassettes (cutoffs of 100 kD 
and lower) that will deliver superior product quality, 
reproducible results, and high yields.
Application Note
A Hands-On Guide to Ultrafiltration/
Diafiltration Optimization using  
Pellicon® Cassettes
EMD Millipore is a division of Merck KGaA, Darmstadt, Germany
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The following are step-by-step protocols for basic optimization experiments.
Set-up and Installation Procedure
Refer to the Maintenance Procedures for Pellicon® and  
Pellicon® 2 Cassette Filters (P17512) or the Pellicon® 3 Filters 
Installation and User Guide (AN1065EN00) when performing 
actual set-up and installation of Pellicon® cassettes. 
1. Assemble the TFF system as shown in Figure 2.
2. Install the Pellicon® cassette(s) (Pellicon® 2 Mini 
with 0.1 m2 membrane area, Pellicon® 3 with 0.11 m2 
membrane area) in the appropriate Pellicon® holder.
3. Flush the system with water, clean with the 
appropriate cleaning agent (per appropriate 



















1. Add 3 L/m2 of the appropriate buffer to the feed tank.
Example:  0.1 m2 membrane area x 3 L/m2 = 0.3 L buffer
2. Direct the retentate and permeate to a waste container.
3. Start the feed pump and achieve the following 
conditions by partially closing the retentate valve and 
adjusting the pump speed:
 – Feed flow of 5 L/min/m2
 – Retentate pressure of 2 – 15 psi (0.14 – 1.03 bar) to 
achieve approximately 30% conversion 
4. When half the buffer has been flushed, put the system 
in total recycle mode 1 and recirculate for 10 minutes; 
verify that the pH and conductivity in the system have 
been equilibrated to the level of the starting buffer.
5. Direct the retentate and permeate to a waste 
container.
6. When the feed tank level reaches the minimum level, 
open the retentate valve fully and stop the feed pump 
to prevent the introduction of air into the system.
Part 1. TMP Excursion at Initial Concentration
1. Add sufficient volume of product to the feed reservoir 
such that final volume or concentration target can be 
reached or slightly exceeded (approximately 1 – 1.5 L  
of final product at final concentration per m2). 
Example:  if Cinitial = 10 g/L and Cretentate = 80 g/L, 
then the concentration factor is 8X. If the minimum 
achievable final volume for 0.1 m2 is 0.1 L, calculate the 
required initial volume: 
Vinitial  =  Vminimum  x  VCF =  0.1 L  x  8X  =  0.8 L
2. Open the retentate valve fully and configure system in 
total recycle mode.
3. Start the feed pump and achieve the following 
conditions by partially closing the retentate valve  
and adjusting the pump speed:
 – Recommended feed flow (QF) rate for the membrane 
device, typically 5 L/min/m2 for Pellicon® 2 and 3 
cassettes
 – Minimal TMP, typically 2 – 5 psi (0.14 – 0.34 bar) for 
more open membranes and 10 psi (0.69 bar) for 
tighter membranes.
4. Recirculate the product for 10 – 15 minutes and ensure 
that stable process flux is achieved 2 . 
5. Record temperatures, pressures, and flows; sample 
feed and permeate for product retention 3 . 
6. Increase TMP by 5 – 10 psid (0.34 – 0.69 bar)  by 
manipulating the retentate valve while keeping the feed 
flow constant. For more open membranes increase by 
2 – 5 psid (0.14 – 0.34 bar). Repeat steps 4 and 5.
7. Repeat step 6 until flux begins to level off4;  
typically 4 – 6 TMP values are evaluated in total.
8. Open the retentate valve fully and allow system to 
continue in a total recycle.
9. Increase or decrease the feed flow by 2 – 3 L/min/m2 
and repeat steps 4 through 8. If desired, a third feed 
flow rate can be investigated.
10. Plot the data as shown in Figure 3.
Tight membranes (1 kD, 5 kD, etc.) Can use large TMP increases since optimum is typically > 30 psi
Open membranes (50 kD, 100 kD, etc.) Can use small TMP increases since optimum is typically < 10 psi
Figure 2. Schematic 
of a TFF System
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Q1 = 5 L/min/m2 Q2 = 3 L/min/m2 Q1/Q2
A [m2] Volume / Time / 150 LMH Volume / Time / 86 LMH 0.57
QF [L/min] (5 L/min/m2) x Volume / Time / 150 LMH (3 L/min/m2) x Volume / Time / 86 LMH 0.95
Calculations
The appropriate combination of feed flow rate and 
TMP will maximize flux while minimizing the impact of 
pumping and shear on the product. The appropriate 
combination of these two parameters will also minimize 
processing time and/or membrane area. To calculate the 
optimum feed flow, compare the required membrane area 
with the required pump rate at each of the two feed flow 
conditions, as shown in Table 1.
 Membrane Area [m2]  =  
  Process Volume [L] / (Flux [LMH] x Process Time [h]) 
 In Figure 3: 
 AreaQ1  =  0.57  x  AreaQ2
 Pump feed rate [L/min]  =  
  Feed flux [L/min/m2]  x  Area [m2] 
 In Figure 3:  
 Pump feed rateQ1  =  0.95  x  Pump feed rateQ2
In this example it is advantageous to run at the higher  
feed flow, Q1, since it only requires 57% of the membrane 
area used at the lower feed flow rate at almost the 
identical pump feed rate.
Note: 
• Anticipated final volume of over-concentrated product must exceed 
minimum working volume of membrane system at selected feed flow rate 
(QF); avoid introduction of air and maintain uniform mixing at end of volume 
reduction.
• Move from least to greatest fouling conditions:
 – Do not test into pressure-independent regime (past the knee of the flux 
vs. TMP curve) 4 
 – Avoid exceeding 30 – 40% conversion ratios
• Check hysteresis if possible by returning the system to the initial conditions 
and taking a final flux measurement; compare initial flux performance to 
final flux performance at initial conditions.
• Ensure that choice of TMP and feed flow have corresponding retention 
values that are acceptable (> 0.998) at both initial and final product 
concentration and in each buffer 5 .
• There is often very little performance difference versus feed flow rate at low 
product concentration. However, at the higher concentrations that will be 
investigated in Parts 2 and 3, the benefits of different feed flow rates should 
become more pronounced.
Figure 3. 
TMP Excursion at  
Two Feed Flows
Table 1. Membrane  
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Optimum Point
TMP = 25 psid
Jf = 86 LMH
Optimum Point
TMP = 30 psid
Jf = 150 LMH
Feed Flux = 3 L/min/m2
Feed ∆P = 10 psid
Feed Flux = 5 L/min/m2
Feed ∆P = 20 psid
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Part 3. TMP Excursion at Final Concentration
1. Use the product from Part 2 at the final concentration in 
the final buffer.




Reference Part 1 and Part 2 notes.
Part 4. Diafiltration
1. Use the product from Part 3 at the optimum 
concentration for diafiltration; dilute as needed using 
the final buffer.
2. Configure the system for constant volume diafiltration.
3. Start the feed pump and achieve the optimum TMP and 
feed flow as determined in Part 1 and Part 3.
4. Diafilter the product with the chosen number of 
diavolumes:
 – Choose the number of diavolumes based on the 
product purity specifications (if known, see calculation 
below) and add a safety factor of 2 diavolumes, or
 – Use 3 – 5 diavolumes as an initial estimate  
for upstream UF/DF steps, or
 – Use 7 – 12 diavolumes as an initial estimate for  
final formulation UF/DF steps
5. Record temperatures, pressures, and flows at every 
diavolume; sample feed and permeate for both product 
retention, and retention and concentration of the 
contaminant of interest.






























The percentage of the original contaminant in the retentate 
at each diavolume can be calculated from the retention 
values using the following: 
 Remaining Contaminant [%]  =  100  x  e (Retention – 1) x N
where N is the number of diavolumes.
However, since contaminant concentration is being directly 
measured in each feed sample throughout diafiltration, plot 
these concentrations as a percentage of the original and 
use the above equation to plot several lines of theoretical 
retention, as shown in Figure 6. This plot will help demonstrate 
the contaminant removal at various retentions.
Select the whole number of diavolumes based on the 
acceptable contaminant levels for the product; always 
add 2 – 3 diavolumes as a 10-fold safety factor for critical 
diafiltration steps, such as final formulation. For upstream 
steps, add 1 – 2 diavolumes. If the goal of diafiltration is not 
to wash out a contaminant but rather to reach a target pH 
or conductivity, then the measurement of that quality can 
be plotted against the number of diavolumes instead.
Note:
• If it appears necessary to diafilter past ~ 14 
diavolumes, any dead-legs or poor mixing areas in 
the system will increase the apparent retention of the 
contaminant and make further removal difficult.
• Ensure that choice of TMP and feed flow have 
corresponding product retention values that are 
acceptable (> 0.998) throughout diafiltration.
Figure 6. contaminant 
removal vs. Diavolumes
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Paper Design and Process Simulation
The optimization parameters obtained from the previous 
experiments can be combined to design a full process 
simulation: concentration, diafiltration, (concentration,) 
and recovery. If time permits, a process simulation should 
be run immediately following the optimization work, and 
should employ the following:
• New set of cassettes; same membrane type,  
same cassette path length
• Fresh feedstock
• Fresh buffer(s)
• Optimized process parameters
• See detailed process simulation calculations below.
After performing the process simulation, the system 
should be cleaned with the appropriate solution according 
to EMD Millipore recommendations11. If possible, the 
process should be rerun using the cleaned membranes to 
determine the effectiveness of the cleaning cycle and the 
consistency of membrane performance from run-to-run. 
If the cleaning cycle does not prove effective, the cleaning 
parameters or cleaning solutions will need to be changed 
and the cleaning cycle will have to be tested again. 
Calculations
The membrane area can be optimized to allow the 
entire process (both concentration and diafiltration) to 
be completed in the specified timeframe (3 – 4 hours is 
recommended). The average flux for each concentration  
and diafiltration step can be estimated from the 
optimization data and combined with the desired volumes 
to be processed. The approximate required membrane 
area can then be calculated for both manufacturing scale 
and scale-down runs.
Assume an example process scenario (this would have 
been determined by optimization data, DF parameter, etc.):
• 2.9X Concentration:  
10 g/L to 29 g/L; flux decreases from 150 LMH to 80 LMH
• 7X Diafiltration:  
29 g/L; flux increases from 80 LMH to 85 LMH
• 3.4X Concentration:  
29 g/L to 100 g/L; flux decreases from 85 LMH to 20 LMH
• Desired process time is 4 hours
Manufacturing scale volumes as determined by the 
customer:
• Feed volume  = 5000 L
• Retentate volume at end of 2.9X concentration  =  
5000 L/2.9  =  1724 L
• Permeate volume removed during 2.9X concentration = 
5000 L – 1724 L  =  3276 L
• 7X Diafiltration buffer volume  =  7  x  1724 L = 12,068 L
• Retentate volume at end of 3.4X Concentration  =  
1724 L/3.4  = 507 L
• Permeate volume removed during 3.4X concentration  = 
1724 L – 507 L  = 1217 L
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Average process flux for concentration step13:
 Javg =  Jfinal + 0.33 (Jinitial – Jfinal)  =  Jinitial  x  0.33 + Jfinal  x  0.67
For 2.9X concentration:  
 Javg =  150 LMH  x  0.33 + 80 LMH  x  0.67 = 103 LMH
For 3.4X concentration:  
 Javg =  85 LMH  x  0.33 + 20 LMH  x  0.67 = 41 LMH
Average process flux for diafiltration step: 
For diafiltration the average flux can be estimated as the 
initial and final process flux during the diafiltration step.
Required area:
 Area = [(Permeate volume/Average flux) Concentration +  (Permeate volume/Average flux) Diafiltration + … ]  / Time
In this example:  
 Area = [(3,276 L/103 LMH) + (12,068 L/83 LMH) + (1,217 L/41 LMH)]  / 4 hours =  51.6 m2
Add 20% safety factor:  
 Area = 62 m2
To perform a scale-down process simulation, the same 
volume to area ratio is used and scaled based on either the 
feed volume that can be used for the simulation or the area 
of the desired filtration device. For example, if the process 
is to be performed on one Pellicon® 2 Mini cassette (with 
an area of 0.1 m2), then the required feed volume will be:
 Scale-down feed volume  =  0.1 m2  x  (5000 L/62 m2)  =  8 L
Instead, if there is a specific volume of feedstock to process 
(example: 25 L), then the required membrane area will be:
 Scale-down membrane area  =  25 L  x  (62 m2/5000 L)  =  0.3 m2
The process parameters, including Pellicon® device type, 
should be consistent between scales, allowing the process 
to be completed in a similar timeframe with similar fluxes, 
pressures and loadings. The concentration factors, number 
of diavolumes and feed quality should be kept consistent 
at all scales to ensure robust scalability. However, to 
demonstrate process robustness and repeatability, the 
process should be tested at pilot scale before proceeding to 
manufacturing.
Efficient fluid transfer in  
high-volume applications
Masterflex B/T process pump systems offer rugged 
design and improved performance. They handle 
the toughest applications, from pumping slurries, 
abrasives, food additives, and media, to corrosive 
fluids and polymers. Designed to be used with the 
unique PerfectPosition® tubing, these complete 
systems ensure reliable, continuous-duty pumping 
with unparalleled ease of use.














– Cast-aluminum housing with epoxy-powder coating eliminates corrosion
– Robust gear reducer provides continuous-duty operation
– Simple latching mechanism allows easy opening and closing without the use of tools 
Easy Tube Loading
– Enhanced tubing retention secures tubing firmly in place during loading process
– Revolutionary PerfectPosition® tubing features graduated markings for foolproof tubing alignment
– No need for extra fittings (potential sources of contamination)—use a single tube length from 
source to delivery point
Improved Performance
– Rotor and occlusion bed design prevents “tubing roll” during operation, extending tubing life
– Housing design eliminates any chance of over- or under-squeezing the tubing in the pump head 
– PerfectPosition® tubing retention marks make it easy to determine exactly where to load the 
tubing to achieve optimal performance with minimal tubing wear
Enhanced Safety 
– Integrated pump interlock shuts unit down when the head is opened
– Rugged housing with window protects user from moving internal  
components—yet shows operator pump is working
1-800-637-3739 | 1-847-381-7050
Masterflex.com
–  PerfectPosition retention marks make it easy  
to load tubing to achieve optimal performance
–  Tubing sizes ensure fully rated performance 
under higher pressure applications
*Determined under the following conditions: 0 psi at inlet, 0.5 psi at  
outlet; water temperature at 72°F (22°C).
†Actual performance varies depending on tubing formulation— 




B/T 87 B/T 91
Inside diameter (nominal) 0.5" (12.7 mm) 0.75" (19.0 mm)
Hose barb size 1⁄2" (12.7 mm) 3⁄4" (19.0 mm)
Flow range (approximate)* 0.67 to 18.9 LPM 1.4 to 42 LPM
with 12 to 321 rpm drive (0.17 to 5.0 GPM) (0.4 to 11.1 GPM)
Maximum pressure† 35 psi (2.4 bar) 30 psi (2.1 bar)
Maximum vacuum† 26" Hg (660 mm Hg)
Suction lift† 29 ft H2O (8.8 m H2O)
B/T 87 B/T 91
Masterflex® B/T® vs  
Watson-Marlow 700 Series*
*Watson-Marlow is a trademark of Watson-Marlow Limited.
Tubing size
Tubing formulation Description B/T 87 B/T 91
Silicone  
(platinum-cured)
• Smooth surface; low protein binding levels
• Fungus-resistant; phthalate- and latex-free
 • Accommodates a wide temperature range 
MK-96510-87 MK-96510-91
3 m (10 ft)/pk 3 m (10 ft)/pk
Silicone  
(peroxide-cured)
•  Smooth surface for minimal particle 
entrapment
•  Very low extractables, with documented 
biocompatibility for sensitive applications
MK-96400-87 MK-96400-91
3 m (10 ft)/pk 3 m (10 ft)/pk
BioPharm Plus  
Silicone  
(platinum-cured)
•  Very low extractable; biocompatible for 
sensitive applications
•  Longest tubing life of any silicone  
pump tubing
•  Lower spallation than regular silicone
MK-96445-87 MK-96445-91
3 m (10 ft)/pk 3 m (10 ft)/pk
Puri-Flex™  • Heat sealable, weldable, and economical
•  Long pump life when compared to silicone 
or many other TPE tubings
MK-96419-87 MK-96419-91
3 m (10 ft)/pk 3 m (10 ft)/pk
C-Flex® • Heat sealable, weldable, economical
 • Longest life of any C-Flex formulation
 • Better resistance to pH fluctuations
MK-06424-87 MK-06424-91
3 m (10 ft)/pk 3 m (10 ft)/pk
PharMed® BPT • Over 10,000 hours of tubing life
• Resists ozone and UV radiation
•  Ideal for tissue and cell culture work
MK-06507-87 MK-06507-91
3 m (10 ft)/pk 3 m (10 ft)/pk
PharmaPure® • Nontoxic and nonhemolytic
• Great for tissue and cell work
•  Low extractables and gas permeability
MK-06437-87 MK-06437-91
3 m (10 ft)/pk 3 m (10 ft)/pk
Chem-Durance® Bio  • Excellent chemical resistance
• Plasticizer-free inner liner
 • Excellent biocompatibility
MK-06443-87 MK-06443-91
3 m (10 ft)/pk 3 m (10 ft)/pk
Tygon® E-LFL  • Longest life of all Tygon formulations
•  USP Class VI, EU Pharmacopoeia 3.2.9, 
FDA 21
MK-06440-87 MK-06440-91
3 m (10 ft)/pk 3 m (10 ft)/pk
Tygon® E-Food  
(B-44-4X)
•  Complies with FDA, NSF, 3A, and  
EU food regulations
•  Smooth inner surface unaffected by 
common commercial sanitizers
MK-06418-87 MK-06418-91
3 m (10 ft)/pk 3 m (10 ft)/pk
Norprene® Food  
(A-60-F)
•  Ideal for high-temperature food 
applications
•  Resists heat, ozone, acids, and alkalies
•  Complies with FDA and NSF food 
regulations
MK-06399-87 MK-06399-91
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B/T® Pump Heads 
Analog Digital Specialty
Description Fixed-speed Variable-speed Modular dispensing Air-powered
Flow range 18.9 or 42 LPM 16 or 35 LPM 0.71 to 42 LPM 0.71 to 42 LPM 2.1 to 42 LPM
Motor size 1 hp (0.75 kW) 1⁄2 hp (0.37 kW) 3⁄4 hp (0.56 kW) 3⁄4 hp (0.56 kW)
rpm 321 271 12 to 321 12 to 321 35 to 321
IP rating IP55 IP56 IP56 IP56
Power  
(VAC, Hz) 115 (60) 230 (50) 115 (50/60) 230 (50/60)
90 to 130  
(50/60)
190 to 260  
(50/60)
Requires 24 cfm (0.68 m3)  
100 psi (6.9 bar) minimum
Amps 12.6 6.3 5 2.5 10.5 5.7 —
Catalog number MK-77111-30 MK-77111-37 MK-77111-60 MK-77111-67 MK-77111-70 MK-77111-77 MK-77111-80
Motor mount NEMA Type 56C IEC 72/ISO 71 with B5 flange
Mounting type Direct-coupled
Motor size
Depends on specifications of type of 
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D.  Material  Safety  Data  Sheets  
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Trade Name or Designation:
Product Number:





1.2. Recommended Use and Restrictions on Use
General Laboratory Reagent
1.3. Details of the Supplier of the Safety Data Sheet
Reagents Inc.
4746 Sweden Road














P264, P270, P301+P310, P321, P330, P405, 
P501
H301Category 3Acute Toxicity - Oral
P260, P264, P280, P301+P330+P331, 
P303+P361+P353, P363, P304+P340, P310, 
P321, P305+P351+P338, P405, P501
H314Category 1Skin Corrosion / Irritation
P280, P305+P351+P338, P310H318Category 1Eye Damage / Irritation
P201, P202, P280, P308+P313, P405, P501H361Category 2Reproductive Toxicity
P260, P264, P270, P308+P311, P405, P501H371Category 2Specific Target Organs/Systemic Toxicity Following Single 
Exposure
P234, P390, P406H290Category 1Corrosive to Metals
For the full text of the Hazard and Precautionary Statements listed below, see Section 16.
2.1. Classification of the Substance or Mixture (in accordance with OSHA HCS 29 CFR 1910.1200)
  SECTION 2: Hazard(s) Identification
Product Number: 2-21660 Page 1 of 11
Safety Data Sheet
2.2. GHS Label Elements
Pictograms:
Signal Word:  Danger
Hazard Statements:
Hazard Number Hazard Statement
H290 May be corrosive to metals.
H301 Toxic if swallowed.
H314 Causes severe skin burns and eye damage.
H318 Causes serious eye damage.
H361 Suspected of damaging fertility or the unborn child.
H371 May cause damage to organs.




P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P234 Keep only in original container.
P260 Do not breathe dust, fumes or mist.
P264 Wash arms, hands and face thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves and eye protection.
P301+P310 IF SWALLOWED: Immediately call a POISON CENTER or physician.
P301+P330+P331 IF SWALLOWED: rinse mouth. Do NOT induce vomiting.
P303+P361+P353 IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water.
P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to 
do. Continue rinsing.
P308+P311 IF exposed or concerned: Call a POISON CENTER or physician.
P308+P313 IF exposed or concerned: Get medical attention.
P310 Immediately call a POISON CENTER or physician.
P321 Specific treatment (Wash areas of contact with water).
P330 Rinse mouth.
P363 Wash contaminated clothing before reuse.
P390 Absorb spillage to prevent material damage.
P405 Store locked up.
P406 Store in corrosive resistant container with a resistant inner liner.
P501 Dispose of contents in accordance with local, state, federal and international regulations.
2.3. WHMIS Classification
WHMIS classification is not included based on the recommended option (Option 4) found in the Canada Gazette Part II, Vol. 149, No.3, page 458
2.4. Hazards not Otherwise Classified or Covered by GHS
Data not available.
  SECTION 3: Composition / Information on Ingredients
3.1. Components of Substance or Mixture
Chemical Name Formula Molecular Weight CAS Number Weight%
Imidazole NHCH:NCH:CH 68.07 g/mol 288-32-4 100.00%
Product Number: 2-21660 Page 3 of 11
Safety Data Sheet
Eye Contact:
  SECTION 4: First-Aid Measures
4.1. General First Aid Information
IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue 
rinsing.
Inhalation: Not expected to require first aid. If necessary, remove to fresh air.
Skin Contact: IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water.
Ingestion: IF SWALLOWED: rinse mouth. Do NOT induce vomiting.
4.2. Most Important Symptoms and Effects, Acute and Delayed
May cause mild irritation to areas of contact.
4.3. Medical Attention or Special Treatment Needed
Immediately call a POISON CENTER or physician. Specific treatment (Wash areas of contact with water).
5.1. Extinguishing Media
Not considered to be a fire or explosion hazard.
  SECTION 5: Fire-Fighting Measures
5.2. Specific Hazards Arising from the Substance or Mixture
Not considered to be a fire or explosion hazard.
5.3. Special Protective Equipment for Firefighters
Wear protective clothing and NIOSH-approved breathing equipment appropriate for the surrounding fire.
6.1. Personal Precautions, Protective Equipment and Emergency Procedures
Wear protective gloves and eye protection.
  SECTION 6: Accidental Release Measures
6.2. Cleanup and Containment Methods and Materials
Absorb with suitable material and dispose of in accordance with local regulations.
7.1. Precautions for Safe Handling and Storage Conditions
Store in corrosive resistant container with a resistant inner liner.
  SECTION 7: Handling and Storage
Product Number: 2-21660 Page 4 of 11
Safety Data Sheet
8.1. Control Parameters
Chemical Name Country Exposure LimitLimit Type Information Source
Data not available. ()
  SECTION 8: Exposure Controls / Personal Protection
8.2. Exposure Controls
Engineering Controls: No specific controls are needed. Normal room ventilation is adequate.
Respiratory Protection: No specific controls are needed. Normal room ventilation is adequate
Skin Protection: Wear protective gloves and eye protection.
Eye Protection: Wear protective gloves and eye protection.
8.3. Personal Protective Equipment
Wear protective gloves and eye protection.








633 G/L at 20°C
1.03
Data not available.
































9.1. Basic Physical and Chemical Properties
  SECTION 9: Physical and Chemical Properties
10.1. Reactivity and Chemical Stability
Stable under normal conditions of use and storage.
  SECTION 10: Stability and Reactivity
10.2. Possibility of Hazardous Reactions
Data not available.
10.3. Conditions to Avoid and Incompatible Materials
Keep only in original container.
10.4. Hazardous Decomposition Products
May emit irritating fumes when heated to decomposition.
Product Number: 2-21660 Page 6 of 11
Safety Data Sheet
Acute Toxicity - Oral Exposure:
Toxic if swallowed. Wash arms, hands and face thoroughly after handling. Do not eat, drink or smoke when using this product.  IF 
SWALLOWED: Immediately call a POISON CENTER or physician. Specific treatment (Wash areas of contact with water). Rinse mouth.  Store 
locked up.  Dispose of contents in accordance with local, state, federal and international regulations.
11.1. Information on Toxicological Effects
  SECTION 11: Toxicological Information
Acute Toxicity - Dermal Exposure:
Not applicable.
Acute Toxicity - Inhalation Exposure:
Not applicable.
Acute Toxicity - Other Information:
Data not available.
Skin Corrosion and Irritation:
Causes severe skin burns and eye damage. Do not breathe dust, fumes or mist. Wash arms, hands and face thoroughly after handling. Wear 
protective gloves and eye protection.  IF SWALLOWED: rinse mouth. Do NOT induce vomiting. IF ON SKIN (or hair): Take off immediately all 
contaminated clothing. Rinse skin with water. Wash contaminated clothing before reuse. IF INHALED: Remove person to fresh air and keep 
comfortable for breathing. Immediately call a POISON CENTER or physician. Specific treatment (Wash areas of contact with water). IF IN 
EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.  Store locked up.  
Dispose of contents in accordance with local, state, federal and international regulations.
Serious Eye Damage and Irritation:
Causes serious eye damage. Wear protective gloves and eye protection.  IF IN EYES: Rinse cautiously with water for several minutes. Remove 










Suspected of damaging fertility or the unborn child. Obtain special instructions before use. Do not handle until all safety precautions have been 
read and understood. Wear protective gloves and eye protection.  IF exposed or concerned: Get medical attention.  Store locked up.  Dispose 
of contents in accordance with local, state, federal and international regulations.
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Specific Target Organ Toxicity from Single Exposure:
May cause damage to organs. Do not breathe dust, fumes or mist. Wash arms, hands and face thoroughly after handling. Do not eat, drink or 
smoke when using this product.  IF exposed or concerned: Call a POISON CENTER or physician.  Store locked up.  Dispose of contents in 
accordance with local, state, federal and international regulations.








  SECTION 12: Ecological Information




12.4. Mobility in Soil
Data not available.
12.5. Other Adverse Ecological Effects
Data not available.
13.1. Waste Treatment Methods
Data not available.
  SECTION 13: Disposal Considerations










14.1. Transportation by Land - Department of Transportation (DOT, United States of America)
  SECTION 14: Transportation Information
III
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14.2. Transportation by Air - International Air Transport Association (IATA)
15.1. Occupational Safety and Health Administration (OSHA) Hazards
Not listed.
  SECTION 15: Regulatory Information
15.2. Superfund Amendments and Reauthorization Act (SARA) 302 Extremely Hazardous Substances
Not listed.
15.3. Superfund Amendments and Reauthorization Act (SARA) 311/312 Hazardous Chemicals
Not listed.
15.4. Superfund Amendments and Reauthorization Act (SARA) 313 Toxic Release Inventory (TRI)
Not listed.
15.5. Massachusetts Right-to-Know Substance List
Not listed.
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15.6. Pennsylvania Right-to-Know Hazardous Substances
Not listed.
15.7. New Jersey Worker and Community Right-to-Know Components
Not listed.
15.8. California Proposition 65
Not listed.
15.9. Canada Domestic Substances List / Non-Domestic Substances List (DSL/NDSL)
Imidazole (CAS # 288-32-4): Present
15.10. United States of America Toxic Substances Control Act (TSCA) List
Imidazole (CAS # 288-32-4): Present
15.11. European Inventory of Existing Commercial Chemical Substances (EINECS), 
European List of Notified Chemical Substances (ELINCS), and No Longer Polymers (NLP)
Not listed.
  SECTION 16: Other Information
16.1. Full Text of Hazard Statements and Precautionary Statements
May be corrosive to metals. Toxic if swallowed. Causes severe skin burns and eye damage. Causes serious eye damage. Suspected of damaging 
fertility or the unborn child. May cause damage to organs. 
Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Keep only in original container. Do 
not breathe dust, fumes or mist. Wash arms, hands and face thoroughly after handling. Do not eat, drink or smoke when using this product. Wear 
protective gloves and eye protection.
IF SWALLOWED: Immediately call a POISON CENTER or physician. IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse 
skin with water. IF INHALED: Remove person to fresh air and keep comfortable for breathing. IF IN EYES: Rinse cautiously with water for several 
minutes. Remove contact lenses, if present and easy to do. Continue rinsing. IF exposed or concerned: Call a POISON CENTER or physician. 
Specific treatment (Wash areas of contact with water). Wash contaminated clothing before reuse. Absorb spillage to prevent material damage.
Store locked up. Store in corrosive resistant container with a resistant inner liner.
Dispose of contents in accordance with local, state, federal and international regulations.
Product Number: 2-21660 Page 10 of 11
Safety Data Sheet




Not Applicable.Canadian Carcinogenicity Hazard Class:
Physical Hazards Not Otherwise Classified (PHNOC):
Health Hazards Not Otherwise Classified (HHNOC):
Biohazardous Infectious Materials Hazard Class:










Last Revision Date: 8/31/2015
  DISCLAIMER
When handled properly by qualified personnel, the product described herein does not present a significant health or safety hazard. Alteration of its 
characteristics by concentration, evaporation, addition of other substances, or other means may present hazards not specifically addressed herein and which 
must be evaluated by the user. The information furnished herein is believed to be accurate and represents the best data currently available to us. No warranty, 
expressed or implied, is made and REAGENTS, INC. assumes no legal responsibility or liability whatsoever resulting from its use.
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Trade Name or Designation:
Product Number:
Other Identifying Product Numbers:
Sodium Phosphate Dibasic Heptahydrate, ACS Reagent Grade
(Disodium Hydrogen Phosphate Heptahydrate)
1-32400
1-32400-1, 1-32400-3, 1-32400-5
1.2. Recommended Use and Restrictions on Use
General Laboratory Reagent
1.3. Details of the Supplier of the Safety Data Sheet
Reagents Inc.
4746 Sweden Road










  SECTION 1: Identification
For the full text of the Hazard and Precautionary Statements listed below, see Section 16.
2.1. Classification of the Substance or Mixture (in accordance with OSHA HCS 29 CFR 1910.1200)
This product is not categorized as hazardous in any GHS hazard class.
  SECTION 2: Hazard(s) Identification
2.2. GHS Label Elements
Pictograms: None required.
Signal Word:  None required.
Hazard Statements: None required.
Precautionary Statements: None required.
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2.3. WHMIS Classification
WHMIS classification is not included based on the recommended option (Option 4) found in the Canada Gazette Part II, Vol. 149, No.3, page 458
2.4. Hazards not Otherwise Classified or Covered by GHS
Data not available.
  SECTION 3: Composition / Information on Ingredients
3.1. Components of Substance or Mixture
Chemical Name Formula Molecular Weight CAS Number Weight%
Sodium Phosphate, Dibasic, Heptahydrate Na₂HPO₄·7H₂O Data not available. 7782-85-6 100.00%
Eye Contact:
  SECTION 4: First-Aid Measures
4.1. General First Aid Information
May cause irritation, redness, pain, and tearing.
Inhalation: Not expected to require first aid. If necessary, remove to fresh air.
Skin Contact: May cause slight irritation to those allergic to phosphates.
Ingestion: Dilute with water or milk. Do not induce vomiting.  Call a physician if necessary.
4.2. Most Important Symptoms and Effects, Acute and Delayed
May cause irritation to the eyes and skin. Wash areas of contact with water. Call a physician if irritation develops. Does not present any significant 
health hazards. May be harmful if swallowed or inhaled. 
 EYE CONTACT: May cause irritation, redness, pain, and tearing. SKIN CONTACT: May cause slight irritation to those allergic to phosphates. 
CHRONIC EFFECTS / CARCINOGENICITY: May sequester calcium and cause calcium phosphate deposits in the kidneys.
4.3. Medical Attention or Special Treatment Needed
Not expected to require special treatment.
5.1. Extinguishing Media
Use any means suitable for extinguishing surrounding fire.
  SECTION 5: Fire-Fighting Measures
5.2. Specific Hazards Arising from the Substance or Mixture
Not considered to be a fire or explosion hazard.
5.3. Special Protective Equipment for Firefighters
Use protective clothing and breathing equipment appropriate for the surrounding fire.
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6.1. Personal Precautions, Protective Equipment and Emergency Procedures
Wear appropriate PPE for the size and nature of the spill. As a general rule, wear safety glasses and gloves.
  SECTION 6: Accidental Release Measures
6.2. Cleanup and Containment Methods and Materials
Pick up in a manner that does not generate dust. Powder may be moistened with water to aid in the clean-up.
7.1. Precautions for Safe Handling and Storage Conditions
As with all chemicals, wash hands thoroughly after handling. Avoid contact with eyes and skin. Protect from physical damage. Keep in tightly closed 
containers in a cool, dry area.
  SECTION 7: Handling and Storage
  SECTION 8: Exposure Controls / Personal Protection
8.2. Exposure Controls
Engineering Controls: No specific controls are needed. Normal room ventilation is adequate.
Respiratory Protection: Normal room ventilation is adequate.
Skin Protection: Chemical resistant gloves.
Eye Protection: Safety glasses or goggles.
8.3. Personal Protective Equipment
 Normal room ventilation is adequate. Chemical resistant gloves. Safety glasses or goggles.











































9.1. Basic Physical and Chemical Properties
  SECTION 9: Physical and Chemical Properties
10.1. Reactivity and Chemical Stability
Stable under normal conditions of use and storage.
  SECTION 10: Stability and Reactivity
10.2. Possibility of Hazardous Reactions
Data not available.
10.3. Conditions to Avoid and Incompatible Materials
Reactive with acids, alkalis.
10.4. Hazardous Decomposition Products
Will not occur.
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Acute Toxicity - Oral Exposure:
Not applicable.
11.1. Information on Toxicological Effects
  SECTION 11: Toxicological Information
Acute Toxicity - Dermal Exposure:
Not applicable.
Acute Toxicity - Inhalation Exposure:
Not applicable.
Acute Toxicity - Other Information:
LD50, Oral, Rat: (Sodium Phosphate, Dibasic, Heptahydrate) 12.93 g/kg, details of toxic effects not reported other than lethal dose value.
Skin Corrosion and Irritation:
Not applicable.












Specific Target Organ Toxicity from Single Exposure:
Not applicable.










  SECTION 12: Ecological Information




12.4. Mobility in Soil
Data not available.
12.5. Other Adverse Ecological Effects
Data not available.
13.1. Waste Treatment Methods
Data not available.
  SECTION 13: Disposal Considerations
14.1. Transportation by Land - Department of Transportation (DOT, United States of America)
  SECTION 14: Transportation Information
Not regulated according to DOT Regulations.







14.2. Transportation by Air - International Air Transport Association (IATA)
15.1. Occupational Safety and Health Administration (OSHA) Hazards
Not listed.
  SECTION 15: Regulatory Information
15.2. Superfund Amendments and Reauthorization Act (SARA) 302 Extremely Hazardous Substances
Not listed.
15.3. Superfund Amendments and Reauthorization Act (SARA) 311/312 Hazardous Chemicals
Sodium Phosphate, Dibasic, Heptahydrate (CAS # 7782-85-6): 5000 lb final RQ; 2270 kg final RQ
15.4. Superfund Amendments and Reauthorization Act (SARA) 313 Toxic Release Inventory (TRI)
Not listed.
15.5. Massachusetts Right-to-Know Substance List
Sodium Phosphate, Dibasic, Heptahydrate (CAS # 7782-85-6): Present
15.6. Pennsylvania Right-to-Know Hazardous Substances
Sodium Phosphate, Dibasic, Heptahydrate (CAS # 7782-85-6): Environmental hazard
Sodium Phosphate, Dibasic, Heptahydrate (CAS # 7782-85-6): Present
15.7. New Jersey Worker and Community Right-to-Know Components
Sodium Phosphate, Dibasic, Heptahydrate (CAS # 7782-85-6): sn 1723
15.8. California Proposition 65
Not listed.
15.9. Canada Domestic Substances List / Non-Domestic Substances List (DSL/NDSL)
Sodium Phosphate, Dibasic, Heptahydrate (CAS # 7782-85-6): Present
15.10. United States of America Toxic Substances Control Act (TSCA) List
Sodium Phosphate, Dibasic, Heptahydrate (CAS # 7782-85-6): Present
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15.11. European Inventory of Existing Commercial Chemical Substances (EINECS), 
European List of Notified Chemical Substances (ELINCS), and No Longer Polymers (NLP)
Not listed.
  SECTION 16: Other Information
16.1. Full Text of Hazard Statements and Precautionary Statements




Not Applicable.Canadian Carcinogenicity Hazard Class:
Physical Hazards Not Otherwise Classified (PHNOC):
Health Hazards Not Otherwise Classified (HHNOC):
Biohazardous Infectious Materials Hazard Class:










Last Revision Date: 8/31/2015
  DISCLAIMER
When handled properly by qualified personnel, the product described herein does not present a significant health or safety hazard. Alteration of its 
characteristics by concentration, evaporation, addition of other substances, or other means may present hazards not specifically addressed herein and which 
must be evaluated by the user. The information furnished herein is believed to be accurate and represents the best data currently available to us. No warranty, 
expressed or implied, is made and REAGENTS, INC. assumes no legal responsibility or liability whatsoever resulting from its use.
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Date of Issue:  
19 February 2019 
 
SAFETY DATA SHEET 
 
1. SUBSTANCE AND SOURCE IDENTIFICATION  
Product Identifier 
SRM Number: 723e 
SRM Name: Tris(hydroxymethyl)aminomethane (HOCH2)3CNH2 Acidimetric Standard 
Other Means of Identification:  Not applicable. 
Recommended Use of This Material and Restrictions of Use 
This Standard Reference Material (SRM) consists of highly purified tris(hydroxymethyl)aminomethane 
(HOCH2)3CNH2 [2-amino-2-(hydroxymethyl)-1,3-propanediol; “Tris”; “THAM”], hereafter referred to as Tris.  
SRM 723e is intended primarily for use in acidimetric standardization.  A unit of SRM 723e consists of 50 g in a 
clear glass bottle. 
Company Information 
National Institute of Standards and Technology  
Standard Reference Materials Program  
100 Bureau Drive, Stop 2300  
Gaithersburg, Maryland 20899-2300  
  
Telephone:  301-975-2200 Emergency Telephone ChemTrec: 
FAX:  301-948-3730  1-800-424-9300 (North America) 
E-mail:  SRMMSDS@nist.gov  +1-703-527-3887 (International) 
Website:  https://www.nist.gov/srm  
 
2. HAZARDS IDENTIFICATION 
Classification  
Physical Hazard: Not classified. 
Health Hazard: Skin Corrosion/Irritation Category 2 
 Serious Eye damage/Eye irritation Category 2A 








H315 Causes skin irritation. 
H319 Causes serious eye irritation. 
H335 May cause respiratory irritation. 
Precautionary Statement(s): 
P261 Avoid breathing dust. 
P264 Wash hands thoroughly after handling. 
P271 Use only outdoors or in a well-ventilated area. 
P280 Wear protective gloves. 
P302+P352 If on skin: Wash with plenty of water. 
P304+P340 If inhaled: Remove person to fresh air and keep comfortable for breathing. 
P305+P351+P338 If in eyes: Rinse cautiously with water for several minutes.  Remove contact lenses, if present 
and easy to do.  Continue rinsing. 
P322+P364 Take off contaminated clothing and wash it before reuse. 
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P332+P337+P313 If skin or eye irritation occurs: Get medical attention. 
P403+P233 Store in a well-ventilated place.  Keep container tightly closed. 
P405 Store locked up. 
P501 Dispose of contents and containers in accordance with all applicable regulations. 
Hazards Not Otherwise Classified:  Not applicable. 
Ingredients(s) with Unknown Acute Toxicity:  Not applicable. 
3. COMPOSITION AND INFORMATION ON HAZARDOUS INGREDIENTS 
Substance: Tris(hydroxymethyl)aminomethane 
Other Designations:  Tris [tris buffering agent; trishydroxymentylaminomethane; tris(methylolamino)methane; 1,1,1 
tris(hydroxymethyl)methanamine; tris(hydroxymethyl)methylamine; tris(hydroxymethyl)methanamine] 
Components are listed in compliance with OSHA’s 29 CFR 1910.1200; for the actual values see the Certificate of 
Analysis. 
Hazardous Component(s) CAS Number EC Number 
(EINECS) 
Nominal Mass Concentration  
(%) 
Tris(hydroxymethyl)aminomethane 77-86-1 201-064-4 100 
 
4. FIRST AID MEASURES 
Description of First Aid Measures:  
Inhalation:  If adverse effects occur, remove to uncontaminated area.  If not breathing, give artificial respiration 
or oxygen by qualified personnel.  Seek immediate medical attention. 
Skin Contact:  Wash skin with soap and water for at least 15 minutes.  Thoroughly clean and dry contaminated 
clothing before reuse. 
Eye Contact:  Flush eyes with water for at least 15 minutes.  If necessary, seek medical attention. 
Ingestion:  If a large amount is swallowed, get medical attention. 
Most Important Symptoms/Effects, Acute and Delayed:  Skin, eye, and possible respiratory irritation.  
Indication of any immediate medical attention and special treatment needed, if necessary:  If any of the above 
symptoms are present, seek medical attention if needed. 
5. FIRE FIGHTING MEASURES 
Fire and Explosion Hazards:  Negligible fire hazard.  See Section 9, “Physical and Chemical Properties” for 
flammability properties. 
Extinguishing Media: 
 Suitable:  Regular dry chemical, dry sand, water, and regular foam. 
 Unsuitable:  None listed. 
Specific Hazards Arising from the Chemical:  None listed. 
Special Protective Equipment and Precautions for Fire-Fighters:  Avoid inhalation of material or combustion 
byproducts.  Wear full protective clothing and NIOSH approved self-contained breathing apparatus (SCBA). 
NFPA Ratings (0 = Minimal; 1 = Slight; 2 = Moderate; 3 = Serious; 4 = Severe) 
 Health = 2 Fire = 0 Reactivity = 0 
6. ACCIDENTAL RELEASE MEASURES 
Personal Precautions, Protective Equipment and Emergency Procedures:  Use suitable protective equipment; 
see Section 8, “Exposure Controls and Personal Protection”. 
Methods and Materials for Containment and Clean up:  Keep out of water supplies and sewers.  Do not touch 
spilled material.  Notify safety personnel of spills.  Collect spilled material in appropriate container for disposal.  
Isolate hazard area and deny entry. 
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7. HANDLING AND STORAGE 
Safe Handling Precautions:  Minimize dust generation.  See Section 8, “Exposure Controls and Personal Protection”. 
Storage:  Store and handling in accordance with all current regulations and standards.  Keep separated from 
incompatible substances (acids, bases, metals, oxidizing materials). 
8. EXPOSURE CONTROLS AND PERSONAL PROTECTION 
Exposure Limits:  No occupational exposure limits have been established.  The exposure limits for Particulates Not 
Otherwise Regulated are applicable. 
OSHA (PEL): 15 mg/m3 (TWA, total particulates) 
 5 mg/m3 (TWA, respirable particulates) 
Engineering Controls:  Provide local exhaust or process enclosure ventilation system.  Ensure compliance with 
applicable exposure limits. 
Personal Protection:  In accordance with OSHA 29 CFR 1910.132, subpart I, wear appropriate Personal Protective 
Equipment (PPE) to minimize exposure to this material. 
Respiratory Protection:  If workplace conditions warrant a respirator, a respiratory protection program that meets 
OSHA 29CFR 1910.134 must be followed.  Refer to NIOSH 42 CFR 84 for applicable certified respirators. 
Eye/Face Protection:  Wear splash resistant safety goggles with a face shield.  An eye wash station should be readily 
available near areas of use. 
Skin and Body Protection:  Personal protective equipment for the body should be selected based on the task being 
performed and the risks involved and should be approved by a specialist before handling this product.  
Chemical-resistant gloves should be worn at all times when handling chemicals. 
 
Descriptive Properties:  
Appearance (physical state, color, etc.): white crystalline, hygroscopic powder 
Molecular Formula: C4H11NO3 
Molar Mass (g/mol): 121.1 
Odor: odorless 
Odor threshold: not available 
pH (solution): 10.4 at 1.2 % 
Evaporation rate: not applicable 
Melting point/freezing point (ºC): 171–172 (340–342 ºF) 
Relative Density (g/L): not available 
Vapor Pressure (mmHg): not applicable 
Vapor Density (air = 1): not applicable 
Viscosity (cP): not applicable 
Solubility(ies): water soluble (55 %); moderately soluble: methanol, ethanol, 
ethylene glycol, dimethylformamide; slightly soluble: 
acetone, ether; very slightly soluble: ethyl acetate, 
cyclohexane, chloroform, carbon tetrachloride 
Partition coefficient (n-octanol/water): log Kow = –1.56 
Particle Size (if relevant) not available 
Thermal Stability Properties: 
 
Autoignition Temperature (ºC): not available 
Thermal Decomposition (ºC): not available 
Initial boiling point and boiling range (ºC): 219–220 (426–428 ºF) at 10 mmHg 
Explosive Limits, LEL (Volume %): not available 
Explosive Limits, UEL (Volume %): not available 
Flash Point (ºC) not available 
Flammability (solid, gas): not available 
9.  PHYSICAL AND CHEMICAL PROPERTIES 
SRM 723e  Page 4 of 6 
10.  STABILITY AND REACTIVITY 
Reactivity:  Stable at normal temperatures and pressure. 
Stability: X Stable  Unstable 
Possible Hazardous Reactions:  None listed. 
Conditions to Avoid:  Avoid generating dust and exposure to moisture. 
Incompatible Materials:  Acids, bases, metals, and oxidizing materials. 
Fire/Explosion Information:  See Section 5, “Fire Fighting Measures”. 
Hazardous Decomposition:  Thermal decomposition will produce oxides of nitrogen and carbon. 
Hazardous Polymerization:  Will Occur X Will Not Occur 
 
11. TOXICOLOGICAL INFORMATION 
Route of Exposure: X Inhalation  Skin  Ingestion 
Symptoms Related to the Physical, Chemical and Toxicological Characteristics:  Skin, eye, and possible 
respiratory irritation.  
Potential Health Effects (Acute, Chronic and Delayed): 
Inhalation:  Inhalation may cause irritation of the mucous membranes with tightness and pain in the chest, 
coughing, and difficulty breathing. 
Skin Contact:  Skin exposure may result in irritation with redness, pain, and possibly sensitization.  Dermatitis 
may develop due to irritation or sensitization over time. 
Eye Contact:  Eye irritation with redness, pain, and possibly corneal damage may occur.  Prolonged or repeated 
exposure may result in conjunctivitis. 
Ingestion:  Ingestion of this material is unlikely under normal conditions of use.  If ingested, gastrointestinal 
irritation and possible burns to the mouth and stomach may result.  A large does to laboratory animals caused 
weakness, collapse, and death. 
Numerical Measures of Toxicity:  
Acute Toxicity:  Not classified. 
Rat, Oral LD50:  >3000 mg/kg 
Skin Corrosion/Irritation:  Category 2 
Rabbit, Dermal:  25 % moderate; 500 mg severe 
Woman, Dermal:  1 % moderate 
Serious Eye damage/Eye irritation:  Category 2A, No data available on effects on the eyes, deemed to be a 
Category 2A based on skin irritation data. 
Respiratory Sensitization:  Not classified; no data available. 
Skin Sensitization:  Not classified; no data available. 
Germ Cell Mutagenicity:  Not classified; no data available. 
Carcinogenicity:  Not classified. 
Listed as a Carcinogen/Potential Carcinogen  Yes X No 
Tris(Hydroxymethyl)Aminomethane is not listed by IARC, NTP or OSHA as a carcinogen. 
Reproductive Toxicity:  Not classified. 
Rat, Oral TDLo:  12 000 mg/kg (prior to copulation 14 d, 4 d, continuous) 
Specific Target Organ Toxicity, Single Exposure:  Not classified; no data available. 
Specific Target Organ Toxicity, Repeated Exposure:  Category 3; May cause respiratory irritation of the 
mucous membranes with tightness and pain in the chest, coughing, and difficulty breathing. 
Aspiration Hazard:  Not classified; no data available. 
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12. ECOLOGICAL INFORMATION 
Ecotoxicity Data:  No data available. 
Persistence and Degradability: Biodegradation may be slow in the environment. 
Bioaccumulative Potential:  Potential for bioconcentration in aquatic organisms is low (estimated BCF equals 3). 
Mobility in Soil:  Very high mobility in soil. 
Other Adverse effects:  No data available. 
13. DISPOSAL CONSIDERATIONS 
Waste Disposal:  Dispose of waste in accordance with all applicable federal, state, and local regulations. 
14. TRANSPORTATION INFORMATION 
U.S. DOT and IATA:  Not regulated by DOT or IATA. 
15. REGULATORY INFORMATION 
U.S. Regulations: 
CERCLA Sections 102a/103 (40 CFR 302.4):  Not regulated. 
SARA Title III Section 302 (40 CFR 355.30):  Not regulated. 
SARA Title III Section 304 (40 CFR 355.40):  Not regulated. 
SARA Title III Section 313 (40 CFR 372.65):  Not regulated. 
OSHA Process Safety (29 CFR 1910.119):  Not regulated. 
SARA Title III Sections 311/312 Hazardous Categories (40 CFR 370.21): 
ACUTE HEALTH: Yes. 





California Proposition 65:  Not listed. 
U.S. TSCA Inventory:  Listed. 
TSCA 12(b), Export Notification:  Not listed. 
Canadian Regulations:  WHMIS Information: Not provided for this material. 
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16. OTHER INFORMATION 
Issue Date:  19 February 2019 
Sources: ChemAdvisor, Inc., SDS Tris(Hydroxymethyl)Aminomethane, 09 December 2015. 
 Hazardous Substances Data Bank, National Library of Medicine, Tromethamine CAS# 77-86-1, Full 
Record, available at https://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB (accessed Feb 2019). 
Center for Disease Control (CDC), NIOSH Pocket Guide to Chemical Hazards, Particulates Not 
Otherwise Regulated, available at https://www.cdc.gov/niosh/npg/npgd0480.html (accessed Feb 2019). 












Key of Acronyms: 
ACGIH American Conference of Governmental Industrial 
Hygienists 
NIOSH  National Institute for Occupational Safety and Health  
ALI Annual Limit on Intake NIST National Institute of Standards and Technology 
CAS  Chemical Abstracts Service  NRC Nuclear Regulatory Commission 
CEN European Committee for Standardization NTP  National Toxicology Program 
CERCLA  Comprehensive Environmental Response, 
Compensation, and Liability Act  
OSHA  Occupational Safety and Health Administration  
CFR  Code of Federal Regulations  PEL  Permissible Exposure Limit 
CPSU Coal Mine Dust Personal Sample Unit RCRA  Resource Conservation and Recovery Act  
DOT  Department of Transportation  REL  Recommended Exposure Limit  
EC50 Effective Concentration, 50 % RM Reference Material 
EINECS European Inventory of Existing Commercial Chemical 
Substances  
RQ  Reportable Quantity  
EPCRA  Emergency Planning and Community Right-to-Know 
Act  
RTECS Registry of Toxic Effects of Chemical Substances 
IARC  International Agency for Research on Cancer  SARA  Superfund Amendments and Reauthorization Act  
IATA  International Air Transport Association  SCBA  Self-Contained Breathing Apparatus  
IDLH  Immediately Dangerous to Life and Health  SRM  Standard Reference Material  
ISO International Organization for Standardization STEL  Short Term Exposure Limit  
LC50 Lethal Concentration, 50 %  TDLo Toxic Dose Low 
LD50 Lethal Dose, 50 % TLV  Threshold Limit Value  
LEL  Lower Explosive Limit  TPQ  Threshold Planning Quantity  
MSDS  Material Safety Data Sheet  TSCA  Toxic Substances Control Act  
NFPA  National Fire Protection Association  TWA  Time Weighted Average  
MSHA Mine Safety and Health Administration UEL  Upper Explosive Limit  











Disclaimer:  Physical and chemical data contained in this SDS are provided only for use in assessing the 
hazardous nature of the material.  The SDS was prepared carefully, using current references; however, NIST does not 
certify the data in the SDS.  The certified values for this material are given in the NIST Certificate of Analysis. 
Users of this SRM should ensure that the SDS in their possession is current.  This can be accomplished by contacting 
the SRM Program: telephone (301) 975-2200; fax (301) 948-3730; e-mail srmmsds@nist.gov; or via the Internet at 
https://www.nist.gov/srm. 
  
E.  Patents  
173  
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
(19) World Intellectual Property Organization
International Bureau
(43) International Publication Date (10) International Publication Number
22 February 2007 (22.02.2007) PCT WO 2007/022425 A2
(51) International Patent Classification: AT,AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
A61K 39/145 (2006.01) C12N 5/06 (2006.01) CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
C07H 21/04 (2006.01) C07K 14/11 (2006.01) GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP,
C12N 7/00 (2006.01) KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT,
LU, LV,LY,MA, MD, MG, MK, MN, MW, MX, MY, MZ,
(21) International Application Number: NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU,
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(54) Title: INFLUENZA RECOMBINANT SUBUNIT VACCINE
Influenza Mouse lmmunogenicity
H3 Ectodomain ELISA Antibody Titers
(Post 3 Vaccinations)
(57) Abstract: The invention provides influenza proteins, including subunit proteins and immunogenic compositions that can be
utilized, with or without adjuvants, as vaccines to protect against influenza infection in animal models and humans. The recombinant
proteins are expressed from transformed insect cells that contain integrated copies of the appropriate expression cassettes in their
genome. The invention uses a Drosophila melanogaster expression system to provide high yields of recombinant subunit proteins
with native-like conformation.
INFLUENZA RECOMBINANT SUBUNIT VACCINE
RELATED APPLICATION
[01] This application claims the benefit of U.S. Provisional Patent Application No.
60/708,988, filed August 16, 2005, the disclosures and drawings of which prior application are
hereby incorporated by reference in their entirety.
INCORPORATION OF SEQUENCE LISTING
[02] A sequence listing file in ST.25 format on CD-ROM is appended to this application
and fully incorporated herein by reference. The sequence listing information recorded in
computer readable form is identical to the written sequence listing (per WIPO ST.25 para. 39,
the information recorded on the form is identical to the written sequence listing). With respect
to the appended CD-ROMs, the format is ISO 9660; the operating system compatibility is MS-
Windows; the single file contained on each CD-ROM is named "FLU.S2.ADJ.04.ST25.txt"
and is a text file produced by Patentln 3.3 software; the file size in bytes is 35 KB; and the date
of file creation is 16 August 2006. The contents of the two CD-ROMs submitted herewith are
identical.
BACKGROUND OF THE INVENTION
TECHNICAL FIELD
[03] The invention relates to vaccine formulations designed to protect against influenza.
In particular, the vaccine formulations comprise recombinant subunit proteins derived from
influenza virus, and optionally include one or more adjuvants. "Subunit protein" is defined
here as any protein derived or expressed independently from the complete organism that it is
derived from. Furthermore, a subunit protein may represent a full length native protein
sequence or any fraction of the full length native protein sequence. Additionally, a subunit
protein may contain in addition to the full length or partial protein sequence, one or more
sequences, which may contain sequences that are homologous or heterologous to the organism
from which the primary sequence was derived. This definition is significantly broader than the
concept of a subunit protein as a single protein molecule that co-assembles with other protein
molecules to form a multimeric or oligomeric protein. The subunit proteins of the invention
are produced in a cellular production system by means of recombinant DNA methods and,
after purification, are formulated in a vaccine.
i nunogen means muc ess pro ein is ee e o pro uce a ro us immune response,
the quality of the immune response is increased, and 3) the efficacy of subunit vaccines is
improved.
[032] There is a clear need for new technologies that can be used to respond quickly to
influenza outbreaks and pandemics, to produce sufficient doses of high quality and safe
vaccine for all populations (including the irαmunodef ϊcient population), and to produce
improved vaccine formulations with increased immunogenicity and efficacy. Some of the
technical problems to be solved are engineering nucleotide sequences for immunogenic and
protective epitopes, expression and purification of the subunit proteins encoded by the
nucleotide sequences through methods that can be scaled up to commercial production, and
determining which adjuvants, if any, should be included in vaccine formulations containing the
subunit proteins. The invention disclosed herein meets the need of developing a new influenza
vaccine production method and solves associated technical problems.
SUMMARY OF THE INVENTION
[033] The invention provides recombinant influenza subunit proteins and immunogenic
compositions that can be utilized as vaccines to afford protection against influenza in animal
models and humans. The recombinant subunit proteins of the invention are expressed from
stably transformed insect cells that contain integrated copies of the appropriate expression
cassettes in their genome. The insect cell expression system provides high yields of
recombinant subunit proteins with native-like conformation. The recombinant subunit proteins
of the invention represent full length or truncated forms of the native influenza proteins.
Additionally, multimeric forms of several of the recombinant subunit proteins have been
produced. Specifically, the subunits are derived from the HA and M l proteins of influenza.
More specifically the subunit proteins are secreted from the transformed insect cells and then
purified from the culture medium following the removal of the host cells. Avoiding lysis of the
host cells by either viral means or by physical means simplifies purification, improves yields,
and avoids potential degradation of the target protein.
[034]The invention also provides for the use of adjuvants as components in an immunogenic
composition compatible with the purified proteins to boost the immune response resulting from
vaccination. One or more preferred adjuvants are selected from the group comprising saponins
(e.g, GP-OlOO), or derivatives thereof, emulsions alone or in combination with carbohydrates
or saponins, and aluminum-based adjuvants (collectively, "alum" or "alum-based adjuvants")
such as aluminum hydroxide, aluminum phosphate, or a mixture thereof. Aluminum
hydroxide (commercially available as "Alhydrogel") was used as alum in the Examples. A
υiun is any pian g ion a ca o ie a sugar an a
sapogenin aglycone. Sapogenin is the nonsugar portion of a saponin. It is usually obtained by
hydrolysis, and it has either a complex terpenoid or a steroid structure that forms a practicable
starting point in the synthesis of steroid hormones. The saponins of the invention can be any
saponin as described above or saponin-like derivative with hydrophobic regions, especially the
strongly polar saponins, primarily the polar triterpensaponins such as the polar acidic
bisdesmosides, e.g. saponin extract from Quillsjabark Araloside A, Chikosetsusaponin IV,
Calendula-Glycoside C, chikosetsusaponin V, Achyranthes-Saponin B.
Calendula-Glycoside A, Araloside B, Araloside C, Putranjia-Saponin III, Bersamasaponiside,
Putrajia-Saponin IV, Trichoside A, Trichoside B, Saponaside A, Trichoside C, Gypsoside.
Nutanoside, Dianthoside C, Saponaside D, aescine from Aesculus hippocastanum or sapoalbin
from Gyposophilla struthium, preferably, saponin extract Quillaja saponaria Molina and
Quil A. In addition, saponin may include glycosylated triterpenoid saponins derived from
Quillaja Saponaria Molina of Beta Amytin type with 8-1 1 carbohydrate moieties as described
in U.S. Patent No. 5,679,354. Saponins as defined herein include saponins that may be
combined with other materials, such as in an immune stimulating complex ("ISCOM")-like
structure as described in U.S. Patent No. 5,679,354. Saponins also include saponin-like
molecules derived from any of the above structures, such as GPI-0100, such as described in
U.S. Patent No. 6,262,029. Preferably, the saponins of the invention are amphiphilic natural
products derived from the bark of the tree, Quillaia saponaria. Preferably, they consist of
mixtures of triterpene glycosides with an average molecular weight (Mw) of 2000. A
particularly preferred embodiment of the invention is a purified fraction of this mixture.
[035] The invention further provides methods for utilizing the vaccines to elicit the
production of antibodies against the various types and subtypes of influenza virus in a
mammalian host as a means of conferring protection against influenza. The vaccine
formulations are shown to induce strong overall antibody titers, as well as strong
hemagglutinin-inhibition antibody titers, in comparison to other formulations. Furthermore, the
vaccine formulations are shown to provide protection against influenza challenge in a mouse
model. In comparison to conventionally produced influenza immunogens, the proteins
produced by the invention have increased immunogenicity and efficacy, are less costly to
produce, and have a shorter production cycle.
BRIEF DESCRIPTION OF THE DRAWINGS
[036] FIG. 1. Lymphocyte proliferation of antigen stimulated splenocytes
[037] FIG. 2. IFN-γ production from antigen stimulated splenocytes.
We claim:
1. A method for producing a recombinant subunit influenza vaccine comprising:
expressing and secreting a recombinant influenza hemagglutinin ectodomain protein
subunit, wherein the protein subunit lacks a C-terminal transmembrane anchor and is
secreted as a soluble protein from stably transformed insect cells; and
formulating said recombinant protein subunit to produce an immunogenic composition
that induces the production of hemagglutinin antibody titers in a host vaccinated with the
immunogenic composition.
2. A method for producing a recombinant subunit influenza vaccine comprising:
expressing and secreting a recombinant influenza hemagglutinin head protein subunit,
wherein the protein subunit lacks a C-terminal transmembrane anchor, lacks an N-terminal
portion, and is secreted as a soluble protein from stably transformed insect cells; and
formulating said recombinant protein subunit to produce an immunogenic composition
that induces the production of hemagglutinin antibody titers in a host vaccinated with the
immunogenic composition.
3. A method for producing a recombinant subunit influenza vaccine comprising:
expressing and secreting a recombinant influenza hemagglutinin ectodomain protein
subunit, wherein the protein subunit lacks a C-terminal transmembrane anchor and is
secreted as a soluble protein from stably transformed insect cells;
expressing and secreting a recombinant influenza matrix 1 protein subunit, wherein the
protein subunit lacks a C-terminal transmembrane anchor, and is secreted as a soluble
tetrameric protein from stably transformed insect cells; and
formulating said recombinant hemagglutinin ectodomain and matrix 1protein subunits
to produce an immunogenic composition that induces the production of hemagglutinin
antibody titers in a host vaccinated with the immunogenic composition.
4. A method for producing a recombinant subunit influenza vaccine comprising:
expressing and secreting a recombinant influenza hemagglutinin head protein subunit,
wherein the protein subunit lacks a C-terminal transmembrane anchor, lacks an N-terminal
portion, and is secreted as a soluble protein from stably transformed insect cells;
expressing and secreting a recombinant influenza matrix 1 protein subunit, wherein the
protein subunit lacks a C-terminal transmembrane anchor, and is secreted as a soluble
tetrameric protein from stably transformed insect cells; and
formulating said recombinant hemagglutinin head and matrix 1 protein subunits to
vu ϊ ii tu ϊO_.ge_.rac_ composi_.ion - a in uces e pro uc. ion o Hemagglutinin
antibody titers in a host vaccinated with the immunogenic composition.
5 . A method for producing a recombinant subunit influenza vaccine comprising:
expressing and secreting a recombinant influenza HA-foldon subunit, wherein the
protein is secreted as a soluble protein from stably transformed insect cells; and
formulating said recombinant protein subunit to produce an immunogenic composition
that induces the production of hemagglutinin antibody titers in a host vaccinated with the
immunogenic composition.
6 . A method for producing a recombinant subunit influenza vaccine comprising:
expressing and secreting a recombinant influenza HA-foldon subunit, wherein the
protein is secreted as a soluble protein from stably transformed insect cells;
expressing and secreting a recombinant influenza matrix 1 protein subunit, wherein the
protein subunit lacks a C-terminal transmembrane anchor, and is secreted as a soluble
tetrameric protein from stably transformed insect cells; and
formulating said recombinant HA-foldon and matrix 1 protein subunits to produce an
immunogenic composition that induces the production o f hemagglutinin antibody titers in a
host vaccinated with the immunogenic composition.
7 . The method of claim 1, 2 , 3 , 4 , 5 , or 6 , wherein the influenza virus i s influenza A virus.
8 . The method of claim 1, 2 , 3 , 4 , 5 , or 6 , wherein the strain o f influenza virus i s selected
from the group consisting of H 5 and H3.
9 . The method of claim 1, 2 , 3 , 4 , 5 , or 6 , wherein the carboxy-teraiinal portion o f the
hemagglutinin protein subunit is truncated within 10% o f the length of a nominal
ectodomain.
10. The method of claim 1, 2, 3 , 4 , 5 , or 6 , wherein the stably transformed insect cells are
Drosophila melanogaster S2 cells.
11. The method of claim 1, 2 , 3 , 4 , 5 , or 6 , wherein formulating the immunogenic composition
further comprises including in the immunogenic composition one or more adjuvants.
12. The method of claim 1, 2 , 3 , 4 , 5 , or 6 , wherein formulating the immunogenic composition
further comprises including in the immunogenic composition one or more adjuvants
selected from the group consisting o f saponin and alum.
13. The method of claim 1, 2 , 3 , 4 , 5 , or 6 , wherein formulating the immunogenic composition
further comprises including in the immunogenic composition GPI-0100 adjuvant.
14. The method of claim 1, 2 , 3 , 4 , 5, or 6 , wherein formulating the immunogenic composition
further comprises including a pharmaceutically acceptable excipient in the immunogenic
composition.
, , , ,
immuno-affinity chromatography.
16. The method of claim 1 or 3, wherein the recombinant influenza hemagglutinin ectodomain
protein subunit has an amino acid sequence selected from the group consisting of SEQ ID
NO:1, SEQ ID NO:2, and SEQ ID NO:3.
17. The method of claim 2 or 4, wherein the recombinant influenza hemagglutinin head protein
subunit has an amino acid sequence selected from the group consisting of SEQ ID NO: 4,
SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7.
18. The method of claim 2 or 4, wherein the truncation points of the hemagglutinin head
protein subunit are selected from the group consisting of N-terminal, C-terminal, and N-
terminal and C-terminal, wherein the one or both terminal points can be varied up to 10%
of the length of a nominal HA-head.
19. The method of claim 3, 4, or 6, wherein the recombinant influenza matrix 1 protein subunit
has an amino acid sequence of SEQ ID NO: 10.
20. The method of claim 5 or 6, wherein the recombinant influenza HA-foldon subunit has an
amino acid sequence selected from the group consisting of SEQ ID NO: 8 and SEQ ID
NO:9.
21. A method for raising an immunogenic response from a subject, comprising administering
in a therapeutically acceptable manner a therapeutically effective amount of the
immunogenic composition of claim 1, 2, 3, 4, 5, or 6, to said subject.
22. An immunogenic composition comprising a recombinant subunit influenza vaccine
comprising a recombinant influenza hemagglutinin ectodomain protein subunit, wherein
the protein subunit lacks a C-terminal transmembrane anchor and is expressed and secreted
as a soluble protein from stably transformed insect cells.
23. An immunogenic composition comprising a recombinant subunit influenza vaccine
comprising a recombinant influenza hemagglutinin head protein subunit, wherein the
hemagglutinin head protein subunit lacks a C-terminal transmembrane anchor, lacks an N-
terminal portion, and is expressed and secreted as a soluble protein from stably transformed
insect cells.
24. An immunogenic composition comprising a recombinant subunit influenza vaccine
comprising a recombinant influenza hemagglutinin ectodomain protein subunit, wherein
the hemagglutinin ectodomain protein subunit lacks a C-terminal transmembrane anchor
and is expressed and secreted as a soluble protein from stably transformed insect cells,
u t m nan n uenza mat x prote n su un t, wnerem the matrix
protein subunit lacks a C-terminal transmembrane anchor, and is expressed and secreted as
a soluble tetrameric protein from stably transformed insect cells.
25. An immunogenic composition comprising a recombinant subunit influenza vaccine
comprising a recombinant influenza hemagglutinin head protein subunit, wherein the
hemagglutinin head protein subunit lacks a C-terminal transmembrane anchor, lacks an N-
terminal portion, and is expressed and secreted as a soluble protein from stably transformed
insect cells,
combined with a recombinant influenza matrix 1 protein subunit, wherein the matrix 1
protein subunit lacks a C-terminal transmembrane anchor, and is expressed and secreted as
a soluble tetrameric protein from stably transformed insect cells.
26. An immunogenic composition comprising a recombinant subunit influenza vaccine
comprising a recombinant influenza HA-foldon protein subunit, wherein the protein
subunit is expressed and secreted as a soluble protein from stably transformed insect cells.
27. An immunogenic composition comprising a recombinant subunit influenza vaccine
comprising a recombinant influenza HA-foldon protein subunit, wherein the HA-foldon
protein subunit is expressed and secreted as a soluble protein from stably transformed
insect cells,
combined with a recombinant influenza matrix 1 protein subunit, wherein the matrix 1
protein subunit lacks a C-terminal transmembrane anchor, and is expressed and secreted as
a soluble tetrameric protein from stably transformed insect cells.
28. The immunogenic composition of claim 22, 23, 24, 25, 26, or 27, wherein the influenza
virus is influenza A virus.
29. The immunogenic composition of claim 22, 23, 24, 25, 26, or 27, wherein the strain of
influenza virus is selected from the group consisting of H5 and H3.
30. The immunogenic composition of claim 22, 23, 24, 25, 26, or 27, wherein the carboxy-
terminal portion of the hemagglutinin protein subunit is truncated within 10% of the length
of a nominal ectodomain.
31. The immunogenic composition of claim 22, 23, 24, 25, 26, or 27, wherein the stably
transformed insect cells are Drosophila melanogaster S2 cells.
32. The immunogenic composition of claim 22, 23, 24, 25, 26, or 27, wherein the
immunogenic composition further comprises one or more adjuvants.
33. The immunogenic composition of claim 22, 23, 24, 25, 26, or 27, wherein the
immunogenic composition further comprises one or more adjuvants selected from the
group consisting of saponin and alum.
, , , , , ,
immunogenic composition further comprises GPI-0100 adjuvant.
35. The immunogenic composition of claim 22, 23, 24, 25, 26, or 27, wherein the
immunogenic composition further comprises a pharmaceutically acceptable excipient.
36. The immunogenic composition of claim 22, 23, 24, 25, 26, or 27, wherein the protein
subunits are purified by immuno-affmity chromatography.
37. The immunogenic composition of claim 22, 23, 24, 25, 26, or 27, wherein the
immunogenic composition is administered to a subject in a vaccine.
38. The immunogenic composition of claim 22 or 24, wherein the recombinant influenza
hemagglutinin ectodomain protein subunit has an amino acid sequence selected from the
group consisting of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3.
39. The immunogenic composition of claim 22 or 24, wherein the recombinant influenza
hemagglutinin ectodomain protein subunit has an amino acid sequence with at least 95%
sequence identity to an amino acid selected from the group consisting of SEQ ID NO:1,
SEQ ID NO:2, and SEQ ID NO:3.
40. The immunogenic composition of claim 22 or 24, wherein the recombinant influenza
hemagglutinin ectodomain protein subunit has an amino acid sequence with at least 90%
sequence identity to an amino acid selected from the group consisting of SEQ ID NO:1,
SEQ ID NO:2, and SEQ ID NO:3.
41. The immunogenic composition of claim 23 or 25, wherein the recombinant influenza
hemagglutinin head protein subunit has an amino acid sequence selected from the group
consisting of SEQ ID NO:4, SEQ DD NO:5, SEQ ID NO:6, and SEQ ID NO:7.
42. The immunogenic composition of claim 23 or 25, wherein the recombinant influenza
hemagglutinin head protein subunit has an amino acid sequence with at least 95% sequence
identity to an amino acid selected from the group consisting of SEQ ID NO:4, SEQ ID
NO:5, SEQ ID NO:6, and SEQ ID NO:7.
43. The immunogenic composition of claim 23 or 25, wherein the recombinant influenza
hemagglutinin head protein subunit has an amino acid sequence with at least 90% sequence
identity to an amino acid selected from the group consisting of SEQ ID NO:4, SEQ ID
NO:5, SEQ IDNO:6, and SEQ ID NO:7.
44. The immunogenic composition of claim 23 or 25, wherein the truncation points of the
hemagglutinin head protein subunit are selected from the group consisting of N-terminal,
C-terminal, and N-terminal and C-terminal, wherein the one or both terminal points can be
varied up to 10% of the length of a nominal HA-head.
c os on o c a m , , or , w ere n e re it iza
matrix 1 protein subunit has the amino acid sequence of SEQ ID NO: 10.
46. The immunogenic composition of claim 24, 25, or 27, wherein the recombinant influenza
matrix 1 protein subunit has an amino acid sequence with at least 95% sequence identity to
SEQ ID NO: 10.
47. The immunogenic composition of claim 24, 25, or 27, wherein the recombinant influenza
matrix 1 protein subunit has an amino acid sequence with at least 90% sequence identity to
SEQ ID NO: 10.
48. The immunogenic composition of claim 26 or 27, wherein the recombinant influenza HA-
foldon protein subunit has an amino acid sequence selected from the group consisting of
SEQ ID NO:8 and SEQ ID NO:9.
49. The immunogenic composition of claim 26 or 27, wherein the recombinant influenza HA-
foldon protein subunit has an amino acid sequence with at least 95% sequence identity to
an amino acid selected from the group consisting of SEQ ID NO:8 and SEQ ID NO:9.
50. The immunogenic composition of claim 26 or 27, wherein the recombinant influenzaHA-
foldon protein subunit has an amino acid sequence with at least 90% sequence identity to
an amino acid selected from the group consisting of SEQ ID NO:8 and SEQ ID NO:9.
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(54) Title: METHOD FOR THE PRODUCTION OF AD26 ADENOVIRAL VECTORS
(57) Abstract: The invention provides methods for large-scale production of recombinant adenovirus 26, using perfusion systems
and infection at very high cell densities.
Title: Method for the production of Ad26 adenoviral vectors
The invention relates to the field of cell culture and adenovirus production. More
particularly, it concerns improved methods for the culturing of mammalian cells,
infection of those cells with adenovirus and the production of adenovirus particles
therefrom.
Background of the invention
Recent developments in the field of DNA vaccination using recombinant viral
vectors have created the need for large scale manufacturing of clinical grade material.
Processes are needed to be able to support the less and least developed world with
sufficient amounts of recombinant adeno-based vaccines to fight e.g. the Tuberculosis
and Malaria problem in the world. An evaluation of the birth cohort shows that more
than 150.000.000 births are expected for the less and least developed world in 2010-
2015. Based on this birth cohort the projected annual demand for a vaccine could
reach approximately 1.5 x 10 19 virus particles (VP) on a yearly basis
(http://esa.un.org/unpp/index. asp?panel=2).
Several processes for production of adenoviruses have been described. These
processes use adherent cell cultures in roller bottles, cell factories (Nunclon from
Nunc or CellStack from Corning), or Cell Cubes (Corning). Production processes on
adherent cell cultures cannot fulfill the worldwide demand for adeno-based vaccines.
Therefore the cells used in the adherent process are adapted to suspension cultures
(e.g. HEK293 and PER.C6® cell lines). With the use of suspension cultures it is
possible to scale-up production processes to large-scale bioreactors. Suspension cell
cultures for adenovirus production are routinely achieved between 3 to 20L scale and
successful scale-up has been reported up to 100L (Kamen et al, 2004), and 250L (Xie
et al, 2003). Experiments are reported in which scaling up to 10.000L is anticipated
(Xie et al, 2003).
However, a major disadvantage of scaling up to 10.000L is the high capital
investment (CAPEX), which is needed to design and build a 10.000L bioreactor
facility. Furthermore, the CAPEX commitment of building a 10.000L facility, under
BSL 2 conditions, must be realized before even knowing if the product will be
successful (Phase IV and beyond). The total investment cost for a 10.000L bioreactor
plant is reported between C225.000.000 and C320.000.000 (Estape et al, 2006).
Therefore, preparation at lower scale, e.g. in 1000L or smaller bioreactors, would be
desirable.
With the use of currently existing processes, more than 150 batches at 1000L
scale a year must be produced in order to reach the target of 1.5xl0 1 VP/year.
Therefore, a need exists to improve systems for adenovirus production, to improve
yields of adenovirus particles in order to fulfil the world-wide demand of adenovirus
vaccines, preferably at non-prohibitive costs.
One of the issues encountered in adenovirus production optimization is the so-
called "cell density effect". In batch-mode operation, several references suggest the
existence of an optimal cell density at infection for adenovirus production. The
optimum lies between 0.5 - lxlO 6 cells/mL (Maranga et al, 2005; Kamen et al.,
2004). It was shown for adenovirus (Ad5) production in a batch stirred tank bioreactor
that the virus productivity per cell remains constant up to around 0.9xl0 6 cells/mL,
but drops abruptly at around lxlO 6 cells/mL (Altaras et al, 2005). Beyond 2xl0 6
cells/mL, no infectious particles were detectable. The breakpoint related to specific
production drop with cell densities at infection is medium dependent. No available
commercial medium to date has shown potential to support high yields of virus
particles, while maintaining the specific production optimal at cell densities beyond
lxlO 6 cells/mL (Kamen et al, 2004). The reasons for this drop is not known yet but
might be due to limited nutrient availability for virus production, or due to high
metabolites concentrations that are inhibitory for virus production.
Fed-Batch operations, like addition of glucose, glutamine and amino acids
allowed infections at cell densities up to 2xl0 6 cells/mL. However, the productivities
attained at high cell densities were lower than those obtained with infection at cell
densities of lxlO 6 cells/mL (Kamen et al., 2004).
In perfusion processes the cells are retained in the bioreactor by hollow fibers,
spin filters or acoustic separators while culture medium is perfused through the
bioreactor. In these processes cell densities of >100xl0 6 cells/mL can sometimes be
reached (e.g., Yallop et al, 2005).
Infected perfusion cells showed premature cell loss during perfusion with a
hollow fiber system. This might be related to their higher shear sensitivity due to the
viral infection (Cortin et al., 2004). The hydro-dynamical stresses induced in the
tubing, the hollow fibers, or the peristaltic pump on more fragile, infected cells was
most likely the cause for this phenomenon. Since infected cells are more fragile,
particularly the acoustic separator (Henry et al, 2004) has been suggested to be
desirable if the perfusion is to be maintained throughout the infection phase.
However, infections performed in perfusion mode could only be maintained for cell
densities up to 3xl0 6 cells/mL with a perfusion rate of 2 vol/day. Infection at a cell
density of 6x1 06 cells/mL led to a fivefold reduction in specific productivity (Henry et
al, 2004).
Despite the reported cell density effect by others, one report (Yuk et al, 2004)
described successful perfusion cultures of human tumor cells as a production platform
for oncolytic adenoviral vectors. That report described a high-cell-density perfusion
process using alternating tangential flow (ATF) technology. At an average viable cell
density at infection of 9 x 106 HeLaS3 cells/mL, an average viral titer of about 4 x
10 1 1 VP/mL was observed. The tumor cells used in that report are not preferred as
production cells, since use of tumor cells may pose safety risks when the produced
adenovirus particles are to be administered to humans. The recombinant adenovirus in
that report was based on Ad5. Such adenoviruses have limited possibilities for use as
vaccines since a majority of the human population contain pre-existing neutralizing
antibodies against Ad5, and recombinant adenoviruses from other serotypes are
therefore more suitable for use as vaccines (see e.g. WO 00/70071). Recombinant
adenoviruses especially advantageous for use as vaccines include Ad26 (WO
00/70071).
Limited information, if any, is available for the large scale production of
recombinant adenoviruses from other serotypes than Ad5, in particular for the
advantageous serotype 26. Some differences between Ad35 and Ad5 production at
large scale have been described previously in e.g. PCT/EP2009/064265. The
somewhat different physical properties of recombinant adenoviruses of different
serotypes may give rise to differences in production processes. Such potential
differences may especially be important at industrial scale, where even seemingly
small differences at small scale may have large economic consequences on the scale
envisaged for production of the annual world-wide demand. For instance, it was
shown by the applicant that the reported cell density effect for Ad5 was different for
Ad35 (PCT/EP2009/064265). Thus, rAd35 propagates differently in producer cells
than rAd5 during large scale production processes. Apparently, the propagation of
adenoviruses from different serotypes is very unpredictable.
In order to fulfil the world-wide demand of recombinant adenovirus serotype
26 (rAd26) vaccines, a need exists to improve systems for rAd26 production.
The present invention provides improved methods for industrial production of rAd26.
Summary of the invention
We have found herein that yet another serotype, i.e. Ad26 behaves differently than
other serotypes Ad5 and Ad35. Indeed, Ad26 tends to show a slight cell density
effect, yet not as accentuated as the density effect seen for Ad5. In addition, cells that
are infected with Ad26 tend to grow further after infection, while cells infected with
Ad35 show a decreased growth post infection.
These results again suggest that processes for specific adenovirus serotypes
may have to be fine-tuned for each serotype, in order to obtain optimal results. The
present invention provides an optimized system for production of rAd26 in terms of
yield, quality of the rAd26 obtained, and ease of handling of the harvest for down
stream processing.
The invention provides a method for producing recombinant adenovirus
serotype 26 (rAd26), the method comprising: a) culturing producer cells in suspension
with a perfusion system; b) infecting said cells at a density of between about lOxlO6
viable cells/mL and 16xl0 6 viable cells/mL with rAd26; c) further culturing the
infected cells with a perfusion system to propagate said rAd26; and d) harvesting said
rAd26.
In certain embodiments said cells in step b) are infected with rAd26 at a
density of between about lOxlO6 and 14xl0 6 viable cells/mL.
In certain preferred embodiments, said perfusion system in step c) is an
alternating tangential flow (ATF) perfusion system. In other preferred embodiments,
said perfusion system in step a) is an alternating tangential flow (ATF) perfusion
system. In a preferred embodiment, said perfusion system in both steps a) and c) is an
alternating tangential flow (ATF) perfusion system.
In certain embodiments, the method of the invention further comprises: e)
purifying the rAd26. In further embodiments, the method further comprises: f)
preparing a pharmaceutical composition containing the purified rAd26.
In certain embodiments, said recombinant adenovirus lacks at least a portion
of the El region, and comprises heterologous nucleic acid.
In preferred embodiments, the physical particle to infectious particle (VP/IU)
ratio of the produced rAd26 is less than 30:1, preferably less than 20:1.
It is also an aspect of the invention to provide a method for producing at least
lxl0 1 rAd26 virus particles (VP)/mL, the method comprising: a) culturing producer
cells in suspension with a perfusion system; b) infecting said cells at a density of
between about lOxlO6 viable cells/mL and 16xl0 6 viable cells/mL with rAd26; c)
further culturing the infected cells with a perfusion system to propagate said rAd26,
whereby the concentration of rAd26 virus particles reaches at least lxlO 12 VP/mL;
and d) harvesting said rAd26.
The invention also provides a bioreactor with a working volume of between
2L and 1000L, comprising: culture medium, producer cells, and at least lxl 012 rAd26
virus particles (VP)/mL. In certain embodiments, the bioreactor has a working volume
of between 50L and 500L. In preferred embodiments, the bioreactor is connected to
an ATF perfusion system.
Brief description of the Figures
FIG. 1. Infection at high cell density in shakers with rAd5.
FIG. 2 . Infection at high cell density in shakers and 2L bioreactor with rAd35.TB-S.
FIG. 3 . Infection at high cell density in shakers with rAd26.
FIG. 4 . Cell growth post infection with rAd26.
FIG. 5 . Cell growth post infection with rAd35.
Detailed description of the invention
The present invention describes a new process for the production of large
quantities of recombinant adenovirus rAd26. This optimized process relies on the
ability to infect cultures at high cell density with preservation of a high virus
productivity per cell. Herewith, it offers a method to obtain a harvested virus solution
with high virus concentration in a single bioreactor. Typical yields of current
processes for rAd26 are about 2-3x1 01 1 VP/mL. Indeed, it is believed that very large
quantities of rAd26 particles can be produced using the processes of the present
invention, for instance quantities of at least about 5x1 01 1 VP/mL, preferably at least
about 6, 7, 8, or 9xlO VP/mL. Preferably at least lxlO 12 VP/mL of rAd26 are
produced, more preferably at least 1.5x1 012 VP/mL, still more preferably at least
2xl0 12 VP/mL, e.g. between about lxlO 12 and 5xl0 12 VP/mL. Typically, the process
Claims
1. A method for producing recombinant adenovirus serotype 26 (rAd26), the
method comprising:
a) culturing producer cells in suspension with a perfusion system;
b) infecting said cells at a density of between lOxlO6 viable cells/mL and
16xl0 6 viable cells/mL with rAd26;
c) further culturing the infected cells with a perfusion system to propagate
said rAd26; and
d) harvesting said rAd26.
2 . A method according to claim 1, wherein said cells in step b) are infected with
rAd26 at a density of between about lOxlO6 and 14xl0 6 viable cells/mL.
3 . A method according to any one of the preceding claims, wherein said
perfusion system in step c) is an alternating tangential flow (ATF) perfusion system.
4 . A method according to any one of the preceding claims, further comprising:
e) purifying the rAd26, and optionally
f preparing a pharmaceutical composition containing the purified rAd26.
5 . A method according to any one of the preceding claims, wherein said
recombinant adenovirus lacks at least a portion of the El region, and comprises
heterologous nucleic acid.
6 . A method according to any one of the preceding claims, wherein said
perfusion system in step a) is an alternating tangential flow (ATF) perfusion system.
7 . A method according to any one of the preceding claims, wherein step a) is
performed in a first bioreactor, and steps b) and c) are performed in a second
bioreactor.
8 . A method according to any one of the preceding claims, wherein the physical
particle to infectious particle (VP/IU) ratio of the produced rAd35 is less than 30:1,
preferably less than 20: 1.
9. A bioreactor comprising culture medium, producer cells, and virus particles
wherein said bioreactor has a working volume of between 2L and 1000L, preferably
between 50L and 500L, and characterized in that said bioreactor comprises at least
lxlO 12 rAd26 virus particles (VP)/mL.
10. A bioreactor according to claim 9, connected to an ATF perfusion system.
11. A bioreactor according to claim 9 or 10, wherein the rAd26 virus particles
have a VP/IU ratio of less than 30:1, preferably less than 20: 1.
12. A method for producing at least lxlO 12 rAd26 virus particles (VP)/mL, the
method comprising:
a) culturing producer cells in suspension with a perfusion system;
b) infecting said cells at a density of between lOxlO6 viable cells/mL and
16xl0 6 viable cells/mL with rAd26;
c) further culturing the infected cells with a perfusion system to propagate said
rAd26, whereby the concentration of rAd26 virus particles reaches at least lxlO 12
VP/mL; and
d) harvesting said rAd26.
